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resumo 
 
 
A BRI2 e a BRI3 são proteínas transmembranares de tipo II cujas funções 
fisiológicas ainda não se encontram bem caracterizadas. Duas mutações 
autossómicas dominantes no gene BRI2 estão na origem de duas formas de 
demência rara: Demência Familiar Britânica e Demência Familiar 
Dinamarquesa. Estas partilham características clinicas e neuropatológicas com 
a doença de Alzheimer, nomeadamente deposição de proteínas anormais no 
cérebro. Apesar de nunca ter sido associada a qualquer doença, a BRI3 está 
enriquecida no sistema nervoso central o que sugere que possa ter uma 
função neuronal. 
Interações proteína-proteína têm adquirido uma importância crescente no 
estudo de funções de proteínas e vias de sinalização subjacentes. Neste 
trabalho, foram identificadas novas interações entre a BRI2 e a proteína 
fosfatase 1 (PP1), bem como entre a BRI3 com a PP1. A PP1 é a uma 
importante fosfatase serina/treonina presente em organismos eucariotas, onde 
se estima que seja capaz de catalisar a maioria dos eventos de defosforilação. 
Adicionalmente, determinámos a BRI2 e BRI3 como substratos da PP1, e 
identificámos os motivos RVxF presentes nos seus N-terminais como 
responsáveis pela ligação à PP1. A relevância fisiológica do complexo 
BRI2:PP1 foi investigada, e demonstrámos pela primeira vez que a fosforilação 
da BRI2, nomeadamente a defosforilação pela PP1, é um mecanismo de 
regulação do seu processamento proteolítico. Estabelecemos ainda uma 
relação entre os níveis de fosforilação da BRI2 com a diferenciação de 
processos neuronais, onde a fosforilação da proteína total parece estar 
envolvida no surgimento de processos neuronais, enquanto o fragmento N-
terminal resultante do seu processamento parece estar relacionado com o 
elongamento e estabilização dos processos neuronais. No decorrer do 
trabalho, identificámos e caracterizámos os interactomas das proteínas BRI2 e 
BRI3 em cérebro, recorrendo a co-imunoprecipitações e identificação das 
proteínas por espectrometria de massa. Análise in silico do interactome da 
BRI2 reforçou os nossos resultados sugerindo um papel para esta proteína na 
diferenciação neuronal, e vários mecanismos subjacentes foram evidenciados. 
Adicionalmente, a análise dos interactomas localiza ambas proteínas na 
sinapse (pré e pós-sinapse). Esta evidência juntamente com a descoberta de 
interações com proteínas estruturais destes compartimentos celulares, 
nomeadamente a PSD-95, sugere um papel importante para ambas as 
proteínas em sinalização e transmissão sináptica. Assim, os nossos resultados 
compreendem informação importante para estudos futuros acerca da biologia 
das proteínas BRI2 e BRI3, e mecanismos celulares envolvidos, bem como na 
sua associação com o desenvolvimento de neuropatologias.  
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abstract 
 
BRI2 and BRI3 are type II transmembrane protein family members whose 
physiological functions are poorly understood. Two different autosomal 
dominant mutations in the BRI2 gene are responsible for the development of 
two rare early-onset forms of dementia: Familial British and Familial Danish 
dementias that share clinical and neuropathological characteristics with 
Alzheimer´s disease, involving abnormal proteins’ deposition in the brain. For 
BRI3 no disease association has been established so far, nevertheless, its 
enriched expression in the central nervous system strongly suggests a role for 
BRI3 in neuronal function. 
Protein-protein interactions are becoming increasingly important in the study of 
protein function and underlying signaling pathways. In this work, both BRI2 and 
BRI3 were identified as novel protein phosphatase 1 (PP1) interacting proteins. 
PP1 is the major Ser/Thr protein phosphatase present in eukaryotic organisms, 
which catalyses the majority of protein dephosphorylation events. Moreover, we 
were able to determine BRI2 and BRI3 as PP1 substrates, which bind to the 
latter through an RVxF-like motif located in their N-terminal part. The 
physiological relevance of BRI2:PP1 complex was pursued, and we provide for 
the first time evidence suggesting that BRI2 phosphorylation, namely via PP1 
dephosphorylation, is a regulatory mechanism for its proteolytic processing. 
Further, a correlation between BRI2 phosphorylation and neurite outgrowth was 
established. The phosphorylation of full-length protein seems to promote the 
emergence of neurites whereas the increased BRI2 N-terminal processing 
fragment plays a role in neurites’ elongation and stabilization. Herein, we also 
identified and characterized the interactome of both BRI2 and BRI3 in the brain 
using co-immunoprecipitation followed by mass spectrometry analysis. In silico 
analysis of the BRI2 interactome strengthened our results suggesting a role in 
neuronal differentiation and some underlying mechanisms were pointed out. 
Moreover, interactomes’ analysis suggested the presence of both BRI2 and 
BRI3 at synapses (pre- and post-synapse). This finding together with their 
ability to form complexes with structural constituents of these compartments, 
namely PSD-95 suggested an important role for both proteins in synaptic 
signaling and synaptic transmission. 
Thus, our results provide valuable information for further studies on BRI2 and 
BRI3 biology, and potential underlying molecular mechanisms, as well as 
associations with neuropathologies. 
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BRI2 ICD BRI2 intracellular domain 
BRI2 NTF BRI2 N-terminal fragment  
CAA cerebral amyloid angiopathy  
CaMKII Calcium/calmodulin-dependent protein kinase II  
CNS Central nervous system 
co-IP Co-immunoprecipitation  
CRMP-2 Collapsin-response mediator protein-2  
Cys Cysteine 
DARPP-32 Dopamine and cAMP-regulated phosphoprotein 
DB Database 
DCX Doublecortin 
DIV Days in vitro 
ECL Enhanced chemiluminescence  
ERK Extracellular-signal-regulated kinase  
FAK Focal adhesion kinase  
FBD Familial British Dementia 
FDD Familial Danish Dementia 
Glu Glutamic acid 
GO Gene Ontology  
GSK3 Glycogen synthase kinase 3 
ITM2A Integral membrane protein 2A 
ITM2B Integral membrane protein 2B 
ITM2C Integral membrane protein 2C 
LAP1 Lamina-associated protein 1  
LTD Long-term depression 
LTP Long-term potentiation  
Lys Lysine 
MAP Microtubule-associated protein  
MAPK Mitogen-activated protein  kinase 
mAPP Mature amyloid precursor protein 
MARK Microtubule Affinity-Regulating Kinase  
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MBP Microtubule binding protein 
mBRI2 Mature BRI2 
MLCK Ca2+/calmodulin myosin light chain kinase 
MLCP Myosin light chain phosphatase 
MS Mass spectrometry 
MT Microtubule 
MW Molecular weight  
MYPT1 Myosin phosphatase targeting subunit 1  
NE Nuclear envelope  
NFT Neurofibrillary tangles  
NgCAM Neuron-glia cell adhesion molecule 
NGF Nerve growth factor  
NIPP1 Nuclear inhibitor of protein phosphatase 1 
NMDA N-methyl-D-aspartate  
NT Neurotrophin 
NTF N-terminal fragment 
OA Okadaic acid 
PAK p21-activated kinase 
PI3K Phosphatidylinositol-3 kinase  
PIP PP1 interacting protein 
PIP3 Phosphatidylinositol (3,4,5)-triphosphate 
PKB Protein kinase B  
PNUTS Phosphatase 1 nuclear targeting subunit 
PP Protein phosphatase 
PP1 Protein phosphatase 1 
PP1-BM Protein phosphatase 1 binding motif mutants 
PP1c Protein phosphatase 1 catalytic subunit 
PPC Proprotein convertases  
PPI Protein-protein interaction 
PPMs Metal-dependent protein phosphatases 
PPPs Phosphoprotein phosphatases 
PSD Postsynaptic density 
PSD-95 Postsynaptic density protein 95 
PSM Peptide spectrum matches  
PTEN Phosphatase and tensin homolog  
PTP Protein tyrosine phosphatase  
RA Retinoic acid 
RIP Regulated intramembrane proteolysis  
RNAPII RNA polymerase II  
ROCK Rho-kinase  
SAD Synapse Amphid Defective 
sAPPα Secreted APP fragment derived from α-secretase APP processing 
SCG10 Superior cervical ganglia neural-specific protein 
Serine  
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SPPL Signal peptidase-like protease 
Thr Threonine 
Tyr Tyrosine 
UPS Ubiquitin-proteasome system 
YTH Yeast two-hybrid 
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I.1. Protein Phosphatase 1 (PP1) 
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Synonyms:  
Phosphoprotein phosphatase 1; Phosphoprotein phosphatase 1 catalytic subunit (PPP1C); 
Phophorylase phosphatase 
 
I.1.1. Historical Background 
Protein phosphatase 1 (PP1), also known as phosphorylase phosphatase, was first studied in 1943 by 
Cori and Green in the context of glycogen metabolism, as the enzyme responsible for the conversion 
of phosphorylase a to phosphorylase b (Cori and Green 1943). A decade later the discovery that this 
enzyme is in fact a phosphatase, together with the discovery of phosphorylase kinase by Fischer and 
Krebs in 1955, marked the beginning of the study of protein phosphorylation/dephosphorylation as 
a ubiquitous regulatory mechanism (Fischer and Krebs 1955). Research on PP1 further focused on 
the understanding of its enzymology and its role in glycogen metabolism. In fact, in the 1970s PP1 
catalytic subunits (PP1c) was isolated from both liver and muscle (Brandt et al. 1975; Gratecos et al. 
1977). Subsequent studies led to the discovery of PP1 inhibitors and targeting subunits, which are 
crucial aspects of PP1 biology. Namely, the role of the inhibitor proteins in regulating protein 
phosphatase activity; the role of targeting subunits that specifically target the PP1 catalytic subunit 
(PP1c) to specific subcellular locations; and the current view that PP1c exists in many holoenzyme 
forms (Cohen 1989). The concept of PP1 holoenzyme emerged and is comprised by the catalytic 
subunit with regulatory subunits. This concept was further supported by the finding that PP1 activity 
is generally associated with high molecular weight complexes (Killilea et al. 1979; Mellgren et al. 
1979). However, the study of PP1 enzymology is still incomplete today. Over the last decade, PP1 
has been implicated in many cellular processes, including, but not limited to, cell cycle control, 
apoptosis, transcription, adhesion, motility, metabolism, memory and HIV-1 viral transcription 
(reviewed in Cohen 2002). 
 
I.1.2. Protein Phosphorylation and Protein Phosphatases 
Reversible protein phosphorylation is one of the most common post-translational modifications in 
eukaryotic organisms and a key mechanism regulating the biological activity of several proteins. It 
involves either the addition of phosphate groups via the transfer of the terminal phosphate from ATP 
to the target residue of the protein by protein kinases (protein phosphorylation) or its removal by 
protein phosphatases (dephosphorylation) (Figure I.1). More than 70% of all eukaryotic proteins are 
regulated by protein phosphorylation occurring mainly at serine (Ser), threonine (Thr) and tyrosine 
(Tyr) residues (Barford et al. 1998). 
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Figure I. 1 - Schematic representation of reversible protein phosphorylation. Protein kinases transfer a phosphate 
group from ATP to the target protein (protein phosphorylation), while protein phosphatases catalyze the hydrolysis of the 
phosphate group from the target protein (protein dephosphorylation). 
 
Based on structural conservation and mechanism of action of their catalytic subunit, protein 
phosphatases can be classified in four distinct superfamilies’. The protein tyrosine phosphatase (PTP) 
superfamily comprises the classical and non-classical protein tyrosine phosphatases. In addition, the 
dual-specificity protein phosphatases that dephosphorylate both Tyr and Ser/Thr residues are also 
included in this superfamily. Beyond protein substrates, some PTPs can also dephosphorylate non-
protein substrates namely phospholipids, RNA and glycogen. The HAD superfamily of hydrolases 
comprises some protein serine/threonine/tyrosine phosphatases. The metal-dependent protein 
phosphatase (PPM) superfamily is mainly composed by monomeric protein Ser/Thr phosphatases 
that are activated by divalent cations. Finally, the phosphoprotein phosphatase (PPP) superfamily 
which also exclusively dephosphorylates Ser and Thr residues (Boens et al. 2013). 
 
I.1.3. Phosphoprotein phosphatase (PPP) superfamily 
PPP family includes PP1, PP2A, PP3 (also known as calcineurin or PP2B), PP4, PP5, PP6 and PP7. 
PPPs comprise a structurally related catalytic core domain that is conserved among species and an 
identical catalytic mechanism (Barford et al. 1998; Shi 2009). The remarkable degree of evolutionary 
conservation of these enzymes is associated with their essential role in the regulation of important 
cellular processes (Honkanen and Golden 2002). Several biochemical studies have indicated that 
PPPs catalyze more than 90% of all dephosphorylation events in eukaryotic cells, mainly performed 
by PP1 and PP2A. Moreover, the functional diversity achieved by PPP family is achieved by the 
existence of several isoforms for each catalytic subunit of each protein phosphatase. Of note, there 
are two genes coding for the PP2A isoforms, PP2Aα and PP2Aβ (PPP2CA and PPP2CB, 
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respectively) that share 97% identity and are highly conserved (Honkanen and Golden 2002). PP3 
comprises 3 isoforms (PP3α, PP3β and PP3γ) that share more than 80% identity in their primary 
amino acid sequence and are coded by 3 distinct genes (PPP3CA, PPP3CB and PPP3CC, 
respectively). Each gene,  in turn,  undergoes alternative  splicing to  each give rise to three 
alternatively  spliced isoforms (reviewed in Korrodi-Gregório et al. 2014). Concerning PP4 and PP6 
they are structurally related to PP2A and are predicted to share around 65% and 57% identity 
respectively, at the amino acid sequence level when compared to PP2A. PP6 has 3 different isoforms 
derived by alternative splicing of the PPP6C gene. Of note PP5 and PP7 belong to this family since 
they contain the catalytic subunit common to the other family members. However, they have different 
N- and C-termini that are implicated in the targeting and regulation of enzymatic activity. PP5 is 
coded by one single gene (PPP5C) resulting in 2 isoforms, while PP7, also named protein 
phosphatase with EF-hand calcium-binding domain (PPEF) is coded by two genes (PPEF1 and 
PPEF2) resulting in 4 isoforms (reviewed in Korrodi-Gregório et al. 2014). PP1 has four isoforms: 
PP1α, PP1β/δ, PP1γ1 and PP1γ2 that are discussed in detail in the next section. Overall, several 
functions have been ascribed to PPP family members and those should not be exclusively attributed 
to the different catalytic subunits, their binding to regulatory proteins should also be considered 
(reviewed in da Cruz e Silva et al. 2004). 
 
I.1.3.1. Protein phosphatase 1 (PP1) 
PP1 is a major protein phosphatase present in eukaryotic organisms and is expected to catalyze the 
majority of protein dephosphorylation events (Bollen et al. 2010; Heroes et al. 2013). Interestingly, 
eukaryotic genomes contain multiple genes encoding PP1 isoforms with an exception for 
Saccharomyces cerevisiae that only contains one gene coding for PP1. PP1 isoforms are about 70% 
identical in the central region being mainly different at the N- and C-terminal sequences. 
Interestingly, PP1 has been indicated as one of the most conserved eukaryotic proteins. PP1 
sequences are highly conserved among species, as is the case of Giardia lamblia which expresses a 
PP1 isoform very similar to the mammalian form. Altogether these results suggest that PP1 might 
have similar functions in different organisms (Ceulemans and Bollen 2004; Lin et al. 1999). In 
mammals, PP1c is encoded by 3 separate genes PPP1CA, PPP1CB and PPP1CC, which originate 
PP1α, PP1β/δ and PP1γ, respectively (Figure I.2). Of note, alternative splicing events on each of the 
transcripts give rise to 3 PP1α isoforms, 2 PP1β/δ isoforms (both with the same coding sequence) 
and 2 PP1γ isoforms (Figure I.2). Particularly interesting is the case of PPP1CC gene that suffers 
tissue-specific splicing, giving rise to PP1γ1 isoform that is ubiquitous expressed and a testis-
enriched and sperm-specific, PP1γ2 (Figure I.2C). The main difference between these two PP1γ 
isoforms resides in the C-terminus (reviewed in Fardilha et al. 2010). 
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Figure I. 2 - Structure of the human PPP1C genes, and respective mRNAs and proteins. A- The human PPP1CA, 
located at chromosome position 11q13 contains 7 exons. Human PPP1CA transcripts variants differ only by an alternative 
splicing of exon 2 in transcript variant 2 or by an alternative in-frame splice site at the 5’ end of exon2 in transcript variant 
3. Human PP1α isoform 2 and 3 has the same N- and C-termini as isoform 1, however isoform 2 lacks an internal region 
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and isoform 3 is longer compared to isoform 1. B- The human PPP1CB, located at chromosome position 2p23 contains 8 
exons. C- The human PPP1CC, located at chromosome position 12q24.1-q24.2 contains 8 exons. Human PPP1CC 
transcript variant 2 is generated by alternative splicing of exon 7, which results in a longer testis-enriched and sperm-
specific PP1γ2 isoform with a distinct C-terminus compared to isoform 1. Coding exons are represented by a white line 
running across the boxes while non-coding sequences in exons are represented by opaque boxes. The in-frame ATG codons 
are indicated by arrows. 
 
PP1 holoenzymes are essentially composed of a highly conserved PP1 catalytic subunit (PP1c) that 
is associated with one or two variable regulatory subunits (also known as PP1 regulatory subunit, 
PP1R or PP1 interacting protein, PIP). The PIPs interact with PP1c through well characterized PP1 
docking motifs. So far, about ten distinct PP1 docking motifs were described, but certainly, more 
will be identified in a near future. These include RVxF, SILK, MyPhoNe, SpiDoC, RNYF, IDoHA, 
BiSTriP, AnkCap, NiHiP and the apoptotic signature (Boens et al. 2013; Ayllón et al. 2000) (Table 
I.1). Of note is that some of the binding motifs are often found in only one of the known PIPs, while 
others have been identified in several PIPs. For example, IDoHA motif only exists in inhibitor-2, 
while the RVxF motif is found in about 90% of all identified PIPs. Additionally, some PP1 binding 
motifs are isoform-specific and thereby specific holoenzymes are formed with only one PP1 isoform. 
The AnkCap motif consists of ankyrin repeats that bind especially to PP1β/δ (Terrak et al. 2004). 
Moreover, most PIPs contain several PP1 docking motifs in order to form a unique and stable 
complex with PP1 (Boens et al. 2013).   
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Table I. 1- PP1 docking motifs. PP1 docking motifs are presented, as well as, the specific sequence, the function, and 
other known characteristics. aa, amino acid; ND, not determined. 
PP1 
docking 
motif 
Consensus sequence Function Other characteristics References 
RVxF [RK]-X(0,1)-[VI]-{P}-
[FW] 
 
X(0,1) is any aa, present 
or absent; 
{P} represents any aa 
except P. 
PP1 
anchoring 
-Binds to a hydrophobic groove of the 
PP1c, which is opposite to the catalytic 
site 
-Binding through this motif does not 
affect PP1 conformation and activity  
(Egloff et al. 
1997; Wakula 
et al. 2003) 
SILK [GS –I–L–[RK] PP1 
anchoring 
- Binds to a hydrophobic groove of the 
PP1c, which is opposite to the catalytic 
site 
-N-terminally positioned to RVxF motif 
-Binding through this motif does not 
affect PP1 conformation  
(reviewed in 
Hendrickx et 
al. 2009; and 
in  Bollen et 
al. 2010) 
MyPhone R–X–X–Q-[VIL]-[KR]– 
X-[YW] 
 
X is any aa. 
Substrate 
selection 
-binds to a shallow hydrophobic cleft of 
PP1 
-N-terminally positioned to RVxF motif 
(reviewed in 
Bollen et al. 
2010) 
SpiDoC 8-residue motif Substrate 
selection 
-binds to the C-terminal groove of PP1 (reviewed in 
Heroes et al. 
2013; and in 
Boens et al. 
2013) 
RNYF R–N–Y-F -- - the binding sequence of the motif on 
PP1c is ND 
(Llanos et al. 
2011) 
IDoHA α-helix structure Inhibition -prevents access to the active site of PP1 
by binding the hydrophobic and acidic 
grooves of PP1  
(reviewed in 
Heroes et al. 
2013) 
BiSTriP Leucine-rich repeats -- - binds to the triangular region of PP1 
delineated by helices α4-6 
(reviewed in 
Ceulemans 
and Bollen 
2004a) 
AnkCap 8 ankyrin repeats Substrate 
selection 
- enclose the C-terminus of PP1β (reviewed in 
Heroes et al. 
2013) 
NiHip α-helix structure -- - binds to the PP1 bottom surface (reviewed in 
Boens et al. 
2013) 
Apoptotic 
signature 
F-X-X-[KR]-X-[KR] 
 
X is any aa. 
 
-- 
- the binding sequence of the motif on 
PP1c is ND 
-the motif is found in several proteins 
involved in the control of cell survival 
pathways 
(Godet et al. 
2010) 
 
 
 
 
MyPhone, Myosin Phosphatase N-terminal Element; SpiDoC, Spinophilin Docking site for the C-terminal groove; IDoHA, 
Inhibitor-2 Docking site for the Hydrophobic and Acidic grooves; BiSTriP, Bipartide docking site of the leucine-rich repeat 
protein SDS22 interacting  with a Triangular region that is delineated by helices α4-6 of PP1; AnkCap, Ankyrin repeat Cap; 
NiHip, NIPP1 Helix that interacts with PP1. 
 
To date, more than 200 PIPs are known and many more will certainly be identified in the future. PIPs 
confer specificity to PP1c by targeting it to a specific subcellular compartment, modulating its 
specificity, inhibiting its catalytic activity, or serving as substrates. According to this, PIPs can be  
categorized as targeting subunits, substrate-specifier subunits (s-s subunits), inhibitory subunits and 
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substrates (Figure I.3) (reviewed in Bollen et al. 2009; in Bollen et al. 2010; and in Rebelo et al. 
2015). However, for most PIPs, the physiological relevance of their binding to PP1 is not known. 
 
 
 
Figure I. 3 - Schematic representation of the PP1 holoenzyme structure. The protein phosphatase 1 catalytic subunit 
(PP1c) interacts with regulatory subunits that can be targeting proteins (A), substrate-specifiers (B), inhibitors of the 
catalytic activity (C) or substrates (D). 
 
Some specific PP1 binding proteins target PP1 to either a specific subcellular compartment or to a 
protein complex. For example, spinophilin directs PP1 to dendritic spines in the brain, near to 
potential substrates, mediating the regulation of PP1 synaptic function (Allen et al. 1997). 
Additionally, other PP1 complexes have been identified, as is the case of APP:Fe65:PP1, where Fe65 
is the scaffolding protein responsible for the bridging between PP1 and the Alzheimer’s amyloid 
precursor protein (APP), being the latter dephosphorylated, apparently by PP1 (Rebelo et al. 2013). 
Phosphatase 1 nuclear targeting subunit (PNUTS) is a PP1 targeting subunit and recently the C-
terminal domain (CTD) of RNAPII was described as the first substrate of the PNUTS:PP1 complex. 
Many substrates that directly associate with PP1c are enzymes that are activated by 
dephosphorylation, as is the case for focal adhesion kinase, E3 ubiquitin ligase and caspase 2 
(reviewed in Bollen et al. 2010). Some substrates are dephosphorylated specifically on a single 
residue, whereas others are dephosphorylated on multiple residues. Recently, Lamina-associated 
protein 1 (LAP1), BRI2 and BRI3 were added to the list of PP1 substrates (Santos et al. 2013; Martins 
et al. 2016a). Some PIPS are substrate specifiers since they enhance PP1 activity towards PP1 
substrates, as is the case of myosin phosphatase targeting subunit 1 (MYPT1). Interaction of the later 
protein with PP1 not only promotes the dephosphorylation of the myosin regulatory light chain but 
also decreases PP1 activity towards other substrates. PP1 inhibitors, are capable of blocking the PP1 
active site and inhibit the dephosphorylation of all substrates. Inhibitor-1, DARPP-32 (dopamine and 
cAMP-regulated phosphoprotein), inhibitor-2 and inhibitor-3 are potent PP1c inhibitors (reviewed 
in Bollen et al. 2010; and in Ceulemans and Bollen 2004a). 
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I.1.3.1.1. PP1 isoforms expression 
All three PP1 isoforms (PP1α, PP1β and PP1γ1) are ubiquitously expressed in mammalian tissues, 
PP1α is particularly enriched in brain and heart, PP1β in the brain, small intestine, muscle and lung 
and PP1γ1 in the brain, heart and skeletal muscle. Regarding PP1γ2 it is now well accepted that is 
highly enriched in testis, presenting only low expression in brain (Aoyama et al. 2011; da Cruz e 
Silva et al. 1995; Lüss et al. 2000; Ouimet et al. 1995; Strack et al. 1999) (Table I.2). All PP1 
isoforms are differentially distributed in the brain and PP1α and PP1γ1 isoforms present the highest 
expression levels. From all brain tissues, PP1α and PP1γ1 were found to be greatly expressed in the 
striatum (da Cruz e Silva et al. 1995) (Table I.2). PP1γ2 is homogeneously expressed in most 
forebrain regions but particularly enriched in the striatum. However, lower levels were observed in 
hindbrain and cerebellum. PP1β levels were quite similar in all forebrain regions analyzed and lower 
in the hindbrain and cerebellum (Strack et al. 1999) (Table I.2). Using in situ hybridization it was 
established that PP1α, PP1β and PP1γ1 genes were widely expressed throughout the rat brain. Broad 
cortical distribution was observed, but their mRNAs were particularly abundant in hippocampus and 
cerebellum. All three PP1 isoforms were found in the striatum, however, a lower signal was observed 
for PP1β compared to PP1α and PP1γ. From the three PP1 isoforms, only PP1β and PP1γ1 presented 
significant expression levels in the midbrain (da Cruz e Silva et al. 1995). Further, using RT-PCR 
and Northern blot techniques it was shown that all three PP1 isoforms are expressed in human 
muscular tissues (heart and skeletal muscle). The expression levels of PP1α, PP1β and PP1γ were 
higher in right ventricles than in right atria (Lüss et al. 2000) (Table I.2). Additional microarray 
studies using failing human hearts revealed that PP1α and PP1γ mRNAs were downregulated, while 
the mRNA for PP1β was upregulated in end-stage of dilated cardiomyopathy (Paul and Jozef 2004). 
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Table I. 2 - Tissue expression and subcellular distribution of the PP1 isoforms  PP1 isoforms’ tissue expression, as 
well as subcellular localization is presented. 
Gene 
name 
PP1 
catalytic 
isoform 
Tissue 
expression 
Subcellular localization   References 
PPP1CA PP1α 
Ubiquitous; 
enriched in 
brain and heart 
- Cytoplasm (centrosomes) and nucleus 
(nuclear matrix and nucleoplasm) - During mitosis is in the centrosomes 
and kinetochores - In neurons is localized at dendritic 
spines, perikaryal cytoplasm and 
nucleus - Present in spermatozoa 
da Cruz e Silva et 
al. 1995; Aoyama et 
al. 2011; 
Lüss et al. 2000; 
Ouimet et al. 1995; 
Strack et al. 1999; 
Korrodi-Gregório et 
al. 2014; 
Trinkle-Mulcahy et 
al. 2003; 
Santos et al. 2012 
PPP1CB PP1β 
Ubiquitous; 
enriched in 
brain, small 
intestine, 
muscle and lung 
- Cytoplasm and nucleus (nucleoplasm 
and nucleolus) - During mitosis is associated with 
chromosomes - In neurons is localized in cell soma and 
associated with microtubules - In spermatozoa is in sperm head and 
tail 
da Cruz e Silva et 
al. 1995; Aoyama et 
al. 2011; Korrodi-
Gregório et al. 
2014; 
Strack et al. 1999; 
Trinkle-Mulcahy et 
al. 2003 
PPP1CC 
 
PP1γ1 
Ubiquitous; 
enriched in 
brain, heart and 
skeletal muscle 
- Cytoplasm and nucleus (nucleolus) - During mitosis is in the kinetochores 
and associated with chromatin - In neurons is localized in dendritic 
spines, pre-synaptic terminals and 
associated with actin cytoskeleton 
da Cruz e Silva et 
al. 1995; Ouimet et 
al. 1995; Trinkle-
Mulcahy et al. 
2003; 
Santos et al. 2012; 
Strack et al. 1999 
PP1γ2 
Highly enriched 
in testis; low 
levels of 
expression in 
brain 
- In spermatozoa, is present in the 
posterior region and equatorial segment 
of sperm head and more predominantly 
at the tail 
da Cruz e Silva et 
al. 1995; Fardilha et 
al. 2011; Korrodi-
Gregório et al. 2014 
 
I.1.3.1.2. PP1 isoforms cellular and subcellular localization 
Interestingly, all PP1 isoforms are present in all mammalian cells analyzed but their localization 
within those cells is surprisingly different and specific. During interphase, all PP1 isoforms are 
present both in cytoplasm and nucleus (Table I.2). Within the nucleus PP1α is found associated with 
the nuclear matrix, PP1β localizes to non-nucleolar whole chromatin and PP1γ1 concentrates in 
nucleoli in association with RNA. Further, using the transient expression of PP1 fused with 
fluorescent proteins (FP) it was established that FP-PP1α is mainly found in a diffuse nucleoplasmic 
pool and largely excluded from the nucleolus. PP1γ accumulates predominantly in the nucleolus and 
PP1β is found in both nucleoplasm and nucleolus but its accumulation in the nucleolus is different 
to that observed for PP1γ (Trinkle-Mulcahy et al., 2003). Furthermore, it is known that PP1 plays a 
key role in mitosis where PP1 isoforms are differentially targeted to specific subcellular structures 
(Table I.2). Essentially during mitosis PP1α and PP1γ are distributed throughout the cell excluding 
the chromosomal area and are also in the mitotic spindle and mid-body. PP1α is also localized to the 
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centrosome, and PP1β strongly associates with chromosomes (Santos et al. 2012; Andreassen et al. 
1998; Trinkle-Mulcahy et al. 2003). Given that PP1α and PP1γ1 isoforms were found particularly 
enriched in medium-sized spiny neurons of the striatum (da Cruz e Silva et al. 1995) the subcellular 
localization of those isoforms in neuronal cells is of particular interest (see Table I.2). Furthermore, 
the PP1γ2 isoform is highly enriched in testis where it is localized at the cytoplasm and nucleus of 
secondary spermatocytes, round spermatids, as well as elongating spermatids, and testicular and 
epididymal spermatozoa (Table I.2). However, all PP1 isoforms are expressed in mammalian testis 
where PP1γ1 is mainly observed in the cytoplasm of interstitial cells, spermatogonia and preleptotene 
spermatocytes, and PP1α in the cytoplasm of Leydig and peritubular cells, spermatogonia, and 
preleptotene spermatocytes (Table I.2). In spermatozoa, only PP1α, PP1β and PP1γ2 were present, 
being the latter more abundant and present in sperm head and more predominantly at the tail (Fardilha 
et al. 2011; Korrodi-Gregório et al. 2014) (Table I.2). 
 
I.1.4. PP1 function  
PP1 has been associated with a variety of cellular functions including glycogen metabolism, 
transcription, protein synthesis, cell cycle, meiosis, and apoptosis. It is known that when nutrients 
are abundant PP1 stimulates glycogen synthesis and also enables the return to the basal state of 
protein synthesis, recycling the transcription factors. PP1 is also important for regulating nuclear 
events, particularly transcription and mRNA processing and cell cycle (interphase and mitosis) 
through association with specific nuclear regulatory proteins (Figure I.4) (reviewed in Rebelo et al. 
2015). Additionally, PP1 can promote apoptosis when cells are subjected to DNA damage. PP1 has 
also been involved in additional cellular processes namely neurotransmission, neurite outgrowth, 
synapse formation (reviewed in Ceulemans and Bollen 2004; and in Cohen 2002) and 
spermatogenesis and sperm motility (reviewed in Han et al.; in Fardilha et al. 2011; and in Silva et 
al. 2014) (Fig. I.4). 
Chapter I  General Introduction 
 
 
28                                                     Functional characterization of novel BRI2 and BRI3 complexes 
 
Figure I. 4 - Diagram of PP1 functions. Examples of PIPs, which together with PP1c have been associated with a 
variety of cellular functions. PIP, PP1 interacting protein; NrbI, neurabin-I; NrBII, neurabin-II. 
 
I.1.4.1. PP1 function in the nucleus 
Protein phosphorylation is a crucial regulatory mechanism involved in key nuclear events, namely 
gene transcription, mRNA processing, cell survival and cell cycle (reviewed in Rebelo et al. 2015). 
PP1, is enriched in the nucleus, and its localization is highly dynamic and changes throughout 
mitosis. The nuclear PP1 binding proteins associated with transcription include PNUTS, RNAPII 
CTD, HDAC1, CREB, Hox11, HCF1, MEF2, SARP1, SARP2, PITK and hnRNP K. From these, the 
transcription factor CREB mediates the expression of cAMP-induced genes. Moreover, when it is 
dephosphorylated at Ser133 by PP1, the c-AMP gene transcription is attenuated (reviewed in Rebelo 
et al. 2015). 
Several reports have already suggested that PP1 activity is required for pre-mRNA splicing. Indeed, 
PNUTS and nuclear inhibitor of protein phosphatase 1 (NIPP1), the most abundant nuclear PIPs, 
bind to RNA and are involved in the regulation of pre-mRNA splicing. For example, PNUTS was 
shown to inhibit the phosphatase activity of PP1γ and PP1α in vitro, and anchors PP1 to specific 
RNA-associated complexes. Moreover, PNUTS interacts with RNA polymerase II (RNAPII) at 
active sites of transcription. PNUTS:PP1 holoenzyme is capable of enhancing the dephosphorylation 
of RNAPII C-terminal domain which suggests that this complex is also important for gene 
transcription regulation (reviewed in Rebelo et al. 2015).  
The following list of nuclear PIPS are the ones involved in mRNA processing, specifically NIPP1, 
CDC5L, SAP155, P54nrb, PSF, Tra2-beta1 and SIPP1. From these proteins NIPP1 has a 
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nucleoplasmic distribution and also accumulates in nuclear speckles where it binds to pre-mRNA 
splicing factors. Further, NIPP mediates the interaction between PP1 and CDC5L (a regulator of pre-
RNA splicing). It has been suggested that CDC5L and PP1:NIPP1 complex may be involved in the 
splice reaction and in the spliceosome disassembly (reviewed in Rebelo et al. 2015). 
A role for PP1 in controlling cell cycle progression is supported by the existence of multiple 
substrates for PP1 in all phases of the cell cycle and by the evidence supporting that PP1 is targeted 
to some mitotic structures such as chromosomes, centrosomes and spindle apparatus. In fact, some 
PP1 complexes are involved in the regulation of numerous cellular architecture changes namely 
chromosome condensation, nuclear envelope disassembly, spindle formation and chromosome 
segregation (reviewed in Rebelo et al. 2015). PP1 is also suggested to be involved in centrosome 
maturation (G2 phase), a process characterized by recruitment of γ-tubulin and other proteins that 
function as nucleation sites for microtubules, by dephosphorylating and activating BRCA1 protein. 
PP1 controls the entry into mitosis by regulating the activity of mitotic kinases. Indeed, activation of 
Cdk1, by Cdc25B and Cdc25C dephosphorylation, in association with the cyclins is a key molecular 
indicator for entry into mitosis. Interestingly, Cdc25 activation is achieved by dephosphorylation 
mediated by PP1, further resulting in the activation of Cdk1 and consequently in the transition 
between G2/M phase (reviewed in Rebelo et al. 2015). 
PP1 may prevent premature splitting of centrosomes, by inactivating some kinases involved in this 
process, namely Aurora A and Nek2A (reviewed in Rebelo et al. 2015). Moreover, after the proper 
separation of centrosomes, they should be correctly positioned near the outer nuclear membrane. 
Nuclear envelope (NE) proteins, namely LAP1 and emerin, are crucial in this process. However, 
LAP1 is not only crucial for centrosome positioning near the NE, but also its depletion results in a 
decrease of mitotic cells and in the levels of acetylated α-tubulin and lamin B1. In addition, LAP1 
activity is regulated by PP1 dephosphorylation at residues Ser306 and Ser310 (Santos et al. 2014b; 
Santos et al. 2014a).  
Additionally, PP1 activity is involved in the maintenance of microtubules-kinetochores attachment 
and spindle assembly checkpoint (SAC) which are crucial for accurate chromosome separation. For 
example, PP1 stabilizes correct microtubule-kinetochore attachment during metaphase by reversing 
the activity of Aurora B, a kinase that phosphorylates numerous proteins involved in the 
destabilization of microtubules-kinetochores binding. Protein phosphatases, namely PP1, are 
required for the mitotic exit which is characterized by mitotic spindle breakdown, chromosome 
decondensation, and reassembly of interphase structures such as the NE.  For example, PP1 and its 
regulatory subunit, Repo-man (recruits PP1 to chromatin at anaphase), are required for chromosome 
decondensation. At the end of mitosis, PP1/Repo-man complex is responsible for histone H3 
dephosphorylation that seems to be correlated with chromosome decondensation. Furthermore, PP1 
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is involved in nuclear envelope reassembly by dephosphorylating lamin-B, a component of the 
nuclear lamina that is phosphorylated at the onset of mitosis leading to nuclear lamina disassembly. 
At the end of mitosis, PP1 is targeted to lamin-B by AKAP149 resulting in reassembly of the nuclear 
lamina (reviewed in Rebelo et al. 2015). Given the presence of PP1γ in the cleavage furrow and 
spindle zone at the end of mitosis and in the center of the midbody during cytokinesis, it has been 
suggested that PP1 may have a role in cytokinesis regulation, however, the precise mode of action 
remains elusive (reviewed in Rebelo et al. 2015).  
 
I.1.4.2. PP1 regulation of neuronal functions  
Protein phosphorylation plays an important and critical role in many aspects of neuronal function, 
namely in neurotransmission, synaptic plasticity, and neurite outgrowth.  In fact, dopamine-regulated 
signaling pathways involving the DARPP-32 and PP1 in the brain, are well documented (reviewed 
in Greengard et al. 1999). Briefly, the neurotransmitter dopamine has an excitatory effect on 
striatonigral neurons expressing D1 receptors, and causes activation of PKA and phosphorylation of 
DARPP-32 on Thr34, leading to PP1 inhibition. In a sharp contrast, striatopallidal neurons 
expressing D2 receptors are inhibited by dopamine, restoring PP1 activity by inhibiting PKA or by 
mediating the dephosphorylation of DARPP-32 by the Ca2+/calmodulin-dependent PP2B. Other 
neurotransmitters could also affect the DARP-32/PP1 pathway. For instance, glutamate binding to 
N-methyl-D-aspartate (NMDA) receptors, stimulates DARPP-32 dephosphorylation by PP2B due to 
the Ca2+ influx. In contrast, the activation of adenosine A2 receptors activates PKA leading to 
DARPP-32 phosphorylation and inhibition of PP1c (reviewed in Greengard et al. 1999). 
Of particular relevance, PP1 has been identified as a key regulator of synaptic plasticity in both long-
term depression (LTD) and long-term potentiation (LTP). PP1 is activated during LTD, whereas 
inhibition of PP1 has been suggested to take place during LTP (Blitzer et al. 1998; Mulkey et al. 
1994). In fact, LTD-inducing stimuli promote the targeting of PP1 to dendritic spines, where it can 
dephosphorylate specific substrates, such as calcium/calmodulin-dependent protein kinase II 
(CaMKII), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and NMDA receptors 
(Mulkey et al. 1994). On the other hand, LTP-inducing stimuli lead to cAMP-dependent 
phosphorylation of the inhibitor-1 resulting in decreased PP1 activity. Consequently, an increase in 
the phosphorylation level of CaMKII at Thr286 is observed and also an increase in its activity, which 
phosphorylates the AMPA receptor subunits and potentiates synaptic current (Soderling and Derkach 
2000). PP1 also binds yotiao, a protein member of the AKAP family. Yotiao functions as a scaffold 
protein that attaches PP1 and PKA to NMDA receptors to regulate channel activity (Westphal et al. 
1999).  
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Protein phosphorylation also plays a dynamic role in regulating the extension and branching of 
neurites in growing neurons in response to specific guidance cues. Indeed, PP1, alongside with PP2A, 
were reported to have a role in the neurite structure. Inhibition of PP1 and PP2A in cultured 
hippocampal neurons leads to decrease number and length of neurites and synapse loss (Malchiodi-
Albedi et al. 1997). Additionally, another study showed that general inhibition of all PP1 isoforms 
in hippocampal neurons, using lower concentrations of tautomycin, reduced neuritis length and 
branching. Further, it was suggested that PP1 is responsible for the focal adhesion kinase (FAK) 
targeting, during growth cone advance and adhesion, in the earlier stages of outgrowth. Indeed, PP1 
could stimulate FAK activity promoting actin polymerization and growth cone movement (Monroe 
and Heathcote 2013).  
Recently it was demonstrated that BRI2 protein is a novel PP1 substrate. It was shown that the 
interaction is mediated through a RVxF motif, specifically 3RVTF6. By using BRI2 PP1 binding 
motif mutant constructs, where the BRI2:PP1 interaction is diminished (Myc-BRI2 KVTA) or 
abolished (Myc-BRI2 KATA), it was possible to observe a dramatic increase in BRI2 
phosphorylation levels. Moreover, when BRI2:PP1 interaction was abolished a phenotype consistent 
with neurite outgrowth and neuronal differentiation was observed (Martins et al. 2016a; Martins et 
al. 2016b). 
 
I.1.4.3. PP1 in cytoskeletal organization 
Cytoskeleton organization and dynamics is controlled by signaling pathways that clearly involve 
protein phosphorylation, namely PP1 and some of its regulatory subunits. Two families of PP1 
regulatory subunits, neurabins and MYPTs, are involved in actin and actomyosin reorganization.  
Neurabin-I and spinophilin (also called neurabin-II) in response to physiological signals, are able to 
target signaling proteins, such as PP1, to the actin cytoskeleton in order to control cell morphology. 
Neurabin-I is a neural-specific actin-binding protein highly enriched in both dendritic spines and 
growth cones and its expression is important to support neurite formation (McAvoy et al. 1999; 
Oliver et al. 2002). In fact, neurabin-I targets PP1 to actin-rich structures, such as postsynaptic 
density to promote the formation of filopodia as well as the maturation of dendritic spines, suggesting 
a significant role in spine morphogenesis. Additionally, PP1/Neurabin-I complex regulates the 
trafficking of AMPA receptors to the synaptic membrane and therefore modulates synaptic 
transmission (Hu et al. 2006). Neurabin-I is phosphorylated near the PP1-binding motif at Ser461 by 
PKA which results in a dramatic reduction of PP1 affinity (Oliver et al. 2002). Spinophilin is a 
ubiquitously expressed actin-binding protein that targets PP1 to the dendritic spine compartment, 
where it associates with the actin-rich cytoskeletal structure known as the postsynaptic density (PSD) 
(Ragusa et al. 2011). In the PSD, the complex PP1:spinophilin regulates actin cytoskeleton 
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organization and spine density by targeting PP1 to several substrates in dendritic spines (such as 
AMPA and NMDA receptors), controlling their phosphorylation (Feng et al. 2000; Ragusa et al. 
2011). Blocking the spinophilin:PP1 complex formation prevents PP1-mediated dephosphorylation 
of the AMPA receptors, decreasing the rundown of AMPA currents and increasing the latter’s 
activity (Yan et al. 1999). Spinophilin knockout mice exhibited a marked increase in spine density 
during development and altered filopodia formation, suggesting it functions as a negative regulator 
of spine morphogenesis. PKA also phosphorylates spinophilin but at Ser94 residue reducing its 
interaction with F-actin, displacing spinophilin from the PSD to the cytosol, which may ultimately 
serve to control PP1-mediated changes in the actin cytoskeleton or PP1 anchoring to receptors 
(Hsieh-Wilson et al. 2003).  
Protein phosphorylation of myosin II regulatory light chain subunit (myosin II LC) regulates the 
contraction of actomyosin fibers which are responsible for several cellular functions, namely smooth 
muscle contraction, cell shape change and cell motility. Phosphorylation of myosin II LC relieves 
their inhibitory action on the contraction of actomyosin fibers, whereas its dephosphorylation favors 
the relaxation of those fibers (Ceulemans and Bollen 2004). Briefly, the phosphorylation of myosin 
II LC enables the interaction of myosin II with actin filaments converting the chemical energy of 
ATP into mechanical force or movement. Several kinases are responsible for myosin II LC 
phosphorylation, nonetheless, the most predominant is the Ca2+/calmodulin myosin light chain kinase 
(MLCK). On the other hand, dephosphorylation of myosin II LC is catalyzed by a myosin light chain 
phosphatases (MLCP) that is composed by PP1β in complex with a myosin phosphatase targeting 
(MYPT) subunit. Therefore, MYPTs are PIPs that confers substrate specificity and subcellular 
localization to PP1β. MYPT subunit family consists of 5 different members, MYPT1, MYPT2, 
protein phosphatase 1 myosin binding subunit of 85 kDa (MBS85), MYPT3 and the TGF-β1-
inhibited, membrane-associated protein (TIMAP) (Grassie ME et al 2011), which possess different 
expression patterns. MYPT1 is ubiquitously expressed but highly enriched in smooth muscle cells 
where it is involved in contraction. Briefly, smooth muscle contraction is activated by a raise of the 
cytosolic Ca2+ concentration which results in the activation of MLCK mediated by calmodulin. 
Further, MLCK phosphorylates myosin II LC at Ser19 promoting the interaction of myosin II with 
actin resulting in the generation of a contractile force. Once this stimulus has stopped, cytosolic Ca2+ 
concentration returns to its basal levels and the myosin II LC is dephosphorylated by the MLCP. 
Therefore, actin and myosin II dissociates allowing for the relaxation of the muscle (Grassie et al. 
2011; reviewed in Ceulemans and Bollen 2004). In addition, the phosphorylation of myosin II LC is 
responsible for the formation of stress fibers that connect focal adhesions thus regulating cell shape, 
migration and adhesion (Xia et al. 2005). MYPT2 is expressed in striated muscles and in the brain, 
and both cardiac and skeletal muscle MLCPs consist of MYPT2 in complex with PP1β. However, in 
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the striated muscle contraction, the phosphorylation of myosin II LC is not a requirement but affects 
the speed and force of contraction (Grassie et al. 2011; reviewed in Ceulemans and Bollen 2004). At 
the postsynaptic density PP1 also binds to NF-L, a major component of the intermediate filament 
network in neurons. NF-L targets PP1 to neuronal membranes and cytoskeleton. Additionally, NF-
L:PP1 complex seems to control NF-L phosphorylation levels as well as other neurofilament 
proteins, thus regulating the neurofilament assembly (Terry-Lorenzo et al. 2000). Moreover, PP1 is 
associated with microtubule network organization and dynamics, namely by association with tau 
protein, a neuronal microtubule-associated protein (MAP). In fact, tau is a PP1 substrate and its 
dephosphorylation enhances its association with microtubules promoting their stability (Gong et al. 
1994; Liao et al. 1998). 
 
I.1.4.4. PP1 in spermatogenesis and sperm motility 
PP1 has been shown to be expressed in testis and/or in spermatozoa, suggesting an important role in 
spermatogenesis and spermatozoa physiology (reviewed in Han et al. 2007; in Fardilha et al. 2011; 
and in Silva et al. 2014). Indeed, Ppp1cc null male mice were shown to be infertile due to defective 
spermatogenesis and increased apoptosis of germ cells, leading to the absence of epididymal 
spermatozoa (reviewed in Han et al. 2007). Remarkably, some PIPs, namely testis/sperm-specific 
PIPs, have been identified. These include, for instance, the spermatogenic zip protein 1 (Spz1), a 
member of the basic helix-loop-helix family of transcription factors that specifically interact with 
PP1γ2.  Remarkably, Spz1 overexpression and PP1γ loss in the testis show similar phenotypes, 
namely increased apoptosis and spermatogenic cycle arrest, suggesting a functional association for 
both proteins (reviewed in Han et al. 2007). Recently, LAP1 was, for the first time, associated with 
the spermatogenesis. LAP1 was found expressed during nuclear elongation in spermiogenesis and 
was located at the centriolar pole of spermatids. LAP1 was found expressed during nuclear 
elongation in spermiogenesis and was located at the centriolar pole of spermatids. In addition, PP1γ2 
staining shares an extraordinary similar pattern to that observed for LAP1, due to their homogenous 
distribution in the cytoplasm at the posterior pole. Given that LAP1 and PP1 interact, and also that 
both proteins have important roles in mitosis, regulating MT dynamics, there is an additional putative 
significance for this complex in the spermatid elongation process (Serrano et al. 2016). 
As mentioned before, in sperm, PP1γ2 is present along the entire flagellum including the mid-piece, 
consistent with a role in sperm motility, but it is also found in the posterior and equatorial regions of 
the head, suggesting a role in the acrosome reaction. Several proteins have been implicated in the 
regulation of PP1γ2 activity during sperm maturation: inhibitor-2, sds22, inhibitor-3, 14-3-3 and 
AKAPs (Fardilha et al. 2011). Inhibitor-2 forms a stable complex with PP1, where PP1 is inactive. 
However, when inhibitor-2 is phosphorylated by GSK3, its inhibitory effect is relieved and PP1 
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becomes active. Thus, it is proposed that in the first segments of the epididymis the sperm is immotile 
because the PP1γ2:inhibitor-2 complex is activated by GSK3. In the last segment of the epididymis, 
the complex is inactive triggering sperm motility (Silva et al. 2014). AKAP4 is a major fibrous sheath 
protein located in the principal piece of spermatozoa that recruits PKA and facilitates local 
phosphorylation to regulate flagellum function (Han et al. 2007). In Akap4 knockout mice, 
spermatozoa lack motility and are infertile. Remarkably, the activity and phosphorylation of PP1γ2 
is significantly altered, suggesting a functional relationship between PP1 and AKAP4 in sperm 
motility (Han et al. 2007; Silva et al. 2014) 
 
I.1.5. Summary 
The major post-translational modification in eukaryotes is reversible protein phosphorylation, a key 
mechanism for signal transduction. Protein phosphatase 1 (PP1) is a ubiquitous serine/threonine 
phosphatase that belongs to the phosphoprotein phosphatase (PPP) superfamily and is responsible 
for about one-third of all the dephosphorylations that occur in the eukaryotic cell. In mammals, three 
PP1 isoforms (PP1α, PP1β/δ and PP1γ) exist that are coded by three different genes (PPP1CA, 
PPP1CB and PPP1CC, respectively). The PPP1CC gene undergoes tissue-specific splicing, giving 
rise to a ubiquitously expressed isoform, PP1γ1, and a testis-enriched and sperm-specific isoform, 
PP1γ2. The PP1 isoforms are expressed in virtually all tissues but exhibit different tissue expression 
and subcellular localization. Since its discovery, several roles have been attributed to PP1 in the 
regulation of several cellular functions, such as glycogen metabolism. In the nucleus, PP1 is involved 
in gene transcription, mRNA processing, cell survival and cell cycle regulation. Moreover, PP1 is 
important in cytoskeleton organization and regulates many aspects associated with 
neurotransmission, synaptic plasticity, neurite outgrowth, and spermatogenesis and sperm motility. 
This versatility of PP1 is determined by the binding of its catalytic subunit (PP1c) to different 
regulatory subunits, also known as PP1 interacting proteins (PIPs). PIPs are essential regulators that 
modulate PP1 cellular localization, substrate specificity and also activity. The binding of PIPs to PP1 
is mediated by conserved PP1 binding motifs and about 10 have already been described. To date, 
more than 200 PIPs were identified and in near the future several more will certainly be found, 
increasing the number of cellular processes involving PP1. 
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I.2. BRI gene family 
The BRI gene family comprises three members, BRI1/ITM2A, BRI2/ITM2B and BRI3/ITM2C, which 
encode three integral type II transmembrane glycoproteins: BRI1, BRI2 and BRI3, respectively. 
Homology searches of expressed sequence tag (EST) databases indicate that the three genes exists 
in humans, rat, mouse, chimpanzee, monkey, cow, chicken, rabbit, pig and horse, and also in non-
vertebrate animals, including flies and worms. The three genes are highly homologues in mouse and 
humans, with similar genomic organization. In fact, mouse BRI3 protein shares 92.9% amino acid 
sequence identity with the human protein. Together, these observations suggest that the BRI genes 
are part of an evolutionarily conserved gene family (Vidal et al. 2001; Rostagno et al. 2005). Several 
studies were carried out, and each of the human BRI gene family members were mapped by 
fluorescence in situ hybridization (FISH) to different human chromosomes: BRI1 gene is located in 
chromosome X (position Xq13.3 – Xq21.2; Pittois et al. 1999), BRI2 in the long arm of chromosome 
13 (position 13q14.3; Pittois et al. 1998; Vidal et al. 1999) and BRI3 in chromosome 2 (position 
2q37; Vidal et al. 2001). Their genomic organization in humans is similar and consists of six exons 
and five introns for BRI1 and BRI2 genes, and seven exons and six introns for BRI3 gene. The first 
intron is remarkably longer in comparison with the others and may contain regulatory sequences 
important for transcription (Pittois et al. 1999; Vidal et al. 2001; Rostagno et al. 2005). 
The Bri1 cDNA was first isolated from a cDNA library of organ cultures from prenatal mouse 
mandibular condyles (Deleersnijder et al. 1996). Database searches revealed that in human two 
alternatively spliced variants encoding different isoforms have been found for this gene: transcript 
variant 1 (GeneBank: NM_004867.4) and transcript variant 2 (GeneBank: NM_001171581.1). 
Transcript variant 1 represents the longest transcript and is identical to the first human BRI1 sequence 
reported in 1999 (Pittois et al. 1999). The transcript variant 2 results from the alternative splicing of 
exon 2. The complete Bri2 cDNA was isolated from a cDNA library of the osteogenic stromal cell 
line MN7 and the cDNA sequence of the human homolog (BRI2) was assembled using data from 
available human ESTs (Pittois et al. 1998). Database searches identified only one transcript 
(GenBank: NM_021999.4) that corresponds to the identified human BRI2 sequence. In a previous 
study, two mRNAs transcripts of BRI2 of 2.0 kb and 1.6 kb were identified by Northern blot analysis, 
however, only one specific DNA fragment was observed. So, the two mRNA transcripts may 
represent alternatively spliced or different polyadenylated isoforms (Vidal et al. 2004). Bri3 cDNA 
was first cloned from a 13.5-day mouse embryonic library in 2001 (Choi et al. 2001). Four alternative 
transcripts were identified using database searches: transcript variant 1 (GenBank: NM_030926.5) 
that represents the longest transcript; transcript variant 2 (GenBank: NM_001012516.2) that lacks 
the exon 4; transcript variant 3 (GenBank: NM_001012514.2) that lacks the exon 4; and transcript 
variant 4 (GenBank: NM_001287240.1) that differs in its 5' UTR and initiates translation from a 
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downstream start codon, compared to variant 1. Transcript variant 1 represents the longest and 
corresponds to the first human BRI3 sequence reported (Vidal et al. 2001). 
As mentioned above these three genes encode BRI1, BRI2 and BRI3 proteins that present 27% of 
amino acid identity (Figure I.5), being the pattern of expression quite different across the tissues. The 
members of this family possess an intracellular N-terminus, a single pass transmembrane domain, 
and an extracellular C-terminus. The three members also contain a furin cleavage site at the C-
terminus and a BRICHOS domain (Tai et al. 2014). 
 
 
 
Figure I. 5 - Amino acid sequence alignment of the three BRI proteins. BRI1 has 263 amino acids, BRI2 has 266 amino 
acids and BRI3 has 267 amino acids. The alignment was obtained using the bioinformatic tool clustal omega 
(http://www.ebi.ac.uk/Tools/msa/clustalo). (*) indicates amino acid identity, (:) indicates conservative amino acid change 
- between groups of strongly similar properties, (.) indicates semi-conservative amino acid change - between groups of 
weakly similar properties. 
 
The BRICHOS domain contains approximately 100 aa residues and is present in several proteins 
associated with dementia, chondrosarcoma, respiratory distress, and stomach cancer. The proteins 
that contain BRICHOS domain are predicted to be type II transmembrane or secretory proteins and 
have in common a complex post-translational processing. Its precise function is unknown, however, 
some roles have been proposed and include: targeting of the protein to the secretory pathway; 
chaperone-like function, preventing misfolding and peptide aggregation; and assisting the proper 
folding and processing of the proproteins (Sánchez-Pulido et al. 2002). 
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I.2.1. BRI1 protein 
The human BRI1, also denominated as ITM2A or E25A, is a 263-residue protein with a calculated 
molecular weight (MW) of 29.7 kDa and theoretical isoelectric point (pI) of 5.62 (Deleersnijder et 
al. 1996; Pittois et al. 1999). BRI1 contains a cytosolic N-terminal domain (1-53-aa) followed by a 
single transmembrane domain (54-74 aa) and a luminal C-terminal of 189 aa which contains the 
BRICHOS domain (133-227 aa) (Figure I.6).  
 
Figure I. 6 - Schematic representation of human BRI1 protein and its domains. Human BRI1 has a short N-terminal 
cytosolic domain, a long C-terminal luminal domain, one transmembrane domain (TM) and one BRICHOS domain. BRI1 
can be phosphorylated at threonine (T) residues and each residue phosphorylated is indicated. BRI1 can also be modified 
by ubiquitination (K) and N-glycosylation (N) at the sites indicated.   
 
BRI1 is expressed in several mesenchymal tissues, and was found to be most abundantly expressed 
in chondro- and osteogenic tissues: postnatal mandibular condyle, bone trabecula of mature bones, 
tooth germs and hair follicles, and strong expression in neonatal calvaria, paws, tail and skin 
(Deleersnijder et al. 1996; Pittois et al. 1999). BRI1 is also highly expressed in skeletal muscle, 
thymus and brain (Van den Plas and Merregaert 2004b; Van den Plas and Merregaert 2004a; 
Kirchner and Bevan 1999). Few studies have so far addressed the subcellular localization of BRI1. 
In a murine thymoma cell line, BRI1 appears to localize in large cytoplasmic vesicles, in the Golgi 
apparatus and also in the plasma membrane (Kirchner and Bevan 1999). In human uterine 
endometrial stoma sarcoma cells was also observed in the nuclei (Kihara et al. 2014). 
A putative furin cleavage site is present on BRI1 but it remains unknown whether cleavage occurs. 
Moreover, for BRI1 are suggested some post-translational modifications that may regulate its cellular 
location and physiological function. Bioinformatic analysis suggests one putative N-glycosylation 
site at Asn166 (Choi et al. 2001). More recently, by using high-throughput techniques three 
phosphorylation sites (Thr8, Thr10 and Thr112; Mertins et al. 2013; Weber et al. 2012) and four 
ubiquitination sites (Lys3, Lys14, Lys37 and Lys238) (Figure I.6) (Mertins et al. 2013; Kim et al. 
2011a; Udeshi et al. 2012) were identified, however its physiological relevance was not pursued. 
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I.2.1.1. BRI1 physiological function and associated proteins 
The cellular function of BRI1 is so far not characterized. However, some data suggests a possible 
involvement of BRI1 in cell differentiation during chondrogenesis, odontogenesis and myogenesis 
(Pittois et al. 1999; Van den Plas and Merregaert 2004b; Van den Plas and Merregaert 2004a; 
Kirchner and Bevan 1999; Kihara et al. 2014). BRI1 was found to interact with ameloblastin, 
homeobox protein MOX-2 and GTPase KRas which corroborates the involvement of BRI1 in the 
previously suggested functions (Table I.1). Recently it was described that BRI1 expression is 
regulated by PAX3, a transcriptional factor important for muscle and neural development in 
vertebrates (Lagha et al. 2013). 
In addition, a study by Kirchner et al revealed that BRI1 expression is enhanced during thymocyte 
selection and T-cell activation causing CD8 downregulation when overexpressed in CD4/CD8 
double-positive thymocytes (Kirchner and Bevan 1999). Given this and the fact that BRI1 expression 
is also regulated by GATA3, a T cell-specific transcription factor, BRI1 may also be involved in T-
cell development (Tai et al. 2014). BRI1 expression was also found to be dependent on the PKA-
CREB pathway, and by interacting and interfering with the function of vacuolar ATPase, negatively 
regulates autophagic flux (Namkoong et al. 2015). 
Furthermore, a recent report suggests a role for BRI1 as a cell cycle regulator, as its expression 
induces G2/M cell cycle arrest, being down-regulated during ovarian carcinogenesis (Nguyen et al. 
2016). This potential role for BRI1 is strengthened by the recently described interaction between 
BRI1 and Polyubiquitin-C, a protein involved in several processes namely in the G2/M transition of 
the cell cycle (Table I.3). 
 
Table I. 3 - List of the identified BRI1 interacting proteins. Information about the identified BRI1 interactors, as well 
as, the experimental evidence supporting the interactions. 
Interactor Description Experimental 
evidence 
References 
Ambn Ameloblastin Two-hybrid (Wang et al. 
2005) 
 
RNF2 E3 ubiquitin-protein ligase RING2 
 
Co-IP and affinity 
chromatography-
MS 
 
(Cao et al. 
2014) 
 
UBC Polyubiquitin-C affinity 
chromatography-
MS 
 
(Udeshi et al. 
2012; Kim et al. 
2011) 
MEOX2 Homeobox protein MOX-2 Two-hybrid (Rolland et al. 
2014) 
 
KRAS GTPase KRas Genetic interference (Luo et al. 
2009) 
 
Co-IP, co-immunoprecipitation; MS, mass spectrometry. 
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I.2.2. BRI2 protein 
BRI2, also denominated as ITM2B or E25B, is a type II transmembrane protein with 266 aa, a 
calculated MW of 30.3 kDa and theoretical pI of 4.86. However, the apparent MW of the BRI2 
protein (42-44 kDa) is higher than predicted from the number and composition of amino acids, 
suggesting that it suffers post-translational modifications. It contains nine cysteine residues and is 
highly rich in leucine (9.02%) and isoleucine (9.02%) (Vidal et al. 2000; Vidal et al. 1999). BRI2 
also contains a cytosolic N-terminal domain (1-54 aa) followed by a single transmembrane domain 
(55-75 aa) and a luminal C-terminal of 191-aa which contains the BRICHOS domain (137-231 aa) 
(Figure I.7). 
 
Figure I. 7 - Schematic representation of human BRI2 protein and its domains. Human BRI2 has a short N-terminal 
cytosolic domain, a long C-terminal luminal domain, one transmembrane domain (TM) and one BRICHOS domain. 
 
BRI2 is a ubiquitously expressed protein; mRNA transcripts are found to be highly expressed in the 
brain, placenta, pancreas, and kidney and presents lower expression levels in heart, lung, liver and 
skeletal muscle. In the brain, analysis of different regions detected predominantly the longer 
transcript in the cerebellum, spinal cord, subthalamic nucleus, substantia nigra, and hippocampus. 
However, lower expression levels were also detected in the cerebral cortex, amygdala, and thalamus 
(Vidal et al. 1999). In situ hybridization studies demonstrated that within the brain, BRI2 mRNA is 
distributed in different cellular populations: neurons, astrocytes, and microglial cells as well as in 
smooth muscle and cerebral endothelial cells (Rostagno et al. 2005). Further immunohistochemistry 
studies in postmortem human brain tissues, detected BRI2 as fine granules in the neuronal cytoplasm, 
as well as in proximal dendrites and axons. In CA3 and CA4 pyramidal neurons of the hippocampus 
and Purkinje cells of the cerebellar cortex, the BRI2 staining is particularly intense (Akiyama et al. 
2004). Additionally, BRI2 was detected in some pathological structures such as globular dystrophic 
neurites in senile plaques in Alzheimer s´ disease. Regarding the subcellular localization, BRI2 is 
mainly localized in the endoplasmic reticulum (ER), Golgi apparatus, plasma membrane and 
cytoplasmic vesicles (Choi et al. 2004). 
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I.2.2.1. BRI2 processing 
BRI2 undergoes regulated intramembrane proteolysis (RIP) in the cis- or medial-Golgi resulting in 
the formation of several secreted peptides (Choi et al. 2004). RIP describes the processing of several 
transmembrane proteins by an ectodomain shedding followed by an intramembrane cleavage. This 
processing is mainly involved in cellular signaling events and in the removal and degradation of 
membrane-retained fragments that are produced by the initial shedding event (Martin et al. 2008). 
First, in its extracellular region, BRI2 is cleaved between Arg243 and Glu244 to release a secreted 
C-terminal 23-residue peptide (3KDa; Figure I.8). The amino acid sequence that flanks this cleavage 
site (QKR243/E244A) is a consensus sequence required for processing by proprotein convertases 
(PPC). Several PPC's including furin, paired basic amino acid cleaving enzyme 4 (PACE4), 
lymphoma proprotein convertase (LPC) and proprotein convertase 5/6 (PC 5/6) are capable of 
processing BRI2. Of these BRI2 cleaving enzymes, furin appears to be the most effective (Choi et 
al. 2004; Kim et al. 1999). However, furin activity is mainly detected in the trans-Golgi and the BRI2 
processing occurs in the cis- or medial-Golgi (Choi et al. 2004), and so it remains unclear whether 
furin is the main BRI2-cleavage enzyme. The function of the released 23-aa peptide remains 
undisclosed however some reports suggest that the peptide may act as signal peptide, since the 
deletion of the C-terminal peptide leads to BRI2 retention in ER and consequently inefficient 
transport to the cell surface (Matsuda et al. 2011a).  
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Figure I. 8 - Schematic representation of BRI2 processing. BRI2 (immature BRI2 – imBRI2) is cleaved by a proprotein 
convertase, namely furin, to release a secreted C-terminal 23-residue peptide (BRI2 propeptide). The remaining membrane-
bound N-terminal fragment is the mature form of BRI2 (mBRI2). BRI2 undergoes an additional cleavage in its ectodomain 
exerted by ADAM -10 which results in the secretion of a soluble peptide containing the BRICHOS domain (BRI2 
BRICHOS) and in a membrane-bound N-terminal fragment (BRI2 NTF). The NTF is subsequently subjected to 
intramembrane proteolysis cleavage by the SPPL2/b, generating a small, secreted, BRI2 C-terminal peptide and an 
intracellular domain (BRI2ICD). 
 
The remaining membrane-bound N-terminal fragment is the mature form of BRI2 that undergoes an 
additional cleavage in its ectodomain exerted by ‘a disintegrin and metalloproteinase domain 10’ 
(ADAM-10) (Figure I.8) (Choi et al. 2004). ADAM10 is a α-secretase that cleaves several other 
transmembrane proteins, including APP, Notch-1 and N- and E-cadherin (Tsachaki et al. 2008). The 
precise cleavage site of ADAM10 in BRI2 remains unidentified, however, it is predicted to occur 
between amino acids 76 and 170 (Choi et al. 2004). ADAM10 processing of BRI2 results in secretion 
of a soluble peptide containing the BRICHOS domain (25KDa) and in a membrane-bound N-
terminal fragment (NTF; 22KDa) (Figure I.8). The secretion of the complete BRICHOS domain 
suggests a physiological function for this peptide. However, this function remains unclear. The NTF 
is subsequently subjected to intramembrane proteolysis cleavage by the signal peptidase-like 
proteases (SPPLs) SPPL2a and SPPL2b, generating a small, secreted, BRI2 C-terminal domain and 
an intracellular domain (BRI2ICD; 10KDa) (Figure I.8). SPPL2a/b are members of the family of 
intramembrane-cleaving aspartyl proteases of the GXGD-type that efficiently processes its substrates 
if their transmembrane domains adopt a β-strand-like conformation (Martin et al. 2008; Martin et al. 
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2009). A recent study suggests that a single glycine in the BRI2 transmembrane domain (Gly60) is 
a determinant of the secondary structure of the BRI2 transmembrane domain in lipid vesicles since 
it is essential for the destabilization of its α-helical structure and consequently for the cleavage 
efficiency of BRI2 by SPPL2a/b. Interestingly, BRI2 shedding by ADAM10 significantly facilitates 
the intramembrane cleavage by SPPL2a/b (Fluhrer et al. 2012). It was recently described that 
BRI2ICD can translocate to the nucleus following its proteolytic liberation suggesting a particular 
function for this fragment in signal transduction and transcriptional regulation as it has been 
described for the APP ICD (AICD) and Notch1 ICD (NICD) (Rebelo et al. 2013; Mentrup et al. 
2015; Artavanis-Tsakonas et al. 1999). Therefore, further research on BRI2 processing and its 
fragments may lead to new insights into the physiological role of BRI2. Of note, BRI2 processing 
by ADAM10 and SPPL2a/b seems to occur independently from furin processing (Martin et al. 2008). 
 
I.2.2.2. BRI2 post-translational modifications 
Moreover, during the maturation process in the cis-medial Golgi, BRI2 suffers post-translational 
modifications, such as glycosylation and phosphorylation, leading to various forms of BRI2 that may 
have different cellular locations and physiological functions (Akiyama et al. 2004; Lashley et al. 
2008; Del Campo and Teunissen 2014; Tsachaki et al. 2011). Several studies demonstrated that BRI2 
is N-glycosylated at Asn170 (Figure I.9). In fact, by using an N-glycosylation mutant (mutation of 
Asn170 to Ala) it was possible to conclude that N-glycosylation is essential for the proper trafficking 
of BRI2 through the secretory pathway to the cell surface (Tsachaki et al. 2011). Surprisingly, this 
mutation did not affect the proteolytic processing of BRI2 by furin or ADAM10 which suggests that 
cleavage by ADAM10 can also take place intracellularly. Interestingly, was described an interaction 
for BRI2 protein with the brain-specific membrane-anchored protein TMEM59L (Table I.2), a 
protein that modulates O- and N-glycosylation occurring during the Golgi maturation of APP (Ullrich 
et al. 2010). Therefore, it is possible that TMEM59L is also able to modulate the described N-
glycosylation of BRI2 protein and this deserve further elucidation. 
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Figure I. 9 - Human BRI2 post-translational modifications. BRI2 can be phosphorylated at numerous serine (S) and 
tyrosine (Y) residues, and each residue phosphorylated is indicated. BRI2 can also be modified by N-glycosylation (N) and 
ubiquitination (K) at the sites indicated. 
 
Additionally, bioinformatic analysis of the BRI2 sequence, suggests several putative phosphorylation 
sites, being only confirmed five phosphoresidues by high-throughput studies: Ser8, Ser22, Tyr76, 
Tyr112 and Tyr165 (Figure I.9) (Demirkan et al. 2011; Sharma et al. 2014a; Wilhelm et al. 2014). 
However, the physiological relevance of BRI2 phosphorylation remains unknown. Moreover, BRI2 
was found to be post-translationally modified by ubiquitination at the residues Lys3 and Lys13 
(Figure I.9) (Udeshi et al. 2012; Shi et al. 2011). Ubiquitination is an important regulatory 
mechanism for various cellular processes, including protein degradation, cell cycle and division, 
DNA repair, transcriptional regulation, differentiation and development, morphogenesis of neuronal 
networks, modulation of cell surface receptors, regulation of the immune and inflammatory 
responses, as well as for controlling stability and localization of proteins (Ciechanover 1994; 
Glickman and Ciechanover 2002).  
 
I.2.2.3. BRI2 physiological function and associated proteins 
The precise biological function of BRI2 remains elusive, however, given some hints proposed by 
previous studies, some BRI2 functions have been suggested. Besides, given the broad distribution, it 
is plausible to assume that BRI2 presents a wide-ranging function.  
The distribution of BRI2 within proximal dendrites and axons, as well as cell bodies, and its presence 
in some neuropathological structures suggests that BRI2 could be transported in nerve terminals and 
that it may have a role at the nerve terminals (Akiyama et al. 2004). In fact, it was demonstrated that 
BRI2 overexpression in human neuronal cells induces neurites elongation, indicating that BRI2 could 
be involved in neurite outgrowth (Choi et al. 2004). The already described interactions of BRI2 with 
the RYK receptor-like tyrosine kinase, Semaphorin-6A, heparan sulfate 6-O-sulfotransferase 1, 
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adhesion molecule with Ig-like domain 1 and leucine-rich repeat and fibronectin type-III domain-
containing protein 3 also supports the putative role BRI2 on neuronal differentiation and neurite 
growth (Table I.4; Berndt et al. 2011; Huttlin et al. 2015). 
BRI2 has a Bcl-2 homology-3 (BH-3) domain encoded in exon 2 characteristic of pro-apoptotic 
proteins of the Bcl-2 family. Interestingly, a short splice variant of BRI2 that lacks exon 1 seems to 
be up-regulated in a murine T cell line before the induction of apoptosis, suggesting that BRI2 could 
participate in the apoptotic pathway. Indeed, overexpression of the short variant of BRI2 in IL-2 
stimulated T cells and also in COS-7 cells induces apoptosis. The BH-3 domain mutation of this 
BRI2 variant abolished the ability of BRI2 to induce apoptosis, suggesting an important role for this 
domain in the BRI2 apoptotic activities. Moreover, BRI2 pro-apoptotic functions seem to be 
associated with the activation of a mitochondrial apoptotic pathway leading to cytochrome c release, 
and with caspase 3 and caspase 9 activation (Fleischer et al. 2002). 
Interestingly, the BRI2 gene is located in the chromosome segment 13q14 and the loss of 
heterozygosity (LOH) on chromosome arm 13q14.2-q14.3 is frequently observed in prostate tumors, 
ovarian carcinoma, head and neck squamous cell carcinoma and in pituitary tumors. In fact, by using 
a real-time quantitative RT-PCR assay, BRI2 expression was found to be significantly reduced in 
sporadic prostate tumors with a correlation with cancer stage and grade. Besides a positive 
association between the decreased BRI2 expression and LOH at 13q14.2 was described. Therefore, 
BRI2 has been suggested as a candidate to act as a tumor suppressor gene (Latil et al. 2003). 
Additionally, was already established an interaction for BRI2 with CREB3, an important signaling 
protein also involved in tumor suppression (Table I.4; Yu et al. 2011; Hein et al. 2015). 
Further studies demonstrated that BRI2 forms homodimers held by disulfide bonds, and the 
extracellular cysteine located at position 89 is involved. The BRI2 dimers seem to be formed in the 
ER and transferred to the cell membrane. Several transmembrane proteins that act as receptors form 
dimers at the cell surface, and thus it is possible to assume that BRI2 could act as a receptor or is a 
part of a receptor complex and participates in signal transduction pathways (Tsachaki et al. 2010). 
Additionally, a yeast two-hybrid screen using a human brain cDNA library as bait allowed the 
identification of proteins that interact with Alzheimer’s amyloid Precursor Protein (APP). This study 
identified BRI2 protein as novel APP binding protein (Table I.4; Fotinopoulou et al. 2005). The aa 
648-719 of APP751 and the aa 46-106 of BRI2, both inclusive of the full transmembrane domains, are 
responsible for the interaction. Therefore, it is possible that both proteins interact when are expressed 
on the same cell membrane, by forming a molecular complex, rather than on adjacent cells as 
receptor/ligand (Matsuda et al. 2005; Fotinopoulou et al. 2005). BRI2 interacts with both APP751 and 
APP695 isoforms, suggesting that the interaction is not APP isoform-dependent (Fotinopoulou et al. 
2005). Besides, only the mature forms of both BRI2 and APP interacts, and the interaction occurs at 
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the cell surface and in endocytic compartments (Matsuda et al. 2011a). BRI2-APP interaction is 
suggested to be a regulatory mechanism of APP processing that inhibits Aβ production (Matsuda et 
al. 2005). In the amyloidogenic pathway that produces Aβ, APP is firstly cleaved by β-secretase (β-
secretase β-amyloid protein converting enzyme 1, BACE1) to release a secreted fragment (sAPPβ) 
and to produce a membrane-bound C-terminal fragment. This fragment is subsequently subjected to 
regulated intramembrane proteolysis by γ-secretase to release extracellularly Aβ and intracellularly 
AICD. Matsuda and colleagues suggested that functionally BRI2 restrict docking of γ-secretase to 
APP and by masking the α- and β-secretase cleavage rather than affecting the secretase activity 
(Matsuda et al. 2008). However, a recent study demonstrates that in fact, BRI2 also interacts with 
BACE1 promoting its lysosomal degradation and also reducing its expression levels (Table I.4; 
Tsachaki et al. 2013). Besides a role in the processing of APP, BRI2 may also inhibit Aβ aggregation 
and several mechanisms have been proposed. Kim and colleagues demonstrated that the 23 aa C-
terminal peptide released by furin processing inhibits Aβ aggregation in vitro (Kim et al. 2008). 
Another study revealed that a BRI2 fragment (90-236 aa) that contains the BRICHOS domain also 
binds to Aβ peptide inhibiting its aggregation and fibril formation (Peng et al. 2010). More recently, 
it was reported that transgenic expression of the BRI2 BRICHOS domain in the Drosophila central 
nervous system efficiently inhibited Aβ42 toxicity (Poska et al. 2016). Furthermore, it was shown 
that BRI2 promotes Aβ degradation by increasing the levels of the secreted insulin-degrading enzyme 
(IDE), a metalloprotease that cleaves insulin and other peptide substrates (Kilger et al. 2011).  
Finally, was described an association between BRI2 and ADAM7, a member of the ADAM family 
that is specifically expressed in the epididymis. ADAM7/BRI2 complexes are present in membrane 
lipid rafts or microdomains at the sperm surface, and the formation of this complex is promoted 
during sperm capacitation suggesting a role for BRI2 in sperm functions and fertilization (Han et al. 
2011).Several other proteins were found to interact with BRI2 that may uncover potentially functions 
for BRI2 (Table I.4). 
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Table I. 4 – List of the identified BRI2 interacting proteins. Information about the identified BRI2 interactors, as well 
as, the experimental evidence supporting the interactions. 
Interactor Description Experimental 
evidence 
References 
APP Amyloid beta A4 protein Two-hybrid 
Co-IP 
(Matsuda et al. 2005; 
Fotinopoulou et al. 2005) 
 
BCL2 Apoptosis regulator Bcl-2 
(protein phosphatase 1, regulatory subunit 
50) 
Co-IP 
 
(Fleischer et al. 2002) 
 
 
BACE1 β-secretase β-amyloid protein converting 
enzyme 1 
Co-IP 
 
(Tsachaki et al. 2013) 
 
UBC Polyubiquitin-C Affinity 
Capture-MS 
(Danielsen et al. 2011; Shi et al. 
2011; Wagner et al. 2011; Kim et 
al. 2011; Oshikawa et al. 2012; 
Udeshi et al. 2012; Emanuele et 
al. 2011; Povlsen et al. 2012; 
Renaudin et al. 2014) 
 
RYK RYK receptor-like tyrosine kinase Affinity 
Capture-MS 
(Berndt et al. 2011) 
 
CREB3 Cyclic AMP-responsive element-binding 
protein 3 
Two-hybrid; 
Affinity 
Capture-MS 
(Yu et al. 2011; Hein et al. 2015) 
 
SEMA6A 
 
Semaphorin-6A Affinity 
Capture-MS 
(Huttlin et al. 2015) 
 
GLG1 
 
Cysteine-rich fibroblast growth factor 
receptor 
Affinity 
Capture-MS 
(Huttlin et al. 2015) 
 
PGAP1 
 
Post-GPI attachment to proteins factor 1 Affinity 
Capture-MS 
(Huttlin et al. 2015) 
 
CACNA2D1 
 
Dihydropyridine-sensitive L-type, calcium 
channel alpha-2/delta subunit 
Affinity 
Capture-MS 
(Huttlin et al. 2015) 
 
HS6ST1 
 
Heparan sulfate 6-O-sulfotransferase 1 Affinity 
Capture-MS 
(Huttlin et al. 2015) 
 
TGFBR3 
 
Transforming growth factor beta receptor 
type 3 
Affinity 
Capture-MS 
(Huttlin et al. 2015) 
 
AMIGO1 
 
Adhesion molecule with Ig-like domain 1 Affinity 
Capture-MS 
(Huttlin et al. 2015) 
 
KIAA1467 
 
Uncharacterized protein KIAA1467 Affinity 
Capture-MS 
(Huttlin et al. 2015) 
 
LRFN3 
 
Leucine-rich repeat and fibronectin type-III 
domain-containing protein 3 
Affinity 
Capture-MS 
(Huttlin et al. 2015) 
 
TMEM219 
 
Insulin-like growth factor binding protein-3 
receptor 
Affinity 
Capture-MS 
(Huttlin et al. 2015) 
B4GALNT1 
 
UDP-N-acetyl-alpha-D-galactosamine:(N-
acetylneuraminyl)-
galactosylglucosylceramide N-
acetylgalactosaminyltransferase (GalNAc-
T) 
 
Affinity 
Capture-MS 
(Huttlin et al. 2015) 
CHST12 
 
Carbohydrate (chondroitin 4) 
sulfotransferase 12 
Affinity 
Capture-MS 
(Huttlin et al. 2015) 
 
UBR1 
 
Ubiquitin protein ligase E3 component n-
recognin 1 
Affinity 
Capture-MS 
(Huttlin et al. 2015) 
 
HLA-A 
 
HLA class I histocompatibility antigen, A-1 
alpha chain 
Affinity 
Capture-MS 
(Huttlin et al. 2015) 
 
MR1 
 
Bajor histocompatibility complex class I-
related gene protein 
Affinity 
Capture-MS 
(Huttlin et al. 2015) 
 
ATF6B 
 
cAMP response element-binding protein-
related protein 
Affinity 
Capture-MS 
(Huttlin et al. 2015) 
 
SEMA4F 
 
Semaphorin-4F Affinity 
Capture-MS 
(Huttlin et al. 2015) 
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BTN2A2 
 
Butyrophilin, subfamily 2, member A2 Affinity 
Capture-MS 
(Huttlin et al. 2015) 
 
TMEM59L 
 
Brain-specific membrane-anchored protein 
(C19orf4) 
Affinity 
Capture-MS 
(Huttlin et al. 2015) 
UL25 Virion-packaging protein UL25 Two-hybrid 
 
(Zhang et al. 2011) 
 
CSF1 Macrophage colony-stimulating factor 1 Pull-down (Cross et al. 2005) 
 
ADAM7 Desintegrin and metalloproteinase domain-
containing protein 7 
Affinity 
Capture-MS 
(Han et al. 2011) 
 
SPPL2B Signal peptide peptidase-like 2B Co-IP (Martin et al. 2008) 
 
SPPL2A Signal peptide peptidase-like 2A Co-IP (Martin et al. 2008) 
 
FCGRT IgG receptor FcRn large subunit p51 Affinity 
Capture-MS 
(Huttlin et al. 2015) 
 
NEK2 Serine/threonine-protein kinase Nek2 Affinity 
Capture-MS 
(Hein et al. 2015) 
 
SHOC2 Leucine-rich repeat protein SHOC-2 Affinity 
Capture-MS 
(Hein et al. 2015) 
 
KIF18A Kinesin-like protein KIF18A Affinity 
Capture-MS 
(Hein et al. 2015) 
 
UNK RING finger protein unkempt homolog Affinity 
Capture-RNA 
(Murn et al. 2015) 
 
TMEM17 Transmembrane protein 17 Proximity 
Label-MS 
(Gupta et al. 2015) 
 
NAALADL2 Inactive N-acetylated-alpha-linked acidic 
dipeptidase-like protein 2 
Two-hybrid (Rolland et al. 2014) 
 
SYNE4 Nesprin-4 Two-hybrid (Rolland et al. 2014) 
 
CCDC155 Protein KASH5 Two-hybrid (Rolland et al. 2014) 
DCBLD2 Discoidin, CUB and LCCL domain-
containing protein 2 
Affinity 
Capture-MS 
(Huttlin et al. 2015) 
 
LMO2 Rhombotin-2 Two-hybrid (Sincennes et al. 2016) 
 
RPL31 60S ribosomal protein L31 Two-hybrid (Bell et al. 2009) 
 
HNF1A Hepatocyte nuclear factor 1-alpha Cross-linking 
study 
(Odom et al. 2004) 
 
ENV 
 
Envelope glycoprotein gp160 Affinity 
Capture-MS 
(Jäger et al. 2011) 
 
Co-IP, co-immunoprecipitation; MS, mass spectrometry. 
 
I.2.2.4. BRI2 associated diseases 
Familial British and Danish dementias (FBD and FDD, respectively), two rare early-onset forms of 
dementia, are associated with different autosomal dominant mutations in the BRI2 gene (ITM2B). 
These diseases share several clinical symptoms such as progressive cognitive impairment, cerebellar 
ataxia, and spasticity (Tsachaki et al. 2008). FBD was first described in 1933 by Worster-Drought 
and the age of onset is in the fourth and fifth decade of life (Worster-Drought et al. 1933; Mead et 
al. 2000; Plant et al. 1990). The majority of affected patients succumb in the sixth decade of life. 
Clinical symptoms include progressive dementia, spastic tetraparesis and cerebellar ataxia (Plant et 
al. 1990; Mead et al. 2000). Neuropathological studies of FBD revealed the presence of pre-amyloid 
(non-fibrillar) and amyloid parenchymal lesions in the brain (primarily localized to the hippocampus 
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and cerebellum), extensive cerebral amyloid angiopathy (CAA) and intraneuronal formation of 
neurofibrillary tangles (NFT) within the limbic regions (Plant et al. 1990; Revesz et al. 1999). FDD 
was first identified in 1970 by Stromgren and collaborators in a Danish kindred and clinically is 
characterized by the development and progression of cataracts during the second decade of life 
(Strömgren et al. 1970; Vidal et al. 2000). Later on the patients develop deafness, cerebellar ataxia, 
paranoid psychosis and progressive dementia. The majority of patients succumb within the fifth or 
sixth decade of life (Strömgren et al. 1970; Vidal et al. 2000). Neuropathological lesions in FDD 
patients are closely similar to those found in FBD, however in FDD was found Aβ deposition and 
co-deposition with the Danish amyloid in all patients with FDD, and parenchymal compact plaques 
are absent (Holton et al. 2002; Vidal et al. 2000). In addition, activation of the proinflammatory 
complement system, which are among the features characteristic of AD, have also been associated 
with FBD and FDD (Rostagno et al. 2005). In FBD, a point mutation in the stop codon of the BRI2 
gene generates a longer open reading frame, resulting in the production of a longer 277 residues 
BRI2 precursor protein (ABriPP) (Figure I.10) (Ghiso et al. 2000). In FDD, there is a 10 nucleotide 
duplication insertion (TTTAATTTGT) between codons 265 and 266, resulting in the production of 
a mutated BRI2 precursor protein (ADanPP) that is also 11 amino acids longer (Figure I.10) (Vidal 
et al. 2000). 
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Figure I. 10 - Schematic representation of the BRI2 protein and its mutated forms, ABriPP and ADanPP, and the 
amyloid peptides in patients affected with FBD and FDD. The BRI2 gene encodes a type II transmembrane protein with 
266 amino acids, BRI2. In FBD, a point mutation at codon 267 in BRI2 gene (Stop ÆArg) originate a longer precursor 
protein, ABriPP, with 277 amino acids. Furin proteolytically processes ABriPP generating the ABri peptide (34 amino 
acids long) which composes the amyloid deposits in FBD. In FDD, a ten nucleotide duplication (TTTAATTTGT) after 
codon 265 in BRI2 gene originate a longer precursor protein, ADanPP, with 277 amino acids. Furin proteolytically 
processes ADanPP generating the ADan peptide (34 amino acids long) which composes the amyloid deposits in FDD. 
Although originated by different genetic defects in the BRI gene, both mutated precursors have 277 amino acids. Both 
amyloids (ABri and ADan) have an identical N-terminal amino acid sequence (first 22 amino acids) and a completely 
different C-terminal sequence (last 12 amino acids). FBD, familial British dementia; FDD, familial Danish dementia; aa, 
amino acid. 
 
Mutated BRI2 proteins undergo furin-like proteolytic processing at the same site as wild-type BRI2 
which results in the release of the 34-aa C-terminal secreted peptides (4KDa), ABri and ADan, in the 
case of FBD and FDD, respectively (Figure I.10). In fact, it was reported that the expression of the 
mutant BRI2 proteins in a neuronal cell line, produced more peptide than those transfected with the 
wild type, indicating that the C-terminal extension enhances PCs proteolysis (Choi et al. 2004). On 
the contrary, a more recent study reported that the cleavage of BRI2 by PCs is more efficient for the 
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wild-type BRI2 than for mutant BRI2 (both FBD and FDD mutants) since the mutant sequences may 
interfere both with the proper folding of BRI2 and the enzymatic activity of PCs. In turn, the reduced 
processing observed for mutant precursor proteins leads to its intracellular accumulation in the Golgi 
of neurons and glial cells (Garringer et al. 2017).  
ABri and ADan are identical in the 22 N-terminal aa but differ in their additional 12 C-terminal aa, 
and in contrast with the normally secreted peptide, shows a high tendency to oligomerize and 
aggregate (Figure I.10) (Kim et al. 1999). Moreover, these peptides were identified in the insoluble 
amyloid deposits, and as soluble monomeric forms in the plasma of patients with FBD and FDD 
(Vidal et al. 1999; Vidal et al. 2000; Ghiso et al. 2001; Tomidokoro et al. 2005). Both ABri and 
ADan peptides contain two cysteine residues in their sequence (Cys248 and Cys265) that were shown 
to form an intramolecular disulfide bond, and thus they can exist in an oxidized or reduced form (El-
Agnaf et al. 2004; Gibson et al. 2004). ABri seems to be more toxic in oxidized forms, aggregating 
in soluble oligomers (El-Agnaf et al. 2004). However, ADan forms soluble oligomers in both 
oxidized and reduced state, being the latter more neurotoxic (Gibson et al. 2004). Therefore, soluble 
oligomers, rather than highly fibrillized peptides seems to be implicated in the neurodegeneration 
process in FBD and FDD, as already has been suggested for AD (Rostagno and Ghiso 2008). In 
addition, in vitro studies determined that both ABri and ADan peptides are able to activate the 
complement cascade at levels compared to those observed in AD (Bradt et al. 1998). 
Moreover, the analysis of genetically congruous with human cases mouse models of the FBD and 
FDD (FBDKI and FDDKI mice, respectively) shows reduced expression of mature BRI2 levels in both 
cases (Tamayev et al. 2010a; Tamayev et al. 2010b), and in the FDDKI mice was found accumulation 
of mature BRI2 in dystrophic neurites (Garringer et al. 2017). Of note, in human FBD brains was 
also detected a significant reduction of mature BRI2 levels (Tamayev et al. 2010a). Besides, BRI2 
haploinsufficient (BRI2+/-) mice exhibit similar synaptic and memory deficits, and in FDDKI mice the 
expression of wt BRI2 in the forebrain prevented the memory deficits. Hence, it is possible that both 
FBD and FDD are caused by loss of BRI2 function rather than amyloidosis or tauopathy as previously 
suggested (Tamayev et al. 2010a; Tamayev et al. 2010b). Noteworthy, in FDDKI mice the APP 
fragments resulting from its processing are significantly increased, and BRI2:APP interaction is 
significantly reduced in synaptic membranes (Tamayev et al. 2011; Matsuda et al. 2011b). In FBDKI 
mice brains there is no alterations in the APP processing, however APP haploinsufﬁciency   
(FBDKI/APP+/-), as well as inhibition of β-processing of APP prevents the associated memory and 
synaptic impairments (Tamayev and D’Adamio 2012). Additionally, Aph1B/C ( a component of the 
γ-secretase complex) deletion, which resulted in increased β-CTF but decreased Aβ production in 
FDDKI mice (FDDKI/Aph1BC-/-), does not rescue the memory deficits as would have been expected 
if Aβ played a pathogenic role in FDDKI mice. In fact, the FDD mutation and the Aph1BC−/− deletion 
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cause similar behavioral deficits in spatial memory and appear to have a small additive negative 
effect. These observations are consistent with a pathological role of β-CTF, which is increased in 
FDDKI mice due to increased production and in Aph1BC−/− mice due to reduced turnover. Therefore, 
given the nature of the functional interaction of BRI2 and APP it is also plausible to assume that the 
pathogenesis of synaptic and memory deficits in FDD, as well as in FBD, is mediated by the toxic 
APP metabolites. 
BRI2 was also found to be deposited in the hippocampus of early stages of AD cases, and clearly 
associated with Aβ plaques. By using western blot analysis it was also possible to detect increased 
levels of unprocessed BRI2 in the brain of AD patients, as well as decreased furin and ADAM10 
levels and increased SPPl2b levels (Figure I.11). Therefore, it is possible that an alternative 
processing of BRI2 leads to the secretion of BRI2 ectodomain, which aggregates and deposits (Figure 
I.2.7). Besides the BRI2 binding to APP was lost in brain homogenates of AD patients. Indeed, 
processing of BRI2 into mature BRI2 and its transport along the secretory pathway are required to 
generate a functional APP processing inhibitor. Thus, BRI2 abnormal accumulation and subcellular 
localization of BRI2 may prevent the formation of the BRI2-APP complex formation leading to an 
increase in the APP processing and Aβ production (Figure I.11). On the other hand, the deposits of 
BRI2 containing the BRICHOS domain also affects its inhibitory function in the aggregation and 
fibrillation of the Aβ peptide (Figure I.11) (Peng et al. 2010; Willander et al. 2012; Del Campo et al. 
2014).  
 
 
Figure I. 11 - Schematic representation of the proposed role for BRI2 deposition in Alzheimer´s disease. Reduced 
cleavage of BRI2 by furin and ADAM10 and the increase of BRI2 processing by SPPL2b leads to the release of the whole 
BRI2 ectodomain. BRI2 ectodomain has high aggregation propensities and therefore its release may lead to accumulation 
Chapter I  General Introduction 
 
 
52                                                     Functional characterization of novel BRI2 and BRI3 complexes 
and deposition of BRI2. BRI2 deposits lead to a loss of BRI2 function and impair the formation of BRI2:APP complexes 
and the subsequent inhibition of Abeta (Aβ) production and aggregation. APP, amyloid precursor protein (adapted from 
Del Campo et al. 2014). 
 
Besides the loss of function of BRI2, the accumulation of BRI2 ectodomain may also lead to a gain 
of toxic function and have a negative impact on cell homeostasis. In human neuroblastoma cells, 
recombinant BRI2 ectodomain was shown to induce apoptosis by increasing the levels of 
proapoptotic protein Bax, decreasing the levels of antiapoptotic protein Bcl-2, and increasing the 
activity of caspase 3 and 9. In addition, the BRI2 ectodomain leads to tau truncation at D421, that 
has already been observed in AD and seems to be involved in the formation of NFT, a 
neuropathological hallmark of AD (Del Campo et al. 2015). Thereby, BRI2 may also be involved in 
the AD pathogenesis and its understanding may open new insights in the development of new 
therapies. Recently, a report by Baron et al identifies BRI2 as a target of BCL6 repression in human 
lymphomas (Baron et al. 2015). BCL6 is a crucial transcriptional repressor involved in the 
pathogenesis of some human lymphomas and binds to a consensus binding site within the first intron 
of BRI2. Knockdown of BCL6 in a B lymphoma cell line significantly increases the levels of 
endogenous BRI2. Besides, it was reported an inverse relationship between BCL6 and BRI2 protein 
levels in B- and T- cell human lymphomas studied by immunohistochemistry (Baron et al. 2015). 
Therefore, the dysfunction of BRI2 and its regulators may be relevant for the pathogenesis of 
lymphomas and may provide insights for the development of new molecular targeted therapies. 
 
I.2.3. BRI3 protein 
BRI3, is a protein composed of 267 aa, with a MW of 30 kDa and a pI of 8.47 (Vidal et al. 2001). 
Contains a cytosolic N-terminal domain (1-54 aa) followed by a single transmembrane domain (55-
75 aa), and a luminal C-terminal of 192-aa which contains the BRICHOS domain (136-230) (Figure 
I.12). It is mainly expressed in the brain with the highest levels of expression in cerebral cortex, 
medulla oblongata, amygdala, hippocampus, thalamus, striatum, caudate nucleus and spinal cord 
(Vidal et al. 2001; Choi et al. 2001). BRI3 is also expressed in plasmocytoid dendritic cells, 
granulocytes, appendix, bone marrow, fetal liver and to a lesser extent in spleen, lymph nodes and 
thymus (Rissoan et al. 2002). Subcellularly, BRI3 is mainly localized in the perinuclear region of 
cytoplasm, Golgi apparatus and plasma membrane (Gong et al. 2008; Martin et al. 2008). 
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Figure I. 12 - Schematic representation of human BRI3 protein and its domains. Human BRI3 has a short N-terminal 
cytosolic domain, a long C-terminal luminal domain, one transmembrane domain (TM) and one BRICHOS domain. Human 
BRI3 is processed at Arg242 by furin resulting in the secretion of a C-terminal 4KDa peptide. BRI3 can be phosphorylated 
in the cytosolic domain at two serine (S) and two threonine (T) residues. Each residue phosphorylated is indicated. BRI3 
can also be modified by ubiquitination (K) and N-glycosylation (N) at the sites indicated.   
 
BRI3 protein is also processed by furin and to a lesser extent by other members of the pro-protein 
convertase family at Arg242, within the sequence RRINKR242GA. This processing within the BRI2 
ectodomain results in the secretion of a C-terminal 4KDa fragment (Figure I.12) (Martin et al. 2009; 
Wickham et al. 2005). The furin processing occurs in the TGN (Trans-Golgi network) or post-TGN 
compartments, where furin is active, generating N- and C-terminal polypeptides that might be 
disulfide linked (Wickham et al. 2005). However, although BRI3 is highly homologous to BRI2, it 
seems that it fails to undergo shedding by ADAM-10 as well as intramembrane proteolysis by 
SPPL2a/b (Martin et al. 2009).  
The sequence of BRI3 predicts a single site of N-glycosylation at Asn169 and several 
phosphorylation sites being four already identified (Ser5, Ser30, Thr32 and Thr37) (Vidal et al. 2001; 
Gauci et al. 2009; Stuart et al. 2015; Sharma et al. 2014b; Mertins et al. 2013). Additionally, BRI3 
is post-translationally modified by ubiquitination at Lys3, Lys14, Lys17, Lys20 and Lys187 (Figure 
I.12) (Mertins et al. 2013; Danielsen et al. 2011; Kim et al. 2011a; Wagner et al. 2011). 
 
I.2.3.1. BRI3 physiological function and associated diseases  
BRI3 biological function remains to be fully elucidated, although it has been suggested that it may 
be involved in neuronal differentiation (Gong et al. 2008). In a yeast two-hybrid screen stathmin-2, 
a neuron-specific microtubule-destabilizing protein was identified as a novel BRI3 interacting 
protein (Table I.5). In addition, overexpression of stathmin-2 seems to significantly enhance neurite 
outgrowth in NGF-treated PC12 cells, while the BRI3 overexpression slightly decreases neurite 
outgrowth. However, the overexpression of both proteins strongly attenuates stathmin-2 induced 
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microtubule disassembly and the outgrowth of neurites. Therefore, it is possible to assume that BRI3 
may inhibit neurite outgrowth through interaction with stathmin-2 by decreasing dynamic instability 
of microtubules caused by stathmin-2 (Gong et al. 2008). The suggested interaction of BRI3 with 
the tyrosine-protein kinase RYK (Table I.5), a protein involved in neuron differentiation and neurite 
outgrowth, also strengthened a role for BRI3 in above-mentioned processes (Berndt et al. 2011). 
Besides, a recent report demonstrated that BRI3 knockdown in rat hippocampal neurons significantly 
decreased neuronal cell survival and induced neuronal cell apoptosis (Yang et al. 2015). Therefore, 
BRI3 may also be involved in neuronal survival and cell death.  
Moreover, as BRI2, BRI3 also binds to APP being considered a negative regulator of Aβ production 
(Table I.3; Matsuda et al. 2009). BRI3 inhibits APP processing by masking the access of APP to α- 
and β-secretases, but is a poor inhibitor of γ-secretase processing (Matsuda et al. 2009). As described 
above, the BRI2 23 aa C-terminal peptide released by furin and a fragment that contains the 
BRICHOS domain also affects Aβ aggregation and deposition, however for BRI3 similar function 
remains to be elucidated. Additionally, as it was already described for BRI2, BRI3 also interacts with 
BACE1 (Table I.3). The functional relevance of this interaction is not addressed, however, it is clear 
that BRI3 does not regulate BACE1 processing of APP (Wickham et al. 2005). It is possible that this 
interaction may assist in the mutual folding and/or targeting of these proteins. 
 
Table I. 5 - List of the identified BRI3 interacting proteins. Information about the identified BRI2 interactors, as well 
as, the experimental evidence supporting the interactions. 
Interactor Description Experimental evidence  References 
BACE1 β-secretase β-amyloid protein 
converting enzyme 1 
Two-hybrid 
Co-IP 
(Wickham et al. 2005) 
 
STT3A Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase subunit 
STT3A 
Two-hybrid (Stelzl et al. 2005) 
MTNR1B Melatonin receptor type 1B Tandem affinity 
purification (Daulat et al. 2007) 
FURIN Furin Two-hybrid (Wickham et al. 2005) 
 
RNF7 RING-box protein 2 Two-hybrid (Rual et al. 2005) 
 
RYK Tyrosine-protein kinase RYK Affinity 
chromatography - MS 
(Berndt et al. 2011) 
LLGL2 Lethal(2) giant larvae protein homolog 
2 
Peptide array (Arbuckle et al. 2010) 
 
POLR2F DNA-directed RNA polymerases I, II, 
and III subunit RPABC2 Co-IP 
 
(Freaney et al. 2013) 
 
UBC Polyubiquitin-C Affinity 
chromatography - MS (Danielsen et al. 2011; 
Kim et al. 2011; 
Wagner et al. 2011; 
Emanuele et al. 2011; 
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Interactor Description Experimental evidence  References 
Povlsen et al. 2012; 
Udeshi et al. 2012) 
EGR1 Early growth response protein 1 Co-IP (Arora et al. 2008) 
 
DLG4 Disks large homolog 4  (Arbuckle et al. 2010) 
CUL7 Cullin-7 Affinity 
chromatography - MS 
(Hanson et al. 2014) 
MVB12B Multivesicular body subunit 12B Affinity 
chromatography - MS 
(Huttlin et al. 2015) 
STMN2 Stathmin-2 Two-hybrid 
Co-IP 
(Gong et al. 2008) 
APP Amyloid beta A4 protein Two-hybrid 
Co-IP 
(Matsuda et al. 2009) 
TMEM216 Transmembrane protein 216 
proximity-dependent 
biotin identification 
(Gupta et al. 2015) 
TMEM17 Transmembrane protein 17 
proximity-dependent 
biotin identification 
(Gupta et al. 2015) 
Co-IP, co-immunoprecipitation; MS, mass spectrometry. 
 
I.2.3.2. BRI3 associated diseases  
Contrary to BRI2, no similar mutation of the stop codon or any form of mutation has yet been 
reported for BRI3. However, a polymorphism (AÆG) of BRI3 (rs3111754) was associated with the 
prevalence of subarachnoid hemorrhage in Japanese individuals, and thus may be beneficial in the 
assessment of the genetic risk for subarachnoid hemorrhage (Yoshida et al. 2010). A recent studied 
demonstrated that miR-323, which has been reported to be upregulated in ischemia/reperfusion brain 
injury, promotes apoptosis and suppresses survival. miR-323 could bind to BRI3 and suppress its 
expression in a post-transcriptional manner. Therefore, it is possible that miR-323 regulate 
ischemia/reperfusion-induced cell death via targeting BRI3 (Yang et al. 2015). 
As mentioned before, BRI3 contains a BRICHOS domain which is found in a variety of proteins 
implicated in dementia, respiratory distress, and cancer (Sánchez-Pulido et al. 2002). Therefore, 
further studies are necessary to assess the involvement of BRI3 in any of these diseases.  
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I.3. Neuronal differentiation  
Neurons are highly polarized cells with two type of processes molecularly and functionally distinct 
which emerge out of the soma: a single long and thin axon and multiple dendrites that are relatively 
short with a tapered morphology (Fukata et al. 2002; Dotti et al. 1988). In fact, is the polarization of 
axon and dendrites that underlie the ability of neurons to integrate and transmit information in the 
brain. Dendrites primary function is to receive information from other neurons that is processed and 
integrated at the level of soma, whereas axons conduct information away from the soma to the 
presynaptic terminals onto target cells (Barnes and Polleux 2009; Dotti et al. 1988).  
However, at the onset of neuronal differentiation, the structure of the neurons is quite distinct from 
the polarized morphology above described. Neurons arise from terminal mitotic cell divisions in 
disperse regions of the nervous system presenting a simple spheroid shape. Before differentiate, the 
immature neuron or its precursor commonly migrates from its birthplace and settles in some other 
specific locations, and neuritogenesis occurs as neurites start to emerge out of the soma. During 
migration, neuronal polarization takes place as the initial sprouting of neurites occur and is followed 
by the polarized emergence of a leading and trailing processes, becoming the axon or the dendrite, 
respectively. This is the case for some neuronal subpopulations undergoing long-range migration as 
cerebellar granule neurons, and cortical and hippocampal pyramidal neurons (Rakic 1971; Komuro 
et al. 2001; Noctor et al. 2004). However, in other neuronal populations, as is the case of retinal 
ganglion cells and bipolar cells in the developing vertebrate retina, neurons can inherit their polarity 
directly from the apico-basal polarity of their progenitors (Hinds and Hinds 1978; Morgan et al. 
2006; Zolessi et al. 2006). Dissociated neuronal culture systems have been extensively used to study 
the mechanisms of neuronal polarization. In fact, using cultured rodent hippocampal neurons Dotti 
et al (Dotti et al. 1988) described for the first time that neurons undergo a stereotypical development 
divided into five consecutive stages, in a similar manner to their in vivo development. The events 
range from cells bearing immature neurites in stage 1, to functionally differentiated neurons 
harboring dendritic spines and synapses, in stage 5 (Figure I.13). During stage 1 the initially spherical 
neurons begin extending broad circumferential lamellipodia and filopodia protrusions around the 
periphery of the cell (Figure I.13). In stage 2 lamellipodia and stable filopodia form growth cone and 
begin extending forming multiple neurites (neuritogenesis) (Figure I.13). At stage 3 the initial 
symmetry breaking event starts as one of the minor neurites elongates at a faster rate to become the 
axon (Figure I.13). Stage 4 comprehends the growth and arborization of the remaining processes 
developing into dendrites (Figure I.13). Neurons then mature and form dendritic spines and 
functional synaptic connections (stage 5) (Dotti et al. 1988) (Figure I.13). 
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Figure I. 13 - Developmental stages of neuronal polarization in cultured rodent embryonic hippocampal neurons. 
Hippocampal neurons transform from round cells bearing lamellipodia (Stage 1) into multipolar cells (Stage 2). One neurite 
enlarges its growth cone and extends rapidly to become the axon (Stage 3). The remaining shorter neurites will develop 
into dendrites (Stage 4). This is followed by functional maturation and formation of dendritic spines and synapses (Stage 
5) (Adapted from Arimura and Kaibuchi 2007). 
 
I.3.1. Cytoskeletal dynamics in neuritogenesis 
Several studies on neurite outgrowth mechanisms have emphasized the crucial roles of cytoskeletal 
dynamics in the process of neurite elongation. In fact, the establishment and maintenance of neuronal 
polarity is coordinated by rearrangements of the cytoskeletal architecture, namely filamentous (F)-
actin and microtubules (MTs). Neuritogenesis depends on the highly motile tip of the neurite, the 
growth cone, which has the ability to sense extracellular guidance cues transducing these signals to 
the cytoskeleton. The cytoskeletal structure of the growth cone is divided into two cytoplasmic 
domains; the central domain (C-domain) which contains organelles and a core of microtubules, and 
the peripheral domain (P-domain) consisting of membrane protrusions containing F-actin (Figure 
I.14). These protrusions take the form of F-actin tapered finger-like projections, called filopodia, and 
veil-like sheets of branched actin, the lamellipodia (Mattson 1999; da Silva and Dotti 2002; Tahirovic 
and Bradke 2009) (Figure I.14). During neuronal polarization, the growth cone of the future axon 
constantly undergoes dynamic changes in its structure, whereas the future dendrites, quiescent at that 
moment, have a static growth cone and retains a rigid actin cytoskeleton (Tahirovic and Bradke 
2009). Briefly, axon outgrowth results from the transformation of the distal C-domain of the growth 
cone into a stable neurite shaft, while the actual growth cone advances at the same time. This 
elongation process progress through three stages that repeat successively: protrusion, engorgement, 
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and consolidation. During protrusion, F-actin polymerization in the P-domain drives membrane 
protrusions at the edges of the growth cone as either filopodia or lamellipodia (Figure I.14). Further, 
microtubule-driven transport of membranous organelles and vesicles into the growth cone occurs 
during the engorgement phase. Finally, in the consolidation phase, actin polymerization and the 
protrusion are suppressed, microtubules become progressively more bundled developing the nascent 
neurite cylindrical shaft. Is the coordination of these three steps that determines neurite extension. 
 
Figure I. 14 - Growth cone cytoskeletal structure. The peripheral (P) domain contains long, bundled actin filaments (F-
actin bundles: green) which form the filopodia, as well as mesh-like branched F-actin networks, which give structure to 
lamellipodia-like veils. The central (C) domain encloses stable, bundled Microtubules that enter the growth cone from the 
axon shaft, in addition to numerous organelles, vesicles and central actin bundles. Finally, the transition (T) zone sits is the 
interface between the P and C domains (Adapted from Tahirovic and Bradke 2009). 
 
I.3.1.1. Actin dynamics 
Actin exists in a balance of ATP-bound monomeric, globular actin (G-actin) and helical actin 
filaments (F-actin) which are polar polymers composed of a barbed end, where the actin monomer 
addition occurs, and a pointed end where dissociation of actin monomers occur (Witte and Bradke 
2008). As already mentioned, actin polymerization occurs preferentially at the leading edge of the 
growth where actin filaments drive the protrusion of lamellipodia and filopodia. In fact, filopodia is 
mainly composed of F-actin bundles with their barbed-end towards the leading edge, whereas 
lamellipodia contain randomly oriented F-actin networks between the filopodia (Tojima and Ito 
2004). These actin structures in the peripheral growth cone are highly dynamic and in constant 
remodeling to direct the movement of the growth cone. Another feature of actin dynamics is the actin 
retrograde flow from the leading edge toward the center of the growth cone powered by myosin 
motors. Is the balance between actin polymerization rate and retrograde flow that regulates growth 
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cone protrusion. Therefore, it is clear that growth cone motility and guidance, and consequently axon 
growth is modulated by actin dynamics and organization which in turn are regulated by a diversity 
of actin-binding proteins (ABP), namely actin nucleating, severing, branching, and bundling proteins 
(Tahirovic and Bradke 2009). Several ABPs promote actin polymerization at the leading edge of the 
protrusions, namely profilin, Arp2/3 complex and ADF/cofilin. Profilin, a G-actin-binding protein, 
allows G-actin to bind F-actin barbed-end thus supporting polymerization (Dominguez 2009). 
Arp2/3 complex is involved in the nucleation of new filaments as a branch on the side of existing F-
actin (Pollard and Beltzner 2002). Actin severing proteins as ADF/cofilin, which are abundant in 
neuronal growth cones, enhances F-actin severing and actin subunit dissociation at the pointed-end. 
ADF/cofilin accelerates F-actin disassembly at the pointed ends which increase the actin monomers 
able to re-associate with the barbed ends (Bamburg 1999). Furthermore, WAVE (Wiscott-Aldrich 
syndrome protein [WASP]-family verprolin-homologues protein) protein which is localized to 
lamellipodia, is able to regulate actin polymerization through Arp2/3 or profiling, promoting axon 
growth. Monomer binding to the barbed ends of filaments is also regulated by capping proteins. 
Therefore, capping proteins such as CapZ, by binding to the barbed ends of actin filaments block the 
access of monomers, halts actin polymerization and reduces F-actin length. On the other hand, 
barbed-end binding proteins such as Ena/VASP proteins, localized to tips of lamellipodia and 
filopodia, accelerate actin polymerization by interacting with profilin:G-actin complexes and 
promoting the transfer of G-actin monomers from profilin to the barbed end. Moreover, Ena/VASP 
proteins exhibit anti-capping activity, by which they protect actin filaments from capping proteins 
(Tahirovic and Bradke 2009).  
In addition to proteins that regulate directly the actin kinetics, other ABPs affects actin architecture 
and dynamic by cross-linking actin filaments and therefore help to determine the arrangement of 
actin filaments into networks. For instance, fascin is an F-actin bundling protein which cross-links 
and stabilizes actin filaments given rise to parallel/unipolar F-actin bundles (Sasaki et al. 2002; 
Aratyn et al. 2007). It is suggested that fascin is crucial for the maintenance of filopodia and normal 
growth cone morphology (Cohan et al. 2001). Spectrins links F-actin cytoskeleton to numerous 
proteins in the cell membrane to form a multiunit structural element which organizes the protein 
network underlying the plasma membrane (Garbe et al. 2007; Hülsmeier et al. 2007).  
 
I.3.1.2. Microtubule dynamics 
Microtubules are cylindrical polar polymers composed of a plus end, where occur dimer addition and 
dissociation, and a minus end where can occur dimer dissociation. In neurons, the minus end of 
microtubules is often stabilized and its dynamics rest mainly on the polymerization and 
depolymerization at the plus end (Flynn 2013). Neurite microtubules show increased stability with 
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neuronal polarization which can be achieved by stabilization of existing microtubules, increased 
polymerization, reduced microtubule destabilization and microtubule bundling. Several microtubule 
binding proteins (MBP) affects microtubule dynamics and organization which can be divided into 
five classes: (1) microtubule-stabilizing proteins, including the structural microtubule-associated 
proteins (MAPs), (2) plus-end tracking proteins (+TIPs), (3) microtubule destabilizing proteins, (4) 
microtubule motor proteins, and (5) microtubule severing proteins (Tahirovic and Bradke 2009; 
Flynn 2013; Dent et al. 2011). Structural MAPs usually act to stabilize microtubule structure and 
consists of two distinct and unrelated families highly expressed in neurons: type I (Map1a/Map1b) 
and type II (Map2/tau) (Flynn 2013). The most abundant neuronal MAPS, Map1b, Map2 and tau are 
differentially distributed in axons and dendrites and have distinct mechanisms to affect microtubule 
stability. Map1b has been shown to be involved in axon guidance, and both Map2 and tau are 
particularly important for neurite formation. Map2 is particularly important in the earliest phases of 
neurite formation given that its suppression in cerebellar neurons affects the extension of neurites, 
whereas tau suppression only affects axon elongation (Caceres and Kosik 1990; Caceres et al. 1992). 
In addition, a particular role for Map2c, a juvenile isoform that is downregulated after the early stages 
of neuronal development, in neuronal development and neurite outgrowth was also highlighted. 
Map2c mediates neurite formation not only due to its microtubule-stabilizing activity which 
facilitates the extension of bundled microtubule, but also due to its ability to bind F-actin and alter 
actin dynamics (Dehmelt and Halpain 2004). Another important microtubule stabilizing protein with 
implications in neuritogenesis is doublecortin (DCX). DCX is found preferentially near the plus ends 
of the microtubules and promotes stability, assembly and nucleation of microtubules. During 
neuritogenesis, DCX activation by dephosphorylation mediated by a PP1-spinophilin pathway, 
promotes the consolidation of the growth cone into the elongating neurite shaft by facilitating the 
bundling of microtubules (Reiner 2013; Bielas et al. 2007). Microtubule destabilizing proteins such 
as stathmin, superior cervical ganglia neural-specific (SCG10), and SCG10-like protein (SCLIP) has 
also been pointed has having a role in neuronal polarity, and prevents polymerization by (1) 
sequestering free tubulin heterodimers and preventing its association with microtubules plus end or 
by (2) associating with tubulin on microtubule plus ends (Grenningloh et al. 2004; Wittmann et al. 
2004). The stathmin/SCG10 family of proteins are highly expressed in developing neurons and its 
expression and activity are important for neurite outgrowth. For instance, stathmin/SCG10 family of 
proteins are negatively regulated by phosphorylation which in turn regulates its microtubule 
destabilizing activity promoting microtubule polymerization which is necessary for axon 
specification (Tahirovic and Bradke 2009; Manna et al. 2006).  
Microtubule elongation is favored by proteins that bind free tubulin heterodimers and increase 
polymerization, as for example the collapsin-response mediator protein-2 (CRMP-2), or by +TIPs, 
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as adenomatous polyposis coli (APC), End-binding protein 1 (EB1) and End-binding protein 3 
(EB3), which stabilize the dynamic plus-end. For instance, CRMP-2 binds to free tubulin subunits 
and promotes their capacity to bind microtubules. During neuronal differentiation, CRMP-2 
accumulates in one neurite before the morphological polarization, which further becomes the axon 
(Tahirovic and Bradke 2009). 
Besides its well-known role in transporting material either anterogradely (kinesins) or retrogradely 
(dynein), microtubule motor proteins also have an important role in microtubule stability. The kinesin 
13 family, namely Kif2A, which is enriched in growth cones, has the ability to destabilize 
microtubules at their plus ends. Finally, two main microtubule severing proteins expressed in 
neurons, katanin and spastin, are also important for microtubule dynamics during neuritogenesis. In 
fact, when katanin and spastin are overexpressed the axon/neurite outgrowth is diminished due to 
increased severing of microtubules (Conde and Cáceres 2009). 
 
In addition, microtubule dynamics during neuritogenesis might also be modulated by post-
translational modifications (detyrosination, glutamylation, glycylation, phosphorylation and 
acetylation) of the tubulin heterodimers which can affect the dynamic properties of microtubules and 
also the binding of structural MBPs. Acetylation is one prominent modification in microtubules 
which occurs in stable microtubules in neurons, and for instance, may affect the binding of 
microtubule motor proteins (Flynn 2013). 
 
I.3.2. Membrane protein trafficking in neuronal polarization 
The plasma membrane of neurons can be divided into the soma-dendritic and the axonal domains, 
which perform distinct functions. This functional specialization is generated by sorting and anchoring 
mechanisms that guarantee the correct delivery and retention of specific membrane proteins. Hence, 
polarized membrane protein trafficking in neurons is necessary for both the establishment and the 
maintenance of neuronal polarity (Fukata et al. 2002). Axonal and dendritic membrane proteins are 
synthesized in the rough endoplasmic reticulum and undergo post-translational modification in the 
Golgi complex. Proteins could be sorted to axon or dendrite by at least three mechanisms: (1) the 
direct transport of the proteins in a polarized manner from the trans-Golgi network to the appropriate 
membrane; (2) the non-polarized transport of proteins within the cell, followed by selective retrieval 
by endocytosis from the incorrect domain and degradation; (3) the sort of proteins in the trans-Golgi 
network and traffic to axon or dendrite domains, which are subsequently endocytosed and resorted 
in endosomes, followed by polarized delivery (transcytosis) (Fukata et al. 2002; Lasiecka and 
Winckler 2011).   
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Briefly, the polarized delivery of proteins to the plasma membrane involves budding, transport, and 
fusion that is orchestrated by a complex set of trafficking proteins. Vesicle budding is mediated by a 
set of coat proteins which are recruited to the membrane from the cytosol, including cargo adaptors. 
Cargo adaptors recognize and bind to transmembrane cargo proteins containing sorting motifs and 
concentrate them in the forming bud, and to other proteins that induce membrane curvature and bud 
fission (Guo et al. 2014; Bentley and Banker 2016). Selective vesicle transport along to either axon 
or dendrites is mediated by kinesin and dyneins which translocate along microtubules. It is the unique 
distribution of microtubules in neurons that underlies significant differences in protein trafficking of 
axonal and dendritic proteins: in axons, the microtubules are oriented with the plus-ends toward, 
whereas in dendrites may have the plus or minus ends outwardly directed. Therefore, it is proposed 
that the dendritic targeting of cargoes is governed by the minus-end microtubules allowing dynein-
dependent sorting, while axonal targeting is facilitated by kinesin-dependent sorting governed by the 
oriented plus-end microtubules (Maeder et al. 2014). These motor proteins normally do not bind 
directly to vesicles being linked by adaptor proteins (Akhmanova and Hammer 2010). Lastly, fusion 
is initiated by tethering proteins that form a complex, linking the vesicle to its target membrane. 
Subsequent formation of a SNARE (N-ethylmaleimide-sensitive factor attachment protein receptor) 
complex drives the fusion of the lipid bilayers of the vesicle and target membrane, which allows the 
incorporation of vesicle cargo proteins into the target membrane (Bentley and Banker 2016). 
 
I.3.3. Local protein translation and degradation regulates neuronal polarization 
Local protein translation and degradation are key mechanisms that could locally regulate proteins 
involved in the establishment of neuronal polarization. The presence of mRNA and the translation 
machinery in developing axon and dendrites suggests an important role for local protein translation 
in axon and dendrite specification. In fact, the target of specific mRNAs to specific neuronal domains 
promotes a rapid change in the local proteome via local translation. Therefore, local protein 
translation links extrinsic signals to particular cellular responses and can mediate stimulus-driven 
adaptive responses. For instance, in axons, it is well established the impact of local translation in 
axon specification, growth and guidance (Polleux and Snider 2010). In isolated retinal growth cones 
it was demonstrated that when translation is inhibited, they lose the ability to respond to the guidance 
cues, namely semaphorin 3A and netrin-1. Therefore, local translation occurring in growing axons 
seems to be implicated in mediating the responses to guidance signals (Campbell and Holt 2001). 
Remarkably, the most frequently identified embryonic mRNAs are those encoding cytoskeletal or 
cytoskeletal binding proteins such as actin, tau and ADF (Piper and Holt 2004).  
Furthermore, the local regulation of protein expression by degradation mediated by the ubiquitin-
proteasome system (UPS) was shown to have a crucial role in the regulation of neuronal development 
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and differentiation, namely in the formation and maintenance of neuronal polarity (Polleux and 
Snider 2010). In fact, several proteins critical for neuronal polarity, such as the serine/threonine 
kinase Akt undergo selective degradation. Akt is important for axon growth and maintenance, and in 
neurites that develop into axons its protein levels are stable, however in neurites that differentiate 
into dendrites are reduced in an ubiquitin-dependent manner. Therefore, the regulated local protein 
degradation of Akt by the UPS seems to be a requirement for neuronal polarization (Yan et al. 2006). 
Further understanding regarding the upstream regulatory signals responsible for the spatially limited 
local protein degradation is crucial.  
 
I.3.4. Importance of extracellular cues for neuronal differentiation  
Several families of extracellular cues have been suggested to be involved in the polarized emergence 
of axon and dendrites (Polleux and Snider 2010). This asymmetric neurite outgrowth requires the 
ability of postmitotic neurons to sense gradients of extracellular cues which lead to the asymmetric 
activation of intracellular signaling cascades converging on axon and dendrites formation. There are 
several extracellular signals acting through distinct receptors existing in the growth cone, converging 
on cytoskeletal arrangements and thereby the direction of axonal elongation (Hall and Lalli 2010). 
Candidate proteins that have been shown to influence axonal and dendritic development include 
mainly neurotrophins, other growth factors, bone morphogenetic proteins (BMPs) and morphogens 
such as retinoic acid, semaphorins, netrins, extracellular matrix proteins and neurotransmitters. 
Neurotrophins are an important family of neurotrophic factors comprised by the nerve growth factor 
(NGF), the brain-derived neurotrophic factor (BDNF), the neurotrophin-3 (NT-3) and NT-4, which 
have been proposed as extracellular regulators of neuronal polarization by enhancing axon growth 
(Yuen et al.). Neurotrophins mediate their functions by selectively binding to two types of cell 
surface receptors, the Trk tyrosine kinase receptors and the p75 neurotrophin receptor (p75NTR), a 
member of the TNF receptor superfamily (Dechant and Barde 2002). Remarkably, Trk receptors 
transmit positive signals whereas p75NTR transmit both positive and negative signals, and the two 
neurotrophin receptors exist in a paradoxical relationship as can either augment or oppose each other 
(Yuen et al.; Kaplan and Miller 2000; Zagrebelsky et al. 2005). Overall, neurotrophins increase the 
dendritic complexity of pyramidal neurons by increasing total dendritic length, the number of 
branchpoints, and/or the number of primary dendrites (Whitford et al. 2002). In addition, other 
growth factors have been shown to be involved in neuronal polarization: (1) the basic fibroblast 
growth factor (bFGF), which accelerates the outgrowth of axons and dendrites in hippocampal 
neurons; (2) and the insulin-like growth factor-1 (IGF-1) that functions as a neurotrophic factor 
regulating neurite growth in developing brain and affects dendritic growth and branching of post-
natal layer 2 cortical neurons (Whitford et al. 2002).  
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BMPs are multifunctional growth factors belonging to the transforming growth factor β (TGFβ) 
superfamily, all of which transduce signals by binding type I and type II Ser/Thr kinases receptors 
(BMPRI and BMPRII). BMP signaling plays an important role in neuronal differentiation, namely 
in the regulation of the number, length, and branching of neurites (Benavente et al. 2012). For 
instance, it was demonstrated that BMP7 activates c-Jun N-terminal kinase (JNK) which induces 
microtubule stabilization and thus rearrangement of the cytoskeletal network to promote dendrite 
outgrowth (Podkowa et al. 2010). 
Retinoic acid (RA) is a potent morphogen capable of inducing neurite outgrowth. RA works by 
binding directly to nuclear transcription factors, which include the retinoic acid receptors (RARs) 
and the retinoid X receptors (RXRs), to influence gene expression (Ross et al. 2000).  
Semaphorins constitute a large family of secreted proteins, transmembrane proteins or membrane-
bound proteins that act as guidance signals for axons and dendrites during neuronal differentiation 
through their interactions with the plexin and neuropilin receptor family (Fiore and Püschel 2003; 
Hall and Lalli 2010). Remarkably, secreted semaphorin 3A (Sema3A) regulates the asymmetric 
growth of neurons either by acting as a chemorepellant for axons or as a chemoattractant for dendrites 
(Polleux and Snider 2010). On the other hand, semaphorin 7A (Sema7A) seems to be only involved 
in axon outgrowth promotion. Interestingly, sema7A signaling is not mediated by plexins or 
neuropilins, but instead seems to be mediated by its binding to integrins which activate MAPKs and 
focal adhesion kinases (FAK) and culminates with alterations in actin dynamics (Guan and Rao 
2003). Netrins are a family of extracellular proteins acting through binding to receptors which include 
deleted in colorectal cancer (DCC), the DCC paralogue neogenin, the UNC-5 homologues UNC5A-
D, and Down syndrome cell adhesion molecule (DSCAM), and function as axon guidance cues 
during neural development (Sun et al. 2011). They act as chemoattractants for some cell types and 
chemorepellents for others. Netrin-mediated axon chemoattraction is mediated by DCC signaling, 
which activates several signal transduction molecules and ultimately leads to rearrangement of the 
actin cytoskeleton and process extension, namely mitogen-activated protein (MAP) kinases, Rac1 
and cdc42.  The signaling mechanisms for netrin-mediated chemorepulsion are less well understood 
than those underlying chemoattraction, although appear to be mediated by UNC5, alone or in 
complex with DCC (Sun et al. 2011; Guan and Rao 2003). Additionally, netrins can also promote 
axon outgrowth by activating the nuclear factor of activated T cell (NFAT) which is mediated by 
DCC signaling (Guan and Rao 2003). 
Several extracellular matrix proteins and adhesion molecules, such as laminin and neuron-glia cell 
adhesion molecule (NgCAM) influence neurite outgrowth and axon elongation (Esch et al. 2000). In 
fact, in dissociated cultures of both cortical and hippocampal pyramidal neurons, plated on striped 
substrates coated with laminin or NgCAM, the first immature neurite contacting the boundary 
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between two stripes of either laminin or NgCAM becomes the axon. In addition, neurotransmitters 
may also regulate the axon and neurite outgrowth during neuronal differentiation. For instance, in 
cultured embryonic hippocampal neurons, glutamate suppresses dendrite elongation whereas axon 
elongation is unaffected. On the other hand, the activation of GABA receptors can counteract the 
inhibiting effects of glutamate on dendritic elongation (Mattson 1999). 
 
I.3.5. Signaling pathways involved in neuronal differentiation 
The events that lead to neuronal differentiation and polarization are controlled by signaling molecules 
that have established roles on cytoskeletal arrangements and protein trafficking converging on axon 
and dendrites formation (Arimura and Kaibuchi 2005). Therefore the extracellular cues acting 
through distinct receptors existing in the growth cone are able to activate several intracellular 
signaling pathways closely associated to growth cone reorientation, and some are discussed in the 
next sections.   
 
I.3.5.1. Rho- and Ras-family of small GTPases  
Rho- and Ras-family of small GTPases are members of the Ras superfamily of small GTPases and 
have been reported as important regulators of axon specification and growth (Colicelli 2004; Arimura 
and Kaibuchi 2007). These proteins function as molecular switches that interact with downstream 
effectors to induce cellular responses in their GTP-bound active state, and are inactive in their GDP-
bound state. The small GTPases exhibit high-affinity binding for GDP and GTP, however, possess 
low intrinsic GTP hydrolysis and GDP/GTP exchange activities. These conversions are controlled 
by two main classes of regulatory proteins: GTPase-exchange factors (GEFs) and GTPase-activating 
proteins (GAPs). GEFs promote the exchange of GDP for GTP promoting the formation of the active 
GTP-bound form, whereas GAPs increase the intrinsic GTPase activity promoting the formation of 
the inactive GDP-bound form (Barnes and Polleux 2009; Hall and Lalli 2010). At least 20 members 
of the Rho-family of small GTPases have been identified, Cdc42, Rac1 and RhoA being the most 
extensively characterized. This family of small GTPases are key regulators of actin reorganization. 
Rac1 and Cdc42 are positive regulators of neurite outgrowth through the promotion of lamellipodia 
and filopodia formation in growth cones, whereas RhoA acts as a negative regulator of neurite 
extension promoting actin stress fiber formation and focal adhesion assembly. So, it has been 
hypothesized that polarity inducing signals switch Rac/Cdc42 to their GTP-bound active states in the 
future axon, whereas Rho remains in its GDP-bound inactive state. In parallel, the other growth cones 
remain with GDP-bound inactive Cdc42/Rac, where the relatively high content of GTP-bound active 
Rho inhibit those neurites elongation (Hall and Lalli 2010).  
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In developing neurons, Cdc42 regulates actin dynamics through the effectors N-WASP and p21-
activated kinase (PAK). N-WASP is an important Cdc42 effector during neurite extension promoting 
actin polymerization through the Arp2/3 complex (Figure I.15) (Hall and Lalli 2010). The PAK 
pathway signals to the actin cytoskeleton via cofilin and seems to be critical for axon formation (Ng 
and Luo 2004). In addition, in cdc42 knockout mice, where an axon specification defect is observed, 
the phosphorylation levels of cofilin (inactive form) were found increased. The phosphorylation of 
cofilin is achieved by LIM kinase (LIMK) whose activity is regulated by PAK (Figure I.15) 
(Garvalov et al. 2007). 
Rac is a positive regulator of axon growth modulating actin cytoskeleton dynamics through its two 
main effectors, PAK and WASP-family verprolin-homologous protein (WAVE) (Figure I.15) 
(Tahirovic and Bradke 2009). In addition, Rac acts on microtubule dynamics to promote axon 
formation. Briefly, the Rac-specific GEF, dedicator of cytokinesis 7 (DOCK7) by regulating Rac 
activity mediate the phosphorylation and inhibition of the microtubule destabilizer stathmin in the 
nascent axon (Figure I.15) (Watabe-Uchida et al. 2006). Besides, two other Rac-specific GEFs, T-
lymphoma and metastasis 1 protein (TIAM1) and TIAM1-like exchange factor (TIAM2), have been 
associated with neuronal polarity by regulating actin reorganization (Arimura and Kaibuchi 2007). 
Rho primary action is to induce actin cytoskeleton rearrangements but also modulates local dynamics 
of microtubules (MTs). The best-characterized RhoA effectors are Rho-kinase (ROCK) and the 
mammalian Diaphanous formin (mDia). RhoA/ROCK signaling negatively regulate the early steps 
of axon outgrowth. For instance, ROCK is able to increase MLC phosphorylation either by 
phosphorylating it directly or by phosphorylating the myosin-binding subunit of myosin phosphatase 
impeding it of dephosphorylating MLC. As result myosin II is activated enhancing actomyosin 
contractility which promotes neurite retraction (Figure I.15) (Narumiya et al. 2009). Moreover, Rho-
mediated neurite retraction can be achieved by phosphorylation and consequently activation of LIM 
kinase by ROCK which in turn phosphorylates and inactivates cofilin (Figure I.15) (Maekawa et al. 
1999). Regarding, the Rho-mDia pathway it has been shown that mDia catalyzes actin nucleation 
and polymerization but is also able to stabilize microtubules through association with the microtubule 
end capping protein complex EB1/APC (Figure I.15) (Bartolini et al. 2008). 
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Figure I. 15 - Signal transduction pathways downstream of the Rho GTPases in the regulation of cytoskeletal 
dynamics. Arp, actin-regulated protein; LIMK, LIM kinase; mDia, a mammalian homologue of the Drosophila diaphanous 
protein; MLC, myosin light chain; MLCP, MLC phosphatase; PAK, p21 activated kinase; ROCK, Rho kinase; WASP, 
Wiskott-Aldrich syndrome protein; WAVE, WASP family verprolin-homologous protein; p, phosphorylated. 
 
Finally, for the Ras family of small GTPases, a crucial role in the establishment and maintenance of 
neuronal differentiation have also been reported. In brief, Ras functions upstream of the 
phosphatidylinositol-3 kinase (PI3K) and the mitogen-activated protein kinase (MAPK) pathways 
(Arimura and Kaibuchi 2007; Barnes and Polleux 2009). 
 
I.3.5.2. PI3K/Akt pathway 
Several evidences support a role for PI3K signaling pathway in the establishment of neuronal 
polarity. PIK3 activity results in the generation of phosphatidylinositol (3,4,5)-triphosphate (PIP3) 
which is able to activate signaling molecules and several regulators of actin and microtubule 
dynamics at the cell membrane. During neuronal differentiation, PI3K activity and PIP3 were found 
concentrated at the distal region and growth cone of one of the immature neurites in stage 2 of 
differentiation, which is crucial for axonal specification and elongation. In fact, the pharmacological 
inhibition of PI3K activity in cultured hippocampal neurons prevents axon formation (Shi et al. 2003; 
Ménager et al. 2004). Different extracellular cues, namely neurotrophins, modulate axonal growth 
behavior through activation of the PI3K signaling pathway. One of the best characterized 
downstream mediators of PI3K signaling in neuronal differentiation is the protein kinase Akt, also 
called protein kinase B (PKB). PI3K activation recruits Akt from the cytosol to the membrane where 
it is activated by dual phosphorylation at Thr308 and Ser473 by phosphoinositide-dependent kinase 
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1 (PKD1) and phosphoinositide-dependent kinase 2 (PKD2), respectively. In addition, integrin-
linked kinase (ILK) is also able to phosphorylate Akt at Ser473. This activated forms of Akt are 
enriched in the growth cones of polarized neurons, and phosphorylates GSK3β on Ser9, inactivating 
it. Therefore, it was shown that as Akt localizes to the tips of the axons in hippocampal neurons the 
inactive GSK3β is also circumscribed to the tips of growing axons (Alessi et al. 1997; Burgering and 
Coffer 1995; Shi et al. 2003). In addition, it has been suggested that the described asymmetric 
distribution of Akt is regulated by localized protein degradation since the inhibition of the ubiquitin-
proteasome system induces multiple axons along with symmetric Akt distribution (Guo and Zhong 
2006). 
 
I.3.5.3. PTEN 
The phosphatase and tensin homolog (PTEN) is a dual-specificity protein phosphatase (Myers et al. 
1997) and a PIP phosphatase (Maehama and Dixon 1998). PTEN and PI3K have opposing effects 
on PIP3 levels since it is able to dephosphorylate PIP3 generating PIP2, and consequently have 
opposing effects in the establishment of neuronal polarity (Barnes and Polleux 2009; Polleux and 
Snider 2010). In fact, overexpression of PTEN blocks axon formation whereas the knockdown of 
PTEN induces multiple axon formation (Jiang and Rao 2005; Shi et al. 2003). 
 
I.3.5.4. LKB1-SAD/MARK pathway 
Serine/threonine kinase LKB1, the mammalian counterpart of the C. elegans Par-4 protein, has a key 
role in axon formation during neuronal polarization by acting on its downstream effectors Synapse 
Amphid Defective (SAD) and Microtubule Affinity-Regulating Kinase (MARK) kinases. In fact, the 
conditional deletion of Lkb1 in mouse forebrain or the down-regulation of LKB1 expression by 
siRNA in rat cortical progenitors abolished axon formation in vivo. LKB1 activity in axon formation 
requires its association with the pseudokinase Strad and phosphorylation at Ser431 by PKA and 
ribosomal protein S6 kinase (p90RSK), which activates it. The LKB1 phosphorylated at Ser431 is 
predominantly found accumulated in only one neurite of undifferentiated neurons (Barnes et al. 
2007; Shelly et al. 2007). In addition, the overexpression of a mutated LKB1 (S431A) with serine to 
alanine mutation at this site impaired axon formation both in vitro and in vivo, presumably by 
interfering with the association of STRAD or other proteins important for LKB1 function (Shelly et 
al. 2007). Once activated, LKB1 phosphorylates and activates the kinases SAD-A/B and MARK1-4 
(Kishi 2005; Chen et al. 2006). Both SAD and MARK kinases phosphorylate several MAPS, 
including MAP2, MAP4, and tau, reducing their microtubule binding affinity which results in 
microtubule destabilization (Polleux and Snider 2010). 
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I.3.5.5. GSK3 
GSK3 (glycogen synthase kinase 3) is a serine/threonine kinase with described functions in the 
regulation of multiple cellular processes. There are two isoforms, GSK3α and GSK3β, encoded by 
two different genes, which presents 85% of amino acid identity (Woodgett 1990). GSK3 has the 
particularity of being constitutively active, and its inactivation is achieved following its 
phosphorylation at Ser9 in GSK3β or Ser21 in GSK3α by upstream regulators in response to stimuli. 
Therefore, several signaling pathways regulate GSK3 activity and emerging evidences points to 
GSK3 as an essential regulator of several neurodevelopmental processes, namely neurogenesis, 
neuronal migration, neuronal polarization and axon growth and guidance (Frame and Cohen 2001; 
Cross et al. 1995; Hur and Zhou 2010). Remarkably, GSK3 signaling exhibits crosstalk with other 
signaling pathways involved in neuronal polarization, including PI3K/Akt, Rho-GTPases, Par3/6, 
and PKA-LKB1. Therefore GSK3 acts an important mediator in the control and maintenance of 
neuronal polarization by transducing upstream signaling, and several kinases including Akt, ILK and 
atypical PKC (aPKC) are reported to be involved in its dephosphorylation (Barnes and Polleux 2009). 
In fact, the decreased activity of GSK3 seems to be required for neuronal polarization. Studies in rat 
hippocampal neurons show that the expression of constitutively active GSK3β (GSK3β-S9A) 
impaired axon formation, whereas the global inhibition of GSK3 by pharmacological inhibitors, a 
peptide inhibitor, and shRNAs induces the formation of multiple axons. Furthermore, it was shown 
that the inactive form of GSK3β is located at the tip of each neurite before polarization, however 
when neurons begin to polarize phospho-GSK3β becomes concentrated at the axonal tip. Together 
these results suggest that localized inactivation of GSK3β at the nascent axon is crucial for 
polarization (Jiang et al. 2005; Shi et al. 2004; Yoshimura et al. 2005).  
Several MBPs involved in neuronal polarization are GSK3 substrates, namely APC, CRMP- 2, which 
localizes to axon tips, and the microtubule-associated proteins MAP1B and tau (Polleux and Snider 
2010). The function of these MBPs is to promote microtubule assembly and stability, and its 
phosphorylation by GSK3 abolishes their ability to interact with microtubules. For instance, CRMP2 
which is enriched in the tip of the nascent axon, is regulated by GSK3, such that phosphorylated 
CRMP2 displays decreased binding affinity for tubulin. Overexpression of CRMP2 induce the 
formation of multiple axons, whereas it’s knocking down antagonizes the multiple axon formation 
induced by GSK3 inactivation, which indicates that the CRMP2 acts downstream of GSK3 
inactivation (Yoshimura et al. 2005). Therefore, GSK3 signaling regulates neuronal polarization by 
controlling cytoskeletal reorganization, in particular, microtubule dynamics. 
Moreover, GSK3 signaling is also involved in the polarized transport of proteins and membrane, 
local protein translation, and local protein degradation, which are key processes for the maintenance 
of the polarized axon extension (Kim et al. 2011b).  
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I.3.5.6. Raf/MEK/ERK pathway 
Several evidences suggest a role for Raf/mitogen-activated protein kinase (MEK)/extracellular-
signal-regulated kinase (ERK), downstream effectors of Ras, in axon growth formation mediated by 
neurotrophic factors (Markus et al. 2002; Zhou and Snider 2006). Briefly, Ras is able to recruit Raf 
to the cell membrane where it becomes activated. Then the activation of Raf phosphorylates and 
activates MEK, a dual-specificity kinase. MEK further phosphorylates and activates ERK that 
translocates to the nucleus and phosphorylates several targets, including transcription factors and 
several microtubule-associated proteins (Polleux and Snider 2010).   
 
I.3.5.7. Calcium-mediated signalling 
Calcium-mediated signaling is also involved in the regulation of neuronal differentiation, 
contributing to the regulation of axonal growth and guidance, and dendritic growth and arborization 
(Rosenberg and Spitzer 2011).  
Briefly, spatiotemporal patterns of calcium transients activate calcium-binding proteins that 
transduce the signals and impact growth cone motility and neurite elongation by regulating 
cytoskeletal dynamics. For example, Ca2+ regulates proteins that are involved in the actin filaments 
dynamics; Ca2+ is able to activate the protein gelsolin, which then cleaves actin filaments (Furukawa 
et al. 1997). 
The Ca2+/calmodulin-dependent serine–threonine phosphatase, calcineurin has also been implicated 
in promoting neurite outgrowth. In fact, it was shown that in Xenopus cultured neurons the 
suppression of calcineurin with pharmacological inhibitors, in the presence of extracellular Ca2+ but 
not in its absence, results in an increase in neurite extension. The expression of an autoinhibitory 
domain of calcineurin in the presence of Ca2+ waves also increases neurite extension, whereas 
expression of a constitutively active form of calcineurin in the absence of Ca2+waves retards neurite 
growth. Moreover, it was shown that Ca2+ waves act via calcineurin to dephosphorylate GAP-43 
protein resulting in a destabilization of actin filaments which affects neurite extension (Lautermilch 
and Spitzer 2000).  
Another well characterized Ca2+-binding protein is calmodulin (CaM), which functions as an 
intracellular Ca2+ sensor, associating with a wide-range of targets to elicit diverse signaling cascades, 
as is the case for Ca2+/CaM-dependent protein kinases (CaMKs). CaMKII is unique for its ability to 
autophosphorylate and seems to function in both growth cone turning and branching. For instance, 
the activation of CaMKII by Ca2+/CaM could promote microtubules depolymerization by 
phosphorylating tau protein (Mattson 1999). 
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Supporting all these findings, in vivo imaging studies have provided direct evidence for a negative 
relationship between the frequency of spontaneous Ca2+ transients and the rate of axon outgrowth 
(Polleux and Snider 2010).  
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Aims 
BRI2 and BRI3 are type II transmembrane proteins family members whose physiological functions 
are poorly understood. Two different autosomal dominant mutations in the BRI2 gene are responsible 
for the development of two rare early-onset forms of dementia, Familial British and Danish 
dementias (FBD and FDD, respectively), that share clinical and neuropathological characteristics 
with Alzheimer s´ disease (AD), involving brain deposition of abnormal proteins. The molecular and 
cellular mechanisms underlying these abnormal protein depositions are not fully elucidated. 
However, it is possible that this abnormal protein deposition might result from abnormal intracellular 
targeting, signaling, and processing of its precursors, which results in cellular/neuronal dysfunction 
that ultimately leads to degeneration and impaired brain function. Therefore, the elucidation of the 
mechanisms physiopathological associated with BRI2 abnormal targeting, signaling, and processing 
that results in neuronal/cellular dysfunction, which ultimately leads to degeneration and impaired 
brain function, is of paramount importance. For BRI3 no disease association has been determined so 
far, however, its enriched expression in the central nervous system strongly suggests a role for BRI3 
in neuronal function. Previous work from our laboratory, using two-hybrid (YTH) screens with a 
brain cDNA library, resulted in the identification of several PP1 binding proteins, namely BRI3. The 
identification of PP1 containing complexes is of paramount importance since opened new avenues 
for the study of BRI3 and BRI2 intracellular signaling where PP1/protein phosphorylation represents 
a key regulatory mechanism. 
Therefore, the aim of this thesis was to validate and characterize the BRI3/PP1 and BRI2/PP1 
complexes and decipher its physiological relevance (Aim 1). In addition, we also identified novel 
protein partners of both BRI2 and BRI3, particularly in the brain, which provided new insights to 
unravel the physiological functions as well as the underlying signaling mechanisms in which they 
are involved (Aim 2). 
Hence, the following specific aims for this thesis were proposed: 
Aim 1. Validation and Functional Characterization of the BRI2:PP1 and BRI3:PP1 complexes 
(Chapter II): 
1. Identification and validation of the interactions of BRI2 and BRI3 with PP1 (Chapter II.A).  
 
2. Determine the physiological relevance of the BRI2:PP1 complex (Chapter II.B). 
Aim 2. Identification of novel BRI2 and BRI3 protein interactors (Chapter III): 
1. Identification of novel BRI2 interactors in the brain: construction and analysis of an 
interaction network (Chapter III.A).  
 
2. Identification of novel BRI3 interactors: construction of a BRI3 interaction network in the 
brain (Chapter III.B).  
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CHAPTER II - VALIDATION AND 
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THE BRI2:PP1 AND BRI3:PP1 
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CHAPTER II.A – IDENTIFICATION AND VALIDATION OF THE INTERACTIONS OF BRI2 
AND BRI3 WITH PP1 
 
 
“BRI2 and BRI3 are functionally distinct phosphoproteins”  
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Abstract 
Three BRI protein family members have been identified. Among these are BRI3 and BRI2, the latter 
is associated with Familial Danish and Familial British dementias. ‘In silico’ sequence analysis 
identified consensus PP1 binding sites in BRI2 and BRI3. This is singularly important, given that 
protein phosphorylation is a major mechanism regulating intracellular processes. Protein 
phosphatase 1 (PP1) interacting proteins are fundamental in determining substrate specificity and 
subcellular localization of this phosphatase. More than 200 PP1 interacting proteins (PIPs) have thus 
far been reported. It is plausible to hypothesize that BRI2 and BRI3 may be functionally regulated 
by protein phosphorylation. 
Both BRI2 and BRI3 are type II transmembrane glycoproteins relevant in neuronal systems. Using 
Myc-BRI2 and Myc-BRI3, wild type and PP1 binding mutant constructs, it was possible to show, 
for the first time, that in fact BRI2 and BRI3 bind PP1. The complexes BRI2:PP1 and BRI3:PP1 
were validated in vitro and in vivo. The subcellular distribution of BRI2 and BRI3 is similar; both 
localize to the perinuclear area and Golgi apparatus in non-neuronal cells. However, in SH-SY5Y 
cells BRI2 and BRI3 could also be detected in elongated cellular projections (‘processes’) and in rat 
cortical neurons both are broadly distributed throughout the cell body, neurites, and the nucleus. 
Consistently, co-localization of BRI2 and BRI3 with PP1 was evident. The functional significance 
of these complexes is apparent given that both BRI proteins are substrates of PP1, thus 
simultaneously this is the first report of BRI2 and BRI3 as phosphoproteins. Moreover, we show that 
when BRI2 is phosphorylated a significant increase in neuronal outgrowth and differentiation is 
evident. 
This is the first report describing both BRI2 and BRI3 as PP1 binding proteins. Thus both are PP1 
substrates, regulated by protein phosphorylation and in the case of BRI2, regulation by protein 
phosphorylation is crucial for neuronal differentiation. Interestingly, the Alzheimer’s amyloid 
precursor protein (APP), forms a trimeric complex composed of PP1 and Fe65, with PP1 having the 
capacity to dephosphorylate APP at Thr668 residue. The emerging consensus appears to be that PP1 
containing complexes are crucial in regulating signaling events underlying neuropathological 
conditions. 
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II.A.1. Introduction 
Reversible protein phosphorylation is a major mechanism controlling key intracellular events in 
eukaryotic cells. In fact, recent phosphoproteomic studies have indicated that more than 70% of all 
eukaryotic cellular proteins are regulated by protein phosphorylation occurring mainly at serine (ser), 
threonine (Thr) and tyrosine (Tyr) residues (Olsen et al. 2010). Protein phosphatase 1 (PP1) is a 
ubiquitous serine/threonine phosphatase, estimated to dephosphorylate about a third of all proteins 
in eukaryotic cells (Cohen 2002; Ceulemans and Bollen 2004). In mammals there are four PP1 
isoforms: PP1α, PP1β/δ and the splice variants PP1J1 and PP1J2 encoded for by three different genes 
PPP1CA, PPP1CB and PPP1CC, respectively (Cohen 2002). PP1 isoforms are extremely similar in 
their sequences and the differences are located mainly at the N- and C-terminals. However, they 
possess specific distinct tissue and subcellular distributions. PP1α, PP1β/δ and PP1J1 are widely 
expressed across mammalian tissues, particularly in brain and PP1J2 is testis-enriched (da Cruz e 
Silva et al. 1995; Bordelon et al. 2005; Peti et al. 2013; Sasaki et al. 1990). PP1 is a key protein, 
functionally diverse, involved in processes including a regulatory role in gene transcription, cell cycle 
regulation, protein targeting and intracellular processing (Cohen 2002; Bollen 2001; Ceulemans et 
al. 2002). The functional versatility and specificity of PP1 relies on the interaction of its catalytic 
subunit with many different specific regulatory subunits also known as PP1 interacting proteins 
(PIPs) (Bollen et al. 2010; Fardilha et al. 2011; Rebelo et al. 2015). These control PP1 subcellular 
localization and determine substrate specificity and activity (Cohen 2002; da Cruz e Silva et al. 1995; 
Bollen 2001; Ceulemans et al. 2002; Bollen et al. 2010; Fardilha et al. 2010; Heroes et al. 2013; 
Hsieh-Wilson et al. 1999; Küntziger et al. 2006). PIPs interact with the PP1 catalytic subunit (PP1c) 
through several PP1 binding motifs such as the RVxF, SILK and MyPhone domains (Hendrickx et 
al. 2009; Jones et al. 2005). Most PIPs interact with PP1c through the well-conserved domain, the 
RVxF motif. This motif has the consensus sequence [R/K]-XA(0-1)-[V/I]-XB-[F/W], where XA is any 
amino acid and XB is any amino acid except proline (Wakula et al. 2003). Recently, other consensus 
sequences have been proposed for the RVxF motif: [HKR]-[ACHKMNQRSTV]-V-[CHKNQRST]-
[FW] and [KRL][KRSTAMVHNQ] [VI]{FIMYDP}[FW] (Hendrickx et al. 2009; Meiselbach et al. 
2006). Given that the regulatory subunits control the specificity and the diversity of PP1 activity, the 
key to fully understanding PP1 function lies in studying these regulatory subunits as well as their 
cellular functions. Yeast two-hybrid (Y2H) screens, of a human brain cDNA library, using the three 
PP1 isoforms (PP1α, PP1γ1 and PP1γ2) as baits were used, and several PIPs were described including 
novel PP1 binding partners (Esteves et al.; Esteves et al. 2013). One of the novel putative PP1 
interacting proteins identified, in these screens, was BRI3 which belongs to the BRI family of 
proteins (Esteves et al. 2013; Cotrim 2009). The BRI gene family comprises at least three members, 
BRI1/ITM2A, BRI2/ITM2B and BRI3/ITM2C, which encode three type II transmembrane 
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glycoproteins BRI1, BRI2 and BRI3, respectively. These three genes have homologues in 
chimpanzee, Rhesus monkey, cow, mouse, rat and humans, and their genomic organization consist 
of six exons and five introns (Rostagno et al. 2005; Tsachaki et al. 2008). The pattern of expression 
of these three members is quite different across different tissues (Tsachaki et al. 2008; Deleersnijder 
et al. 1996; Lashley et al. 2008). BRI1, is a 263-residue protein, expressed in several mesenchymal 
tissues and was found to be most abundantly expressed in chondro- and osteogenic tissues, in thymus 
and skeletal muscle (Deleersnijder et al. 1996; Kirchner and Bevan 1999; Pittois et al. 1999; 
Akiyama et al. 2004). Data suggests a possible involvement of BRI1 in chondro- and osteogenic 
differentiation (Deleersnijder et al. 1996; Pittois et al. 1999). The second BRI family member, BRI2, 
is a 266-residue protein ubiquitously expressed protein, with high levels of expression in the brain, 
placenta, pancreas, heart, kidney and liver. In the brain, the hippocampus and cerebellum are the 
regions with the highest mRNA expression levels for BRI2 (Tsachaki et al. 2008; Lashley et al. 
2008; Akiyama et al. 2004). The precise biological function of BRI2 remains unknown. However, 
some reports indicate that it might be involved in the plasticity of neuronal processes and in the 
promotion of neuritic outgrowth (Choi et al. 2004). It has also been suggested that BRI2 may be 
involved in apoptosis and in signal transduction, acting as a cell surface receptor since it forms 
disulfide-linked homodimers that occur at the cell surface. Moreover, several studies demonstrated 
that BRI2 is post-translationally modified by N-glycosylation at asparagine 170, affecting its 
trafficking through the secretory pathway to the cell surface (Lashley et al. 2008; Akiyama et al. 
2004; Del Campo and Teunissen 2014; Tsachaki et al. 2010). Additionally, bioinformatic analysis 
of the BRI2 sequence, suggests several putative phosphorylation sites, being only confirmed 4 
phosphoresidues (Ser8, Tyr76, Tyr112, and Tyr165) (Tsachaki et al. 2011; Sharma et al. 2014; 
Demirkan et al. 2011). The third family member, BRI3, is a protein composed of 267 amino acids, 
it is mainly expressed in the brain with the highest levels of expression in cerebral cortex, medulla 
oblongata, amygdala, hippocampus, thalamus, striatum, caudate nucleus and spinal cord (Tsachaki 
et al. 2008; Vidal et al. 2001). This protein is also expressed in plasmocytoid dendritic cells, 
appendix, peripheral blood leukocytes, bone marrow and fetal liver (Rissoan et al. 2002). BRI3 s´ 
biological function remains to be fully elucidated, although it has been suggested that it may play a 
role in TNF-induced cell death and in neuronal differentiation (Wu et al. 2003; Gong et al. 2008). 
The sequence of BRI3 predicts a single site of N-glycosylation at Asn169 and some phosphorylation 
sites being 4 already identified (Ser5, Ser30, Thr32 and Thr37) (Wickham et al. 2005; Gauci et al. 
2009; Sharma et al. 2014; Mertins et al. 2013; Shiromizu et al. 2013; Tweedie-Cullen et al. 2009; 
Munton et al. 2007). 
BRI2 undergoes regulated intramembrane proteolysis (RIP). First, it is cleaved by a furin and related 
proteases in the ectodomain, generating a C-terminal 23-residue peptide (3KDa). Additionally, the 
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remaining membrane-bound, N-terminus undergoes processing by ADAM-10 and a peptide 
containing the BRICHOS domain (25KDa) is released. The resulting membrane associated N-
terminal fragment (NTF; 22KDa) undergoes intramembrane cleavage by SPPL2a/2b to produce a 
small, secreted, BRI2 C-terminal domain and an intracellular domain (BRI2ICD; 10KDa), that can 
translocate to the nucleus (Tsachaki et al. 2008; Peng et al. 2010; Vidal et al. 1999; Mentrup et al. 
2015). BRI3 is also processed by a furin in the ectodomain resulting in the secretion of a C-terminal 
23-residue long peptide (Wickham et al. 2005). However, although BRI3 is highly homologous to 
BRI2, it seems that it fails to undergo shedding by ADAM-10 as well as intramembrane proteolysis 
by SPPL2a/b (Wickham et al. 2005; Martin et al. 2009). With respect to BRI1 processing, very little 
is known, although by aligning the BRI family members one would predict that BRI1 can be cleaved 
by furin or another related proprotein convertase (Wickham et al. 2005). To date, the precise 
biological functions and the proteolytic processing pathways of BRI family protein members have 
not been fully elucidated. 
In the present study by in silico analysis the RVxF motif was identified in all the BRI family protein 
members, signifying that BRI1, BRI2 and BRI3 might be regulated by protein phosphorylation. 
Given that BRI1 is chondro- and osteogenic tissue-specific while the other two proteins, BRI2 and 
BRI3, are ubiquitous and brain specific, respectively, the work here presented focused on BRI2 and 
BRI3. Consequently, the putative complexes BRI2:PP1 and BRI3:PP1 were validated, using several 
in vitro and in vivo techniques, namely blot overlay assay and co-immunoprecipitations. 
Furthermore, we established that the KVTF and KISF motifs are the PP1 binding motifs responsible 
for the interaction between the phosphatase and BRI2 and BRI3 respectively. The functional 
relevance of the novel complexes was pursued and it was possible to establish that both BRI2 and 
BRI3 are novel PP1 substrates and both can be dephosphorylated by PP1 in vitro. Additionally, BRI2 
is important for neuronal differentiation, particularly for neuronal outgrowth that is regulated by 
protein phosphorylation.  
 
II.A.2. Materials and Methods 
II.A.2.1. Antibodies 
The following primary antibodies were used: mouse monoclonal BRI2 C-8 (Santa Cruz 
Biotechnology, Inc.), that recognizes the N-terminal of BRI2; rabbit polyclonal BRI3 (Abcam), 
raised against amino acids 110-258 of human BRI3; rabbit polyclonal CBC2C and CBC3C, that 
recognizes the C-terminal of PP1α and PP1J, respectively (da Cruz e Silva et al. 1995); rabbit 
polyclonal APP (Cell Signaling), that recognizes the C-terminal of amyloid precursor protein; and 
Myc-tag antibody (Cell Signaling), that recognizes myc-fusion proteins. The secondary antibodies 
used were horseradish peroxidase-conjugated anti-mouse and anti-rabbit (GE Healthcare) for 
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enhanced chemiluminescence (ECL) detection, and Alexa 594-conjugated anti-mouse IgG and Alexa 
488-conjugated anti-rabbit IgG (Molecular Probes) for co-localization analysis.  
 
II.A.2.2. Expression vectors and DNA constructs 
pCMV-BRI2 and pCMV-BRI3 were obtained from the I.M.A.G.E. consortium (MRC Geneservice, 
UK) and they correspond to BRI2 (GenBank Accession: BC016148) and BRI3 (GenBank Accession: 
BC098563) cDNAs, respectively, inserted into the mammalian expression vector pCMV-SPORT6. 
Full-length BRI2 and BRI3 were further subcloned into two different vectors: pET-28c vector 
(Novagen) and the mammalian expression vector pCMV-Myc (Clontech) to obtain myc-fusion 
proteins. BRI2 and BRI3 PP1 binding (PP1BM) mutants (Hendrickx et al. 2009) were generated 
with the QuikChange Site-Directed Mutagenesis Kit (Stratagene). The BRI2 F6A (KVTA; BRI2 
single mutant), BRI2 V4AF6A (KATA; BRI2 double mutant), BRI3 F6A (KISA; BRI3 single 
mutant) and BRI3 K3AF6A (AISA; BRI3 double mutant) mutants cDNAs were generated using 
pCMV-Myc vectors containing wild-type BRI2 and BRI3 with appropriate primers (Table II.A.S1). 
All constructs and mutations were confirmed by DNA sequencing (ABI PRISM 310 Genetic 
Analyzer, Applied Biosystems). 
 
II.A.2.3. Brain dissection 
Wistar Hannover rats (9-12 weeks) were obtained from Harlan Interfaune Ibérica, SL. All 
experimental procedures observed the European legislation for animal experimentation 
(2010/63/EU). No specific ethics approval under EU guidelines was required for this project, since 
the rats were only euthanized, by cervical stretching followed by decapitation, for brain removal. 
This is within the European law (Council Directive 86/609/EEC) and during this procedure, we took 
all steps to ameliorate animal suffering and used the minimum number of animals possible. The 
procedures were approved and supervised by our Institutional Animal Care and Use Committee 
(IACUC): Comissão Responsável pela Experimentação e Bem-Estar Animal (CREBEA). Briefly, 
animals were sacrificed by cervical stretching followed by decapitation and both cortex and 
hippocampus were dissected out on ice. Tissues were further weighed and homogenized on ice with 
a Potter-Elvehjem tissue homogenizer with 10-15 pulses at 650-750 rpm, in non-denaturating lysis 
buffer (50 mM Tris-HCl pH 8.0, 120 mM NaCl and 4% CHAPS) containing protease inhibitors (1 
mM PMSF, 10 mM Benzamidine, 2 µM Leupeptin, 1.5 µM Aprotinin and 5 µM Pepstatin A) (Santos 
et al. 2014b). The tissue extracts were used for immunoprecipitation analysis as described below. 
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II.A.2.4. Cell culture and transient transfection 
HeLa cells (ATTC CRM-CCL-2) were grown in Minimal Essential Medium (MEM) with Earle s´ 
salts and GlutaMAX supplemented with 10% FBS, 1% MEM non-essential amino acids, 100U/ml 
penicillin and 100 mg/ml streptomycin. SH-SY5Y (ATCC CRL-2266) cells were grown in Minimal 
Essential Medium (MEM) supplemented with F-12 nutrient mixture, 10% FBS, 1.5 mM L-
glutamine, 100U/ml penicillin and 100 mg/ml streptomycin. Rat cortical primary cultures were 
established from Wistar Hannover 18 days embryos, as previously described (Henriques et al. 2007). 
Briefly, after dissociation with trypsin (0.45 mg/ml) in Hank s´ balanced salt solution cells were 
plated onto poly-D-lysine-coated dishes at a density of 1.0x105 cells/cm2 in B27-supplemented 
Neurobasal medium (GIBCO Invitrogen), a serum-free medium combination. The medium was 
supplemented with glutamine (0.5 mM) and gentamicin (60 µg/ml). All cultures were maintained in 
an atmosphere of 5% CO2 at 37oC. 
Transient transfections were performed using the cationic lipid LipofectAMINE 2000 (Invitrogen 
Life technologies), according to the manufacturer s´ instructions and previous studies (Rebelo et al. 
2007a). Upon 24 hours of transfection, cells were harvested for immunoprecipitation assays or fixed 
using 4% paraformaldehyde and processed for immunocytochemistry analysis as previously 
described (Rebelo et al. 2008).  
 
II.A.2.5. Immunocytochemistry analysis  
Once fixed as described above, cells were permeabilized with methanol for 2 minutes and washed 
with 1x PBS. For immunolocalization studies of BRI2 and BRI3, both wild-type and mutant proteins, 
cells were incubated with the primary antibody (anti-myc) for 2 hours at room temperature. After 
washing with 1x PBS, cells were subsequently incubated with anti-mouse Alexa 594-conjugated 
secondary antibody. For co-localization studies of both BRI2 and BRI3 with APP or PP1J, HeLa 
cells were first incubated with one of the primary antibodies (APP C-terminal or CBC3C) followed 
by anti-rabbit Alexa 488-conjugated secondary antibody. After washing with 1x PBS, cells were 
subsequently incubated with a second primary antibody (anti-myc), followed by anti-mouse Alexa 
594-conjugated secondary antibody. All preparations were washed with PBS, mounted using 
Vectashield mounting media with DAPI (Vector) and visualized using an LSM510-Meta confocal 
microscope (Zeiss) and 63x/1.4 oil immersion objectives. The argon laser lines of 405 nm (DAPI), 
488 nm (Alexa 488), and a 561nm DPSS laser (Alexa 594) were used. Microphotographs were 
acquired in a sole section in the Z-axis (xy mode) and represent a mean of 16 scans.  
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II.A.2.6. Blot overlay assays 
BRI2 and BRI3 proteins were generated by in vitro transcription and translation (IVT) from pET-
BRI2 and pET-BRI3 expression vectors, respectively using the TnT-coupled transcription/translation 
kit (Promega), according to the manufacturer s´ instructions. For the overlay assays, four samples of 
200 ng of purified recombinant PP1J1 (Watanabe et al. 2003) were on a 10% SDS-PAGE and 
subsequently transferred onto nitrocellulose membranes. One was overlaid for 1 hour with the BRI2-
IVT while the other was overlaid with the BRI3-IVT. Afterward, membranes were washed to remove 
excess protein and bound proteins were detected by incubating with BRI2 or BRI3 antibody, 
respectively, and subsequently developed by ECL (GE Healthcare).  
 
II.A.2.7. Co-immunoprecipitation assays 
For analysis of endogenous proteins rat cortex and hippocampus were collected in lysis buffer (50 
mM Tris-HCl pH 8, 120 mM NaCl and 4% CHAPS) containing protease inhibitors (1 mM PMSF, 
10 mM Benzamidine, 2 µM Leupeptin, 1.5 µM Aprotinin and 5 µM Pepstatin A). Dynabeads Protein 
G (Dynal, Invitrogen) were washed in 3% BSA/1x PBS and primary antibodies were cross-linked to 
Dynabeads according to the manufacturer s´ instructions. Afterward, lysates were pre-cleared with 
0.6 mg Dynabeads for 1 hour at 4oC with agitation and incubated with antibody-Dynabeads overnight 
at 4oC with agitation. The immunoprecipitates were washed in 1x PBS and proteins denatured by 
boiling in loading buffer followed by SDS-PAGE and immunoblotting. 
SH-SY5Y cells were transiently transfected with pCMV-Myc-BRI2, pCMV-Myc-BRI2 KVTA, 
pCMV-Myc-BRI2 KATA, pCMV-Myc-BRI3, pCMV-Myc-BRI3 KISA or with the pCMV-Myc-
BRI3 AISA and immunoprecipitated as described above.  
 
II.A.2.8. SDS-PAGE and Immunoblotting 
Samples were separated on SDS-PAGE and electrophoretically transferred onto nitrocellulose, 
followed by immunological detection with specific antibodies as indicated. Membranes were 
saturated in 5% non-fat dry milk in TBS-T for 4 hours and further incubated with primary antibodies. 
The incubations with the CBC2C and CBC3C antibodies were performed overnight while the 
incubation with anti-myc was carried out for 4 hours. Detection was achieved using horseradish 
peroxidase-conjugated anti-mouse or anti-rabbit IgGs as secondary antibody and proteins were 
visualized by ECL (GE Healthcare). 
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II.A.2.9. Protein phosphorylation analysis by Phos -tag SDS-PAGE 
SH-SY5Y cells were transfected with pCMV-Myc-BRI2 or with pCMV-Myc-BRI3 and treated with 
0.25 nM or 500 nM okadaic acid (OA) for 3 hours. Cells were then harvested in PP1 buffer (50 mM 
Tris-HCl pH 7.5, 0.1 mM EGTA, 1 mM MnCl2, 5 mM DTT) containing protease inhibitors (1 mM 
PMSF, 10 mM Benzamidine, 2 µM Leupeptin, 1.5 µM Aprotinin and 5 µM Pepstatin A). The lysates 
were incubated for 1 hour at 30oC with (100 ng or 200 ng) or without purified recombinant PP1J1 
(Watanabe et al. 2003). Samples were further analyzed by phos-tag SDS-PAGE performed with 
8.5% polyacrylamide gels containing 50 µM phos-tagTM acrylamide (AAL-107, Wako Pure 
Chemicals Industries, Ltd) and 100 µM MnCl2 as previously described (Santos et al. 2014a). After 
electrophoresis, phos-tag acrylamide gels were washed with transfer buffer (25 mM Tris, 192 mM 
glycine and 20% methanol) containing 10 mM EDTA, for 10 minutes with agitation and then with 
transfer buffer without EDTA for 10 minutes according to the manufacturer s´ protocol. Proteins were 
transferred electrophoretically onto nitrocellulose membranes followed by immunoblotting detection 
as indicated above. 
The same analysis was performed using lysates from SH-SY5Y cells transfected with pCMV-Myc-
BRI2, pCMV-Myc-BRI2 KATA, pCMV-Myc-BRI3 KISA and pCMV-Myc-BRI3 AISA. 
 
II.A.2.10. Data analysis and statistics 
For the morphological analysis of BRI2 and BRI3 (wild-type and mutant proteins) transfected SH-
SY5Y cells, after image acquisition, the analysis was carried out using ImageJ Fiji software.  The 
number of processes per cell was determined by counting the projections arising from the cell body 
and process length was determined using the ‘Measure’ tool of the ImageJ Fiji software. Data were 
expressed as mean ± SEM from at least 3 different sets of experiments. Statistical analysis was 
additionally performed using GraphPad Prism software. The 1-way ANOVA was conducted 
followed by the Tukey-Kramer multi-comparison test. Three levels of significance were used, 
depending if the p-value was under 0.05, 0.01 or 0.001. 
Regarding the co-localization studies, quantifications were performed using the Zeiss LSM 510 4.0 
software as previously described (Santos et al. 2013). 
 
II.A.3. Results and Discussion 
II.A.3.1. BRI2 and BRI3 are novel putative PP1 binding proteins 
More than 200 PIPs have been identified and it is expected that more will be discovered in the next 
few years (Fardilha et al. 2011; Fardilha et al. 2010; Heroes et al. 2013; Hendrickx et al. 2009; 
Esteves et al. 2013; Esteves et al.). Typically PIPs comprise at least one conserved PP1 binding 
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domain, namely the RVxF motif. From our previous work on yeast two-hybrid screens novel PIPs 
were identified using PP1α, PP1γ1 and PP1γ2 as baits (Esteves et al. 2013; Esteves et al.). Of the 
screen (Cotrim 2009). BRI3 belongs to the BRI family of proteins, which has three members (BRI1, 
BRI2 and BRI3), exhibiting tissue-specific expression. Further in silico analysis of all three BRI 
family members revealed that they have the conserved PP1 binding motif (RVxF): KIAF, KVTF and 
KISF, for BRI1, BRI2 and BRI3, respectively. Interestingly, the PP1 binding motif is localized to 
exactly the same intracellular domain position (amino acids 3-6) in each of the different human BRI 
proteins (Figure II.A.1A and II.A.1B). Given that the BRI1 expression is mainly in chondro- and 
osteogenic tissues, while BRI2 is ubiquitous and BRI3 is brain specific, the focus was placed on 
BRI2 and BRI3 proteins. In silico characterization of the two potential PP1 binding motifs, KVTF 
(BRI2) and KISF (BRI3) was achieved using the ClustalOmega algorithm, which allowed for the 
evaluation of the homology between species.  
 
 
Figure II.A. 1 - Schematic representation of human BRI2 and BRI3. A- Schematic representation of BRI2 functional 
related domains and motifs. The conserved PP1 binding motif (KVTF) is highlighted in red (position 3-6 in aa sequence), 
the transmembrane domain is highlighted in orange (position 58-80 in aa sequence) and the BRICHOS domain highlighted 
in green (position 136-230 in aa sequence). Sequence of human BRI2 was aligned against others species using the 
ClustalOmega algorithm. Sequence conservation is indicated by asterisks (identical sequences), colons (conserved 
substitutions) and periods (semi-conserved substitutions). B- Schematic representation of BRI3 functional associated 
domains and motifs. The conserved PP1 binding motif (KISF) is highlighted in red (position 3-6 in aa sequence), the 
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transmembrane domain is highlighted in orange (position 58-80 in aa sequence) and the BRICHOS domain highlighted in 
green (position 136-230 in aa sequence). Sequence of human BRI2 was aligned against others species using ClustalOmega 
algorithm. Sequence conservation is indicated by asterisks (identical sequences), colons (conserved substitutions) and 
periods (semi-conserved substitutions). KVTF and KISF, RVxF-like PP1 binding motif; TM, transmembrane domain. 
 
Remarkably, both motifs are totally conserved in the species analyzed (Human, Chimpanzee, 
Monkey, Mouse, and Rat). Moreover, both BRI2 and BRI3 proteins share a conserved domain, the 
BRICHOS domain, which seems to be involved in protein processing and/or targeting to the 
secretory pathway (Sánchez-Pulido et al. 2002). Our results regarding the homology between species 
of the BRICHOS domain also indicated that it is also highly conserved among the species analyzed, 
in the case of both BRI2 and BRI3 (Figure II.A.1A and II.A.1B). Given the YTH data and the BRI2 
and BRI3 in silico characterization, the putatively novel BRI2:PP1 and BRI3:PP1 complexes were 
validated in vitro and in vivo. 
 
II.A.3.2. BRI2 and BRI3 interact with PP1 in vitro 
The in vitro validation of the BRI2:PP1 and BRI3:PP1 complexes was accomplished using a blot 
overlay assay. Briefly, BRI2 and BRI3 proteins were generated by in vitro transcription/translation 
(IVT). For the overlay assays, four samples of 200 ng of purified recombinant PP1J1 were loaded 
and separated on an SDS-PAGE and subsequently transferred onto nitrocellulose membranes. Two 
of these membranes were overlaid for 1 hour with the BRI2-IVT or with the BRI3-IVT and the other 
two were subjected to the same procedure but were overlaid with the BRI2 and BRI3- IVT negative 
controls. Afterward, for all the four membranes, were subjected to specific antibodies directed 
against BRI2 or BRI3, respectively. The results are presented in Figure II.A.2. It was possible to 
detect a band around 37 kDa corresponding in size to PP1γ1 only in the membranes that were 
incubated with the BRI2-IVT and BRI3-IVT. No immunoreactive bands were detected in the 
negative controls. These results indicate that both BRI2 and BRI3 bind directly to PP1 in vitro, thus 
confirming the hypothesis that BRI2 and BRI3 are novel PP1 binding proteins. 
 
 
 
Figure II.A. 2 - Blot overlay assay of full-length BRI2 and BRI3. Samples of purified recombinant PP1J protein were 
separated by SDS-PAGE and the resulting blot was overlaid with BRI2-IVT, BRI3-IVT or without (controls) and further 
detected using specific antibodies against BRI2 and BRI3 IB, immunoblotting. 
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II.A.3.3. BRI2:PP1 and BRI3:PP1 complexes are formed in vivo 
Having shown that both BRI2 and BRI3 interact directly with PP1 in vitro, the existence of these 
complexes in vivo was addressed, using distinct models, namely a neuronal-like cell line (SH-SY5Y) 
and rat brain (cortex and hippocampus). Co-immunoprecipitations, using the specific antibodies 
directed against PP1α, PP1γ (recognizes both PP1γ1 and PP1γ2), BRI2 and BRI3 were carried out. 
Briefly, rat cortical and hippocampal extracts were immunoprecipitated with BRI2, BRI3, PP1γ and 
PP1α antibodies and the results are presented in Fig. II.A.3A. Using rat cortical (Figure II.A.3A1) 
and hippocampal (Figure II.A.3A2) brain extracts it was possible to confirm that both BRI2:PP1 and 
BRI3:PP1 complexes are formed in the brain, since a 37 kDa band was detected, corresponding to 
PP1α and PP1J, after IP with BRI2 or BRI3 specific antibodies (Figure II.A.3, A1 and A2). 
Furthermore, since two specific antibodies directed against two different PP1 isoforms (PP1J and 
PP1α) were used, in the immunoblotting, one we can confirm that both BRI2 and BRI3 interact in 
vivo with these two PP1 isoforms. However, the most intense bands were obtained for BRI3 
hippocampal immunoprecipitated when blotted with PP1J antibody, and for BRI3 cortical 
immunoprecipitated when blotted with PP1α. Additionally, when the immunoprecipitation was 
carried out with PP1J and PP1α antibodies, BRI3 for both brain regions (cortex and hippocampus) 
could be detected (Figure II.A.3, A1 and A2). 
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Figure II.A. 3 - In Vivo validation of BRI2:PP1 and BRI3:PP1 complexes. A- Co-immunoprecipitation of the 
BRI2:PP1 and BRI3:PP1 complexes in rat cortex and hippocampus lysates. Rat cortex (A1) and hippocampus (B2) 
extracts were immunoprecipitated with BRI2, BRI3, PP1γ and PP1α antibodies bound to protein G Dynabeads. The 
negative controls were performed by incubating cell extracts with G Dynabeads. Lysates 1 were subsequently used for 
negative controls and lysates 2 and 3 for immunoprecipitation with the respective antibodies. B- Co-immunoprecipitation 
of the Myc-BRI2, Myc-BRI3 and the respective BRI2 and BRI3 PP1BM mutants. SH-SY5Y transfected lysates with 
the following Myc-BRI2 and Myc-BRI2 KATA were immunoprecipitated with both the PP1J and PP1α antibodies bound 
to protein G Dynabeads (B1). SH-SY5Y transfected lysates with the following Myc-BRI3 and Myc-BRI3 AISA were 
immunoprecipitated with both PP1J and PP1α antibodies bound to protein G Dynabeads (B2). NC, Negative control; Myc-
N, Empty Myc vector; IP, immunoprecipitation; IB, immunoblotting. 
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In a different experimental model, SH-SY5Y cells were transfected with both Myc-BRI2 and Myc-
BRI3 and two PP1BM mutants (Myc-BRI2 KATA and Myc-BRI3 AISA). Consequently, 
immunoprecipitations (IP) were carried out with the PP1γ (CBC3C) and PP1α (CBC2C) antibodies 
(Figure II.A.3B). The use of the double mutants at the PP1BM for BRI2 and BRI3, allowed one to 
determine if PP1 bound the BRI proteins at the domains identified by the in silico analysis, as 
previously described (Korrodi-Gregório et al. 2013). The results presented in Figure II.A.3B 
indicated that it was possible to detect BRI2 and BRI3 when both the PP1 antibodies (PP1α and 
PP1J) were used for the IP, indicating once again that BRI2 and BRI3 interact in vivo with these two 
PP1 isoforms. Consistently, when the PP1BM mutant for BRI2 was used, namely Myc-BRI2 KATA, 
the interaction with PP1α and PP1J was abolished. These results show that the interaction between 
BRI2 and PP1 is mediated by the KVTF motif (Figure II.A.3A1). Considering the Myc-BRI3 AISA 
the results were not so evident, even though a dramatic reduction in the interaction between PP1 and 
BRI3 (Figure II.A.3A2) was clear.  Thus it is reasonable to deduce that the KISF is important for the 
BRI3:PP1 interaction, but that PP1 mediated activity is being exerted at another level which is not 
abolished by the double BRI3 mutation. 
Additionally, for both BRI2 and BRI3 PP1BM single mutants (Myc-BRI2 KVTA and Myc-BRI3 
KISA) were evaluated, a decrease in the binding was evident although not as marked as that detected 
in the double mutants (data not shown). 
 
II.A.3.4. Immunolocalization of BRI2 and BRI3 in non-neuronal and neuronal models 
Given that both complexes are formed in vivo, it is evident that these two proteins are functionally 
related and therefore it became important to evaluate their localization. The localization of BRI2 and 
BRI3 was achieved using several models; a non-neuronal (HeLa cells), a neuronal-like (SH-SY5Y) 
and primary culture neuronal model (rat cortical neurons). For HeLa and SY-SY5Y cells, BRI2 was 
similarly localized, mainly in the ER, Golgi apparatus, membrane and vesicles (Figure II.A.4A and 
II.A.4B) as described in previous reports (Vidal et al. 2001; Choi et al. 2004). The enrichment of 
BRI2 in the Golgi apparatus was confirmed by co-localization with a Golgi marker (CFP-Golgi). 
However, in SH-SY5Y cells, it was also evident that BRI2 is present in a few elongated cellular 
projections (´processes’) and in the cell membrane (Figure II.A.4B). The localization of BRI2 in rat 
cortical neurons is however quite different; it is distributed through the cell soma and neuritis. It can 
also be detected in the nucleus (Figure II.A.4C).  
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Figure II.A. 4 - Subcellular distribution of BRI2 protein in, HeLa cells, SH-SY5Y cells and rat cortical neurons. 
HeLa cells, SH-SY5Y cells and rat cortical neurons were transfected with Myc-BRI2 and then processed for 
immunofluorescence using specific antibodies against Myc-tag. A- Localization of Myc-BRI2 in HeLa cells and its co-
localization with a Golgi marker (CFP-Golgi). B- Localization of Myc-BRI2 in SH-SY5Y cells. C- Localization of Myc-
BRI2 in rat cortical neurons. Bars, 10 µm. 
 
Regarding BRI3 localization (Figure II.A.5), it is apparently similar to that observed for BRI2 and 
as previously described (Gong et al. 2008; Martin et al. 2008). Hence, BRI3 is localized to the 
perinuclear space and Golgi apparatus. It also co-localized with CFP-Golgi indicating that it is 
strongly enriched in this subcellular compartment (Figure II.A.5A and II.A.5B). As observed for 
BRI2, BRI3 is presented in some elongated projections that in the case of BRI3 seem to be more 
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elongated (Figure II.A.5B). In rat cortical neurons BRI3 is broadly distributed through the cell body, 
neuritis and nucleus (Figure II.A.5C). Taken together these results show that BRI is positioned at 
key cellular compartments consistent with this being a RIP protein; expressed at the cell surface, 
undergoing cleavage and reaching the nucleus where it can influence gene expression. Furthermore, 
its localization in neuritis opens possibilities with respect to neuronal associated functions. 
 
 
Figure II.A. 5 - Subcellular distribution of BRI3 protein in, HeLa cells, SH-SY5Y cells and rat cortical neurons. 
HeLa cells, SH-SY5Y cells and rat cortical neurons were transfected with Myc-BRI3 and then processed for 
immunofluorescence using specific antibodies against M yc-tag. A- Localization of Myc-BRI3 in HeLa cells and its co-
localization with a Golgi marker (CFP-Golgi). B- Localization of Myc-BRI3 in SH-SY5Y cells. C- Localization of Myc-
BRI3 in rat cortical neurons. Bars, 10 µm. 
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II.A.3.5. Co-localization of the novel complexes 
Once the localization of BRI2 and BRI3 was determined, the co-localization of each with a 
previously described binding partner, the Alzheimer’s amyloid precursor protein, APP (Matsuda et 
al. 2005; Matsuda et al. 2009) (Figure II.A.6A), was addressed, as well as their co-localization with 
the novel binding partner, PP1 (Figure II.A.6B). HeLa cells were transiently transfected with both 
Myc-BRI2 and Myc-BRI3 and subjected to immunocytochemistry using a Myc-tag antibody. 
Endogenous APP was detected, using a C-Terminal antibody against APP (Figure II.A.6A). All 
proteins have the expected subcellular distribution. APP is localized in ER, the Golgi apparatus, 
vesicles and plasma membrane (Rebelo et al. 2007b; da Cruz E Silva et al. 2004). Given the similar 
subcellular distribution between BRI proteins and APP it is evident that they co-localize as observed 
by the yellowish color (Figure II.A.6A). Quantitative analysis of the co-localization was performed; 
using a specific co-localization software (Zeiss LSM 510 4.0 software) as previously described 
(Santos et al. 2013; Rebelo et al. 2013). Essentially, BRI2 and BRI3 co-localize similarly with APP 
(49% ± 1.4 and 51% ± 1.5, respectively), whereas the co-localization of APP with both BRI2 and 
BRI3 is slightly lower (35% ± 1.4 and 44% ± 2, respectively).  
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Figure II.A. 6 - Subcellular distribution of the BRI2:APP, BRI3:APP, BRI2:PP1 and BRI3:PP1 complexes in HeLa 
cells. HeLa cells were transfected with Myc-BRI2 and Myc-BRI3 and then processed for immunofluorescence using 
specific antibodies against Myc-tag and to endogenous APP and  PP1γ. A- Co-localization of Myc-BRI2 and Myc-BRI3 
with endogenous APP and respective quantification of the % of co-localization between BRI2 and BRI3 with APP. Values 
are mean ± SEM, n=32 cells for BRI2 and 30 cells for BRI3. B- Co-localization of Myc-BRI2 and Myc-BRI3 with 
endogenous PP1γ. The quantification of the % of co-localization between BRI2 and BRI3 with PP1γ. Values are mean ± 
SEM, n=35 cells for BRI2 and 39 cells for BRI3.  
 
The co-localization of BRI2 and BRI3 with the new binding partner, PP1, is presented in Fig. II.A.6B. 
Once again BRI2 and BRI3 present the expected localization as well as PP1J. PP1γ presented a 
normal subcellular distribution, and was found predominantly throughout the nucleus, and in the 
cytoplasm (Figure II.A.6B). Despite the different subcellular distribution of BRI2, BRI3 and PP1γ it 
is evident that they co-localize in the cytoplasm, mainly around the perinuclear area, as observed by 
the yellow color (Figure II.A.6B). The quantitative analysis of the percentage of co-localization was 
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calculated. Essentially, some differences in the co-localization of BRI2 and BRI3 with PP1γ were 
observed (40% ± 1.6 and 53% ± 1.8, respectively). BRI3 co-localizes more with PP1γ. However the 
co-localization of PP1γ with BRI2 and BRI3 is lower (30% ± 1.5 and 44% ± 1.9, respectively), but 
once again PP1γ co-localizes to a higher degree with BRI3. Interestingly, both BRI2 and BRI3 
presented a similar percentage of co-localization with the well-known BRI2 or BRI3 binding partner 
(APP) or the novel binding protein, PP1. It is perhaps not surprising that the percentage of PP1 
binding to BRI is comparatively lower, given that for PP1 many PIPs have been described. 
 
II.A.3.6. PP1 regulation of both BRI2 and BRI3 
Having determined that both complexes, BRI2:PP1 and BRI3:PP1, are formed in vitro and in vivo 
and that BRI proteins and PP1 co-localize at several subcellular compartments, it is reasonable to 
postulate that protein phosphorylation may play a regulatory role in BRI function. Therefore BRI2 
and BRI3 were tested for their potential as PP1 substrates. To date, there are some data suggesting 
BRI2 and BRI3 as putative phosphoproteins but this was not directly shown before. In order to 
analyze the phosphorylation state of BRI2 and BRI3 proteins, both Myc-BRI2 and Myc-BRI3 
constructs were used to transiently transfect SH-SY5Y cells, followed by incubation with two 
different concentrations of Okadaic Acid (OA, a protein phosphatase inhibitor) and further incubated 
with two different amounts of recombinant purified PP1γ1 protein. The resulting cellular extracts 
were analyzed by immunoblotting (Figure II.A.7A1 and II.A.7B1) and were also loaded onto Phos-
tag polyacrylamide gels (Figure II.A.7A2 and II.A.7B2). The SDS-PAGE with the polyacrylamide-
bound Mn2-Phos-tag system, traps phosphorylated proteins by the Phos-tag sites, thus delaying their 
migration (Hosokawa et al. 2010; Kinoshita et al. 2006). The analysis of the Figure II.A.7A1 reveals 
two strong bands corresponding to BRI2 in the cellular extracts from SH-SY5Y cells transfected 
with Myc-BRI2 in all conditions. Of particular interest, the intensity of the immunoreactive bands 
increases in a linear fashion in response to OA addition. Given that OA inhibits protein 
dephosphorylation it is likely that the increased BRI phosphorylation is affecting the protein in some 
way, such as processing or turnover time, and this deserves further attention. This effect, of protein 
phosphorylation increasing the half-life of proteins, namely APP, has previously been reported 
(Vieira et al. 2010; Vieira et al. 2009). Of note, BRI phosphorylation can be partially reversed by the 
addition of purified PP1γ1 protein (Figure II.A.7A1). Consequently, BRI2 phosphorylation was 
addressed by resorting to the phos-tag SDS-PAGE (Figure II.A.7A2). Inhibition of protein 
phosphatases with OA, resulted in BRI2 separating as multiple bands which is consistent with an 
increase in BRI2 phosphorylation levels. The higher phosphorylation level was achieved when PP1 
was inhibited (OA 500nM). When cells were treated with OA and further incubated with purified 
PP1J1 protein (100ng and 200ng) the effects were partially reversed and the slower migrating bands 
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were barely detected. This indicates an in vitro dephosphorylation of BRI2 by PP1J1 (Figure 
II.A.7A2).  
 
 
 
Figure II.A. 7 - Phosphorylation analysis of BRI2, BRI3 and PP1BM mutant proteins by phos-tag SDS-PAGE. 
Transfected SH-SY5Y cells with Myc-BRI2 or Myc-BRI3 were incubated with 0, 0.25 or 500 nM okadaic acid (OA) for 3 
hours and collected in PP1 buffer. Lysates were further incubated at 30ºC for 1 hour with or without 100 ng of PP1γ1 
protein. A- SH-SY5Y cells transfected with Myc-BRI2: A1 – Samples were loaded onto a normal SDS-PAGE; A2- 
Samples were loaded onto a phos-tag SDS-PAGE. B- SH-SY5Y cells transfected with Myc-BRI3: B1 – Samples were 
loaded onto a normal SDS-PAGE; B2- Samples were loaded onto a phos-tag SDS-PAGE. C. SH-SY5Y cells transfected 
with Myc-BRI2, Myc-BRI3 and PP1BM mutants (Myc-BRI2 KATA and Myc-BRI3AISA): C1- Samples were loaded 
onto a normal SDS-PAGE; C2- Samples were loaded onto a phos-tag SDS-PAGE. 
 
For BRI3 the results are quite similar. In the SDS-PAGE one can only detect two strong bands 
corresponding to BRI3 in the cellular extracts from SH-SY5Y cells transfected with Myc-BRI3 for 
all conditions tested (Figure II.A.7B1). In the phos-tag SDS-PAGE (Figure II.A.7B2) an increase is 
observed in BRI3 phosphorylation levels with OA treatment, particularly at the concentration that 
inhibits PP1 (OA 500 nM), as indicated by the presence of two slower migrating bands. Similarly to 
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BRI2 when cells are treated with OA and the lysates incubated with purified PP1J1 protein (100ng 
and 200ng) a decrease in the intensity of the two slower bands is observed, it appears that BRI3, is 
likewise, dephosphorylated in vitro by PP1J1. From the already suggested phosphorylated residues 
for BRI2 only Ser8 located at the intracellular domain. Regarding BRI3 the four suggested 
phosphorylated residues are located at the BRI3 intracellular domain. Given the localization of these 
residues, they are the putative PP1 target residues, and this issue deserves further investigation. 
Moreover, when using the same phos-tag SDS-PAGE approach to evaluate the phosphorylation 
levels of both BRI2 and BRI3 PP1BM double mutants (Figure II.A.7C), the relevance of the PP1BM 
is reinforced. As shown before, in Figure II.A.3B, Myc-BRI2 KATA mutant abolishes the interaction 
between PP1 and BRI2, while Myc-BRI3 AISA mutant significantly decreases the interaction 
between PP1 and BRI3. Therefore, the phosphorylation levels of the BRI2 and BRI3 double mutants 
were evaluated. For the Myc-BRI2 KATA multiple bands were observed, which is consistent with 
an increase in BRI2 phosphorylation levels (Figure II.A.7C2), which cannot be dephosphorylated 
given that the PP1 BM has been mutated and therefore PP1 cannot bind. The result was not so evident 
for the Myc-BRI3 AISA mutant. Although an extra slower migrating band could be detected with 
this mutant (Figure II.A.7C2*). Thus there is a contribution of this PP1BM to BRI3 
dephosphorylation, but consistent with the results shown in Figure II.A3, PP1 regulation of BRI3 
dephosphorylation is likely to involve levels other than the KISF domain identified.  
Given that both BRI2 and BRI3 PP1BM mutants produced dramatic alterations regarding PP1 
binding and consequently BRI2 and BRI3 phosphorylation levels, the consequence of partially or 
totally disrupting the BRI2:PP1 and BRI3:PP1 complexes was evaluated. Briefly, the subcellular 
localization of transiently transfected SH-SY5Y cells with the following constructs: Myc-BRI2, 
Myc-BRI2 KVTA, Myc-BRI2 KATA, Myc-BRI3, Myc-BRI3 KISA and Myc-BRI2 AISA, was 
compared. The results for BRI2 and BRI3 are presented in Figure II.A.8 and Figure II.A.9, 
respectively. For the subcellular distribution of Myc-BRI2, results were as described before in Fig. 
4B. Essentially, BRI2 is localized in ER, Golgi, vesicles and also to a few and short elongated cellular 
projections (‘processes’) (Figure II.A.8A and II.A.8B). For both the single (Myc-BRI2 KVTA) and 
double (Myc-BRI2 KATA) mutant there is a significant increase in the number of cellular projections 
and in the mean length of the higher elongated projection in the cell (Figure II.A.8A and II.A.8B). A 
remarkable phenotype was observed with the BRI2 double mutant, where a higher number of cellular 
processes per cell, and longer processes were clearly evident (Figure II.A.8A). A quantitative 
analysis using the ImageJ software was carried out, to determine the number of cellular projections 
and length of the longest process as previously described (da Rocha et al. 2015), results are presented 
in Figure II.A.8B. It was possible to establish that with Myc-BRI2 KATA, the mean value of cellular 
projections was around 14.81 ±1.94, and the mean length of the higher process around 22.98 Pm ± 
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0.48 (Figure II.A.8B). As mentioned, these results were significantly different from those determined 
for the wild-type Myc-BRI2, with the following results for the number of processes and length of the 
higher process: 2.54 ± 0.20 and 10.14 Pm ± 0.11, respectively (Figure II.A.8B). Consistently, the 
Myc-BRI2 KVTA (single mutant) produced an intermediate phenotype (Figure II.A.8A and 
II.A.8B). One can, therefore, conclude that BRI2 phosphorylation is a key event capable of 
modulating the number of neuritis, as well as the length of these processes in cells. This would place 
BRI2 at the forefront of neuritogenesis related events that will be further investigated. 
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Figure II.A. 8 - Immunolocalization of both Myc-BRI2 and PP1BM mutants (Myc-BRI2 KVTA and Myc-BRI2 
KATA). SH-SY5Y cells were transfected with Myc-BRI2 and both PP1BM mutants and then processed for 
immunofluorescence using specific antibodies against Myc-tag. A- Localization of Myc-BRI2, Myc-BRI2 KVTA and 
Myc-BRI2 KATA. B- Values are mean ± SEM (n=3, with each group containing 35 cells). Symbols represent the statistical 
significance: *, p-value<0.05; **, p-value<0.01; ***, p-value<0.001. Bars, 10 µm.  
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Myc-BRI3 subcellular distribution was similar to that previously presented in Fig. 5B, where it 
exhibits a higher number of elongated cellular projections (´processes’). Quantification was carried 
out using the ImageJ software and presented in Figure II.A.9A and II.A.9B. As for BRI2, the number 
of cellular projections emerging per cell was counted and the length of the longest projection for both 
Myc-BRI3 and its mutants were determined. Myc-BRI3 presented around 6.96 ± 0.09 projections 
per cell, the highest projection is around 19.77 Pm ± 1,87 (Figure II.A.9B). These results were not 
so different for both mutants where values of 8.66 ± 1.42 and 6.77 ± 0.43 were obtained for the 
number of processes for the single and double mutant, respectively. Regarding the length of the 
higher process, a decrease was observed, around 15.24 ± 0.45 and 17.01 ± 0.64 for Myc-BRI3 KISA 
and Myc-BRI3 AISA, respectively. Thus in BRI3 protein phosphorylation does not appear to 
promote the number or the length of processes associated with each cell. This is in marked contrast 
to the results observed for BRI2, where protein phosphorylation is the regulatory event modulating 
neuritic number and process length. However, it is also evident that the basal levels for BRI3 are 
much higher than those for BRI2. That is, the neuronal BRI3 isoform can sustain a neuronal 
phenotype independent of the PP1 BM. Whereas BRI2 depends on PP1 binding to the KVTF domain 
to repress neuritogenesis, it appears that if the protein is not dephosphorylated then neurite outgrowth 
is promoted. 
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Figure II.A. 9 - Immunolocalization of both Myc-BRI3 and PP1BM mutants (Myc-BRI3 KVTA and Myc-BRI3 
KATA). SH-SY5Y cells were transfected with Myc-BRI3 and both PP1BM mutants and then processed for 
immunofluorescence using specific antibodies against Myc-tag. A- Localization of Myc-BRI3, Myc-BRI3 KVTA and 
Myc-BRI3 KATA. B- Values are mean ± SEM (n=3, with each group containing 35 cells). Bars, 10 µm. 
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II.A.4. Conclusions 
BRI2 and BRI3 are two novel PP1 interacting proteins and it was demonstrated that the BRI2:PP1 
and BRI3:PP1 complexes exist in vitro and in vivo. The complexes appear to be physiologically 
relevant where BRI2 and BRI3 are phosphoproteins and simultaneously PP1 substrates.  
The use of BRI2 and BRI3 PP1BM mutants was crucial for determining the importance of RVxF 
motif for the PP1-BRI interaction. For BRI2, the interaction with PP1was abolished in the BRI2 
KATA mutant, presumably because that protein entered into an irreversible phosphorylation state; 
that is PP1 could no longer bind to dephosphorylate BRI2. For BRI3 it was not so clear since the 
interaction between BRI3 and PP1 was not completely abolished, it was nonetheless partially 
decreased, resulting in an increase in the phosphorylation levels of BRI3.  
BRI2 and BRI3 are proteins whose main cellular functions remain to be elucidated. Thus, the 
identification of the novel complexes, BRI2:PP1 and BRI3:PP1 is of paramount importance since it 
opens new avenues for the study of intracellular targeting and signaling events where protein 
phosphorylation represents a key regulatory mechanism. In fact, the BRI2 function is highly 
regulated by protein phosphorylation and upon abolishing PP1 binding, a dramatic increase in neurite 
outgrowth and cellular differentiation is observed. It seems that BRI2 is important for neuronal 
differentiation, namely for neuronal outgrowth. Interestingly, APP is also relevant for neuronal 
function, it is up-regulated in the developing nervous system and it is found enriched in growing 
neurites and neuritic growth cones (Schubert et al. 1991; Masliah et al. 1992; Ferreira et al. 1993). 
Moreover, it was shown that APP mediates in vitro neuritic outgrowth promoted by NGF (Milward 
et al. 1992) and RA plus brain-derived neurotrophic factor (Ruiz-León and Pascual 2003; Holback 
et al. 2005). It is noteworthy that BRI binds APP, both are phosphoproteins and both are PP1 
regulatory proteins. 
Two mutations have been described in the gene encoding the BRI2 protein associated with the 
development of Familial British Dementia (FBD) and Familial Danish Dementia (FDD); two 
autosomal dominant neurodegenerative diseases that share clinical and neuropathological 
characteristics with AD (Peng et al. 2010; Vidal et al. 2000). As already described both BRI2 and 
BRI3 interact with APP and play a strong regulatory role in the processing of APP, consequently 
regulating Aβ production (Matsuda et al. 2009; Matsuda et al. 2008; Fotinopoulou et al. 2005; 
Matsuda et al. 2011). The Aβ peptide is the major constituent of AD amyloid plaques, a key player 
in AD pathology. Increased Aβ production and aggregation is associated with neurotoxicity, 
activation of the inflammatory response, and apoptotic cascades (Jakob-Roetne and Jacobsen 2009). 
Furthermore, abnormal protein phosphorylation levels have been associated with several 
neuropathological disorders including AD due to abnormal protein kinase and protein phosphatase 
activities (Chung 2009; Gong et al. 2006; da Cruz e Silva and da Cruz e Silva 2003; Oliveira et al. 
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2015). For instance, APP was found to be hyperphosphorylated at Thr668 residue in AD brains, 
which is thought to increase Aβ production (Chung 2009). Recently we also reported that APP forms 
a trimeric complex with PP1 and Fe65 and that PP1 is responsible for dephosphorylation of APP at 
the Thr668 residue (Rebelo et al. 2013). Thus it seems critical to explore the hypothesis of a common 
physiopathological mechanism between the above mentioned neurodegenerative diseases. In closing, 
PP1 containing complexes, such as APP:Fe65:PP1 (Rebelo et al. 2013), LAP1:PP1 (Santos et al. 
2013), BRI2:PP1 and BRI3:PP1 are critical in regulating the phosphorylation-dependent molecular 
mechanisms associated with neuropathologies.  
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Supplementary Data 
 
Table II.A.S  1 - Oligonucleotides used to generate BRI2 and BRI3 PP1BM mutants generate d by Site-Directed 
Mutagenesis. 
Plasmid Name Template DNA Oligonucleotide sequence (5´-3´) 
FW RV 
pCMV-Myc-BRI2 
KVTA 
pCMV-Myc-BRI2 ATGGTGAAGGTGACGGCCAACTCCGC
TCTG 
CAGAGCGGAGTTGGCCGTCACCTTCA
CCAT 
pCMV-Myc-BRI2 
KATA 
pCMV-Myc-BRI2 
KVTA 
ATGGTGAAGGCGACGGCCAACTCCGC
TCTG 
CAGAGCGGAGTTGGCCGTCGCCTTCA
CCAT 
pCMV-Myc-BRI3 
KISA 
pCMV-Myc-BRI3 GTGAAGATTAGCGCCCAGCCCGCCGT
GGCTG 
CAGCCACGGCGGGCTGGGCGCTAATC
TTCAC 
pCMV-Myc-BRI3 
AISA 
pCMV-Myc-BRI3 
KISA 
ATGGTGGCGATTAGCGCCCAGCCCGC
CGT 
ACGGCGGGCTGGGCGCTAATCGCCAC
CAT 
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CHAPTER II.B – FUNCTIONAL CHARACTERIZATION OF THE BRI2:PP1 
COMPLEX 
 
“BRI2 processing and its neuritogenic role are modulated by protein phosphatase 1 
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Abstract 
BRI2 is a ubiquitously expressed type-II transmembrane phosphoprotein. BRI2 undergoes 
proteolytic processing into secreted fragments and during the maturation process it suffers post-
translational modifications. Of particular relevance, BRI2 is a protein phosphatase 1 (PP1) 
interacting protein, where PP1 is able to dephosphorylate the former. Further, disruption of the 
BRI2:PP1 complex, using BRI2 PP1 binding motif mutants, leads to increased BRI2 phosphorylation 
levels. However, the physiological function of BRI2 remains elusive; although findings suggest a 
role in neurite outgrowth and neuronal differentiation.  
In the work here presented, BRI2 expression during neuronal development was investigated. This 
increases during neuronal differentiation and an increase in its proteolytic processing is also evident. 
To elucidate the importance of BRI2 phosphorylation for both proteolytic processing and 
neuritogenesis, SH-SY5Y cells were transfected with the BRI2 PP1 binding motif mutant constructs. 
For the first time, it was possible to show that BRI2 phosphorylation is an important regulatory 
mechanism for its proteolytic processing and its neuritogenic role. Furthermore, by modulating BRI2 
processing using an ADAM10 inhibitor, a dual role for BRI2 in neurite outgrowth is suggested: 
phosphorylated full-length BRI2 appears to be important for the formation of neuritic processes, and 
BRI2 NTF promotes neurite elongation. This work significantly contributed to the understanding of 
the physiological function of BRI2 and its regulation by protein phosphorylation. 
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II.B.1. Introduction 
Reversible protein phosphorylation is a major regulatory mechanism for controlling several 
intracellular events in eukaryotic cells. PP1 catalyzes the majority of protein dephosphorylation 
events and it is involved in various cellular functions (Bollen et al. 2010; Heroes et al. 2013). PP1 
functional diversity is largely determined by the binding of its catalytic subunit to different specific 
regulatory subunits. For instance, when associated with its regulatory proteins, PP1 is involved in 
neuronal responses at several levels; neurotransmission, neurite outgrowth and synapse formation 
(Shi 2009; Wakula et al. 2003; Rebelo et al. 2015; da Cruz e Silva et al. 2004).  
BRI2 is a ubiquitously expressed type-II transmembrane protein. In the brain, it is particularly 
abundant in the hippocampus and cerebellum, when compared to the cerebral cortex (Vidal et al. 
1999). Interestingly, BRI2 undergoes proteolytic processing resulting in the formation of several 
secreted peptides. Cleavage in its ectodomain by a furin-like protease results in the release of a C-
terminal peptide of 23 amino acids and the remaining membrane-bound N-terminal portion was 
identified as the mature form of BRI2. Mature BRI2 is further cleaved by disintegrin and 
metalloproteinase domain-containing protein 10 (ADAM10) resulting in the secretion of a 25 kDa 
peptide which contains the conserved BRICHOS domain. The remaining membrane-associated N-
terminal fragment (NTF) can be further processed by SPPL2a/b; releasing an intracellular domain 
(BRI2 ICD) to the cytosol and a secreted C-terminal domain (Choi et al. 2004; Tsachaki et al. 2008; 
Lashley et al. 2008; Vidal et al. 1999). Moreover, during the maturation process in the cis-medial 
Golgi, the protein suffers post-translational modifications, such as glycosylation and 
phosphorylation, leading to various forms of BRI2 that may have different cellular locations and 
physiological functions (Martins et al. 2016; Lashley et al. 2008; Akiyama et al. 2004; Del Campo 
and Teunissen 2014; Tsachaki et al. 2011). In fact, four phosphorylatable residues have already been 
confirmed for BRI2: Ser8, Tyr76, Tyr112 and Tyr165 (Sharma et al. 2014; Demirkan et al. 2011). 
The precise physiological role of BRI2 remains elusive, however, some functions have been ascribed. 
Recently, using several techniques including BRI2 PP1-binding motif (PP1-BM) mutant constructs 
(Myc-BRI2 KVTA and Myc-BRI2 KATA constructs), we established that BRI2 is a novel PP1 
interacting protein, thus determining the importance of the RVxF motif (3KVTF6) for BRI2:PP1 
complex formation. Additionally, by using the Myc-BRI2 KATA mutant it was possible to 
completely abolish the interaction between BRI2 and PP1 and as a consequence, the BRI2 mutants 
mimic an irreversibly phosphorylated state in which PP1 is no longer able to dephosphorylate it. 
Interestingly, an increase in neurite outgrowth was observed when these mutants were expressed in 
SH-SY5Y cells (Martins et al. 2016). Moreover, BRI2 morphological distribution within proximal 
dendrites and axons, as well as cell bodies, and its presence in some pathological structures such as 
dystrophic neurites in senile plaques, suggests that BRI2 is transported along the axons’ processes 
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(Akiyama et al. 2004; Martins et al. 2016). Thus, it is plausible to assume that BRI2 is involved in 
the plasticity of neuronal processes and that it may also have a role at the nerve terminals (Akiyama 
et al. 2004; Choi et al. 2004). In fact, it was demonstrated that BRI2 promotes neurite outgrowth in 
BRI2 overexpressing human neuronal cells (Choi et al. 2004).  
Neuritogenesis is a complex and dynamic phenomenon in which neurites first emerge from the cell 
body and then begin extending away. These neurites are critical to generate the axons and dendrites 
of mature neurons that will further compose the adult brain. Therefore, neurite outgrowth is 
considered a prerequisite and early event for neuronal differentiation that involves several highly 
dynamic morphogenetic processes including neurite initiation, elongation, branching, growth cone 
motility, and collapse (da Silva and Dotti 2002). Interestingly, each of these phases involves 
morphological changes that are determined mostly by the regulation of specific signaling cascades, 
which in turn controls neuronal cytoskeletal dynamics, trafficking and also cellular adhesion.  
Thus, the aim of this study was to explore the functional relevance of the BRI2 phosphorylation on 
both BRI2 proteolytic processing and its neuritogenic role. BRI2 processing was monitored and 
modulated using an ADAM10 inhibitor in SH-SY5Y cells transfected with BRI2 PP1 binding motif 
mutants. Concomitantly a detailed characterization of the alterations related with neuritogenic 
phenotype was performed. BRI2 phosphorylation was further modulated using okadaic acid, a well-
established phosphatase inhibitor. Our results suggest a strong relationship between BRI2 
phosphorylation, namely PP1 dephosphorylation, and its processing. Based on the findings here 
presented, a role for the BRI2:PP1 complex in neurite outgrowth and neuronal differentiation is 
proposed, whereby phosphorylated full-length BRI2 seems to be crucial for the formation of neurites 
while increased BRI2 NTF assists neurite elongation.  
 
II.B.2. Materials and Methods 
II.B.2.1. Cell line culture and transfection  
The SH-SY5Y human neuroblastoma cell line was maintained in Minimal Essential Medium /F-12 
Nutrient Mixture (Gibco) using procedures previously described (Santos et al. 2013). Transient 
transfections of SH-SY5Y cells with the following constructs: Myc-BRI2; Myc-BRI2 3KVTA6 and 
Myc-BRI2 3KATA6 (mutated in the consensus PP1 binding motif 3KVTF6; PP1-BM mutants) were 
performed using TurboFect reagent (ThermoFisher Scientific) according to the manufacturer’s 
protocols. These constructs were previously produced and described (Martins et al. 2016).  
 
II.B.2.2. Neuronal primary cultures time-course 
Pregnant Wistar rats (12-16 weeks) were obtained from Harlan Interfaune Ibérica, SL. All 
experimental procedures followed the European legislation for animal experimentation 
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(2010/63/EU) and our Institutional Animal Care and Use Committee (IACUC): Comissão 
Responsável pela Experimentação e Bem-Estar Animal (CREBEA), approved the procedures 
performed. Essentially, the E18 pregnant rats were euthanized, by cervical stretching following 
decapitation and the 18 days rat embryos were decapitated and used for the isolation of cortex. This 
is within the European law (Council Directive 86/609/EEC), and during this procedure, all steps were 
taken to ameliorate animal suffering. Rat cortical primary cultures were established as previously 
described (Santos et al. 2014). Briefly, after dissociation with 0.45 mg/ml trypsin, cells were plated 
onto poly-D-lysine-coated dishes at a density of 1.06x105 cells/ cm2 in B27-supplemented 
Neurobasal medium (Gibco), a serum-free medium combination. The medium was supplemented 
with glutamine (0.5 mM) and gentamicin (60 mg/ml). Cultures were maintained in an atmosphere of 
5% CO2 at 37˚C. The cortical neurons were collected every two days, until 14 days in vitro (DIV), 
and further analyzed by SDS-PAGE and immunoblotting. 
 
II.B.2.3. Modulation of BRI2 phosphorylation levels  
SH-SY5Y cells were transfected with Myc-BRI2 and treated with 0.25 nM or 500 nM okadaic acid 
(OA) for 3 hours, and controls were exposed to vehicle (DMSO) for the same period. The cells were 
further harvested and processed for SDS-PAGE. 
 
II.B.2.4. Modulation of BRI2 processing 
SH-SY5Y transiently transfected cells were incubated for 48 hours with 10 µM of the GI254023X 
inhibitor, and controls were exposed to vehicle (DMSO) for the same period. GI254023X is a potent 
and selective ADAM10 metalloproteinase inhibitor that hinders BRI2 cleavage into BRI2 NTF. The 
cells were further processed for SDS-PAGE, and immunocytochemistry followed by morphometric 
analysis. 
 
II.B.2.5. SDS-PAGE and immunoblotting 
Cells were harvested using 1% boiling SDS and subsequently collected. Cell lysates were sonicated 
for 30 s and the total protein content was determined using Pierce s´ BCA kit (ThermoFisher 
Scientific). Mass-normalized samples were resolved on 5-20% gradient SDS-PAGE and 
electrophoretically transferred onto nitrocellulose membranes. These were initially stained with 
Ponceau S in order to assess gel loading, as previously described (Santos et al. 2015a; Klein et al. 
1995; Romero-Calvo et al. 2010). Primary antibodies used were: mouse monoclonal anti-Myc (Cell 
Signaling Technology), mouse monoclonal anti-BRI2 (raised against amino acids 1-54 at the N-
terminus of ITM2B of human origin; Santa Cruz Biotechnology), rabbit polyclonal anti-PP1γ (da 
Cruz e Silva et al. 1995), rabbit polyclonal anti-PP1α (da Cruz e Silva et al. 1995), mouse monoclonal 
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anti-acetylated α-tubulin (Sigma-Aldrich), mouse monoclonal anti-synaptophysin (Synaptic Systems 
GmbH), mouse monoclonal anti-β-III tubulin (Promega) and mouse monoclonal anti-β-actin (Novus 
Biologicals). These primary antibodies were incubated for 2 hours (anti-β-actin, anti-acetylated α-
tubulin, and anti-synaptophysin) to overnight (anti-Myc, anti-BRI2, anti-PP1γ and anti-PP1α). 
Detection was achieved using anti-mouse or anti-rabbit horseradish peroxidase-linked secondary 
antibodies (GE Healthcare) and proteins visualized by an enhanced chemiluminescence-based 
system. 
 
II.B.2.6. Morphological analysis by confocal microscopy  
For immunocytochemistry analysis, cells grown on coverslips were fixed using 4% 
paraformaldehyde and permeabilized with 0.2% TRITON X-100 (Rebelo et al. 2008). The following 
primary antibodies and secondary antibodies were used and incubated for 1hr to 2hrs: mouse 
monoclonal anti-Myc (Cell Signaling Technology), rabbit polyclonal anti-Myc (Cell Signaling 
Technology); mouse monoclonal acetylated α-tubulin (Sigma-Aldrich); Alexa Fluor® 488, 594 and 
405- conjugated IgGs (Molecular Probes). To stain filamentous actin (F-actin) Alexa Fluor® 568 
Phalloidin (Molecular Probes) in 1% bovine serum albumin phosphate-buffered saline was added for 
30 min. Preparations were mounted with Vectashield® media with or without DAPI (Vector 
Laboratories) and visualized using an LSM510-Meta confocal microscope (Carl Zeiss Microimaging 
GmbH) and a 63x/1.4 oil immersion objective. Microphotographs were acquired in a sole section in 
the Z-axis (xy mode) and represent a mean of 16 scans. Morphometric analyses of SH-SY5Y cells 
were performed using ImageJ software (U. S. National Institutes of Health). The total numbers of 
cellular processes emerging from the cell were counted and the length of the longest process was 
measured. Processes were categorized as indicated: ‘< 20 µM’ – processes shorter than ‘20 µM; 20-
35 µM’ – processes longer than 20 µM but shorter than 35 µM (also named pre-neurites); ‘> 35 µM’ 
– processes longer than 35 µM (also named neurites, since they are longer than two cell body lengths) 
(da Rocha et al. 2015; Dehmelt and Halpain 2004). Data were expressed as the number of processes 
per cell and the percentages of cells that possess each of the categories of the processes. The 
fluorescence intensity of F-actin staining was also quantified using the ImageJ software and data 
were expressed as the ratio of the fluorescence intensity of the transfected cells per the fluorescence 
intensity of the non-transfected cells (Santos et al. 2015b).  
 
II.B.2.7. Data analysis and statistics 
Ponceau-S stained membranes and autoradiograms were scanned (GS-800 calibrated imaging 
densitometer; Bio-Rad) and protein bands quantified using the Image Lab software. All data were 
corrected relative to loading control (Ponceau-S) and were expressed as mean ± SEM (standard error) 
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of at least three independent experiments. Statistical significance analysis was conducted (GraphPad 
Prism6 software) and, when appropriate, data were analyzed using unpaired two-tailed student’s t-
test and one-way ANOVA followed by the Dunnett's multi-comparisons test, for comparison of data 
with control values. 
 
II.B.3. Results 
II.B.3.1. BRI2 protein levels during neuronal development 
Given our previous results and the work of Choi and colleagues (Choi et al. 2004), BRI2 seems to 
have a relevant but undisclosed role in neuritogenesis, which incited the work here presented. Hence, 
BRI2 intracellular levels were assessed during neuronal development (establishment of rat cortical 
primary cultures up to 14 DIV). The data showed that full-length BRI2 levels significantly increased 
during neuronal development (Figure II.B.1) reaching a maximum level between 10 DIV and 12 DIV 
and decreased slightly at 14 DIV. Of note, the mature BRI2 was more evident upon 10 DIV, which 
is consistent with a robust increase in the BRI2 NTF (Figure II.B.1). These results indicated that 
BRI2 is highly expressed in functional mature neurons since its intracellular levels correlated well 
with synaptophysin levels, a pre-synaptic marker. Interestingly, the full-length BRI2 and BRI2 NTF 
levels also seemed to correlate with the levels of a neuron-specific and well-characterized marker of 
neuronal differentiation, β-III tubulin. Both PP1γ and PP1α were used as additional differentiation 
markers confirming that BRI2 expression appeared to correlate with neuronal differentiation. 
Ponceau S staining was used as a loading control, as previously described (Romero-Calvo et al. 2010; 
Klein et al. 1995; Santos et al. 2014) (Figure II.B.1). 
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Figure II.B. 1 - BRI2 expression during neuronal differentiation. Endogenous BRI2 levels were detected for 14 days 
in vitro (DIV), during the establishment of rat cortical primary neurons from 2 DIV to 14 DIV. Synaptophysin, PP1α, PP1γ, 
and β-III tubulin levels of expression are also presented. Ponceau S staining was used to assess gel loading. The quantitative 
data for relative BRI2 levels are presented graphically on the bottom as mean ± SEM of 3 independent experiments. # p < 
0.05 for comparisons to 2DIV condition by using one-way ANOVA followed by the Dunnett’s test. imBRI2, immature 
BRI2; mBRI2, mature BRI2; BRI2 NTF, BRI2 N-terminal fragment. 
 
II.B.3.2. BRI2 processing is modulated by protein phosphatase 1 binding 
Given that both BRI2 and BRI2 NTFs levels in cortical neurons seem to correlate with neuronal 
differentiation we hypothesized that the same was occurring with our previously described BRI2 
PP1-BM mutants. Therefore, BRI2 processing was monitored in SH-SY5Y cells transiently 
transfected with the Myc-BRI2, Myc-BRI2 KVTA and Myc-BRI2 KATA constructs (BRI2 PP1-BM 
mutants) for 24 hrs and 48 hrs (Figure II.B.2).  Essentially, at the 24hrs time point, an intracellular 
accumulation of BRI2 NTFs with the Myc-BRI2 KATA construct was observed, resulting from an 
increase in its processing (Figure II.B.2A). The result was quite robust at the 48hrs time point, where 
a significant increase of the BRI2 NTFs was observed with both mutants, Myc-BRI2 KVTA (p<0.05 
by the one-way ANOVA) and Myc-BRI2 KATA (p<0.001 by the one-way ANOVA). Additionally, 
given that during neuronal development there appears to be an increase in BRI2 NTF, which 
correlates with an increase in β-III tubulin (Figure II.B.1), the levels of the latter protein were also 
assessed. The neuron-specific β-III tubulin, which is a well-established SH-SY5Y differentiation 
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marker (Dwane et al. 2013; Forster et al. 2016), was present in non-transfected cells, but the levels 
increased in cells transfected with either the Myc-BRI2 or the BRI2 PP1-BM constructs. After 24hrs 
of transfection, the levels of β-III tubulin showed a tendency to increase, particularly with the BRI2 
PP1-BM (Figure II.B.2B). At the 48 hrs time point, this tendency rendered a significant increase in 
β-III tubulin levels with the BRI2 PP1-BM mutant constructs (p<0.001 by the one-way ANOVA for 
Myc-BRI2 KVTA and p<0.0001 by the one-way ANOVA for Myc-BRI2 KATA; Figure II.B.2B), 
which suggests the appearance of neuronal features. 
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Figure II.B. 2 - BRI2 processing analysis in SH-SY5Y cells transfected with Myc-BRI2 constructs. Analysis of Myc-
tagged BRI2 proteins by immunoblotting were performed using a Myc monoclonal antibody. In order to assess BRI2 
processing, the ratio of BRI2 N-terminal fragments (BRI2 NTFs) with BRI2 full-length protein was calculated. Of note, 
the same results were obtained when an N-terminal BRI2 antibody was used (data not shown). A -SH-SY5Y cells were 
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transfected with Myc-BRI2, Myc-BRI2 KVTA and Myc-BRI2 KATA constructs for 24 hrs and 48 hrs. The quantitative 
data are presented as mean ± SEM of at least 4 independent experiments.  #/* p < 0.05, ** p < 0.01, ### p < 0.001. Statistical 
symbols: (#) for comparisons with the Myc-BRI2 24 hrs by using one-way ANOVA followed by the Dunnett’s test; (*) for 
comparisons between each construct at 24 hrs and 48 hrs by using t -student´s test. B – SH-SY5Y cells were transfected 
with Myc-BRI2, Myc-BRI2 KVTA and Myc-BRI2 KATA constructs for 24 hrs and 48 hrs and analyzed the β-III tubulin 
levels by immunoblotting. The protein levels were plotted as fold increases of CNT for both 24 hrs and 48 hrs. The 
quantitative data are presented as mean ± SEM of at least 4 independent experiments.  ### p < 0.001, #### p < 0.001 for 
comparisons to 48 hrs CNT by using one-way ANOVA followed by the Dunnett’s test . BRI2 NTF, BRI2 N-terminal 
fragment; CNT, non-transfected control. C - SH-SY5Y cells were transfected with Myc-BRI2 were incubated with 0, 0.25 
or 500 nM of okadaic acid (OA) for 3 hours. The quantitative data are presented as mean ± SEM of 3 independent 
experiments.  # p < 0.05, for comparisons with the Myc-BRI2 without okadaic acid by using one-way ANOVA followed 
by the Dunnett’s test.  
 
Our previous studies using a phos-tag SDS-PAGE approach revealed an increase in the BRI2 
phosphorylation levels upon treatment with okadaic acid (OA), a protein phosphatase inhibitor. 
Remarkably, higher BRI2 phosphorylation levels were achieved when PP1 was inhibited (higher OA 
concentration - OA 500 nM) this is partially reversed when purified PP1 protein is added (Martins et 
al. 2016). Therefore, in order to clearly determine if protein phosphorylation is an important 
regulatory mechanism of BRI2 processing, particularly by involving PP1 mediated 
dephosphorylation, SH-SY5Y cells transfected with the Myc-BRI2 construct, were incubated with 
two concentrations of OA, for 3 hours. In fact, upon OA treatment an increase in the BRI2 processing 
(BRI2 NTF/BRI2 ratio) was achieved, being only significant when PP1 was inhibited (OA 500 nM) 
(Figure II.B.2C). 
 
II.B.3.3. Characterization of the BRI2 neuritogenic-related alterations 
A detailed cellular morphometric analysis was performed upon transient transfection of SH-SY5Y 
cells, for 24hrs and 48hrs, with wild-type BRI2 and BRI2 PP1-BM constructs. Overall, there was an 
increase in the total number of cellular processes upon 48hrs of transfection with Myc-BRI2 (Figure 
II.B.3A1), Myc-BRI2 KVTA (Figure II.B.3A2) and Myc-BRI2 KATA (Figure II.B.3A3), when 
compared with the 24 hrs time point. The mean value of cellular processes significantly increased 
from 2.5 to 7.3 (p<0.01 by the two-tailed Student’s t-test) for Myc-BRI2, from 4.6 to 15.8 (p<0.001 
by the two-tailed Student’s t-test) for Myc-BRI2 KVTA and from 14.8 to 36.9 (p<0.01 by the two-
tailed Student’s t-test) for Myc-BRI2 KATA (Figure II.B.3A1, 3A.2 and 3A.3). Neuritogenesis was 
further evaluated by scoring the length of the longest cellular process presented by the transfected 
cells as described in the materials and methods sections. Upon 24hrs of transfection with Myc-BRI2, 
more than 86 % of the cells analyzed had processes shorter than 20 Pm, while only 9% and 4.5 % of 
cells presented processes that were between 20-35 Pm and > 35 Pm, respectively (Figure II.B.3B). 
The phenotype observed with Myc-BRI2 KVTA was slightly different, presenting a higher 
percentage of cells with pre-neurites and neurites (Figure II.B.3B). However, the phenotype changed 
dramatically with the Myc-BRI2 KATA displaying a significant decrease in the number of processes 
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shorter than 20 Pm (p<0.001 by the one-way ANOVA) and a concomitant increase in the number of 
processes with 20-35 Pm and longer > 35 Pm (p<0.01 and p<0.01, respectively, by the one-way 
ANOVA) when compared with Myc-BRI2 (Figure II.B.3B). Interestingly, upon 48hrs of 
transfection, the results were quite different from those observed at the 24hrs time point. With Myc-
BRI2 a significant decrease in the % of cells with smaller length processes (<20 Pm) was observed 
(p<0.001 by the two-tailed Student’s t-test), while for the other two categories of processes the 
percentage significantly increased (pre-neurites and neurites; p<0.001 by the two-tailed Student’s t-
test) (Figure II.B.3B). A dramatic alteration was evident with the Myc-BRI2 KVTA and Myc-BRI2 
KATA mutants; where a significant decrease in the number of processes shorter than 20 Pm was 
scored (p<0.0001 by the two-tailed Student’s t-test), as well as a corresponding increase in the 
processes with a longer length, particularly those more than 35 Pm (p<0.05 for Myc-BRI2 KVTA 
and p<0.001 for Myc-BRI2 KATA, by the two-tailed Student’s t-test) (Figure II.B.3B).  
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Figure II.B. 3 - Morphometric analysis of the cellular processes in SH-SY5Y cells transfected with Myc-BRI2, Myc-
BRI2 KVTA and Myc-BRI2 KATA constructs. A- Subcellular distribution of Myc-BRI2 (A.1), Myc-BRI2 KVTA (A.2) 
and Myc-BRI2 KATA (A.3) and the respective quantitative analysis of the total number of processes in SH-SY5Y cells 
transfected for 24 hrs and 48 hrs. Quantitative data are presented as mean ± SEM and obtained by analyzing at least 30 
cells per condition from three independent experiments. ** p < 0.01, *** p < 0.001 for comparisons between 24 hrs and 48 
hrs, by using t-student´s test. Bars, 10 µm. B – Percentage of cells with each type of processes in SH-SY5Y cells transfected 
with Myc-BRI2, Myc-BRI2 KVTA and Myc-BRI2 KATA constructs for 24 hrs and 48 hrs. Processes were categorized 
according to their lengths, and the percentages of processes with length inferior to 20 µm (< 20 µm), pre-neurites (20–35 
µm) and neurites (≥ 35 µm) calculated out of the total number of processes. The quantitative data are presented as mean ± 
SEM and was obtained by analyzing at least 30 cells per condition from three independent experiments. #/* p < 0.05, 
++/##/** p < 0.01, +++/*** p < 0.001, #### p < 0.0001. Statistical symbols: (+) for comparisons to Myc-BRI2 at 24 hrs 
by using one-way ANOVA followed by the Dunnett’s test; (#) for comparisons to Myc-BRI2 at 48 hrs by using one-way 
ANOVA followed by the Dunnett’s test; (*) for comparisons between each construct at 24 hrs and 48 hrs by using t -
student´s test. 
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Given that the morphological alterations observed when BRI2 became phosphorylated (BRI2 PP1-
BM mutants) are consistent with neurite outgrowth and neuronal differentiation, cytoskeleton 
alterations were subsequently investigated. Essentially, the levels of acetylated α-tubulin 
(microtubules (MT) stabilization), β-actin and F-actin (actin remodeling) were evaluated upon 
transfection with Myc-BRI2 and both BRI2 PP1-BM mutants for 24 hrs and 48 hrs (Figure II.B.4 
and Figure II.B.5). Acetylated α-tubulin levels (an indirect measure of MTs stabilization) were 
significantly lower with both mutants, Myc-BRI2 KVTA (p<0.05 by the one-way ANOVA) and 
Myc-BRI2 KATA (p<0.05 by the one-way ANOVA) after 24 hrs of transfection (Figure II.B.4A). 
This decrease correlates with the requirement of MTs instability, during the initial steps of 
neuritogenesis, and is associated with the emergence of processes and the elongation of smaller 
processes (da Rocha et al. 2015). Interestingly, after 48 hrs of transfection, the acetylated α-tubulin 
levels increased significantly for Myc-BRI2 KVTA (p<0.05 by the one-way ANOVA) and Myc-
BRI2 KATA (p<0.01 by the one-way ANOVA) constructs, which are associated with the longer 
neuritic elongation observed in these conditions (Figure II.B.4A). Upon evaluating the levels of β-
actin a slight increase, at 24 hrs and 48 hrs of transfection with both BRI2 PP1-BM constructs, was 
observed (Figure II.B.4B).  
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Figure II.B. 4 - Profiles of acetylated α-tubulin and β-actin in SH-SY5Y cells transfected with Myc-BRI2, Myc-BRI2 
KVTA and Myc-BRI2 KATA constructs. Analysis of acetylated α-tubulin (A) and β-actin (B) levels by immunoblotting 
in SH-SY5Y transfected cells with Myc-BRI2, Myc-BRI2 KVTA and Myc-BRI2 KATA constructs for 24 hrs and 48 hrs. 
The protein levels were plotted as fold increases of CNT for both 24 hrs and 48 hrs. The quantitative data are presented as 
mean ± SEM of at least 4 independent experiments. +/# p < 0.05, ##/** p < 0.01, **** p < 0.0001. Statistical symbols: (+) 
for comparisons to CNT at 24 hrs by using one-way ANOVA followed by the Dunnett’s test; (#) for comparisons to CNT 
at 48 hrs by using one-way ANOVA followed by the Dunnett’s test; (*) for comparisons between each construct at 24 hrs 
and 48 hrs by using t-student´s test. CNT, non-transfected control; Acetyl Tub, acetylated α-tubulin.  
 
Furthermore, we investigated actin remodeling by immunocytochemistry using F-actin as a specific 
marker of actin polymerization, thereby monitoring actin dynamics (Figure II.B.5). Overall, it was 
clear that the F-actin levels in transfected cells were higher than in the non-transfected cells for both 
time points analyzed (24 hrs and 48 hrs of transfection; Figure II.B.5A and B, respectively).  
Quantification clearly indicated that F-actin levels significantly increased with both Myc-BRI2 
mutants (p<0.0001 by the one-way ANOVA for Myc-BRI2 KVTA, and p<0.0001 by the one-way 
ANOVA for Myc-BRI2 KATA) at the 24 hrs time point compared with Myc-BRI2 (Figure II.B.5A 
and C). This increase was also observed with both mutants at the 48 hrs time point (Figure II.B.5B 
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and C), being significant for the Myc-BRI2 KATA mutant (p<0.05 by the one-way ANOVA). 
Consistent with the previous results, we observed decreased α-tubulin acetylation upon 24 hrs of 
transfection and an increase after 48 hrs (Figure II.B.5A and B).  
 
 
 
Figure II.B. 5 - Cellular localization of Myc-tagged BRI2 proteins, acetylated α-tubulin, and F-actin in SH-SY5Y 
cells transfected with Myc-BRI2, Myc-BRI2 KVTA and Myc-BRI2 KATA constructs. Subcellular localization of 
Myc-tagged BRI2 (green) and acetylated α-tubulin (blue) were analyzed by immunocytochemistry analysis using the 
polyclonal Myc-tag and monoclonal acetylated α-tubulin antibodies upon 24 hrs (A) or 48 hrs (B) of SH-SY5Y cells 
transfection. F-actin was probed with red fluorescent-labelled phalloidin. C- The quantitative data for F-actin stain are 
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presented as mean ± SEM of the ratio of the fluorescence intensity of the transfected cells per the fluorescence intensity of 
the non-transfected cells (n = 30). #/* p < 0.05, ++++ p < 0.0001. Statistical symbols: (+) for comparisons to Myc-BRI2 at 
24 hrs by using one-way ANOVA followed by the Dunnett’s test; (#) for comparisons to Myc-BRI2 at 48 hrs by using one-
way ANOVA followed by the Dunnett’s test; (*) for comparisons between each construct at 24 hrs and 48 hrs by using t -
student´s test. Bars, 10 µm. Acetyl. Tub., acetylated α-tubulin; F-actin FI, F-actin fluorescence intensity. 
 
 
II.B.3.4. Modulating BRI2 NTF levels using an ADAM10 inhibitor 
As presented above, it was possible to establish that BRI2 phosphorylation induced robust 
morphological alterations consistent with neuritogenesis. Interestingly, this neuritogenic phenotype 
not only correlated well with BRI2 phosphorylation levels but also with the BRI2 processing profile. 
Thus, further evidence for the involvement of BRI2 NTF on the neuritogenic phenotype induced by 
BRI2 phosphorylation was sought. Hence, BRI2 NTFs levels were modulated in SH-SY5Y cells 
expressing either the Myc-BRI2 or the Myc-BRI2 PP1-BM mutants by inhibiting BRI2 cleavage by 
ADAM10 using 10 µM of GI254023X inhibitor for 48 hrs. Upon modulation of BRI2 processing 
(Fig. II.B.6), morphological evaluation of the cells was performed and the quantitative data is 
presented in figure II.B.7. In fact, using the specific ADAM10 inhibitor (GI254023X) for 48 hrs a 
significant decrease was observed in the levels of BRI2 NTF (p<0.0001 by the two-tailed Student’s 
t-test for Myc-BRI2, and p<0.05 by the two-tailed Student’s t-test for Myc-BRI2 KVTA) when 
compared with control (Fig. II.B.6). 
 
 
Figure II.B. 6 - Modulation of BRI2 processing in SH-SY5Y cells transfected with Myc-BRI2, Myc-BRI2 KVTA 
and Myc-BRI2 KATA constructs. SH-SY5Y cells were transfected with Myc-BRI2, Myc-BRI2 KVTA and Myc-BRI2 
KATA constructs for 24 hrs and 48 hrs, incubated with GI254023X inhibitor. Controls were exposed to vehicle (DMSO). 
Analysis of Myc-tagged BRI2 proteins by immunoblotting after 24 hrs and 48 hrs of transfection. The quantitative data are 
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presented as mean ± SEM of the ratio of BRI2 N-terminal fragments (BRI2 NTFs) with BRI2 full-length protein. * p < 
0.05, ### p < 0.001, **** p < 0.0001. Statistical symbols: (#) for comparisons with the Myc-BRI2 24 hrs by using one-
way ANOVA followed by the Dunnett’s test; (*) for comparisons between each construct at 24 hrs and 48 hrs by using t -
student´s test. BRI2 NTF, BRI2 N-terminal fragment. 
 
Moreover, morphometric analysis clearly indicated that when the BRI2 NTF’s levels are diminished 
a significant increase in the number of cellular processes was evident (p<0.001 for Myc-BRI2 (Fig. 
II.B.7A.1), p<0.05 for Myc-BRI2 KVTA (Fig. II.B.7A.2) and p<0.05 for Myc-BRI2 KATA (Fig. 
II.B.7A.3), all determined by the two-tailed Student’s t-test; Fig. II.B.7A). Neuritogenesis was 
further evaluated as previously described, by scoring the length of the longest cellular process 
presented by the transfected cells in control and inhibitor conditions (Fig. II.B.7B). Interestingly, 
upon 48 hrs of transfection with GI254023X exposure, the results were quite different from those 
observed in the control condition. With Myc-BRI2 the % of cells with smaller length processes (<20 
Pm) were quite similar, while for the higher length processes (neurites) the percentage decreased 
(Fig. II.B.7B). Similar results were observed for PP1-BM mutants, however, a significant decrease 
in the number of processes higher than 35 Pm was clear (p<0.05 by the two-tailed Student’s t-test), 
mirrored by a corresponding increase of processes between 20-35 Pm length (p<0.05 by the two-
tailed Student’s t-test) with Myc-BRI2 KATA (Fig. II.B.7B). 
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Figure II.B. 7 - Morphometric analysis of the cellular processes in SH-SY5Y cells transfected with Myc-BRI2, Myc-
BRI2 KVTA and Myc-BRI2 KATA constructs followed by treatment with GI254023X inhibitor. A- Subcellular 
distribution of Myc-BRI2, Myc-BRI2 KVTA and Myc-BRI2 KATA after 48 hrs of transfection and the respective 
quantitative analysis of the total number of processes. Quantitative data are presented as mean ± SEM and obtained by 
analyzing at least 30 cells per condition from 3 independent experiments. * p < 0.05, *** p < 0.001 for comparisons between 
control and GI254023X conditions, by using t-student´s test. Bars, 10 µm. B – Percentage of cells with each type of 
processes. Processes were categorized according to their lengths, and the percentages of processes with length inferior to 
20 µm (< 20 µm), pre-neurites (20–35 µm) and neurites (≥ 35 µm) calculated out of the total number of processes. The 
quantitative data are presented as mean ± SEM and was obtained by analyzing at least 30 cells per condition from three 
independent experiments. +/#/* p < 0.05, ++/** p < 0.01, +++ p < 0.001. Statistical symbols: (+) for comparisons to Myc-
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BRI2 at control condition by using one-way ANOVA followed by the Dunnett’s test; (#) for comparisons to Myc-BRI2 at 
GI254023X condition by using one-way ANOVA followed by the Dunnett’s test; (*) for comparisons between each 
construct at control and GI254023X conditions by using t-student´s test. 
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II.B.4. Discussion 
BRI2 is a type II transmembrane protein whose main physiological role remains to be elucidated. 
Nevertheless, some functions have already been proposed, namely its association with neurite 
outgrowth and neuronal differentiation (Akiyama et al. 2004; Martins et al. 2016; Choi et al. 2004). 
In fact, here we showed that both BRI2 levels and processing significantly increased during neuronal 
development (Figure II.B.1). The impact of BRI2 phosphorylation in the suggested BRI2 
neuritogenic role was unequivocally demonstrated upon, a detailed morphometric analysis of SH-
SY5Y cells transfected with BRI2 and BRI2 PP1-BM constructs. It was extremely clear that when 
BRI2:PP1 interaction is abolished a phenotype consistent with neurite outgrowth and neuronal 
differentiation is observed. Of note, morphological changes and remodeling occurring during 
neuronal differentiation depend on cytoskeleton alterations. In line with this, we found that upon 24 
hrs of transfection, particularly with the BRI2 PP1-BM constructs, a significant decrease in 
acetylated α-tubulin and a significant increase in actin polymerization were evident (Figure II.B.4A 
and Fig. 5, respectively). This is consistent with the emergence and elongation of cellular processes, 
which requires MT instability and remodeling of actin filaments (da Rocha et al. 2015; Sliogeryte et 
al. 2014; Xu et al. 2009). At the 48 hrs time point, the significant increase in actin polymerization 
was maintained with the transfection of BRI2 PP1-BM constructs (Figure II.B.5). Interestingly, at 
this time point with the PP1-BM mutants acetylated tubulin increases significantly (Fig. 4A) which 
is related to the neuritic elongation and stabilization (da Rocha et al. 2015). Taken together, these 
findings suggest protein phosphorylation, namely dephosphorylation by PP1, is a regulatory 
mechanism for BRI2’s neuritogenic role. This hypothesis is in line with numerous evidence 
implicating post-translational modifications in the regulation of dynamic events such as neurite 
outgrowth, hence the downstream signaling pathways deserve to be investigated. Interestingly, it is 
well known that phosphorylation of APP which has been previously shown to be functionally related 
to BRI2, plays a significant role in neurite outgrowth (Ando et al. 1999). These neurotrophic 
activities were attributed to both full- length APP and the sAPPα (secreted APP fragment derived 
from α-secretase APP processing) (Perez et al. 1997; Young-Pearse et al. 2008). 
Moreover, in this manuscript we provide for the first time evidence suggesting that BRI2 
phosphorylation, namely PP1 dephosphorylation, regulates BRI2 processing (Figure II.B.2A and 2C) 
since when BRI2:PP1 interaction is abolished (using BRI2 PP1-BM mutants) or PP1 inhibition 
(using OA) an increase in BRI2 phosphorylation is observed; that is well correlated with a significant 
increase in BRI2 processing. Therefore, having established that BRI2 phosphorylation is well 
correlated with its processing and neuritogenic role, we further investigated the involvement of BRI2 
NTF on neurite outgrowth. By decreasing BRI2 cleavage by ADAM10 with a specific inhibitor, 
GI254023X, in SH-SY5Y cells transfected with BRI2 and the BRI2 PP1-BM constructs (Figure 
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II.B.6) there was an increase in the number of total processes per cell compared to control and a 
decrease in the % of cells with longer processes (>35 µM), with both of the PP1-BM mutants that 
correlated well with the decrease in BRI2 NTF. It can, therefore, be contemplated that for BRI2 
mediated neurite outgrowth, phosphorylation of full-length protein promotes the emergence of 
neurites, whereas the increased BRI2 NTFs play a relevant role in neurites’ elongation and 
stabilization. BRI2 is able to form homodimers linked by disulfide bonds that together with 
monomers appear at the cell surface (Tsachaki et al. 2010). As described for other proteins, BRI2 
may act as a cell surface receptor that participates in signal transduction pathways, namely neurite 
outgrowth signaling pathways, triggered by ligand interaction. It is also possible that the importance 
of full-length BRI2 in mediating neurite outgrowth was modulated by protein interactions that require 
BRI2 phosphorylation since it induces conformational changes in the protein, potentially affecting 
binding specificity and affinity. Regarding the role of BRI2 processing in neuritogenesis, it is 
reasonable to assume that if BRI2 s´ NTF increase, the secreted fragment which contains the 
conserved BRICHOS domain also increases, where ADAM10 is responsible for the increased 
processing. In addition, it is possible that subsequent intramembrane cleavage of this fragment by 
SPPL2a/2b is also augmented. As a result of this proteolysis, a small secreted BRI2 C-terminal 
domain, and an intracellular domain, the BRI2ICD are generated. Recently it was described that 
BRI2ICD can translocate to the nucleus suggesting a particular function for this fragment in signal 
transduction and transcriptional regulation as already demonstrated for the APP intracellular domain 
(AICD) (Mentrup et al. 2015; Rebelo et al. 2013). Actually, AICD translocation to the nucleus is 
regulated by APP phosphorylation and facilitates neurite outgrowth (Zhou et al. 2012; Chang et al. 
2006). Thus, further studies are required to unravel the precise mechanisms underlying the BRI2 
neuritogenic role. 
In summary, the data here presented supports a functional role for the BRI2:PP1 complex by 
modulating BRI2 phosphorylation, and simultaneously regulating BRI2 processing and consequently 
its neuritogenic role. Thereby, we further suggest that the BRI2:PP1 complex is essential to 
dynamically regulate neurite outgrowth (Figure II.B.8).  
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Figure II.B. 8 - Schematic depiction of BRI2 phosphorylation induced neurite outgrowth. BRI2 and PP1 interact 
through the RVTF motif (RVxF conserved motif) present in BRI2 protein regulating its phosphorylation levels, namely 
dephosphorylation by PP1. When BRI2:PP1 complex formation is impaired BRI2 becomes phosphorylated. The increase 
in BRI2 phosphorylation levels favors its processing and greatly induces neurite outgrowth: promotes the formation of 
cellular processes and its elongation and stabilization. 
 
BRI2 was found mutated in two autosomal dominant neurodegenerative diseases, Familial British 
Dementia (FBD) and Familial Danish Dementia (FDD) that share clinical and neuropathological 
features with Alzheimer s´ disease. Both disorders are characterized by the deposition of the 
amyloidogenic peptides ABri and ADan in the patients’ brains. These peptides derive from the 
proteolytic processing of mutated forms of BRI2 (ABriPP and ADanPP) by furin in FBD and FDD, 
respectively (Rostagno et al. 2005). Interestingly, Choi and colleagues demonstrated that expression 
of ABriPP and ADanPP in N2a cells induces elongation of neurites (Choi et al. 2004). By unraveling 
the importance of BRI2 phosphorylation and proteolytic processing for the function of BRI2 we are 
contributing to the understanding of the pathological events leading to FBD and FDD. Functionally, 
the BRI2:PP1 complex may have important direct implications for the development of all these 
neurodegenerative disorders and this issue should be further investigated in the future. 
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Abstract 
BRI family proteins are ubiquitous type II transmembrane proteins but BRI2 is highly expressed in 
some neuronal tissues. Possible BRI2 functions include neuronal maturation and differentiation. 
BRI2 protein complexes appear to be important in mediating some of the functions attributed to this 
protein. Previously described BRI2 interactors include Alzheimer’s amyloid precursor protein and 
protein phosphatase 1, however the identification of novel interactors provides an important tool to 
understand the role and function of BRI2. To this end three rat brain regions (cerebellum, 
hippocampus, and cerebral cortex) were processed for BRI2 immunoprecipitation; co-precipitating 
proteins were identified by Nano-HPLC-MS/MS. The pool of the brain regions resulted in 511 BRI2 
interacting proteins (BRI2 brain interactome) of which 120 were brain specific and 49 involved in 
neuronal differentiation. Brain region specific analyses were also carried out for the cerebellum, 
hippocampus, and cerebral cortex. Several novel BRI2 interactors were identified among them 
DLG4/PSD-95, which is singularly important as it places BRI2 in the postsynaptic compartment. In 
essence, the results elucidating the BRI2 brain interactome, associated this protein with neurite 
outgrowth and neuronal differentiation, and synaptic signaling and plasticity. It follows that further 
studies should address BRI2 particularly given its relevance to neuropathological conditions. 
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III.A.1 Introduction 
BRI2 (also known as ITM2B, integral membrane protein 2B) is a ubiquitously expressed type II 
transmembrane protein that belongs to a family comprising two additional members, BRI1 and BRI3. 
BRI2 mRNA was found highly expressed in the brain, placenta, pancreas, and kidney, whereas lower 
expression levels were observed in heart, lung, liver and skeletal muscle. Remarkably, in the brain, 
BRI2 is predominantly detected in the cerebellum, spinal cord, subthalamic nucleus, substantia nigra, 
and hippocampus. However, lower expression levels were detected in the cerebral cortex, amygdala, 
and thalamus (Vidal et al. 1999). Moreover, using in situ hybridization it was demonstrated that 
within the brain, BRI2 mRNA is distributed in different cellular populations, namely in neurons, 
astrocytes and microglial cells as well as in smooth muscle and cerebral endothelial cells (Rostagno 
et al. 2005). Subcellularly, BRI2 is mainly localized in the endoplasmic reticulum (ER), Golgi 
apparatus, plasma membrane and cytoplasmic vesicles (Choi et al. 2004). BRI2 undergoes regulated 
intramembrane proteolysis (RIP) in the cis- or medial-Golgi resulting in the formation of several 
secreted peptides, including the C-terminal 23-residue peptide, the BRICHOS domain, the NTF and 
BRI2 C-terminal domain, and an intracellular domain (BRI2 ICD), as consequence of the activity of 
several proteases (Choi et al. 2004).  
The distribution of BRI2 within proximal dendrites and axons, as well as cell bodies, and its presence 
in some neuropathological structures like dystrophic neurites, suggests that BRI2 could be 
anterogradely transported to the nerve terminals, where it may have a role (Akiyama et al. 2004). In 
fact, BRI2 overexpression in human neuronal cells induces neurites’ elongation, indicating that BRI2 
could be involved in neurite outgrowth (Choi et al. 2004; Martins et al. 2016). Moreover, BRI2 
expression increases during neuronal maturation and differentiation suggesting an important role for 
BRI2 both during neuronal development but also in the adult brain (Martins et al. 2017). In addition, 
some BRI2 binding proteins have been identified; as is the case with the Alzheimer’s amyloid 
precursor protein (APP). BRI2:APP interaction occurs at the cell surface and in endocytic 
compartments, and this complex could potentially regulate APP processing and inhibit Abeta 
production (Matsuda et al. 2005; Matsuda et al. 2011). Interestingly, BRI2 accumulates in the 
hippocampus in the early stages of Alzheimer’s disease (AD) preventing the BRI2:APP complex 
formation and therefore resulting in increased APP processing and consequently more Abeta1-40 and 
Abeta1-42 is produced (Del Campo et al. 2014). Additionally, we recently reported that BRI2 interacts 
with protein phosphatase 1 (PP1) via a BRI2 well conserved RVxF motif (3KVTF6). Further, we 
established that BRI2 is dephosphorylated by this protein phosphatase; given that when the BRI2:PP1 
interaction is abolished, BRI2 phosphorylation levels increase dramatically. The morphological 
consequence of inhibiting PP1 binding was a phenotype consistent with neurite outgrowth and 
neuronal differentiation (Martins et al. 2016; Martins et al. 2017).  
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In addition to AD, the clinical relevance of this protein lies in two different autosomal dominant 
mutations in the ITM2B gene, which are associated with two rare early-onset forms of dementia, the 
Familial British and Danish dementias (FBD and FDD, respectively). These diseases share several 
clinical symptoms, such as progressive cognitive impairment cerebellar ataxia and spasticity 
(Tsachaki et al. 2008). Neuropathological hallmarks of FBD consist in the presence of pre-amyloid 
and amyloid parenchymal lesions in the brain (primarily localized to the hippocampus and 
cerebellum), extensive cerebral amyloid angiopathy (CAA) and intraneuronal formation of 
neurofibrillary tangles (NFT) within the limbic regions (Plant et al. 1990; Revesz et al. 1999). 
Neuropathological lesions in FDD patients are closely similar to those found in FBD, however in 
FDD co-deposition of Abeta and Danish amyloid is found, but parenchymal compact plaques are 
absent (Holton et al. 2002; Vidal et al. 2000).  
To date, the precise physiological BRI2 function is not fully elucidated. Even so several lines of 
evidence strengthen the association of BRI2 with neuronal functions, in particular, the identification 
and functional characterization of BRI2 interactors, namely APP and PP1. Therefore, the 
identification of novel BRI2 interactors that may play important roles in regulating its trafficking, 
processing and signaling effect is an essential point. Additionally, specific cellular signaling 
pathways and processes which are crucial to the understanding of the physiological and pathological 
role of BRI2, in particular in the brain, may be forthcoming. The work here described proposes novel 
BRI2 interactors in rat brain, which represent a valuable tool to study the brain function in mammals. 
BRI2 interactors in three different brain regions were investigated; the cerebellum, hippocampus, 
and cerebral cortex, followed by in silico analysis, such as Gene Ontology (GO), biological 
pathways, and protein-protein interaction (PPI) network analysis. This permitted identifying 
potentially novel BRI2 functional relationships via analyzing its interacting proteins in the brain. 
 
III.A.2 Materials and Methods 
III.A.2.1 Preparation of rat brain lysates  
Wistar Hannover rats (9-12 weeks) were obtained from Harlan Interfaune Ibérica, SL, and all 
experimental procedures were conducted in accordance with the European legislation for animal 
experimentation (2010/63/EU). No specific ethics approval under EU guidelines was required for 
this project, since the rats were euthanized, by cervical stretching followed by decapitation, for brain 
removal. This is within the European law (Council Directive 86/609/EEC) and the number and 
suffering of the animals were minimized as much as possible. The procedures were approved and 
supervised by our Institutional Animal Care and Use Committee (IACUC): Comissão Responsável 
pela Experimentação e Bem-Estar Animal (CREBEA). Briefly, animals were sacrificed by cervical 
stretching followed by decapitation and the cerebral cortex, hippocampus and cerebellum were 
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dissected on ice. Tissues were further weighed and homogenized on ice with a Potter-Elvehjem tissue 
homogenizer with 10-15 pulses at 650-750 rpm, in non-denaturating lysis buffer (50 mM Tris-HCl 
pH 8.0, 120 mM NaCl and 4% CHAPS) containing protease inhibitors (1 mM PMSF, 10 mM 
Benzamidine, 2 µM Leupeptin, 1.5 µM Aprotinin and 5 µM Pepstatin A) (Santos et al. 2014). The 
tissue extracts were used for immunoprecipitation analysis as described below. 
 
III.A.2.2 Co-immunoprecipitation  
The lysates from rat cerebral cortex, hippocampus and cerebellum extracts were divided into three 
equal parts (2 controls and 1 BRI2 co-immunoprecipitation) and pre-cleared separately using 
Dynabeads Protein G (Life Technologies). A direct immunoprecipitation approach was performed 
using mouse anti-BRI2 antibody (1µg/500µg protein; sc-374362, Santa Cruz Biotechnology), pre-
incubated with Dynabeads Protein G for 1 hour at 4oC with rotation. After, the pre-cleared extracts 
were applied to antibody-Dynabeads and incubated overnight at 4oC with rotation. The 
immunoprecipitates were washed three times with PBS in 3% BSA for 10 min at 4oC with rotation 
and beads were re-suspended in 1% SDS.  As a control extracts only incubated with dynabeads 
protein G or with dynabeads protein G coupled with mouse IgGs were used. The whole procedure 
was triplicated for each of the distinct brain regions. 
 
III.A.2.3 In-gel protein digestion, nano-HPLC and mass spectrometry  
The eluted fractions from the brain BRI2 co-IP assays were separated by SDS-PAGE on a 12% Bis-
Tris gel and gels bands excised, cut into small pieces, and alternately washed with buffer A (50 mM 
ammonium hydrogen carbonate (NH4HCO3)) and B (50 mM NH4HCO3/50% ACN (acetonitrile)). 
Following dehydration of gel pieces in vacuo, trypsin (Serva, Germany) was solved in 10 mM HCl 
and 50 mM NH4HCO3 and used for overnight in gel digestion at 37 °C (trypsin:protein ratio 1:20). 
Peptides were then extracted once with 200 μl of 50% ACN/0.05% TFA (trifluoroacetic acid) and 
once with 100 μl of 50% ACN/0.05% TFA. Extracts were combined and centrifuged for 5 min at 
16,000 ×g. The supernatant was transferred to a new vial in order to get rid of potential gel residuals. 
Then, ACN was removed in vacuo. For LC–MS analysis, a final volume of 16 μl was prepared by 
addition of 0.1% TFA. 
Peptide extracts were used for mass spectrometry analysis. Therefore, samples were injected via the 
autosampler of an RSLC nano system (Thermo Scientific), concentrated on a C18 trapping column 
(2 cm length, 100 μm i.d., 5 μm particle size, Thermo Scientific), and separated on a C18 analytical 
column (50 cm length, 75 μm i.d., 2 μm particle size, Thermo Scientific) heated at 60 °C before being 
emitted via a coated silica tip (FS360-20-10-D-20, New Objective, USA) of the nanospray-
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electrospray source of an Q Exactive (Thermo Scientific). The HPLC separation was performed with 
a gradient method of in total 120 min consisting of: 7 min of loading the sample and washing the 
column with 0.1% TFA at a flow rate of 30 μl min−1 on the trapping column, followed by separation 
applying a linear gradient at a flow rate of 400 nl min−1 with the solvents A (0.1% FA (formic acid) 
in HPLC grade water) and B (84% ACN/0.1% FA in HPLC grade water) starting from 5% B to 40% 
B in 98 min on the heated analytical column, a linear gradient of 40% B to 95% B in 2 min, and 
washing for 7 min with 95% B. Finally, a gradient was applied from 95% B to 5% B in 1 min followed 
by equilibration for 5 min with 5% B. For ionization a spray voltage of 1.6 kV and capillary 
temperature of 250 °C was used. The acquisition method consisted of two scan events, Full MS and 
MS/MS. The Full MS was monitored from m/z 350 to 1400, with an Orbitrap resolution of 70,000, 
a maximum injection time of 80 ms and an automatic gain control (AGC) value of 3e6. The m/z 
values initiating MS/MS were set on a dynamic exclusion list for 35 s. Lock mass 
polydimethylcyclosiloxane (m/z 445.120) was used for internal recalibration. The 10 most intensive 
ions (charge N1) were selected for MS/MS-fragmentation and fragments were scanned at a resolution 
of 35,000, with a maximum injection time of 120 ms and an AGC value of 2e5. Fragments were 
generated by higher-energy collisional-induced dissociation (HCD) on isolated ions. 
For peptide identification .raw files were processed in Proteome Discoverer 1.4 and analyzed using 
the Mascot search algorithm with a mass tolerance of 10 ppm and a fragment mass tolerance of 0.02 
Da. Searches were performed allowing one missed cleavage site after tryptic digestion. Oxidation 
(M) and phosphorylation (STY) were considered as variable modifications. Targeted Decoy PSM 
Validator was implemented with an FDR of 1%. All data were searched against a database containing 
the whole Uniprot/Swissprot entries of the taxonomy Rattus norvegicus. 
For each sample condition (i.e. for each specific brain region), two mock IPs were used as negative 
controls. Therefore, the proteins identified in the mock IPs were excluded from the list of the proteins 
identified in the BRI2 co-IPs, with one exception: the ratio between the number of peptide-spectrum 
matches (PSM) for a given protein in a BRI2 co-IP sample and the PSM in the mock IPs, of the same 
brain region, were equal or higher than 2.0. In addition, well-described common contaminants as 
presented in (Hodge et al. 2013) and proteins characteristic of hair, skin/epidermis, tongue and gums 
(KRT33A, KRT78, KRT85, KRT14, KRT5, KRT3, KRT31, KRT32, KRT33B, KRT35, KRT36, 
KRT4, KRT77, KRT8, KRT17) which are also highly probable contaminants, were excluded.  
 
III.A.2.4 Bioinformatic data analysis 
Experimentally detected BRI2 protein-protein interactions already described in the literature were 
retrieved using PSIQUIC View web service (del-Toro et al. 2013) (version 1.4.5, downloaded 
October 2016), which enabled access to multiple PSI-MI compliant resources.  In addition, two BRI2 
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interacting proteins identified and validated recently in our laboratory, protein phosphatase 1 alpha 
(PPP1CA) and protein phosphatase 1 gamma (PPP1CC), were added manually.  
Tissue expression analysis was performed using the following databases: The Human Protein Atlas 
(HPA; available from www.proteinatlas.org) (Uhlén et al. 2015); TiGER (available 
from  http://bioinfo.wilmer.jhu.edu/tiger) (Liu et al. 2008); and UniGene (Wheeler et al. 2003). The 
HPA was searched for proteins strongly expressed in the brain and a list of proteins within the brain 
‘Tissue enriched’, ‘Tissue enhanced’ and ‘Group enriched’ categories was obtained. Annotated 
protein expression is a manually curated score based on IHC staining patterns in normal tissues from 
two or more paired antibodies binding to different epitopes of the same protein, which describes the 
distribution and strength of expression of each protein in cells. The TiGER database was searched 
for proteins, preferentially expressed in the brain, based on ESTs by searching ‘Brain’ in ‘Tissue 
View’. The UniGene database was searched for brain-restricted genes by using the following search 
criteria: [brain][restricted]. 
Functional enrichment analysis of Gene Ontology (GO) categories (biological process and cellular 
component) was performed using PANTHER (Protein Annotation Through Evolutionary 
Relationship; version 11.1, accessed January 2016), online resource (Mi et al. 2017). For the 
PANTHER enrichment analysis, the overall set of rat/human protein-coding genes were used as 
reference set, and only enriched annotation with a p-value <0.05 were considered.  In addition, 
functional enrichment analysis of KEGG pathways was performed using the ClueGo plugin version 
2.3.2, (accessed January 2016) (Bindea et al. 2009) of the Cytoscape software version 3.4.0, freely 
available online (Shannon et al. 2003). Construction of protein-protein interaction (PPI) networks 
was achieved also using the Cytoscape software and further analyzed using the NetworkAnalyzer 
plugin version 3.3.1 (accessed January 2016). In order to perform network augmentation, protein-
protein data was retrieved from the International Molecular Exchange (IMEx) consortium partners. 
Given the lack of information for Rattus norvergicus in these databases, the lists of proteins were 
extrapolated by homology to Homo sapiens. Rat UniProt accession numbers were converted to a 
human using the Uniprot tool available online - Uniprot Retrieve/ID mapping 
(http://www.uniprot.org/uploadlists/).  
 
III.A.2.5 Interaction validation by immunoblotting 
Brain lysates and eluted proteins from the co-immunoprecipitation assays were resolved on 5-20% 
gradient SDS-PAGE and electrophoretically transferred onto nitrocellulose membranes. Nonspecific 
protein-binding sites were blocked using 5% nonfat dry milk in TBST. Afterward, the membranes 
were incubated with the following primary antibodies: anti-BRI2 antibody (catalog no.: sc-374362, 
Santa Cruz Biotechnology) and anti-PSD95 (catalog no.: AB9708, Merck Millipore) overnight at 
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4°C with shaking. The membranes were then washed three times for 10 minutes with TBST and 
incubated for 2 h at room temperature with horseradish peroxidase-linked secondary antibodies (GE 
Healthcare). Finally, the membranes were washed three times for 10 minutes with TBST and 
enhanced chemiluminescence-based system were used for protein detection.  
 
 
III.A.3 Results  
III.A.3.1 Identification of BRI2 brain interactome 
Given that BRI2 has been recently associated with neuronal functions, the identification of BRI2 
brain interactors is of paramount importance. Therefore, our main goal was the identification of novel 
putative BRI2 interacting proteins in rat brain. Given the expression pattern of BRI2 in the brain, 
three different regions were chosen, namely cerebral cortex, hippocampus and cerebellum, and the 
workflow carried out was summarized and presented in Figure III.A.1. Briefly, the mentioned brain 
regions were dissected out and further subjected to co-immunoprecipitation (co-IP) using a BRI2 
specific antibody against the N-terminal region of the protein. For the co-IP experiments, two 
negative controls were used for each specific brain region. The first one consists, in addition, 
Dynabeads Protein G in the absence of the BRI2 antibody to the tissue lysates, while in the second 
control Dynabeads Protein G was conjugated with anti-mouse IgGs. The co-IP proteins were further 
analyzed by HPLC-MS. The co-IPs experiments followed by MS analysis were repeated at least 
three times for each specific brain region. The obtained set of proteins was subjected to data 
processing and filtering since some proteins were only identified in the BRI2 co-IP samples and 
never in the controls, while others appear both controls and co-IPs samples but were found 
significantly enriched in BRI2 co-IP samples. These were considered as a BRI2 interactor candidate 
if peptide spectrum matches (PSM) ratio between co-IP samples and controls ≥ 2.0.  
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Figure III.A. 1 - Workflow for the identification of novel brain BRI2 interacting proteins using rat brain tissue 
lysates. Two different approaches were used, the first one is represented on left and the second one on the right. DB, 
database; CC, cerebral cortex; HP, hippocampus; CB, cerebellum; MS, mass-spectrometry. 
 
Overall, upon data processing 511 putative BRI2 interacting proteins were identified in the rat brain 
(Supplementary Table III.A.S1). Of note, 342 proteins were identified in the cerebral cortex, 257 in 
the hippocampus and 262 in the cerebellum (Supplementary Table III.A.S1). In Supplementary Table 
III.A.S1, the Uniprot accession numbers are listed as well as the gene and protein name, and the rat 
brain region in which the peptides were detected. The first analysis of the BRI2 brain interactome 
(pool of the three brain regions studied) using bioinformatic approaches indicates that the majority 
of proteins identified in this study belong to the protein classes of cytoskeletal proteins (16%; half of 
which belong to the actin family), hydrolases (12%), enzyme modulators (11%; mainly G-proteins) 
and transporters (11%; half of which belong to cation transporters family). Other represented protein 
classes included membrane traffic proteins (7%), oxidoreductases (7%), calcium-binding proteins 
(5%), ion channels (5%; being 2 % anion channels), dehydrogenases (5%), chaperones (3%), 
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structural proteins (3%), ATP synthases (2%), transmembrane receptor regulatory/adaptor proteins 
(2%) and transcription factors (1%) (Figure III.A.2 and Supplementary Table III.A.S2). 
 
Figure III.A. 2 - Panther Protein class of the novel BRI2 interactome using the PANTHER online resource. The 
percentage of the BRI2 interacting proteins in each category was calculated and plotted. A – Panther Protein class of all 
the identified BRI2 interacting proteins (BRI2 brain interactome). B - Panther Protein class of the identified brain-enriched 
or specific BRI2 interacting proteins (BRI2 brain ES interactome). 
 
In parallel, a curated list of 45 proteins that were previously identified as putative BRI2 interacting 
proteins was retrieved, as described above (Supplementary Table III.A.S3). Overall, most of these 
proteins were identified by yeast-two-hybrid and high-throughput screens and were not further 
validated by additional assays. Of note, in the study here described, 2 of the 45 previously reported 
BRI2 interacting proteins were also identified: the dihydropyridine-sensitive L-type, calcium channel 
alpha-2/delta subunit (Cacna2d1) and the serine/threonine-protein phosphatase PP1-alpha catalytic 
subunit (Ppp1ca).  
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III.A.3.2 Highly enriched and specific brain BRI2 interacting proteins 
Given that the main goal of this work is to unravel putative associations of BRI2 to specific cellular 
functions as well as pathways where BRI2 participates in the brain related processes, a tissue-
specific/enriched network approach was employed. For this purpose, the enriched and specific brain 
proteins from the candidate BRI2 pooled interactome (cerebral cortex + hippocampus + cerebellum) 
using three different databases were retrieved, as explained in the materials and methods section. 
From the 511 putative BRI2 interacting proteins identified by Nano-HPLC-MS/MS, a total of 120 
proteins are highly enriched/specifically (ES) expressed in the brain (BRI2 ES interactome) (Table 
III.A.1).  
 
Table III.A. 1 – Novel candidate BRI2 interacting proteins highly enriched or specific for the brain tissue. Uniprot 
accession numbers, gene and protein names, are listed, as well as the rat brain tissues where the proteins were found. CC, 
cerebral cortex; HP, hippocampus; CB, cerebellum. 
Uniprot accession Gene name Protein name Brain regions 
P13233 Cnp 2',3'-cyclic-nucleotide 3'-phosphodiesterase  CC, HP, CB 
P23565 Ina Alpha-internexin  CC, HP, CB 
O08838 Amph Amphiphysin CC, HP, CB 
P0C6S7 Anks1b Ankyrin repeat and sterile alpha motif domain-containing protein 1B  CC 
Q8CGU4 Agap2 Arf-GAP with GTPase, ANK repeat and PH domain-containing 
protein 2  
CC 
Q6PST4 Atl1 Atlastin-1  CC 
Q05764 Add2 Beta-adducin  HP 
P85969 Napb Beta-soluble NSF attachment protein  HP 
Q05175 Basp1 Brain acid soluble protein 1  HP 
P55068 Bcan Brevican core protein  HP, CB 
P11275 Camk2a Calcium/calmodulin-dependent protein kinase type II subunit alpha  CC, HP 
P08413 Camk2b Calcium/calmodulin-dependent protein kinase type II subunit beta  CC, HP, CB 
Q62717 Cadps Calcium-dependent secretion activator 1  HP 
Q63092 Camkv CaM kinase-like vesicle-associated protein  HP 
Q1WIM1 Cadm4 Cell adhesion molecule 4  CB 
Q5FVI4 Cend1 Cell cycle exit and neuronal differentiation protein 1 CC, HP 
Q05140 Snap91 Clathrin coat assembly protein AP180  CC, HP 
P63041 Cplx1 Complexin-1  HP 
Q9Z1T4 Cnksr2 Connector enhancer of kinase suppressor of ras 2  CC 
Q63198 Cntn1 Contactin-1  CC, HP 
P97846 Cntnap1 Contactin-associated protein 1  CC, CB 
Q5BJS7 Cpne9 Copine-9  HP 
Q62950 Crmp1 Dihydropyrimidinase-related protein 1  HP 
Q62951 Dpysl4 Dihydropyrimidinase-related protein 4  CB 
Q63622 Dlg2 Disks large homolog 2  CC 
Chapter III                                                                                Results 
164                                                Functional characterization of novel BRI2 and BRI3 complexes 
Uniprot accession Gene name Protein name Brain regions 
P31016 Dlg4 Disks large homolog 4  CC, HP, CB 
P97836 Dlgap1 Disks large-associated protein 1  CC 
P97837 Dlgap2 Disks large-associated protein 2  CC 
P97838 Dlgap3 Disks large-associated protein 3  CC 
P21575 Dnm1 Dynamin-1  CC, HP 
Q8R491 Ehd3 EH domain-containing protein 3 HP 
Q8CH84 Elavl2 ELAV-like protein 2  CC 
O35179 Sh3gl2 Endophilin-A1  CC, CB 
P24942 Slc1a3 Excitatory amino acid transporter 1  CC, HP, CB 
P31596 Slc1a2 Excitatory amino acid transporter 2  CC, HP, CB 
O35921 Slc1a6 Excitatory amino acid transporter 4  CB 
O88871 Gabbr2 Gamma-aminobutyric acid type B receptor subunit 2  CC 
P47819 Gfap Glial fibrillary acidic protein  CC, HP, CB 
P19490 Gria1 Glutamate receptor 1  CC 
P19491 Gria2 Glutamate receptor 2  CC, HP, CB 
P35439 Grin1 Glutamate receptor ionotropic, NMDA 1  CC 
Q00960 Grin2b Glutamate receptor ionotropic, NMDA 2B  CC 
Q9WTT6 Gda Guanine deaminase  CC 
P19627 Gnaz Guanine nucleotide-binding protein G CC, HP 
P59215 Gnao1 Guanine nucleotide-binding protein G CC, HP, CB 
Q9Z214 Homer1 Homer protein homolog 1  CC 
Q9ESM2 Hapln2 Hyaluronan and proteoglycan link protein 2  CC, CB 
Q9QYU4 Crym Ketimine reductase mu-crystallin  HP 
Q6QLM7 Kif5a Kinesin heavy chain isoform 5A  CC, HP, CB 
P56536 Kif5c Kinesin heavy chain isoform 5C  CC, CB 
P37285 Klc1 Kinesin light chain 1  CC, HP, CB 
Q62813 Lsamp Limbic system-associated membrane protein  CC, CB 
P34926 Map1a Microtubule-associated protein 1A  CC, HP 
P15205 Map1b Microtubule-associated protein 1B  CC, HP, CB 
P15146 Map2 Microtubule-associated protein 2  CC 
Q63560 Map6 Microtubule-associated protein 6  CC, HP, CB 
Q505J6 Slc25a18 Mitochondrial glutamate carrier 2  CC 
P02688 Mbp Myelin basic protein  CC 
P60203 Plp1 Myelin proteolipid protein  CC, CB 
P07722 Mag Myelin-associated glycoprotein  CC, CB 
Q63345 Mog Myelin-oligodendrocyte glycoprotein CC, CB 
P13596 Ncam1 Neural cell adhesion molecule 1  CB 
P55067 Ncan Neurocan core protein  CC, HP, CB 
O35095 Ncdn Neurochondrin  CC 
P19527 Nefl Neurofilament light polypeptide  CC, HP, CB 
P12839 Nefm Neurofilament medium polypeptide  CC, CB 
P07936 Gap43 Neuromodulin  CC 
Q9ESI7 Dcx Neuronal migration protein doublecortin CC 
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Uniprot accession Gene name Protein name Brain regions 
Q9WU34 Sept3 Neuronal-specific septin-3  HP 
Q62718 Ntm Neurotrimin  CC, CB 
P11506 Atp2b2 Plasma membrane calcium-transporting ATPase 2  CC 
Q64568 Atp2b3 Plasma membrane calcium-transporting ATPase 3  HP 
P10499 Kcna1 Potassium voltage-gated channel subfamily A member 1  CC 
Q6MG82 Prrt1 Proline-rich transmembrane protein 1  HP 
O88778 Bsn Protein bassoon CC, CB 
P63319 Prkcg Protein kinase C gamma type  CC, HP, CB 
Q9JKS6 Pclo Protein piccolo  CC 
P47709 Rph3a Rabphilin-3A  CC, HP 
P63012 Rab3a Ras-related protein Rab-3A CC, HP, CB 
P62824 Rab3c Ras-related protein Rab-3C CC, HP 
Q9JIR4 Rims1 Regulating synaptic membrane exocytosis protein 1  CC 
Q64548 Rtn1 Reticulon-1  CC, HP, CB 
Q9JKE3 Scamp5 Secretory carrier-associated membrane protein 5  CC, HP 
Q9JJM9 Sept5 Septin-5  CC, HP 
O08875 Dclk1 Serine/threonine-protein kinase DCLK1  CC, HP 
Q9WV48 Shank1 SH3 and multiple ankyrin repeat domains protein 1  CC, CB 
P0DJJ3 Sgip1 SH3-containing GRB2-like protein 3-interacting protein 1  CC, HP 
P31647 Slc6a11 Sodium- and chloride-dependent GABA transporter 3  CC, CB 
P48768 Slc8a2 Sodium/calcium exchanger 2  CC 
P06686 Atp1a2 Sodium/potassium-transporting ATPase subunit alpha-2  CC 
P06687 Atp1a3 Sodium/potassium-transporting ATPase subunit alpha-3  CC, HP 
P13638 Atp1b2 Sodium/potassium-transporting ATPase subunit beta-2  CC, HP, CB 
Q63633 Slc12a5 Solute carrier family 12 member 5  HP 
Q9QWN8 Sptbn2 Spectrin beta chain, non-erythrocytic 2  CC, CB 
Q9QXY2 Srcin1 SRC kinase signaling inhibitor 1  CC, CB 
P09951 Syn1 Synapsin-1  CC, HP 
Q63537 Syn2 Synapsin-2  CC 
Q02563 Sv2a Synaptic vesicle glycoprotein 2A  CC, HP, CB 
Q63564 Sv2b Synaptic vesicle glycoprotein 2B  CC, HP 
P07825 Syp Synaptophysin  CC, HP 
P60881 Snap25 Synaptosomal-associated protein 25  HP, CB 
P21707 Syt1 Synaptotagmin-1  CC, HP, CB 
P97610 Syt12 Synaptotagmin-12  CC, CB 
P29101 Syt2 Synaptotagmin-2  CB 
Q62747 Syt7 Synaptotagmin-7  CB 
P32851 Stx1a Syntaxin-1A  CC 
P61265 Stx1b Syntaxin-1B  CC, HP, CB 
P61765 Stxbp1 Syntaxin-binding protein 1  CC, HP 
Q05546 Tnr Tenascin-R  CC, HP, CB 
P70566 Tmod2 Tropomodulin-2  CC, CB 
P85108 Tubb2a Tubulin beta-2A chain CC, HP, CB 
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Uniprot accession Gene name Protein name Brain regions 
Q3KRE8 Tubb2b Tubulin beta-2B chain  CC, HP 
Q4QRB4 Tubb3 Tubulin beta-3 chain  CC, HP, CB 
Q9QUL6 Nsf Vesicle-fusing ATPase  CC, HP, CB 
Q62634 Slc17a7 Vesicular glutamate transporter 1  CC, HP 
Q9JI12 Slc17a6 Vesicular glutamate transporter 2  CC 
O35458 Slc32a1 Vesicular inhibitory amino acid transporter  CC, HP 
P62762 Vsnl1 Visinin-like protein 1  CB 
Q71RJ2 Cacng2 Voltage-dependent calcium channel gamma-2 subunit  CB 
Q6QIX3 Slc30a3 Zinc transporter 3  CC 
 
Almost half of these interactors are cytoskeletal proteins (around 18%; mainly actin and 
microtubules) or transporters (around 18%; half of which belong to cation transporters family), 
followed by membrane traffic proteins (14%; half of which are regulatory), structural proteins (6%: 
half of which are myelin proteins), transmembrane receptor regulatory/adaptor proteins (3%) and 
nucleic acid binding proteins (2%) (Figure III.A.2B and Supplementary Table III.A.S4). 
In order to elucidate if the proteins identified in BRI2 ES interactome could be assigned to specific 
functions, and ultimately to provide more information regarding the physiological role of BRI2, 
particularly in the brain, a further classification was performed into functional categories according 
to Gene Ontology (GO) annotation using the PANTHER online resource. Regarding the analysis of 
the over-represented biological process GO terms (Figure III.A.3A and Supplementary Table 
III.A.S5), the results revealed that the BRI2 ES interactome included proteins involved in several 
functional roles, from which the synaptic vesicle cycle (60.3%), neuron development (32.2%), brain 
development (26.4%), regulation of synaptic plasticity (24.0%), ion transport (22.3%), and 
cytoskeleton organization (16.5%) stand out (Figure III.A.3A). Cellular component annotation 
analysis revealed several statistically enriched categories (Supplementary Table S6). Of note, a high 
percentage of proteins in the BRI2 ES interactome that localized to the synapse (57.0%), dendrite 
(30.6%), postsynaptic density (25.6%), synaptic vesicle (24.0%), axon terminus (17.4%) and 
presynaptic membrane (10.7%) were found (Figure III.A.3B). 
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Figure III.A. 3 - Functional enrichment analysis of the BRI2 brain ES interactome using the PANTHER online 
resource. The percentage of the BRI2 interacting proteins in each category was calculated and plotted. A – Biological 
process analysis of the identified BRI2 interacting proteins particularly brain-enriched or specific. B – Cellular 
component analysis of the identified BRI2 interacting proteins particularly brain-enriched or specific. 
 
III.A.3.3 BRI2 role in neuronal differentiation 
Previous results strongly suggested a role for BRI2 in neuronal differentiation (Akiyama et al. 2004; 
Martins et al. 2016; Martins et al. 2017), however to date the exact mechanisms or pathways 
involving BRI2 have not been revealed. Hence from the BRI2 brain ES interactors, the proteins 
annotated with GO terms related to neuronal differentiation were retrieved. This resulted in a list of 
49 proteins corresponding to the BRI2 ES neuronal differentiation interactome (Supplementary Table 
III.A.S7). To evaluate the interconnection of these BRI2 candidate interactors, a PPI network 
augmentation was performed, using the Cytoscape software (Shannon et al. 2003), which enhanced 
the experimental data with additional known and experimentally validated PPI from public databases 
(see materials and methods section). In addition, the proteins annotated with GO terms related to 
neuronal differentiation from the previously identified list of BRI2 interactors (Supplementary Table 
S3), were manually added to this PPI network. The PPI network augmentation provides interesting 
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and valuable information, permitting a systems approach to analyze the complexes formed from the 
co-immunoprecipitating proteins rather than a single interaction.  
The network construction and analysis were achieved using the NetworkAnalyzer plugin of the 
Cytoscape (Shannon et al. 2003). In the resulting BRI2 (gene ITM2B) PPI network (Figure III.A.4), 
the grey nodes correspond to PPI added by the Cytoscape analysis, the colored nodes to the proteins 
identified in this study (blue for proteins identified in cerebral cortex, orange for proteins identified 
in hippocampus, and green for proteins identified in cerebellum) annotated with GO terms related to 
neuronal differentiation, and the node size corresponds to its degree (k; the number of edges linked 
to it). The total number of proteins mapped in the neuronal differentiation-specific PPI network was 
144 (nodes), and the total number of connections between them was 286 (edges) (Figure III.A.4). 
The average number of neighbors for a node in the network, which indicates the average connectivity 
of a node in the network, is 3.972. The mean clustering coefficient of the network, which 
characterizes how nearest neighboring nodes of a node are connected to each other, is 0.09, being 
4.5 times larger than the clustering coefficient expected for a sparse random uncorrelated network 
(0.02) (Doncheva et al. 2012; Newman 2006).  
 
Figure III.A.4 - BRI2 brain ES sub-network for neuronal differentiation annotated proteins. Node colors represent 
the source of the protein: blue nodes correspond to proteins identified in this study in the cerebral cortex, orange nodes 
correspond to proteins identified in this study in the hippocampus, green nodes correspond to proteins identified in this 
study in the cerebellum, and grey nodes are proteins added by network augmentation. Node size according to the degree in 
the network. Edge color represents the source of interaction: light red edges correspond to the novel BRI2 interactions 
identified in our study, whereas the grey edges correspond to interactions added by network augmentation. 
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From all the nodes, the TUBB3 (k=23) was noteworthy since it presents the highest node degree and 
in this study, it was identified in the three different brain regions analyzed (Figure III.A.4). TUBB3 
(Tubulin beta-3 chain), is a neuron-specific beta-tubulin which has been suggested to have a critical 
role in proper axon guidance and maintenance (Tischfield et al. 2010). Additionally, the following 
proteins were highlighted in the network: the TUBB2B (k=16), CAMK2A (k=15), CRMP1 (k=15), 
MAP1B (k=13), CAMK2B (k=11), NEFL (k=11), KIF5A (k=11), NEFM (K=10) and DLG4 (k=9) 
(Figure III.A.4).  
In order to establish the signaling pathways that are most associated with BRI2, an integrated KEGG 
pathway enrichment analysis of the 144 proteins in BRI2 brain ES neuronal differentiation PPI 
network was performed using the ClueGo plugin of the Cytoscape software (Bindea et al. 2009). 
This analysis placed BRI2 into signalling networks well related to neuronal differentiation, namely 
ErbB signalling pathway (pValue = 1.812E-08), neurotrophin signalling pathway (pValue =6.443E-
05), estrogen signalling pathway (pValue =1.163E-05), FoxO signalling pathway (pValue = 5.248E-
03), axon guidance (pValue =1.571E-03), adherens junction (pValue =2.896E-02) and HIF-1 
signalling pathway (pValue =2.675E-02) (Table III.A.2). 
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Table III.A. 2 - KEGG category enrichment analysis of the neuronal differentiation annotated network obtained using ClueGo plugin of the Cytoscape software . Enriched 
categories identified are those with p-value <0.05. 
KEGG Term ID KEGG Term Nr. Genes % Associated Genes 
pValue Associated Genes Found 
KEGG:04721 Synaptic vesicle cycle 6 9.523809 3.4E-03 RAB3A, RIMS1, SNAP25, STX1B, STXBP1, SYT1 
KEGG:05014 Amyotrophic lateral sclerosis (ALS) 8 15.686275 6.070E-06 BCL2, BID, GRIN1, GRIN2B, NEFL, NEFM, TNFRSF1B, TP53 
KEGG:05130 Pathogenic Escherichia coli infection 6 10.909091 1.699E-03 ABL1, FYN, NCK1, TUBB2B, TUBB3, YWHAQ 
KEGG:04360 Axon guidance 10 5.681818 1.571E-03 ABL1, CAMK2A, CAMK2B, DPYSL2, FYN, NCK1, RYK, SEMA4F, SEMA6A, SRC 
KEGG:04520 Adherens junction 5 6.756757 2.896E-02 CSNK2B, EGFR, FYN, SMAD2, SRC 
KEGG:04066 HIF-1 signaling pathway 6 5.8252425 2.675E-02 AKT1, BCL2, CAMK2A, CAMK2B, CDKN1A, EGFR 
KEGG:04725 Cholinergic synapse 7 6.3063064 8.587E-03 AKT1, BCL2, CAMK2A, CAMK2B, FOS, FYN, GNAO1 
KEGG:04728 Dopaminergic synapse 10 7.6923075 1.195E-04 AKT1, ARRB2, CAMK2A, CAMK2B, FOS, GNAO1, GRIN2B, KIF5A, KIF5C, 
PPP1CA 
KEGG:04921 Oxytocin signaling pathway 10 6.289308 6.652E-04 CAMK2A, CAMK2B, CDKN1A, EGFR, FOS, GNAO1, JUN, PPP1CA, RGS2, SRC 
KEGG:05031 Amphetamine addiction 7 10.294118 5.916E-04 CAMK2A, CAMK2B, FOS, GRIN1, GRIN2B, JUN, PPP1CA 
KEGG:04713 Circadian entrainment 7 7.2916665 4.341E-03 CAMK2A, CAMK2B, FOS, GNAO1, GRIN1, GRIN2B, MTNR1A 
KEGG:04720 Long-term potentiation 5 7.4626865 2.505E-02 CAMK2A, CAMK2B, GRIN1, GRIN2B, PPP1CA 
KEGG:04724 Glutamatergic synapse 7 6.140351 9.391E-03 DLG4, DLGAP1, GNAO1, GRIN1, GRIN2B, SHANK1, SLC1A3 
KEGG:05030 Cocaine addiction 4 8.163265 4.038E-02 DLG4, GRIN1, GRIN2B, JUN 
KEGG:04012 ErbB signaling pathway 12 13.636364 1.812E-08 ABL1, AKT1, CAMK2A, CAMK2B, CDKN1A, EGFR, ERBB4, GRB2, JUN, MYC, 
NCK1, SRC 
KEGG:04068 FoxO signaling pathway 8 5.970149 5.248E-03 AGAP2, AKT1, CDKN1A, EGFR, GABARAPL2, GRB2, MDM2, SMAD2 
KEGG:04110 Cell cycle 8 6.451613 3.526E-03 ABL1, CDKN1A, MDM2, MYC, SMAD2, TP53, YWHAG, YWHAQ 
KEGG:04210 Apoptosis 7 5.0 2.714E-02 AKT1, BCL2, BID, FOS, IKBKG, JUN, TP53 
KEGG:04380 Osteoclast differentiation 8 6.060606 5.022E-03 AKT1, FOS, FYN, GRB2, IKBKG, JUN, STAT1, TRAF6 
KEGG:04620 Toll-like receptor signaling pathway 6 5.6603775 2.808E-02 AKT1, FOS, IKBKG, JUN, STAT1, TRAF6 
KEGG:04660 T cell receptor signaling pathway 7 6.6666665 6.308E-03 AKT1, FOS, FYN, GRB2, IKBKG, JUN, NCK1 
KEGG:04662 B cell receptor signaling pathway 5 6.849315 2.886E-02 AKT1, FOS, GRB2, IKBKG, JUN 
KEGG:04722 Neurotrophin signaling pathway 10 8.264462 6.443E-05 ABL1, AKT1, BCL2, CAMK2A, CAMK2B, GRB2, JUN, MAP3K3, TP53, TRAF6 
KEGG:04912 GnRH signaling pathway 7 7.6086955 3.597E-03 CAMK2A, CAMK2B, EGFR, GRB2, JUN, MAP3K3, SRC 
KEGG:04915 Estrogen signaling pathway 10 10.0 1.163E-05 AKT1, EGFR, ESR2, FOS, GNAO1, GRB2, HSP90AA1, HSP90AB1, JUN, SRC 
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KEGG Term ID KEGG Term Nr. Genes % Associated Genes 
pValue Associated Genes Found 
KEGG:04917 Prolactin signaling pathway 6 8.333333 5.765E-03 AKT1, ESR2, FOS, GRB2, SRC, STAT1 
KEGG:04919 Thyroid hormone signaling pathway 7 5.9322033 1.114E-02 AKT1, MDM2, MYC, RXRB, SRC, STAT1, TP53 
KEGG:05142 Chagas disease (American trypanosomiasis) 7 6.730769 6.148E-03 AKT1, FOS, GNAO1, IKBKG, JUN, SMAD2, TRAF6 
KEGG:05145 Toxoplasmosis 6 5.084746 3.829E-02 AKT1, BCL2, GNAO1, IKBKG, STAT1, TRAF6 
KEGG:05160 Hepatitis C 8 6.0150375 5.137E-03 AKT1, CDKN1A, EGFR, GRB2, IKBKG, STAT1, TP53, TRAF6 
KEGG:05161 Hepatitis B 12 8.219178 6.068E-06 AKT1, BCL2, CDKN1A, FOS, GRB2, IKBKG, JUN, MYC, SRC, STAT1, TP53, 
YWHAQ 
KEGG:05169 Epstein-Barr virus infection 13 6.372549 3.203E-05 AKT1, BCL2, CDKN1A, CSNK2B, IKBKG, JUN, MDM2, MYC, TP53, TRAF6, VIM, 
YWHAG, YWHAQ 
KEGG:05205 Proteoglycans in cancer 13 6.3414636 3.324E-05 AKT1, CAMK2A, CAMK2B, CDKN1A, EGFR, ERBB4, GRB2, MDM2, MYC, 
PPP1CA, SMAD2, SRC, TP53 
KEGG:05210 Colorectal cancer 7 11.290322 3.318E-04 AKT1, BCL2, FOS, JUN, MYC, SMAD2, TP53 
KEGG:05212 Pancreatic cancer 6 9.090909 4.118E-03 AKT1, EGFR, IKBKG, SMAD2, STAT1, TP53 
KEGG:05213 Endometrial cancer 5 9.615385 9.083E-03 AKT1, EGFR, GRB2, MYC, TP53 
KEGG:05214 Glioma 8 12.121212 4.402E-05 AKT1, CAMK2A, CAMK2B, CDKN1A, EGFR, GRB2, MDM2, TP53 
KEGG:05215 Prostate cancer 10 11.235955 4.003E-06 AKT1, BCL2, CDKN1A, EGFR, GRB2, HSP90AA1, HSP90AB1, IKBKG, MDM2, 
TP53 
KEGG:05218 Melanoma 5 7.0422535 2.831E-02 AKT1, CDKN1A, EGFR, MDM2, TP53 
KEGG:05219 Bladder cancer 6 14.634147 3.292E-04 CDKN1A, EGFR, MDM2, MYC, SRC, TP53 
KEGG:05220 Chronic myeloid leukemia 8 10.958904 9.260E-05 ABL1, AKT1, CDKN1A, GRB2, IKBKG, MDM2, MYC, TP53 
KEGG:05222 Small cell lung cancer 7 8.139535 2.458E-03 AKT1, BCL2, IKBKG, MYC, RXRB, TP53, TRAF6 
KEGG:05223 Non-small cell lung cancer 5 8.928572 1.144E-02 AKT1, EGFR, GRB2, RXRB, TP53 
KEGG:05224 Breast cancer 9 6.1643834 1.997E-03 AKT1, CDKN1A, EGFR, ESR2, FOS, GRB2, JUN, MYC, TP53 
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III.A.3.4 BRI2 brain region specific interactome 
A second analytical approach used in this study of the BRI2 interactome, took into account the 
different brain regions, since this could be important and may reveal differences providing novel 
insights into specific BRI2 associated brain region-dependent processes. Therefore, the identification 
and characterization of the specific candidate BRI2 interactors from the three different brain regions: 
cerebral cortex, hippocampus, and cerebellum, was carried out (Figure III.A.5). A comparative 
analysis of the 511 candidate BRI2 interacting proteins identified in this study revealed that 108 
proteins were specifically identified in the cerebral cortex, 62 in the hippocampus and 85 in the 
cerebellum (Figure III.A.5A). Further, 92 proteins were common to all regions, while 61 were shared 
by the cerebral cortex and cerebellum, 23 between cerebellum and hippocampus and 80 between 
cerebral cortex and hippocampus (Figure III.A.5A). Furthermore, given the particular interest in 
studying BRI2 function(s) in the CNS (central nervous system), a comparative analysis of the BRI2 
ES interactome was also carried out (Figure III.A.5C). The results evidenced that while the majority 
of proteins were shared between brain regions (27 shared in all three regions, 17 shared in the cerebral 
cortex and cerebellum, 21 shared in cerebral cortex and hippocampus, and 2 shared in cerebellum 
and hippocampus), a subset of proteins were found to co-IP with BRI2 in specific brain regions (31 
in cerebral cortex, 14 in hippocampus, and 8 in cerebellum) (Figure III.A.5C). 
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Figure III.A. 5 - Brain region specific protein interactions in the BRI2 interactome. (A, B) - Brain region specific 
protein interactions revealed in the identified BRI2 interactome. A- Venn diagram comparison of the brain region (cerebral 
cortex, hippocampus, and cerebellum) specific BRI2 protein interactions identified in this study. B- BRI2 interactome 
identified in this study. Node size according to the degree in the network. Edge color represents the source of interaction: 
blue edges correspond to the BRI2 interactions identified in the cerebral cortex, orange edges correspond to the BRI2 
interactions identified in the hippocampus, and green edges correspond to the BRI2 interactions identified in the 
cerebellum. (C, D) - Brain region specific protein interactions revealed in the identified BRI2 ES interactome. C- Venn 
diagram comparison of the brain region (cerebral cortex, hippocampus, and cerebellum) specific BRI2 protein interactions 
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identified in this study, highly enriched or specific for the brain. D- BRI2 ES interactome identified in this study. Node size 
according to the degree in the network. Edge color represents the source of interaction: blue edges correspond to the BRI2 
interactions identified in the cerebral cortex, orange edges correspond to the BRI2 interactions identified in the 
hippocampus, and green edges correspond to the BRI2 interactions identified in the cerebellum. 
 
Once the BRI2 ES region specific interactomes were established (Fig. 4D), network augmentation 
was performed to enhance the experimental data with additional known and experimentally validated 
protein partners and obtain PPI networks (BRI2 ES region specific networks). For the cerebral cortex 
specific PPI network (Supplementary Figure III.A.S1A), a total of 292 proteins (nodes) with 330 
connections (edges) between them was mapped. This network presents an average number of 2.243 
neighbors. Regarding the hippocampus specific PPI network (Supplementary Figure III.A.S1B), 160 
proteins, with 165 connections between them was mapped. The topological analysis revealed an 
average number of neighbors of 2.0625. The cerebellum-specific PPI network (Supplementary 
Figure III.A.S1C) was the smallest, with only 47 nodes connected by 47 edges, and with an average 
of 2.0 neighbors. To further address if the BRI2 interactome could be assigned to selective brain 
region-dependent processes, functional enrichment analysis of the BRI2 ES region specific networks, 
using the PANTHER online resource, was performed (Table III.A.3). Remarkably, biological 
process annotation evidenced that for the three BRI2 ES region specific networks, the highly enriched 
terms were similar to those previously associated with the BRI2 ES interactome, namely neuron 
differentiation and synaptic vesicle cycling (Table III.A.3 and Figure III.A.3A)
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Table III.A. 3 -- Biological process enrichment analysis of the BRI2 ES regional specific networks (cerebral cortex, hippocampus and cerebellum) using Panther online resource . 
Enriched categories are identified as those with p-value <0.05, and GO terms presented correspond to the two most specific for each category retrieved in the analysis. Nr. Number. 
GO term Nr. proteins 
Fold enrichment 
(%) p-value Associated proteins 
 
BRI2 ES cerebral cortex specif ic network analysis  
synaptic vesicle fusion to presynaptic active zone membrane (GO:0031629) 9 55.78 1.28E-09 SNAP25, SNAP23, SNAP47, STX3, STX2, SNAP29, STX11, STX1A, STX4 
vesicle fusion with Golgi apparatus (GO:0048280) 6 44.62 5.70E-05 VTI1B, SEC22B, BET1, GOSR2, STX5, SEC22A 
dendrite morphogenesis (GO:0048813) 9 13.66 2.62E-04 DLG4, ITGB1, FYN, DCX, ABI1, SHANK3, SHANK1, CAMK2A, MAP2 
protein localization to membrane (GO:0072657) 22 4.07 3.48E-04 
RTP2, TNF, VAMP4, VAMP3, VAMP2, DLG4, SNAP25, ITGB7, SNAP47, 
NUP54, DLG2, TMED2, STX3, SHANK3, DLG1, DLG3, STX1A, NSF, VAMP5, 
EGFR, RPS8, TNIK 
learning (GO:0007612) 13 7.11 5.05E-04 
DLG4, SNAP25, SLC8A2, ITGB1, SHANK2, FYN, HTT, SHANK3, ATP1A2, 
SHANK1, APP, PARK2, GRIN1 
regulation of protein localization to plasma membrane (GO:1903076) 10 10.47 5.25E-04 VTI1B, ITGB1, PIK3R1, STX8, STX3, GOPC, DLG1, STX7, EGFR, STX4 
ERBB2 signaling pathway (GO:0038128) 8 15.26 6.70E-04 GRB2, CDC37, PTPN12, SRC, PIK3R1, ERBB4, ERBB2, EGFR 
long-term synaptic potentiation (GO:0060291) 8 14.87 8.11E-04 VAMP2, SNAP25, SLC8A2, SHANK2, SNAP47, STX3, SHANK3, STX4 
retrograde vesicle-mediated transport, Golgi to ER (GO:0006890) 10 9.18 1.74E-03 TMED9, RINT1, SEC22B, KDELR1, TMED2, KIF18A, HTT, USE1, BNIP1, NSF 
retrograde transport, endosome to Golgi (GO:0042147) 10 9.07 1.95E-03 
TRIM27, VAMP3, TMED9, DCTN1, VTI1B, STX10, STX16, GOSR2, STX5, 
STX6 
post-Golgi vesicle-mediated transport (GO:0006892) 10 8.55 3.32E-03 
VAMP4, VAMP3, VAMP2, VTI1B, SNAP23, GOSR2, GOPC, NSF, VAMP5, 
STX4 
receptor localization to synapse (GO:0097120) 5 33.80 4.14E-03 DLG4, DLG2, ANKS1B, DLG1, DLG3 
regulation of ion transport (GO:0043269) 25 3.17 4.50E-03 
TRIM27, CREB3, VAMP3, KCNA3, PRKACA, VAMP2, PLN, DLG4, GPM6B, 
YWHAE, KCNA1, PLCG1, HTT, SHANK3, ATP1A2, PRKCD, ATP2B2, ABL1, 
HOMER1, SHANK1, DLG1, CALCA, KCNA10, CAMK2A, PARK2 
vesicle-mediated transport to the plasma membrane (GO:0098876) 9 9.70 4.52E-03 VAMP4, VAMP3, VAMP2, SNAP25, SNAP47, STX3, GOPC, NSF, VAMP5 
positive regulation of excitatory postsynaptic potential (GO:2000463) 6 20.28 5.65E-03 RIMS1, DLG4, SHANK3, SHANK1, STX1A, GRIN1 
GDP metabolic process (GO:0046710) 5 28.60 9.33E-03 MAGI3, DLG4, DLG2, DLG1, DLG3 
neuromuscular process (GO:0050905) 10 7.36 1.25E-02 DLG4, KCNA1, PTPRQ, SHANK3, ATP2B2, ABL1, SHANK1, APP, PARK2, 
GRIN1 
SNARE complex assembly (GO:0035493) 4 49.58 1.33E-02 VAMP4, VAMP3, VAMP1, STX4 
protein localization to synapse (GO:0035418) 6 17.16 1.47E-02 DLG4, SNAP25, SNAP47, STX3, SHANK1, PCLO 
regulation of intracellular transport (GO:0032386) 22 3.24 1.54E-02 
CREB3, TNF, VAMP3, RIMS1, VAMP2, PLN, NAPB, SRC, EMD, YWHAE, 
RINT1, NUP54, PIK3R1, RNASE2, ERBB4, ERBB2, PRKCD, HMOX1, MDM2, 
STX1A, PARK2, EGFR 
peptidyl-tyrosine phosphorylation (GO:0018108) 13 5.14 1.83E-02 
TRIM27, INSR, CDC37, SRC, ABI3, FYN, PIBF1, ERBB4, ERBB2, ABI1, 
PRKCD, ABL1, EGFR 
COPII vesicle coating (GO:0048208) 8 9.75 1.86E-02 GOLGA2, GRIA1, SEC22B, BET1, TMED2, GOSR2, STX5, NSF 
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GO term Nr. proteins 
Fold enrichment 
(%) p-value Associated proteins 
activation of protein kinase activity (GO:0032147) 16 4.09 2.38E-02 
TNF, AGAP2, INSR, ITGB3, PRKACA, SRC, PIBF1, CRK, PLCG1, PRKCD, 
ABL1, CD81, DLG1, CALCA, EGFR, TNIK 
synaptic vesicle docking (GO:0016081) 4 37.18 4.12E-02 SNAP25, STX3, BLOC1S6, STX1A 
 
BRI2 ES hippocampus specif ic network analysis  
synaptic vesicle fusion to presynaptic active zone membrane (GO:0031629) 7 77.92 6.23E-08 STX19, STX1B, STX3, STX2, SNAP29, STX1A, STX4 
cytoskeleton organization (GO:0007010) 28 3.97 3.85E-06 
CRMP1, PFN1, DPYSL3, UBE2B, MYO18A, KLHL20, DPYSL2, ACTR2, SRC, 
FLNA, ADD2, DBN1, SDCBP, LIMA1, ZAK, ANK2, KIF18A, HTT, PIP5K1A, 
ANLN, SPRY2, SEPT1, SYNE4, CCDC155, AXIN1, MYH9, VIM, CDK5RAP2 
vesicle docking (GO:0048278) 9 20.73 6.79E-06 STX19, STX1B, STX3, STX2, STX16, STX5, STX1A, STX4, STX6 
intracellular protein transport (GO:0006886) 23 4.15 7.66E-05 
AP3M1, CDC37, NAPB, STX19, EHD3, YWHAE, SDCBP, STX1B, VCP, STX3, 
MICALL1, ANK2, STX2, PIP5K1A, MYO1C, MCM3AP, STX16, BID, STX5, 
ARL6IP1, STX1A, STX4, STX6 
cell projection organization (GO:0030030) 25 3.23 1.95E-03 
CRMP1, MAPK8IP2, UBE2B, IQCB1, RTN4, DPYSL2, HMGB1, ACTR2, SRC, 
FLNA, EHD3, TMEM17, YWHAE, SDCBP, RPS6KA5, LIMA1, INTU, STX3, 
MICALL1, IQGAP1, PIP5K1A, SNAP29, SLC12A5, MYH9, CDK5RAP2 
Golgi vesicle transport (GO:0048193) 14 5.62 2.22E-03 MYO18A, KLHL20, EHD3, RBSN, BET1, TFG, VCP, ANK2, KIF18A, HTT, 
STX5, STX4, ANKFY1, STX6 
spindle localization (GO:0051653) 6 20.04 5.83E-03 ACTR2, HTT, SPRYZ, CCDC155, MYH9, CDK5RAP2 
cell differentiation (GO:0030154) 50 1.95 1.00E-02 
CRMP1, DPYSL3, MAPK8IP2, UBE2B, MAPK6, RTN4, ATF2, DPYSL2, 
HMGB1, ACTR2, SRC, FLNA, AGR2, DBN1, IL33, YWHAE, PSMD11, 
RPS6KA5, BASP1, STX1B, INTU, STX3, CDK5RAP3, ZAK, MICALL1, ANK2, 
IQGAP1, STX2, RNF8, FXR1, PIP5K1A, ANLN, SMPD3, SPRY2, HNRNPH3, 
RIPK3, SYNE4, SLC12A5, HSPE1, CCDC155, AXIN1, GNB2L1, MYH9, 
ANXA7, VIM, TRIP13, CDK5RAP2, CPNE9, FAS, RGS2 
protein complex assembly (GO:0006461) 23 3.04 1.75E-02 
DPYSL3, MAPK8IP2, TK1, RTN4, SRC, ADD2, EHD3, PSMD11, BET1, TFG, 
VCP, CADPS, NDUFV2, STX2, AMFR, ANLN, SNAP29, RIPK3, BID, STX5, 
AXIN1, STX4, FAZ 
regulation of cysteine-type endopeptidase activity involved in apoptotic process 
(GO:0043281) 
10 6.61 2.92E-02 HMGB1, SRC, YWHAE, VCP, SERPINB9, BID, ARL6IP1, HSPE1, GNB2L1, 
FAZ 
actin filament-based process (GO:0030029) 15 4.14 3.50E-02 PFN1, DPYSL3, MYO18A, ACTR2, SRC, FLNA, ADD2, DBN1, SDCBP, 
LIMA1, ANK2, PIP5K1A, CCDC155, MYH9, VIM 
supramolecular fiber organization (GO:0097435) 13 4.72 3.97E-02 DPYSL3, ACTR2, SRC, FLNA, ADD2, DBN1, LIMA1, KIF18A, RIPK3, 
CCDC155, AXIN1, VIM, HSP90AB1 
positive regulation of intracellular signal transduction (GO:1902533) 21 3.08 4.21E-02 
MAPK8IP2, RGL2, PELI2, HMGB1, SRC, FLNA, SDCBP, TFG, CDK5RAP3, 
ZAK, IQGAP1, HTT, PLA2G2A, SPRY2, RIPK3, BID, CCL18, AXIN1, 
GNB2L1, EEF1D, FAS 
cytosolic transport (GO:0016482) 8 8.62 4.29E-02 KLHL20, ACTR2, EHD3, RBSN, STX16, STX5, ANKFY1, STX6 
 
BRI2 ES cerebellum specif ic network analysis 
synaptic vesicle recycling (GO:0036465) 4 60.13 5.56E-03 SH3GL2, SYT2, SYT7, SH3GL1 
endocytosis (GO:0006897) 9 7.44 2.22E-02 
SH3GL3, SH3GL2, WIPF1, DPYSL2, SYT2, SYT7, CSNK1E, SH3GL1, 
CACNG2 
developmental process (GO:0032502) 28 2.42 2.29E-03 SH3GL3, COL10A1, SH3GL2, GFI1B, DPYSL4, DPYSL2, PRKD2, RHEB, SYT2, SIAH1, ITM2B, KIF18A, PTPRO, HTT, SRPK2, CSNK1E, SH3GL1, 
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GO term Nr. proteins 
Fold enrichment 
(%) p-value Associated proteins 
SPRED1, TFF1, LITAF, SYNE4, UCHL1, CCDC155, TRIP13, ARIH2, SPRY3, 
SPRED2, NCAM1 
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III.A.3.5 Validation of HPLC-MS/MS-identified BRI2 interactors by immunoblotting 
analysis 
The identification of DLG4, also known as PSD-95, in the BRI2 ES interactome is of paramount 
importance since it suggests, for the first time, the presence of BRI2 in the postsynaptic compartment, 
particularly at the postsynaptic density (PSD). For this reason, PSD-95 was selected for experimental 
validation. Briefly, we co-immunoprecipitated BRI2 from the three brain regions as well as the mock 
negative controls using a specific antibody. These Co-IPs were analyzed using SDS-PAGE and 
immunoblotted with the BRI2 antibody (Figure III.A.6). First, it was possible to confirm that the 
BRI2 co-immunoprecipitation approach in the 3 brain regions was effective since when a BRI2 
antibody was used in immunoblotting, a signal in the range of 37-40 kDa was detected, corresponding 
to the full-length BRI2 protein (Figure III.A.6). Nonetheless, lower signals in the negative controls 
(mock IP controls – dynabeads protein G coupled with mouse IgG; Figure III.A.6) were also detected. 
Moreover, using a PSD-95 specific antibody, a prominent signal in the range of 95-100 kDa was 
evident in all the BRI2 co-immunoprecipitations, which is consistent with the molecular weight of 
the PSD-95 protein. These results were consistent with the mass spectrometry data, validating the 
formation of a complex containing BRI2 and PSD-95 (Figure III.A.4 and Figure III.A.6). 
 
 
Figure III.A. 6 - Co-immunoprecipitation of the BRI2 in rat brain tissue lysate and western blot for BRI2 and PSD-
95. Rat cerebral cortex (A), hippocampus (B) and cerebellum (C) were immunoprecipi tated with a mouse monoclonal 
BRI2 antibody bound to protein G Dynabeads . The mock IP negative controls  were performed by incubating cell extracts 
with G Dynabeads  coupled with mouse IgG. NC, mock IP negative controls . 
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III.A.4 Discussion 
BRI2 is a relevant protein in the pathogenesis of the neurodegenerative diseases FBD and FDD, as 
well as in AD, given its association with APP and its effects on Abeta production, aggregation and 
degradation (Fotinopoulou et al. 2005; Matsuda et al. 2005; Matsuda et al. 2011; Willander et al. 
2012). Several lines of evidence suggest a role for BRI2 at the nerve terminals (Akiyama et al. 2004) 
and in neurite outgrowth (Choi et al. 2004; Martins et al. 2016; Martins et al. 2017), however, its 
precise physiological function and associated signaling pathways remain elusive. The study of PPI 
networks is a valuable methodology to uncover the role of previously uncharacterized proteins in 
pathways or protein complexes, both in healthy and diseased states. Therefore, the identification of 
the BRI2 interactome is crucial for understanding the biological functions of BRI2 in the CNS. This 
study focused on elucidating and characterizing the BRI2 brain interactome, which was isolated from 
rat cerebral cortex, hippocampus and cerebellum by co-immunoprecipitation assays, using a specific 
BRI2 antibody. This approach identified 511 protein candidates as potential BRI2 brain interactors, 
of which two were previously reported in public protein interaction databases: Ppp1ca and Cacna2d1. 
PP1 is a major serine/threonine phosphatase that was recently found to interact directly with BRI2. 
The BRI2:PP1 complex seems to be of paramount importance in the nervous system since BRI2 
dephosphorylation by PP1 appears to be responsible for the regulation of its role in neurite outgrowth 
(Martins et al. 2016; Martins et al. 2017). In total, approximately 5% of the currently suggested BRI2 
interacting proteins were identified in the work here presented. Of note, only a small number of these 
previously reported BRI2 interacting proteins have actually been validated. Moreover, the failure to 
identify other known BRI2 interactors might be due to several factors. For instance, limitations of 
this study include the possibility of poor recovery of the membrane and nuclear proteins, not 
detecting weak or transient interactions, and the cellular/tissue expression of the proteins previously 
detected. It is also crucial to take into account that the HPLC-MS/MS technique identifies co-
complex interactions which include direct physical interactions but also indirect co-complex 
associations (Kim et al. 2010). Remarkably, although the BRI2 interactors here identified do not 
present a high overlap with the others previously reported in the literature, many were functionally 
similar or related. It is also important to note that a specific BRI2 antibody that recognizes the N-
terminal of the protein was used. Since BRI2 suffers proteolytic cleavages that originate different 
BRI2 N-terminal fragments, when we perform the co-IP experiments we isolated not only full-length 
BRI2 but also the different BRI2 N-terminal fragments.  
In this study, the BRI2 brain interactome was identified, and thus a tissue-specific network-based 
approach was used. Of the 511 candidate BRI2 brain interactors identified in this study, 120 were 
highly specific or strongly expressed in the brain. Functional enrichment analysis for cellular 
component of the brain BRI2 interactome suggests a subcellular localization for the BRI2 protein in 
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neuron projections, synapses, both presynapse and postsynapse, and associated with synaptic vesicles 
(Figure III.A.3B). These results together with the fact that the majority of these BRI2 interactors are 
cytoskeletal proteins, transporters and membrane traffic proteins (Figure III.A.2) are consistent with 
the concept that BRI2 in the CNS has a role in nerve terminals and neuronal differentiation (Choi et 
al. 2004; Akiyama et al. 2004; Martins et al. 2016; Martins et al. 2017). Analysis of the BRI2 ES 
interactome resulted in the identification of proteins associated with several processes of the synaptic 
vesicle cycle, such as neurotransmitter uptake and vesicle docking, priming, fusion and exocytosis 
(Figure III.A.3A and Supplementary Table III.A.S5). For instance, syntaxin 1 (Stx1a; Stx1b) and 
synaptosome-associated protein 25 (Snap25) are core components of a SNARE (soluble N-
ethylmaleimide-sensitive factor [NSF]-attachment protein receptor) complex, formed by V and T-
SNARE proteins. This complex assembly between vesicle and plasma membrane constitutes a key 
step in exocytosis and neurotransmitter release that is rendered Ca2+-dependent by interaction with 
synaptotagmin-1 (Syt1), a Ca2+ sensor synaptic vesicle-associated protein (Sørensen et al. 2006; 
Südhof and Rothman 2009; Jahn and Fasshauer 2012; Geppert et al. 1994; Voets et al. 2001). 
Moreover, several proteins in the BRI2 ES interactome associated with the microtubule transport 
machinery were found, in particular β-tubulin isotype III (Tubb3b), β-tubulin isotype IIb (Tubb2b), 
kinesin heavy chain isoforms 5a and 5c (Kif5a and kif5c, respectively), and kinesin light chain 
isoform 1 (Klc1). Neuronal trafficking is a crucial process to the formation and dynamics of both 
presynaptic and postsynaptic structures and depends on molecular motor proteins that move along 
the cytoskeleton. Kif5a and Kif5c are two kinesin heavy chain (KHC) neuron-specific isoforms, and 
klc1 is a neuronally enriched kinesin light chain (KLC) isoform that are components of the kinesin 
I, a motor protein important for trafficking in axons and dendrites (Rahman et al. 1998; Xia et al. 
1998). Therefore, these results suggest that in neurons, BRI2 is transported within axons by 
anterograde axonal transport to the distal nerve terminals where the full-length protein or even its N-
terminal fragments may interact with the neurotransmitter machinery release and contribute to 
synaptic signaling.  
The present results regarding the BRI2 ES interactome also suggest an association for BRI2 with 
synaptic transmission, plasticity, and learning. Several BRI2 brain interactome members including 
disk large homolog 4 (Dlg4/PSD-95), calcium/calmodulin-dependent protein kinase II alpha 
(Camk2a/CamkIIα), calcium/calmodulin-dependent protein kinase II beta (Camk2b/CamkIIβ), 
protein phosphatase 1 (PP1/Ppp1ca), (glutamate receptor ionotropic NMDA1 (Grin1/NR1/GluN1), 
glutamate receptor ionotropic NMDA2B (Grin2b/GluN2B/NR2B), glutamate receptor ionotropic 
AMPA1 (Gria1/GluA1/GluR-1) and glutamate receptor ionotropic AMPA2 (Gria2/GluA2/GluR-2) 
all participate in these processes. The PSD-95 protein was identified in our interactome firstly by MS 
analysis and further validated by immunoblotting analysis as novel BRI2 interactor in all three brain 
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regions, suggesting the presence of BRI2 in the postsynaptic compartments. PSD-95 is a major 
scaffold protein in the brain and concentrated in the postsynaptic density (PSD) of excitatory 
synapses, implicated in synapse maturation and in regulating synaptic strength and plasticity (Nelson 
et al. 2013; Yoshii and Constantine-Paton 2014; Kim et al. 2007). PSD-95 interacts with both AMPA 
receptors (AMPARs) and NMDA-type glutamate receptors (NMDARs) through its PDZ (PSD-
95/Dlg/ZO-1) domain, and its overexpression increases the number of synapses expressing AMPARs 
(Béïque and Andrade 2003; El-Husseini et al. 2000). The NMDAR subunit GluN2B was also found 
to bind directly and to colocalize with PSD-95 in rat hippocampal neurons, and the interaction serves 
to anchor the NMDARs to the submembrane cytoskeleton (Niethammer et al. 1996; Kornau et al. 
1995). Therefore, it is plausible to hypothesize that BRI2 may also be involved in synaptic 
transmission and plasticity by altering the AMPAR and NMDAR trafficking which affects excitatory 
synaptic transmission. Consistent with a role for BRI2 in synaptic plasticity, learning and memory, 
Itm2b (+/-) mice exhibit synaptic and memory deficits. Knock-in mouse models of FDD and FBD, 
FDDKI and FBDKI respectively, exhibit similar deficits which are attributed to the loss of BRI2 
function in those neurodegenerative diseases (Tamayev et al. 2010a; Tamayev et al. 2010b). 
Moreover, in a synaptosomal proteome characterization of the mouse model FDDKI, PSD-95 
expression was found decreased and pointed as a potential player in the altered synaptic transmission 
and activity observed in this mice (Vitale et al. 2012). PSD-95 knockout mice display several 
phenotypic similarities, such as abnormal synaptic plasticity as well as abnormal memory and 
learning (Feyder et al. 2010). The synaptic accumulation of PSD-95 is a key feature in its ability to 
potentiate synaptic transmission. PSD-95 phosphorylation of Ser295 by JNK1 enhances its synaptic 
accumulation, whereas dephosphorylation of this PSD-95 residue by PP1/PP2A is required for 
AMPA receptor internalization and LTD (Kim et al. 2007). However, there are no clear evidence 
whether Ser295 phosphorylation enhances synaptic transport or postsynaptic stability of PSD-95.  
An exciting feature of this BRI2 interactome, is the high number of cytoskeleton proteins which 
translated into an overrepresentation of functions like cytoskeleton organization and microtubule-
based processes, evidently important for neuronal differentiation (Figure III.A.3A). Rearrangements 
of actin and microtubules cytoskeletons are crucial to establish and maintain polarity in neurons, in 
neural migration and vesicle trafficking (Barnes and Polleux 2009; Stiess and Bradke 2011). In fact, 
almost 50% (49 out of the 120) of the brain BRI2 ES interactome proteins are annotated with 
neuronal differentiation related biological processes (Supplementary Table III.A.S7), and the 
construction of a BRI2-neuronal differentiation-specific PPI subnetwork (Figure III.A.4) allowed us 
to explore the biological functionalities and the potential underlying molecular mechanisms of BRI2 
in these processes. In line with this observation, functional enrichment pathway analysis of the 
expanded BRI2-neuronal differentiation-specific interactome associated BRI2 interactors to 
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signalling pathways involved in several neuronal differentiation related events, namely adherens 
junction, axon guidance, ErbB signalling pathway (Iwakura and Nawa 2013; Mei and Nave 2014), 
FoxO signalling pathway (Wen et al. 2012), neurotrophin signalling pathway (Reichardt 2006) and 
estrogen signalling pathway (Wang et al. 2003) (Table III.A.2). These results strengthen the proposed 
role for BRI2 in neuronal differentiation and neurite outgrowth and an association of BRI2 with these 
signaling pathways deserve further investigations.  
The identification of adhesion proteins, such as neural cell adhesion molecule (Ncam1), a member 
of the Ig superfamily of cell-adhesion molecules (Kleene et al. 2010) in the study here presented lead 
us to propose that one of the mechanisms by which BRI2 promotes neurite outgrowth might be by 
regulating cell-cell adhesion. Ncam associates with numerous cytoskeletal components but also with 
some signaling pathways associated with a neurite outgrowth response (Hansen et al. 2008). For 
instance, Ncam interacts with spectrin, a protein involved in linking cellular membranes to the actin 
filament cytoskeletal system, which in turns interacts with the growth-associated protein 43 (GAP-
43), a protein that is highly expressed in growth cones and believed to be important for growth cone 
extension. Likewise, Ncam-mediated neurite outgrowth was inhibited in neurons from GAP-43 
knockout mice, supporting a functional relationship between Ncam and GAP-43 (Hansen et al. 
2008). Remarkably, both spectrin (Sptbn2) and GAP-43 (Gap43) were identified in our BRI2 
interactome and therefore these mechanisms deserve further investigation. Moreover, it has already 
been described that BRI2 is able to form homodimers linked by disulfide bonds that appear at the 
cell surface resembling the structure of a cell-surface receptor (Tsachaki et al. 2010). Although a 
receptor function for BRI2 has not been established it is possible to hypothesize that BRI2, triggered 
by ligand interaction, may act as a cell surface receptor participating in the above-mentioned 
signaling pathways. It was recently demonstrated by our group that BRI2 phosphorylation modulates 
its proteolytic processing and neuritogenic role. Moreover, for BRI2 mediated neurite outgrowth, it 
appears that phosphorylation of full-length protein promotes the emergence of neurites whereas the 
increased BRI2 NTFs play a relevant role in neurites’ elongation and stabilization (Martins et al. 
2017). Thus, it is also plausible to assume that mechanisms underlying BRI2 role in neurite 
outgrowth may also involve: (1) BRI2 full-length phosphorylation induces conformational changes 
in the protein which affect protein-protein binding, and for instance could affect binding to 
neurotrophic effectors of the above signalling pathways; (2) increased BRI2 proteolytic processing 
to its secreted fragment (containing the BRICHOS domain) which can activate the above signalling 
pathways via a growth factor receptor. 
Finally, a comparative analysis approach of the BRI2 ES interactome in the three different brain 
regions was employed, resulting in the identification of 31 proteins specifically in the cerebral cortex, 
14 in the hippocampus, and 8 in the cerebellum (Figure III.A.5C). The results evidenced that in the 
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different brain regions BRI2 seems to be associated to cellular processes also highlighted in the 
analysis of the total BRI2 ES interactome, namely neuron development and synaptic vesicle cycle 
(Table III.A.3), supporting that the majority of the biological functions of BRI2 in the CNS are in 
fact relatively stable across the three brain regions.  
In summary, these results provide important insights on BRI2 brain interactome, comprising several 
new putative interacting partners. We observed a complex interaction of BRI2 with proteins related 
to neuronal differentiation, neurite outgrowth, synaptic signaling and plasticity. Further, we validated 
both PSD-95 as novel BRI2 interactor in the brain using co-IP and immunoblotting analysis. 
Therefore, the work here presented provides a valuable list of BRI2 interacting proteins for further 
studies to investigate their potential roles in BRI2 biology and the underlying molecular mechanisms, 
as well as novel insights in its associated pathologies (FBD, FDD, and AD). 
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Figure III.A.S  1 - BRI2 ES-based region specific sub-networks. A- BRI2 ES-based sub-network for the cerebral 
cortex. Node colors represent the source of the protein: blue nodes correspond to proteins identified in this study in the 
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cerebral cortex, grey nodes to proteins added by network augmentation, and red nodes correspond to protein added by 
network augmentation that are also identified in this study as BRI2 ES interactors. Node size according to the degree in the 
network. Edge color represent the source of interaction: blue edges correspond to the cortex specific BRI2 interactions 
enriched or specific for brain identified in our study, whereas the grey edges correspond to interactions added by network 
augmentation. B- BRI2 ES-based sub-network for the hippocampus. Node colors represent the source of the protein: 
orange nodes correspond to proteins identified in this study in the cerebral cortex, grey nodes to proteins added by network 
augmentation, and red nodes correspond to protein added by network augmentation that are also identified in this study as 
BRI2 ES interactors. Node size according to the degree in the network. Edge color represent the source of interaction: 
orange edges correspond to the cortex specific BRI2 interactions enriched or specific for brain identified in our study, 
whereas the grey edges correspond to interactions added by network augmentation. C- BRI2 ES-based sub-network for 
the cerebellum. Node colors represent the source of the protein: green nodes correspond to proteins identified in this study 
in the cerebral cortex, grey nodes to proteins added by network augmentation, and red nodes correspond to protein added 
by network augmentation that are also identified in this study as BRI2 ES interactors. Node size according to the degree in 
the network. Edge color represent the source of interaction: green edges correspond to the cortex specific BRI2 interactions 
enriched or specific for brain identified in our study, whereas the grey edges correspond to interactions added by network 
augmentation.  
 
Table III.A.S1- Candidate BRI2 interacting proteins identified by Nano-HPLC-MS/MS . Uniprot accession numbers, 
gene and protein names, are listed, as well as the rat brain tissues where the proteins were identified. CC, cerebral cortex; 
HP, hippocampus; CB, cerebellum. 
Uniprot 
accession 
Gene 
name 
Protein name  
Brain regions 
 
P62260 Ywhae 14-3-3 protein epsilon  HP 
P61983 Ywhag 14-3-3 protein gamma  CC, HP 
P68255 Ywhaq 14-3-3 protein theta  CC 
P63102 Ywhaz 14-3-3 protein zeta/delta  CB 
P13233 Cnp 2',3'-cyclic-nucleotide 3'-phosphodiesterase  CC, HP, CB 
Q4FZT9 Psmd2 26S proteasome non-ATPase regulatory subunit 2 CC, CB 
P11960 Bckdha 2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial  CC 
O70351 Hsd17b10 3-hydroxyacyl-CoA dehydrogenase type-2  HP 
P63326 Rps10 40S ribosomal protein S10 CB 
P62282 Rps11 40S ribosomal protein S11 CC 
P62278 Rps13 40S ribosomal protein S13 CC, CB 
P62250 Rps16 40S ribosomal protein S16 CC, CB 
P17074 Rps19 40S ribosomal protein S19 CC, CB 
P60868 Rps20 40S ribosomal protein S20 CB 
P62853 Rps25 40S ribosomal protein S25 CB 
P62856 Rps26 40S ribosomal protein S26 CB 
P62909 Rps3 40S ribosomal protein S3  CC, HP, CB 
P49242 Rps3a 40S ribosomal protein S3a  CB 
P62703 Rps4x 40S ribosomal protein S4, X isoform CC, CB 
P62083 Rps7 40S ribosomal protein S7  CB 
P38983 Rpsa 40S ribosomal protein SA  CC, CB 
Q794F9 Slc3a2 4F2 cell-surface antigen heavy chain  HP 
P63039 Hspd1 60 kDa heat shock protein, mitochondrial  CC, HP 
P19945 Rplp0 60S acidic ribosomal protein P0  CB 
P62914 Rpl11 60S ribosomal protein L11 CB 
P23358 Rpl12 60S ribosomal protein L12 CC, HP, CB 
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P41123 Rpl13 60S ribosomal protein L13 CB 
P47198 Rpl22 60S ribosomal protein L22 CC 
P61354 Rpl27 60S ribosomal protein L27 CC, CB 
P50878 Rpl4 60S ribosomal protein L4  CB 
P21533 Rpl6 60S ribosomal protein L6  CB 
P05426 Rpl7 60S ribosomal protein L7 CC, CB 
P06761 Hspa5 78 kDa glucose-regulated protein  CC, HP, CB 
P49911 Anp32a Acidic leucine-rich nuclear phosphoprotein 32 family member A  CC, CB 
Q9ER34 Aco2 Aconitate hydratase, mitochondrial  HP 
P68035 Actc1 Actin, alpha cardiac muscle 1  CC 
P60711 Actb Actin, cytoplasmic 1  CC, HP, CB 
P63269 Actg2 Actin, gamma-enteric smooth muscle  CC, HP, CB 
Q6KC51 Ablim2 Actin-binding LIM protein 2  CC, CB 
Q4V7C7 Actr3 Actin-related protein 3  CB 
P69682 Necap1 Adaptin ear-binding coat-associated protein 1  CC, HP 
B5DFN2 Ahcyl1 Adenosylhomocysteinase 2  CB 
P39069 Ak1 Adenylate kinase isoenzyme 1  HP 
P52481 Cap2 Adenylyl cyclase-associated protein 2  CC, HP 
Q05962 Slc25a4 ADP/ATP translocase 1  CC, HP 
Q09073 Slc25a5 ADP/ATP translocase 2  CC, HP 
P61751 Arf4 ADP-ribosylation factor 4 CC, HP 
Q62848 Arfgap1 ADP-ribosylation factor GTPase-activating protein 1  CB 
P07897 Acan Aggrecan core protein  HP 
P06238 A2m Alpha-2-macroglobulin  CC, HP, CB 
Q9Z1P2 Actn1 Alpha-actinin-1  CC 
Q63028 Add1 Alpha-adducin  HP, CB 
P85515 Actr1a Alpha-centractin  HP 
P04764 Eno1 Alpha-enolase  CC, HP 
P23565 Ina Alpha-internexin  CC, HP, CB 
P54921 Napa Alpha-soluble NSF attachment protein  HP, CB 
P21396 Maoa Amine oxidase [flavin-containing] A  HP 
O08838 Amph Amphiphysin CC, HP, CB 
P0C6S7 Anks1b Ankyrin repeat and sterile alpha motif domain-containing protein 1B  CC 
O70511 Ank3 Ankyrin-3  CC, HP, CB 
P52303 Ap1b1 AP-1 complex subunit beta-1  CC, HP 
Q32Q06 Ap1m1 AP-1 complex subunit mu-1  CC 
P18484 Ap2a2 AP-2 complex subunit alpha-2  CC, HP, CB 
P62944 Ap2b1 AP-2 complex subunit beta  CC, HP, CB 
P84092 Ap2m1 AP-2 complex subunit mu  CC, HP 
P62744 Ap2s1 AP-2 complex subunit sigma  CC, HP, CB 
P0C1X8 Aak1 AP2-associated protein kinase 1  CC, HP 
Q8CGU4 Agap2 Arf-GAP with GTPase, ANK repeat and PH domain-containing protein 2  CC 
P00507 Got2 Aspartate aminotransferase, mitochondrial  CB 
P15178 Dars Aspartate--tRNA ligase, cytoplasmic  CB 
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Q6PST4 Atl1 Atlastin-1  CC 
P19511 Atp5f1 ATP synthase F CC, HP 
P15999 Atp5a1 ATP synthase subunit alpha, mitochondrial CC, HP 
P10719 Atp5b ATP synthase subunit beta, mitochondrial  HP 
P31399 Atp5h ATP synthase subunit d, mitochondrial  HP 
P35434 Atp5d ATP synthase subunit delta, mitochondrial  HP 
P29419 Atp5i ATP synthase subunit e, mitochondrial  CC 
D3ZAF6 Atp5j2 ATP synthase subunit f, mitochondrial HP, CB 
Q6PDU7 Atp5l ATP synthase subunit g, mitochondrial  HP, CB 
P35435 Atp5c1 ATP synthase subunit gamma, mitochondrial  CC, HP, CB 
Q06647 Atp5o ATP synthase subunit O, mitochondrial  CC, HP, CB 
P21571 Atp5j ATP synthase-coupling factor 6, mitochondrial  HP 
Q7TNJ2 Abca7 ATP-binding cassette sub-family A member 7 HP 
P47858 Pfkm ATP-dependent 6-phosphofructokinase, muscle type  HP 
P47860 Pfkp ATP-dependent 6-phosphofructokinase, platelet type  HP 
Q9WTP0 Epb41l1 Band 4.1-like protein 1  CC, HP, CB 
Q9ESS6 Bcam Basal cell adhesion molecule  CC, HP, CB 
Q05764 Add2 Beta-adducin  HP 
P29066 Arrb1 Beta-arrestin-1  CC 
P85969 Napb Beta-soluble NSF attachment protein  HP 
O35567 Atic Bifunctional purine biosynthesis protein PURH 
Phosphoribosylaminoimidazolecarboxamide formyltransferase  
CB 
Q05175 Basp1 Brain acid soluble protein 1  HP 
Q6GMN2 Baiap2 Brain-specific angiogenesis inhibitor 1-associated protein 2  CC 
P55068 Bcan Brevican core protein  HP, CB 
P11275 Camk2a Calcium/calmodulin-dependent protein kinase type II subunit alpha  CC, HP 
P08413 Camk2b Calcium/calmodulin-dependent protein kinase type II subunit beta  CC, HP, CB 
P15791 Camk2d Calcium/calmodulin-dependent protein kinase type II subunit delta  CC, CB 
P11730 Camk2g Calcium/calmodulin-dependent protein kinase type II subunit gamma  CC, CB 
Q66HR5 Calcoco1 Calcium-binding and coiled-coil domain-containing protein 1 CC, HP 
Q62717 Cadps Calcium-dependent secretion activator 1  HP 
P62161 Calm1 Calmodulin  HP, CB 
Q07009 Capn2 Calpain-2 catalytic subunit  CB 
Q63092 Camkv CaM kinase-like vesicle-associated protein  HP 
P27791 Prkaca cAMP-dependent protein kinase catalytic subunit alpha  CC 
P48284 Ca4 Carbonic anhydrase 4  CB 
P19139 Csnk2a1 Casein kinase II subunit alpha  CC, HP, CB 
P67874 Csnk2b Casein kinase II subunit beta  CC 
Q9WU82 Ctnnb1 Catenin beta-1  CC, CB 
B5D5N9 Slc7a2 Cationic amino acid transporter 2  CC, HP 
Q5M7A7 Cnrip1 CB1 cannabinoid receptor-interacting protein 1  CB 
P40241 Cd9 CD9 antigen  CC, HP, CB 
B0K020 Cisd1 CDGSH iron-sulfur domain-containing protein 1  CC 
Q1WIM1 Cadm4 Cell adhesion molecule 4  CB 
Q5FVI4 Cend1 Cell cycle exit and neuronal differentiation protein 1 CC, HP 
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B2RYL1 Chtf8 Chromosome transmission fidelity protein 8 homolog isoform 2 CC 
Q8VHF5 Cs Citrate synthase, mitochondrial  CC 
Q05140 Snap91 Clathrin coat assembly protein AP180  CC, HP 
P11442 Cltc Clathrin heavy chain 1 CC, HP 
P08081 Clta Clathrin light chain A  CC, HP 
P08082 Cltb Clathrin light chain B  CC, HP 
Q99P82 Cldn11 Claudin-11 CC 
Q99JD4 Clasp2 CLIP-associating protein 2  CB 
P45592 Cfl1 Cofilin-1  CC, HP, CB 
P13941 Col3a1 Collagen alpha-1 CB 
P31720 C1qa Complement C1q subcomponent subunit A HP 
P31721 C1qb Complement C1q subcomponent subunit B CC, HP, CB 
P31722 C1qc Complement C1q subcomponent subunit C CC 
P01026 C3 Complement C3 [Cleaved into: Complement C3 beta chain; C3-beta-c  CC, HP 
O35796 C1qbp Complement component 1 Q subcomponent-binding protein, mitochondrial  CB 
P63041 Cplx1 Complexin-1  HP 
Q9Z1T4 Cnksr2 Connector enhancer of kinase suppressor of ras 2  CC 
Q63198 Cntn1 Contactin-1  CC, HP 
P97846 Cntnap1 Contactin-associated protein 1  CC, CB 
Q5BJS7 Cpne9 Copine-9  HP 
Q02874 H2afy Core histone macro-H2A.1  CB 
P48199 Crp C-reactive protein CB 
P00564 Ckm Creatine kinase M-type  CB 
P25809 Ckmt1 Creatine kinase U-type, mitochondrial  CC, HP, CB 
P97536 Cand1 Cullin-associated NEDD8-dissociated protein 1  CB 
O08565 Cxcr4 C-X-C chemokine receptor type 4  HP 
Q03114 Cdk5 Cyclin-dependent-like kinase 5  CC 
P97874 Gak Cyclin-G-associated kinase  CC, HP 
P32551 Uqcrc2 Cytochrome b-c1 complex subunit 2, mitochondrial  CC, HP, CB 
Q7TQ16 Uqcrq Cytochrome b-c1 complex subunit 8  CC, HP, CB 
P20788 Uqcrfs1 Cytochrome b-c1 complex subunit Rieske, mitochondrial  HP, CB 
P00406 Mtco2 Cytochrome c oxidase subunit 2  HP 
P10888 Cox4i1 Cytochrome c oxidase subunit 4 isoform 1, mitochondrial  CC, HP 
P11240 Cox5a Cytochrome c oxidase subunit 5A, mitochondrial  CB 
P12075 Cox5b Cytochrome c oxidase subunit 5B, mitochondrial  CC, HP 
P11951 Cox6c2 Cytochrome c oxidase subunit 6C-2  HP 
P35171 Cox7a2 Cytochrome c oxidase subunit 7A2, mitochondrial  HP 
P38650 Dync1h1 Cytoplasmic dynein 1 heavy chain 1  CC, HP 
Q6Q0N1 Cndp2 Cytosolic non-specific dipeptidase  CB 
O08651 Phgdh D-3-phosphoglycerate dehydrogenase  CC, CB 
P29147 Bdh1 D-beta-hydroxybutyrate dehydrogenase, mitochondrial  CC, HP 
P08461 Dlat Dihydrolipoyllysine-residue acetyltransferase component of pyruvate 
dehydrogenase complex, mitochondrial  
CC 
Q01205 Dlst Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate 
dehydrogenase complex, mitochondrial  
HP, CB 
Q62950 Crmp1 Dihydropyrimidinase-related protein 1  HP 
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P47942 Dpysl2 Dihydropyrimidinase-related protein 2  CC, HP 
Q62951 Dpysl4 Dihydropyrimidinase-related protein 4  CB 
Q63342 Dmgdh Dimethylglycine dehydrogenase, mitochondrial  CC 
Q62696 Dlg1 Disks large homolog 1  CC, CB 
Q63622 Dlg2 Disks large homolog 2  CC 
P31016 Dlg4 Disks large homolog 4  CC, HP, CB 
P97836 Dlgap1 Disks large-associated protein 1  CC 
P97837 Dlgap2 Disks large-associated protein 2  CC 
P97838 Dlgap3 Disks large-associated protein 3  CC 
Q07266 Dbn1 Drebrin  CC, HP 
Q01986 Map2k1 Dual specificity mitogen-activated protein kinase kinase 1  HP, CB 
Q6AYH5 Dctn2 Dynactin subunit 2 CC, HP 
P21575 Dnm1 Dynamin-1  CC, HP 
O35303 Dnm1l Dynamin-1-like protein  CC, HP 
Q2TA68 Opa1 Dynamin-like 120 kDa protein, mitochondrial  CC 
B0BND0 Enpp6 Ectonucleotide pyrophosphatase/phosphodiesterase family member 6  CB 
Q8R491 Ehd3 EH domain-containing protein 3 HP 
Q8CH84 Elavl2 ELAV-like protein 2  CC 
Q9JI66 Slc4a4 Electrogenic sodium bicarbonate cotransporter 1  HP, CB 
P62630 Eef1a1 Elongation factor 1-alpha 1  CC, HP 
Q68FR6 Eef1g Elongation factor 1-gamma  CB 
P05197 Eef2 Elongation factor 2  CC, HP, CB 
P85834 Tufm Elongation factor Tu, mitochondrial CC, HP, CB 
O35179 Sh3gl2 Endophilin-A1  CC, CB 
Q5PPJ9 Sh3glb2 Endophilin-B2  CC, HP, CB 
Q66HD0 Hsp90b1 Endoplasmin  CC, HP, CB 
O88339 Epn1 Epsin-1  CC 
B5DEH2 Erlin2 Erlin-2  CB 
Q5RKI1 Eif4a2 Eukaryotic initiation factor 4A-II  HP, CB 
P24942 Slc1a3 Excitatory amino acid transporter 1  CC, HP, CB 
P31596 Slc1a2 Excitatory amino acid transporter 2  CC, HP, CB 
O35921 Slc1a6 Excitatory amino acid transporter 4  CB 
B2GUZ5 Capza1 F-actin-capping protein subunit alpha-1  CB 
Q3T1K5 Capza2 F-actin-capping protein subunit alpha-2  CC 
Q5XI32 Capzb F-actin-capping protein subunit beta  CC, CB 
P12785 Fasn Fatty acid synthase  HP 
Q5XI81 Fxr1 Fragile X mental retardation syndrome-related protein 1 CB 
P05065 Aldoa Fructose-bisphosphate aldolase A  CC, HP 
O88871 Gabbr2 Gamma-aminobutyric acid type B receptor subunit 2  CC 
P08050 Gja1 Gap junction alpha-1 protein  CC, HP, CB 
Q68FP1 Gsn Gelsolin  CC, CB 
Q63228 Gmfb Glia maturation factor beta  CC 
P47819 Gfap Glial fibrillary acidic protein  CC, HP, CB 
P19490 Gria1 Glutamate receptor 1  CC 
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P19491 Gria2 Glutamate receptor 2  CC, HP, CB 
Q63226 Grid2 Glutamate receptor ionotropic, delta-2  CB 
P35439 Grin1 Glutamate receptor ionotropic, NMDA 1  CC 
Q00960 Grin2b Glutamate receptor ionotropic, NMDA 2B  CC 
P28492 Gls2 Glutaminase liver isoform, mitochondrial  HP 
P09606 Glul Glutamine synthetase  CC, HP, CB 
P04797 Gapdh Glyceraldehyde-3-phosphate dehydrogenase  CC 
P35571 Gpd2 Glycerol-3-phosphate dehydrogenase, mitochondrial  HP 
P53534 Pygb Glycogen phosphorylase, brain form  CC, HP 
P08644 Kras GTPase KRas  CC 
Q63942 Rab3d GTP-binding protein Rab-3D HP 
Q9WTT6 Gda Guanine deaminase  CC 
P43425 Gng7 Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-7 CC 
P63095 Gnas Guanine nucleotide-binding protein G(s) subunit alpha isoforms short CC 
P52287 Gnb3 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3 CC 
P82471 Gnaq Guanine nucleotide-binding protein G(q) subunit alpha CB 
P54311 Gnb1 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 CC, HP 
P10824 Gnai1 Guanine nucleotide-binding protein G(i) subunit alpha-1 CC, HP 
P19627 Gnaz Guanine nucleotide-binding protein G(z) subunit alpha CC, HP 
P59215 Gnao1 Guanine nucleotide-binding protein G(o) subunit alpha CC, HP, CB 
P04897 Gnai2 Guanine nucleotide-binding protein G(i) subunit alpha-2 CC, HP, CB 
O35353 Gnb4 Guanine nucleotide-binding protein subunit beta-4  HP, CB 
P55063 Hspa1l Heat shock 70 kDa protein 1-like  CC 
O88600 Hspa4 Heat shock 70 kDa protein 4  CB 
P63018 Hspa8 Heat shock cognate 71 kDa protein  CC 
P82995 Hsp90aa1 Heat shock protein HSP 90-alpha  CC, HP, CB 
P34058 Hsp90ab1 Heat shock protein HSP 90-beta  CC, HP, CB 
P11517 ND Hemoglobin subunit beta-2  CB 
Q6URK4 Hnrnpa3 Heterogeneous nuclear ribonucleoprotein A3  CC, CB 
G3V9R8 Hnrnpc Heterogeneous nuclear ribonucleoprotein C  CC, CB 
Q9JJ54 Hnrnpd Heterogeneous nuclear ribonucleoprotein D0  CC, CB 
Q3SWU3 Hnrnpdl Heterogeneous nuclear ribonucleoprotein D-like  CC, HP, CB 
Q794E4 Hnrnpf Heterogeneous nuclear ribonucleoprotein F  CC, CB 
Q8VHV7 Hnrnph1 Heterogeneous nuclear ribonucleoprotein H  CC 
Q6AY09 Hnrnph2 Heterogeneous nuclear ribonucleoprotein H2  CC, HP, CB 
P61980 Hnrnpk Heterogeneous nuclear ribonucleoprotein K  CC, HP, CB 
Q62826 Hnrnpm Heterogeneous nuclear ribonucleoprotein M  CB 
Q7TP47 Syncrip Heterogeneous nuclear ribonucleoprotein Q  CB 
A7VJC2 Hnrnpa2b1 Heterogeneous nuclear ribonucleoproteins A2/B1  CC, CB 
P05708 Hk1 Hexokinase-1  CC, HP 
P02262 ND Histone H2A type 1 CC, CB 
P0C0S7 H2afz Histone H2A.Z  CC, HP 
Q00715 ND Histone H2B type 1 CC, HP, CB 
P62804 Hist1h4b Histone H4  CC, HP, CB 
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Q9Z214 Homer1 Homer protein homolog 1  CC 
Q9Z2X5 Homer3 Homer protein homolog 3  CB 
P03994 Hapln1 Hyaluronan and proteoglycan link protein 1  CC, HP, CB 
Q9ESM2 Hapln2 Hyaluronan and proteoglycan link protein 2  CC, CB 
Q9WVK7 Hadh Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial  CC, HP 
Q63617 Hyou1 Hypoxia up-regulated protein 1  CC, HP, CB 
P20761 Igh-1a Ig gamma-2B chain C region  CC, HP 
P29994 Itpr1 Inositol 1,4,5-trisphosphate receptor type 1  CB 
Q63269 Itpr3 Inositol 1,4,5-trisphosphate receptor type 3  CB 
D3ZGS3 Ocrl Inositol polyphosphate 5-phosphatase OCRL-1  CC, HP 
Q63416 Itih3 Inter-alpha-trypsin inhibitor heavy chain H3  CC, HP 
Q7TP98 Ilf2 Interleukin enhancer-binding factor 2  CB 
Q9WVE9 Itsn1 Intersectin-1  CC, HP 
Q99NA5 Idh3a Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial  CC, HP 
Q68FX0 Idh3B Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial  CC, HP, CB 
P41565 Idh3g Isocitrate dehydrogenase [NAD] subunit gamma 1, mitochondrial  CC 
P56574 Idh2 Isocitrate dehydrogenase [NADP], mitochondrial  CB 
Q9QYU4 Crym Ketimine reductase mu-crystallin  HP 
Q6QLM7 Kif5a Kinesin heavy chain isoform 5A  CC, HP, CB 
P56536 Kif5c Kinesin heavy chain isoform 5C  CC, CB 
P37285 Klc1 Kinesin light chain 1  CC, HP, CB 
Q2PQA9 Kif5b Kinesin-1 heavy chain  CC, HP, CB 
Q9WV63 Kif2a Kinesin-like protein KIF2A  CB 
Q5XI51 Kif2b Kinesin-like protein KIF2B CC 
P70615 Lmnb1 Lamin-B1 CB 
Q5XIN6 Letm1 LETM1 and EF-hand domain-containing protein 1, mitochondrial  CB 
P97829 Cd47 Leukocyte surface antigen CD47  CC, HP 
Q62813 Lsamp Limbic system-associated membrane protein  CC, CB 
P04642 Ldha L-lactate dehydrogenase A chain  HP 
P04636 Mdh2 Malate dehydrogenase, mitochondrial  HP 
O08873 Madd MAP kinase-activating death domain protein  HP 
P43244 Matr3 Matrin-3  CC, HP 
Q4L1J4 Magi1 Membrane-associated guanylate kinase, WW and PDZ domain-containing 
protein 1  
HP 
Q00566 Mecp2 Methyl-CpG-binding protein 2  CB 
D4A7N1 Chchd6 MICOS complex subunit Mic25  CC, CB 
Q3KR86 Immt MICOS complex subunit Mic60  CC, HP, CB 
D3ZHV2 Macf1 Microtubule-actin cross-linking factor 1  CC, CB 
P34926 Map1a Microtubule-associated protein 1A  CC, HP 
P15205 Map1b Microtubule-associated protein 1B  CC, HP, CB 
P15146 Map2 Microtubule-associated protein 2  CC 
Q5M7W5 Map4 Microtubule-associated protein 4  CC, HP 
Q63560 Map6 Microtubule-associated protein 6  CC, HP, CB 
F1LP90 Mink1 Misshapen-like kinase 1  CC, HP 
P97700 Slc25a11 Mitochondrial 2-oxoglutarate/malate carrier protein  CC, HP, CB 
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Q505J6 Slc25a18 Mitochondrial glutamate carrier 2  CC 
O08839 Bin1 Myc box-dependent-interacting protein 1  CC, HP 
P02688 Mbp Myelin basic protein  CC 
P60203 Plp1 Myelin proteolipid protein  CC, CB 
P07722 Mag Myelin-associated glycoprotein  CC, CB 
Q63345 Mog Myelin-oligodendrocyte glycoprotein CC, CB 
Q6VBQ5 Myadm Myeloid-associated differentiation marker  CC 
Q9QZ76 Mb Myoglobin HP 
P02600 Myl1 Myosin light chain 1/3, skeletal muscle isoform  HP 
P16409 Myl3 Myosin light chain 3  HP, CB 
Q64119 Myl6 Myosin light polypeptide 6  CC, HP, CB 
P13832 Rlc-a Myosin regulatory light chain RLC-A  CC, CB 
Q64122 Myl9 Myosin regulatory light polypeptide 9  CC 
Q9JLT0 Myh10 Myosin-10  CC, CB 
Q62812 Myh9 Myosin-9  CC, CB 
Q5RJQ4 Sirt2 NAD-dependent protein deacetylase sirtuin-2  CC, CB 
Q561S0 Ndufa10 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 10, 
mitochondrial  
HP, CB 
Q5BK63 Ndufa9 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9, 
mitochondrial  
HP 
P19234 Ndufv2 NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial  HP, CB 
Q641Y2 Ndufs2 NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrial  HP 
P52504 Ndufs6 NADH dehydrogenase [ubiquinone] iron-sulfur protein 6, mitochondrial  HP 
Q66HF1 Ndufs1 NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial  CC, HP, CB 
O35867 Ppp1r9a Neurabin-1  CC 
P13596 Ncam1 Neural cell adhesion molecule 1  CB 
P55067 Ncan Neurocan core protein  CC, HP, CB 
O35095 Ncdn Neurochondrin  CC 
P97685 Nfasc Neurofascin CC, HP, CB 
P16884 Nefh Neurofilament heavy polypeptide  CC, HP, CB 
P19527 Nefl Neurofilament light polypeptide  CC, HP, CB 
P12839 Nefm Neurofilament medium polypeptide  CC, CB 
P07936 Gap43 Neuromodulin  CC 
Q9ESI7 Dcx Neuronal migration protein doublecortin CC 
Q9WU34 Sept3 Neuronal-specific septin-3  HP 
P97546 Nptn Neuroplastin  CC 
Q62718 Ntm Neurotrimin  CC, CB 
P08460 Nid1 Nidogen-1  CB 
Q9EPI6 Nsmf NMDA receptor synaptonuclear signaling and neuronal migration factor  CC 
A1L1I3 Numbl Numb-like protein CC 
P04218 Cd200 OX-2 membrane glycoprotein  CC 
P10111 Ppia Peptidyl-prolyl cis-trans isomerase A  CB 
Q9QVC8 Fkbp4 Peptidyl-prolyl cis-trans isomerase FKBP4  CB 
Q63716 Prdx1 Peroxiredoxin-1  CC, HP 
P35704 Prdx2 Peroxiredoxin-2  CC 
O35244 Prdx6 Peroxiredoxin-6  CC, HP 
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Q642G4 Pex14 Peroxisomal membrane protein PEX14  CC 
P16036 Slc25a3 Phosphate carrier protein, mitochondrial  CC, HP, CB 
O08662 Pi4ka Phosphatidylinositol 4-kinase alpha  CC 
P16617 Pgk1 Phosphoglycerate kinase 1  HP 
P16290 Pgam2 Phosphoglycerate mutase 2  CB 
P11505 Atp2b1 Plasma membrane calcium-transporting ATPase 1  CC 
P11506 Atp2b2 Plasma membrane calcium-transporting ATPase 2  CC 
Q64568 Atp2b3 Plasma membrane calcium-transporting ATPase 3  HP 
Q64542 Atp2b4 Plasma membrane calcium-transporting ATPase 4  CC 
P30427 Plec Plectin  CC, CB 
Q9EPH8 Pabpc1 Polyadenylate-binding protein 1  CB 
P0CG51 Ubb Polyubiquitin-B [Cleaved into: Ubiquitin] CC 
P10499 Kcna1 Potassium voltage-gated channel subfamily A member 1  CC 
P48679 Lmna Prelamin-A/C [Cleaved into: Lamin-A/C] CB 
Q9JMJ4 Prpf19 Pre-mRNA-processing factor 19  HP 
P62963 Pfn1 Profilin-1  CC 
P67779 Phb Prohibitin CC, HP, CB 
Q5XIH7 Phb2 Prohibitin-2  CC, HP, CB 
P04961 Pcna Proliferating cell nuclear antigen  CB 
Q6AYD3 Pa2g4 Proliferation-associated protein 2G4 CC 
Q6MG82 Prrt1 Proline-rich transmembrane protein 1  HP 
O88778 Bsn Protein bassoon CC, CB 
O88767 Park7 Protein deglycase DJ-1  CC 
P04785 P4hb Protein disulfide-isomerase  CB 
P63319 Prkcg Protein kinase C gamma type  CC, HP, CB 
Q8VBU2 Ndrg2 Protein NDRG2  HP 
Q9JKS6 Pclo Protein piccolo  CC 
Q6MG48 Prrc2a Protein PRRC2A  CC 
P23606 Tgm1 Protein-glutamine gamma-glutamyltransferase K  CB 
P52873 Pc Pyruvate carboxylase, mitochondrial  HP, CB 
P26284 Pdha1 Pyruvate dehydrogenase E1 component subunit alpha, somatic form, 
mitochondrial  
CC, CB 
P49432 Pdhb Pyruvate dehydrogenase E1 component subunit beta, mitochondrial  CC, HP, CB 
P11980 Pkm Pyruvate kinase PKM  CC, HP 
P50399 Gdi2 Rab GDP dissociation inhibitor beta  HP, CB 
P47709 Rph3a Rabphilin-3A  CC, HP 
F1M386 Rapgef2 Rap guanine nucleotide exchange factor 2  CC 
Q9QUH6 Syngap1 Ras/Rap GTPase-activating protein SynGAP  CC 
Q6RUV5 Rac1 Ras-related C3 botulinum toxin substrate 1  CC, CB 
P35281 Rab10 Ras-related protein Rab-10 CC, HP 
P61107 Rab14 Ras-related protein Rab-14 CC, CB 
Q6NYB7 Rab1A Ras-related protein Rab-1A CC, CB 
P10536 Rab1b Ras-related protein Rab-1B CB 
P05712 Rab2a Ras-related protein Rab-2A CC 
P63012 Rab3a Ras-related protein Rab-3A CC, HP, CB 
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Q63941 Rab3b Ras-related protein Rab-3B CC 
P62824 Rab3c Ras-related protein Rab-3C CC, HP 
M0RC99 Rab5a Ras-related protein Rab-5A  CB 
P09527 Rab7a Ras-related protein Rab-7a  CB 
P61227 Rap2b Ras-related protein Rap-2b HP 
P63245 Rack1 Receptor of activated protein C kinase 1  CC, CB 
Q6AXX6 Fam213a Redox-regulatory protein FAM213A  CC, HP 
Q9JIR4 Rims1 Regulating synaptic membrane exocytosis protein 1  CC 
Q62703 Rcn2 Reticulocalbin-2  CB 
Q64548 Rtn1 Reticulon-1  CC, HP, CB 
Q6RJR6 Rtn3 Reticulon-3 CC, HP, CB 
Q9JK11 Rtn4 Reticulon-4  CC 
D4AE41 Rbmxl1 RNA binding motif protein, X-linked-like-1  CC, CB 
Q3B7K9 Rundc3b RUN domain-containing protein 3B CC, HP 
Q64578 Atp2a1 Sarcoplasmic/endoplasmic reticulum calcium ATPase 1  CC, CB 
P11507 Atp2a2 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2  HP 
O88453 Safb Scaffold attachment factor B1  CB 
P56603 Scamp1 Secretory carrier-associated membrane protein 1  CC, HP 
Q9JKE3 Scamp5 Secretory carrier-associated membrane protein 5  CC, HP 
B3GNI6 Sept11 Septin-11 CC, CB 
Q9JJM9 Sept5 Septin-5  CC, HP 
Q9WVC0 Sept7 Septin-7  CB 
G3V6S8 Srsf6 Serine/arginine-rich splicing factor 6  CB 
O08875 Dclk1 Serine/threonine-protein kinase DCLK1  CC, HP 
O08679 Mark2 Serine/threonine-protein kinase MARK2  CC 
Q4QQT4 Ppp2r1b Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A beta 
isoform  
CC 
P63329 Ppp3ca Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform  CC 
Q64620 Ppp6c Serine/threonine-protein phosphatase 6 catalytic subunit  CC 
Q562B5 Pgam5 Serine/threonine-protein phosphatase PGAM5, mitochondrial  CC 
P62138 Ppp1ca Serine/threonine-protein phosphatase PP1-alpha catalytic subunit  CC 
Q6P799 Sars Serine--tRNA ligase, cytoplasmic  CB 
P12346 Tf Serotransferrin  CC, HP, CB 
P23680 Apcs Serum amyloid P-component  CB 
Q9WV48 Shank1 SH3 and multiple ankyrin repeat domains protein 1  CC, CB 
Q9QX74 Shank2 SH3 and multiple ankyrin repeat domains protein 2  CC, CB 
Q9JLU4 Shank3 SH3 and multiple ankyrin repeat domains protein 3  CC 
P0DJJ3 Sgip1 SH3-containing GRB2-like protein 3-interacting protein 1  CC, HP 
Q63965 Sfxn1 Sideroflexin-1  CC, HP 
Q9JHY2 Sfxn3 Sideroflexin-3 CC, CB 
P31647 Slc6a11 Sodium- and chloride-dependent GABA transporter 3  CC, CB 
P48768 Slc8a2 Sodium/calcium exchanger 2  CC 
P06685 Atp1a1 Sodium/potassium-transporting ATPase subunit alpha-1  CC 
P06686 Atp1a2 Sodium/potassium-transporting ATPase subunit alpha-2  CC 
P06687 Atp1a3 Sodium/potassium-transporting ATPase subunit alpha-3  CC, HP 
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P07340 Atp1b1 Sodium/potassium-transporting ATPase subunit beta-1  CC, HP, CB 
P13638 Atp1b2 Sodium/potassium-transporting ATPase subunit beta-2  CC, HP, CB 
Q63633 Slc12a5 Solute carrier family 12 member 5  HP 
Q66HR0 Slc12a9 Solute carrier family 12 member 9  HP 
P11167 Slc2a1 Solute carrier family 2, facilitated glucose transporter member 1  CC, HP, CB 
O35413 Sorbs2 Sorbin and SH3 domain-containing protein 2  CC 
P16086 Sptan1 Spectrin alpha chain, non-erythrocytic 1  CC, HP, CB 
Q9QWN8 Sptbn2 Spectrin beta chain, non-erythrocytic 2  CC, CB 
Q9QXY2 Srcin1 SRC kinase signaling inhibitor 1  CC, CB 
Q4FZT0 Stoml2 Stomatin-like protein 2, mitochondrial  CC 
D4AB66 Ston2 Stonin-2 CC, HP 
P21913 Sdhb Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial  CB 
P13086 Suclg1 Succinate--CoA ligase [ADP/GDP-forming] subunit alpha, mitochondrial  CB 
P09951 Syn1 Synapsin-1  CC, HP 
Q63537 Syn2 Synapsin-2  CC 
Q02563 Sv2a Synaptic vesicle glycoprotein 2A  CC, HP, CB 
Q63564 Sv2b Synaptic vesicle glycoprotein 2B  CC, HP 
Q62876 Syngr1 Synaptogyrin-1  CC, CB 
Q62910 Synj1 Synaptojanin-1  CC, HP 
P07825 Syp Synaptophysin  CC, HP 
Q9Z327 Synpo Synaptopodin CC 
P60881 Snap25 Synaptosomal-associated protein 25  HP, CB 
P21707 Syt1 Synaptotagmin-1  CC, HP, CB 
P97610 Syt12 Synaptotagmin-12  CC, CB 
P29101 Syt2 Synaptotagmin-2  CB 
Q62747 Syt7 Synaptotagmin-7  CB 
P32851 Stx1a Syntaxin-1A  CC 
P61265 Stx1b Syntaxin-1B  CC, HP, CB 
P61765 Stxbp1 Syntaxin-binding protein 1  CC, HP 
Q5XIM9 Cct2 T-complex protein 1 subunit beta  HP, CB 
Q7TPB1 Cct4 T-complex protein 1 subunit delta  HP, CB 
Q68FQ0 Cct5 T-complex protein 1 subunit epsilon  CC, HP, CB 
Q6P502 Cct3 T-complex protein 1 subunit gamma  HP, CB 
Q05546 Tnr Tenascin-R  CC, HP, CB 
Q920J4 Txnl1 Thioredoxin-like protein 1  HP 
P01830 Thy1 Thy-1 membrane glycoprotein  HP, CB 
Q5U1Z2 Trappc3 Trafficking protein particle complex subunit 3 HP 
P86252 Pura Transcriptional activator protein Pur-alpha  CC, HP, CB 
Q68A21 Purb Transcriptional activator protein Pur-beta  CC, HP, CB 
Q5M7W4 Tmc5 Transmembrane channel-like protein 5 HP 
Q64428 Hadha Trifunctional enzyme subunit alpha, mitochondrial  CC 
Q60587 Hadhb Trifunctional enzyme subunit beta, mitochondrial  HP 
P48500 Tpi1 Triosephosphate isomerase  CC 
Q6AYT3 Rtcb tRNA-splicing ligase RtcB homolog  CB 
Chapter III   Results 
200                                                   Functional characterization of novel BRI2 and BRI3 complexes 
P70566 Tmod2 Tropomodulin-2  CC, CB 
Q63610 Tpm3 Tropomyosin alpha-3 chain  CC 
P09495 Tpm4 Tropomyosin alpha-4 chain  HP 
Q6P7B0 Wars Tryptophan--tRNA ligase, cytoplasmic  CC, HP 
P68370 Tuba1a Tubulin alpha-1A chain  CC, HP, CB 
Q6AYZ1 Tuba1c Tubulin alpha-1C chain  HP 
Q68FR8 Tuba3a Tubulin alpha-3 chain  CC 
Q5XIF6 Tuba4a Tubulin alpha-4A chain  CC, HP, CB 
Q6AY56 Tuba8 Tubulin alpha-8 chain  CB 
P85108 Tubb2a Tubulin beta-2A chain CC, HP, CB 
Q3KRE8 Tubb2b Tubulin beta-2B chain  CC, HP 
Q4QRB4 Tubb3 Tubulin beta-3 chain  CC, HP, CB 
Q6P9T8 Tubb4b Tubulin beta-4B chain  CC, HP, CB 
P69897 Tubb5 Tubulin beta-5 chain CC, HP, CB 
B2RYG6 Otub1 Ubiquitin thioesterase OTUB1  HP 
Q63357 Myo1d Unconventional myosin-Id  CC 
Q9QYF3 Myo5a Unconventional myosin-Va  CC, CB 
Q9JJW3 Usmg5 Up-regulated during skeletal muscle growth protein 5  CC, HP, CB 
Q793F9 Vps4a Vacuolar protein sorting-associated protein 4A  CB 
Q04462 Vars Valine--tRNA ligase  CB 
Q9ERB4 Vcan Versican core protein  CB 
Q63666 Vamp1 Vesicle-associated membrane protein 1  CB 
P63045 Vamp2 Vesicle-associated membrane protein 2  CB 
P63025 Vamp3 Vesicle-associated membrane protein 3  CC, CB 
Q9Z270 Vapa Vesicle-associated membrane protein-associated protein A  HP, CB 
Q9QUL6 Nsf Vesicle-fusing ATPase  CC, HP, CB 
Q62634 Slc17a7 Vesicular glutamate transporter 1  CC, HP 
Q9JI12 Slc17a6 Vesicular glutamate transporter 2  CC 
O35458 Slc32a1 Vesicular inhibitory amino acid transporter  CC, HP 
P31000 Vim Vimentin CC, CB 
P62762 Vsnl1 Visinin-like protein 1  CB 
Q9Z2L0 Vdac1 Voltage-dependent anion-selective channel protein 1  CC, HP 
P81155 Vdac2 Voltage-dependent anion-selective channel protein 2  CC, HP 
Q9R1Z0 Vdac3 Voltage-dependent anion-selective channel protein 3  CC, HP, CB 
Q71RJ2 Cacng2 Voltage-dependent calcium channel gamma-2 subunit  CB 
P54290 Cacna2d1 Voltage-dependent calcium channel subunit alpha-2/delta-1  CC 
P54287 Cacnb3 Voltage-dependent L-type calcium channel subunit beta-3  HP 
Q5J3M4 Vom1r94 Vomeronasal type-1 receptor 94  CC 
P25286 Atp6v0a1 V-type proton ATPase 116 kDa subunit a isoform 1  CC, HP, CB 
P63081 Atp6v0c V-type proton ATPase 16 kDa proteolipid subunit  CC, HP, CB 
P62815 Atp6v1b2 V-type proton ATPase subunit B, brain isoform  CC 
Q6PCU2 Atp6v1e1 V-type proton ATPase subunit E 1  HP 
O54715 Atp6ap1 V-type proton ATPase subunit S1  CC 
Q9ERH3 Wdr7 WD repeat-containing protein 7  CC 
Results                                                                                                                            Chapter III 
 
 
 
Functional characterization of novel BRI2 and BRI3 complexes  201 
 
Q6QIX3 Slc30a3 Zinc transporter 3  CC 
 
Table III.A.S2 -Panther Protein class analysis of all candidate BRI2 interactors identified in this study . In the table 
are listed the Panther protein class terms and the respective IDs, as well as the Uniprot accessions of the proteins that belong 
to each class 
Panther Protein Class (term ID) Uniprot accessions of  mapped proteins 
 
ATP synthase (PC00227) P15999, Q06647, P25286, O54715, D3ZAF6, P62815, P10719, P63081 
G-protein (PC00095) B3GNI6, P62630, P61227, P21575, O35303, P08644, P10824, P61751, 
P54311, P59215, P82471, P05197, Q9JJM9, P19627, Q9WVC0, Q6RUV5, 
Q6PST4, P85834, P43425, O35353, Q9WU34, Q2TA68, P04897, P52287  
actin family cytoskeletal protein (PC00085) P0DJJ3, O35413, P63269, Q05764, P09495, Q9QYF3, P45592, B2GUZ5, 
Q64122, P85515, P68035, Q64119, Q3T1K5, Q63610, Q5XI32, Q9Z1P2, 
P16409, P52481, O08839, D3ZHV2, P70566, P30427, P16086, Q9JLT0, 
O08838, Q07266, P13832, Q68FP1, Q4V7C7, Q9QWN8, Q6KC51, 
P60711, Q62812, Q9Z327, Q63028, P09951, P02600, Q63357, Q63537  
anion channel (PC00002) P15999, P81155, Q9R1Z0, P62815, P10719, Q9Z2L0 
calcium-binding protein (PC00060) Q9QVC8, P62161, P97700, Q8R491, Q05962, P62161, Q64122, Q505J6, 
Q07009, Q5XIN6, Q64119, Q64620, P16409, Q62717, P63319, P62161, 
P62138, P13832, Q62703, Q9WVE9, P63329, Q09073, P02600, P16036  
cation transporter (PC00227) P15999, P06687, Q06647, Q9JI12, Q9JHY2, P11507, P13638, P11505, 
Q63965, P25286, P06685, P48768, O54715, D3ZAF6, O35921, P07340, 
P11506, P62815, Q62634, Q64542, P06686, Q64568, P31596, Q9JI66, 
P10719, P63081, P24942, Q64578, P31647 
chaperone (PC00072) P68255, Q9QVC8, P82995, Q7TPB1, P97874, Q6P502, P34058, P63102, 
P61983, P62260, P63039, Q66HD0, Q5XIM9, Q68FQ0 
cytoskeletal protein (PC00085) P34926, P0DJJ3, O35413, Q9WV63, P47819, B3GNI6, P63269, Q05764, 
P09495, Q9QYF3, P45592, B2GUZ5, P85108, P21575, Q68FR6, O35303, 
Q64122, P85515, Q4QRB4, Q5XI51, Q6P9T8, Q63279, P68035, P12839, 
Q64119, Q3T1K5, O70511, Q63610, Q5XI32, Q9Z1P2, P31000, P56536, 
P16409, Q68FR8, P52481, O08839, P70615, P19527, Q6AY56, Q5XIF6, 
Q9JJM9, P38650, Q3KRE8, P15205, Q4FZT0, D3ZHV2, Q6IG00, P70566, 
Q6QLM7, P30427, P16086, Q9WVC0, Q9JLT0, O08838, Q9WU82, 
P68370, P69897, Q07266, P13832, P48679, Q68FP1, Q4V7C7, Q9QWN8, 
Q9WU34, Q6KC51, Q2TA68, P60711, Q6AYH5, Q2PQA9, Q62812, 
Q9Z327, Q793F9, P23565, Q63028, Q6AYZ1, P09951, Q68FR8, P02600, 
Q63357, Q63537 
dehydrogenase (PC00176 P11960, P04636, P29147, O70351, P04642, P19234, Q64428, O08651, 
Q9WVK7, Q641Y2, P41565, Q68FX0, Q99NA5, P21913, Q63342, 
P26284, P49432, P04797, Q5BK63, P12785, Q66HF1 
enzyme modulator (PC00095) O35413, B3GNI6, F1M386, Q9QYF3, Q63228, Q8R491, P62630, P61227, 
P21575, O35303, P08644, P10824, Q5PPJ9, P29066, P49911, P61751, 
P54311, P59215, P67874, P82471, P05197, Q9QUH6, O08839, P50399, 
Q9JJM9, P06238, Q9JIR4, P97846, P19627, Q9WVC0, Q8CGU4, Q9JLT0, 
O08838, Q6RUV5, Q6PST4, P85834, P01026, P43425, O35179, O35353, 
Q7TP98, Q9WVE9, Q9WU34, Q2TA68, Q62848, Q9ERH3, P97829, 
P04897, Q4FZT9, Q62812, Q63416, P52287, P61980, Q9Z1T4, Q63357 
heterotrimeric G-protein (PC00095) P10824, P54311, P59215, P82471, P19627, Q6PST4, P43425, O35353, 
P04897, P52287 
hydrolase (PC00121) P15999, P06687, Q06647, Q62950, P62630, P21575, O35303, P32551, 
Q62951, O08565, Q794F9, P11507, Q07009, Q63198, Q5RJQ4, P13233, 
P54311, Q64620, D3ZGS3, P11505, B5DFN2, O35567, P25286, B0BND0, 
P05197, Q9WTT6, P06685, O54715, B2RYG6, Q6AYD3, P38650, P11506, 
P62815, P97846, P62138, P13596, P85834, Q4QQT4, Q6Q0N1, O35353, 
Q64542, P06686, Q7TP98, Q2TA68, P28492, Q64568, Q62910, Q9ERH3, 
P97685, P63329, P12346, P10719, P63081, Q9QUL6, P52287, Q64578, 
P12785, P47942, O88767 
intermediate filament (PC00085) P47819, Q63279, P12839, P31000, P70615, P19527, Q6IG00, P48679, 
P23565 
ion channel (PC00068) P15999, P06687, Q63226, P81155, P54287, P11507, P11505, P06685, 
Q9R1Z0, P11506, P62815, Q71RJ2, P19491, Q63269, Q64542, Q00960, 
P06686, P29994, Q64568, P10719, Q9Z2L0, Q64578, P19490  
membrane traffic protein (PC00150) P0DJJ3, Q3B7K9, Q8R491, P63025, P61765, P21707, P97610, Q9JK11, 
P54921, Q6RJR6, P07825, P08081, P11442, P61265, P29101, P08082, 
P32851, P52303, Q63666, Q9WVE9, Q64548, P62944, P85969, P09951, 
Q5BJS7, P63045, Q9Z270, Q05140, P62744, P47709, P60881, Q62876, 
Q63537 
membrane trafficking regulatory protein (PC00150) P0DJJ3, P61765, P21707, P97610, P07825, P29101, P09951, Q9Z270, 
P47709, Q62876, Q63537 
microtubule family cytoskeletal protein (PC00085) P34926, Q9WV63, P85108, P21575, O35303, Q4QRB4, Q5XI51, Q6P9T8, 
P56536, Q68FR8, Q6AY56, Q5XIF6, P38650, Q3KRE8, P15205, 
Q6QLM7, P68370, P69897, Q2TA68, Q6AYH5, Q2PQA9, Q793F9, 
Q6AYZ1, Q68FR8 
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Panther Protein Class (term ID) Uniprot accessions of  mapped proteins 
 
non-motor actin binding protein (PC00085) Q05764, P45592, B2GUZ5, Q3T1K5, Q5XI32, Q9Z1P2, D3ZHV2, P70566, 
P30427, P16086, Q07266, Q68FP1, Q9QWN8, Q9Z327, Q63028, P09951, 
Q63537 
oxidoreductase (PC00176) P11960, P04636, P29147, O70351, P21396, P04642, Q68FR6, P 19234, 
Q64428, O08651, Q9WVK7, Q641Y2, P35171, P41565, P11240, O35244, 
Q68FX0, Q99NA5, P21913, P52504, Q920J4, P12075, Q63342, P00406, 
P97846, P26284, P49432, Q63716, P35704, P04797, Q5BK63, P12785, 
Q66HF1 
small GTPase (PC00095) B3GNI6, P61227, P21575, O35303, P08644, P61751, Q9JJM9, Q9WVC0, 
Q6RUV5, Q9WU34, Q2TA68 
structural protein (PC00211) Q99JD4, P47819, P60203, Q63279, P12839, P31000, P70615, P19527, 
Q6IG00, P02688, P48679, Q6KC51, P07722, P23565 
transcription factor (PC00218) P97536, Q6MG48, P86252, Q68A21, Q6AYD3, O88767 
transmembrane receptor regulatory/adaptor protein (PC00226) Q62696, P97838, P0C6S7, P31016, P18484, P97546, P97837, P97836  
transporter (PC00227) P15999, P06687, Q06647, P97700, Q63226, Q9JI12, P81155, Q05962, 
Q505J6, P54287, Q9JHY2, P61765, P11507, O35458, P13638, P11505, 
Q63965, Q6QIX3, P25286, P06685, P48768, O54715, D3ZAF6, O35921, 
P07340, Q9R1Z0, P11506, P62815, Q71RJ2, P97846, P19491, P69682, 
Q63269, Q62634, Q64542, Q00960, P06686, P29994, Q64568, B5D5N9, 
Q7TNJ2, P31596, Q9JI66, P10719, P63081, P24942, Q09073, Q9Z2L0, 
Q64578, P19490, P16036, P31647 
tubulin (PC00085) P85108, Q4QRB4, Q6P9T8, Q68FR8, Q6AY56, Q5XIF6, Q3KRE8, 
P68370, P69897, Q6AYZ1, Q68FR8 
 
 
Results                                                                                                                                Chapter III 
 
 
 
Functional characterization of novel BRI2 and BRI3 complexes         203 
 
Table III.A.S  3 - BRI2 interactors retrieve from online databases. The BRI2 interactors, as well as, the uniprot accession number, the species and the experimental evidence supporting 
the interactions, as well as the cell line or tissue where they were detected is indicated. 
Gene Protein 
Uniprot 
accession 
number 
Species Experimental evidence Cell line/Tissue References 
Adam7 Desintegrin and metalloproteinase domain-containing protein 7 O35227 Mus Musculus Affinity Capture-MS Mouse sperm 
 
(Han et al. 2011) 
 
AMIGO1 Adhesion molecule with Ig-like domain 1 Q86WK6 Homo sapiens Affinity Capture-MS HEK293T cells (Huttlin et al. 2015) 
APP Amyloid beta A4 protein  P05067 Homo sapiens Two-hybrid 
Co-IP  
HEK293 cells stably 
expressing APP751, 
transfected with myc-
tagged BRI2 
 
 
(Matsuda et al. 
2005; 
Fotinopoulou et 
al. 2005) 
 
ATF6B cAMP response element-binding protein-related 
protein Q99941 Homo sapiens Affinity Capture-MS HEK293T cells 
(Huttlin et al. 
2015) 
B4GALNT1 
UDP-N-acetyl-alpha-D-galactosamine:(N-
acetylneuraminyl)-galactosylglucosylceramide N-
acetylgalactosaminyltransferase (GalNAc-T) 
Q00973 Homo sapiens Affinity Capture-MS HEK293T cells (Huttlin et al. 
2015) 
BACE1 β-secretase β-amyloid protein converting enzyme 
1 P56817 Homo sapiens 
Co-IP  
 
SH-SY5Y cells (Tsachaki et al. 
2013) 
Bcl2 Apoptosis regulator Bcl-2 
(protein phosphatase 1, regulatory subunit 50) P10415 Mus musculus 
Co-IP  
 
TS1 alpha beta cells 
 
(Fleischer et al. 
2002) 
 
BTN2A2 Butyrophilin, subfamily 2, member A2  Q8WVV5 Homo sapiens Affinity Capture-MS HEK293T cells (Huttlin et al. 2015) 
CACNA2D1 Dihydropyridine-sensitive L-type, calcium channel alpha-2/delta subunit P54289 Homo sapiens Affinity Capture-MS HEK293T cells 
(Huttlin et al. 
2015) 
CCDC155 Protein KASH5 Q8N6L0 Homo sapiens Two-hybrid ---- (Rolland et al. 
2014) 
CHST12 Carbohydrate (chondroitin 4) sulfotransferase 12  Q9NRB3 Homo sapiens Affinity Capture-MS HEK293T cells (Huttlin et al. 2015) 
CREB3 Cyclic AMP-responsive element-binding protein 3 O43889 Homo sapiens 
Two-hybrid; 
Affinity Capture-MS 
HeLa cells expressing 
GFP-tagged proteins 
 
(Yu et al. 2011; 
Hein et al. 2015) 
 
Csf1 Macrophage colony-stimulating factor 1  P07141 Mus musculus Pull-down M1 myeloid cells (Cross et al. 
2005) 
DCBLD2 Discoidin, CUB and LCCL domain-containing 
protein 2 Q96PD2 Homo sapiens Affinity Capture-MS HEK293T cells 
 
(Huttlin et al. 
2015) 
FCGRT IgG receptor FcRn large subunit p51  P55899 Homo sapiens Affinity Capture-MS HEK293T cells 
 
(Huttlin et al. 
2015) 
GLG1 Cysteine-rich fibroblast growth factor receptor Q92896 Homo sapiens Affinity Capture-MS HEK293T cells 
 
(Huttlin et al. 
2015) 
 
Chapter III        Results 
204                                                    Functional characterization of novel BRI2 and BRI3 complexes 
Gene Protein 
Uniprot 
accession 
number 
Species Experimental evidence Cell line/Tissue References 
HLA-A HLA class I histocompatibility antigen, A-1 alpha chain P30443 Homo sapiens Affinity Capture-MS HEK293T cells 
(Huttlin et al. 
2015) 
HNF1A Hepatocyte nuclear factor 1-alpha P20823 Homo sapiens Cross-linking study Liver and pancreas 
 
(Odom et al. 
2004) 
HS6ST1 Heparan sulfate 6-O-sulfotransferase 1 O60243 Homo sapiens Affinity Capture-MS HEK293T cells 
 
(Huttlin et al. 
2015) 
KIAA1467 Uncharacterized protein KIAA1467  A2RU67 Homo sapiens Affinity Capture-MS HEK293T cells 
 
(Huttlin et al. 
2015) 
KIF18A Kinesin-like protein KIF18A Q8NI77 Homo sapiens Affinity Capture-MS HeLa cells (Hein et al. 2015) 
Lmo2 Rhombotin-2 P25801 Mus musculus Two-hybrid ---- 
 
(Sincennes et al. 
2016) 
LRFN3 Leucine-rich repeat and fibronectin type-III 
domain-containing protein 3 Q9BTN0 Homo sapiens Affinity Capture-MS HEK293T cells 
 
(Huttlin et al. 
2015) 
MR1 Bajor histocompatibility complex class I-related 
gene protein Q95460 Homo sapiens Affinity Capture-MS HEK293T cells 
 
(Huttlin et al. 
2015) 
NAALADL2 Inactive N-acetylated-alpha-linked acidic dipeptidase-like protein 2 Q58DX5 Homo sapiens Two-hybrid ---- 
 
(Rolland et al. 
2014) 
Nek2 Serine/threonine-protein kinase Nek2 O35942 BRI2 Hs - Nek2 Ms Affinity Capture-MS HeLa cells (Hein et al. 2015) 
PGAP1 Post-GPI attachment to proteins factor 1  Q75T13 Homo sapiens Affinity Capture-MS HEK293T cells 
 
(Huttlin et al. 
2015) 
 
PPP1CA/Ppp1ca Serine/threonine-protein phosphatase PP1-alpha catalytic subunit 
P62136 
Homo sapiens 
 Co-IP  
SH-SY5Y cells 
transfected with myc-
bri2 
(Martins et al. 
2016) 
P62138 Rattus norvegicus Co-IP  Rat primary cortical and hippocampal cultures 
PPP1CC/Ppp1cc Serine/threonine-protein phosphatase PP1-gamma 
catalytic subunit 
P36873 Homo sapiens  Co-IP  
SH-SY5Y cells 
transfected with myc-
bri2 (Martins et al. 
2016) 
P63088 Rattus norvegicus Co-IP  Rat primary cortical and 
hippocampal cultures 
RPL31 60S ribosomal protein L31 P62899 Homo sapiens Two-hybrid ---- (Bell et al. 2009) 
RYK RYK receptor-like tyrosine kinase P34925 Homo sapiens Affinity Capture-MS HEK293T cells (Berndt et al. 2011) 
SEMA4F Semaphorin-4F O95754 Homo sapiens Affinity Capture-MS HEK293T cells 
 
(Huttlin et al. 
2015) 
 
SEMA6A Semaphorin-6A Q9H2E6 Homo sapiens Affinity Capture-MS HEK293T cells (Huttlin et al. 2015) 
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Gene Protein 
Uniprot 
accession 
number 
Species Experimental evidence Cell line/Tissue References 
Shoc2 Leucine-rich repeat protein SHOC-2 O88520 BRI2 Hs - SHOC2 Ms Affinity Capture-MS HeLa cells expressing GFP-tagged proteins (Hein et al. 2015) 
SPPL2A Signal peptide peptidase-like 2A Q8TCT8 Homo sapiens Co-IP  HEK293T cells 
 
(Martin et al. 
2008) 
SPPL2B Signal peptide peptidase-like 2B Q8TCT7 Homo sapiens Co-IP  HEK293T cells 
 
(Martin et al. 
2008) 
SYNE4 Nesprin-4 Q8N205 Homo sapiens Two-hybrid ---- 
 
(Rolland et al. 
2014) 
TGFBR3 Transforming growth factor beta receptor type 3  Q03167 Homo sapiens Affinity Capture-MS HEK293T cells 
 
(Huttlin et al. 
2015) 
TMEM17 Transmembrane protein 17  Q86X19 Homo sapiens Proximity Label-MS ---- 
 
(Gupta et al. 
2015) 
TMEM219 Insulin-like growth factor binding protein-3 receptor Q86XT9 Homo sapiens Affinity Capture-MS HEK293T cells 
 
(Huttlin et al. 
2015) 
TMEM59L Brain-specific membrane-anchored protein (C19orf4) Q9UK28 Homo sapiens Affinity Capture-MS HEK293T cells 
 
(Huttlin et al. 
2015) 
UBC Polyubiquitin-C P0CG48 Homo sapiens Affinity Capture-MS 
HEK293T cells 
expressing HA-tagged 
ubiquitin; 
HEK293Tcells 
expressing strep-HA 
tagged ubiquitin; 
HEK293T and HCT116 
cells 
(Danielsen et al. 
2011; Wagner et 
al. 2011; Kim et 
al. 2011) 
 
 
 
 
UBR1 Ubiquitin protein ligase E3 component n-recognin 1 Q8IWV7 Homo sapiens Affinity Capture-MS HEK293T cells 
 
(Huttlin et al. 
2015) 
UNK RING finger protein unkempt homolog  Q9C0B0 Homo sapiens Affinity Capture-RNA SH-SY5Y and HeLa 
cells 
 
(Murn et al. 
2015) 
Co-IP, co-immunoprecipitation; MS, mass spectrometry; Hs, Homo sapiens; Ms, Mus musculus
Chapter III   Results 
206                                                   Functional characterization of novel BRI2 and BRI3 complexes 
Table III.A.S4 - Panther Protein class analysis of candidate BRI2 interactors identified by Nano-HPLC-MS/MS, 
and highly enriched or specific in the brain tissue . Panther protein class terms and the respective IDs, as well as the 
Uniprot accessions of the proteins that belong to each class are listed. 
Panther Protein Class (term ID) 
 
Uniprot accessions of  mapped proteins 
 
cation transporter (PC00227) P06687, Q9JI12, P13638, P48768, O35921, P11506, Q62634, 
P06686, Q64568, P31596, P24942, P31647 
cytoskeletal protein (PC00085) P34926, P0DJJ3, P47819, Q05764, P85108, P21575, Q4QRB4, 
P12839, P56536, P19527, Q9JJM9, Q3KRE8, P15205, P70566, 
Q6QLM7, O08838, Q9QWN8, Q9WU34, P23565, P09951, Q63537 
membrane traffic protein (PC00150) P0DJJ3, Q8R491, P61765, P21707, P97610, P07825, P61265, 
P29101, P32851, Q64548, P85969, P09951, Q5BJS7, Q05140, 
P47709, P60881, Q63537  
membrane trafficking regulatory protein (PC00150) P0DJJ3, P61765, P21707, P97610, P07825, P29101, P09951, 
P47709, Q63537 
microtubule family cytoskeletal protein (PC00085) P34926, P85108, P21575, Q4QRB4, P56536, Q3KRE8, P15205, 
Q6QLM7, Q63537  
myelin protein (PC00211) P60203, P02688, P07722  
nucleic acid binding(PC00022) Q505J6, Q8CGU4  
structural protein (PC00129) P47819, P60203, P12839, P19527, P02688, P07722, P23565  
transmembrane receptor regulatory/adaptor protein(PC00226) P97838, P0C6S7, P31016, P97837, P97836 
transporter(PC00227) P06687, Q9JI12, Q505J6, P61765, O35458, P13638, Q6QIX3, 
P48768, O35921, P11506, Q71RJ2, P97846, P19491, Q62634, 
Q00960, P06686, Q64568, P31596, P24942, P19490, P31647 
tubulin(PC00085) P85108, Q4QRB4, Q3KRE8 
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Table III.A.S5 - Biological process enrichment analysis of the brain specific BRI2 interactome using Panther online resource. Enriched categories are identified as those with p-
value <0.05, and GO terms presented correspond to the two most specific for each category retrieved in the analysis. Nr. Number. 
Biological Process GO term 
Nr. 
prote
ins 
Fold 
enrichme
nt (%) 
p-value Associated proteins 
Brain development 
(GO:0007420) 
brain development (GO:0007420) 31 7.39 1.31E-14 Slc17a6, P lp1, Ntm, Bcan, Syt1, Basp1, Cntn1, Nefm, Cnp, Gnao1, Slc32a1, Grin1, Dclk1, 
Slc8a2, Nefl, Atp2b2, Dcx, Mbp, Cend1, Ncam1, Kcna1, Slc17a7, Grin2b, Sptbn2, Mag, 
Atp2b3, Tnr, Slc1a2, Ina, Rph3a, Slc6a11 
forebrain development (GO:0030900) 16 7.07 1.02E-05 Slc17a6, Bcan, Nefm, Cnp, Gnao1, Slc32a1, Grin1, Dclk1, Slc8a2, Nefl, Dcx, Ncam1, 
Kcna1, Grin2b, Tnr, Slc1a2 
substantia nigra development (GO:0021762) 6 25.51 1.42E-03 Plp1, Basp1, Cnp, Mbp, Mag, Ina 
telencephalon development (GO:0021537) 12 7.99 3.69E-04 Slc17a6, Bcan, Nefm, Slc32a1, Grin1, Slc8a2, Nefl, Dcx, Kcna1, Grin2b, Tnr, Slc1a2 
hippocampus development (GO:0021766) 8 14.80 7.56E-04 Slc17a6, Bcan, Nefm, Slc32a1, Nefl, Dcx, Kcna1, Grin2b 
Neuron development 
(GO:0048666) 
positive regulation of dendrite extension (GO:1903861) 4 42.07 2.51E-02 Syt1, Syt2, Rims1, Cpne9 
regulation of dendrite extension (GO:1903859) 4 39.97 3.06E-02 Syt1, Syt2, Rims1, Cpne9 
neuron projection regeneration (GO:0031102) 5 24.98 1.75E-02 Gfap, Nefm, Nefl, Map1b, Ncam1 
neuron projection development (GO:0031175) 31 10.22 1.33E-18 Gfap, Crmp1, P lp1, Dpysl4, Tubb3, Stxbp1, Ncdn, Cntn1, Nefm, Dlg4, Cnp, Gnao1, Dclk1, 
Kif5c, Map6, Slc12a5, Nefl, Map1b, Dcx, Rab3a, Kif5a, Map2, Cntnap1, Agap2, Ncam1, 
Atl1, Gap43, Shank1, Snap91, Snap25, Camk2a 
dendrite morphogenesis (GO:0048813) 7 23.71 2.12E-04 Dlg4, Dclk1, Map6, Dcx, Map2, Shank1, Camk2a 
dendrite development (GO:0016358) 9 16.65 4.23E-05 Dlg4, Dclk1, Map6, Slc12a5, Map1b, Dcx, Map2, Shank1, Camk2a 
neuron projection morphogenesis (GO:0048812) 24 11.08 2.40E-14 Crmp1, Dpysl4, Tubb3, Stxbp1, Dlg4, Cnp, Dclk1, Kif5c, Map6, Nefl, Map1b, Dcx, Rab3a, 
Kif5a, Map2, Cntnap1, Agap2, Ncam1, Atl1, Gap43, Shank1, Snap91, Snap25, Camk2a 
cell morphogenesis involved in neuron differentiation 
(GO:0048667) 
23 11.58 5.08E-14 Crmp1, Tubb3, Stxbp1, Dlg4, Cnp, Dclk1, Kif5c, Map6, Map1b, Atp2b2, Dcx, Rab3a, Kif5a, 
Map2, Agap2, Ncam1, Atl1, Gap43, Shank1, Slc1a3, Snap91, Snap25, Camk2a 
axonogenesis (GO:0007409) 17 10.26 9.76E-09 Crmp1, Tubb3, Stxbp1, Cnp, Dclk1, Kif5c, Map1b, Dcx, Rab3a, Kif5a, Map2, Agap2, 
Ncam1, Atl1, Gap43, Snap91, Snap25 
axon development (GO:0061564) 20 10.95 2.51E-11 Crmp1, P lp1, Tubb3, Stxbp1, Nefm, Cnp, Dclk1, Kif5c, Nefl, Map1b, Dcx, Rab3a, Kif5a, 
Map2, Agap2, Ncam1, Atl1, Gap43, Snap91, Snap25 
Regulation of  synaptic 
plasticity 
(GO:0048167) 
positive regulation of excitatory postsynaptic potential 
(GO:2000463) 
6 42.82 6.87E-05 Dlg4, Grin1, Stx1b, Rims1, Stx1a, Shank1 
modulation of excitatory postsynaptic potential 
(GO:0098815) 
6 31.55 4.12E-04 Dlg4, Grin1, Stx1b, Rims1, Stx1a, Shank1 
positive regulation of synaptic transmission 
(GO:0050806) 
17 24.98 5.86E-15 Gfap, Syt1, Syt12, Dlg4, Grin1, Stx1b, Slc8a2, Rims1, Gria2, Stx1a, Grin2b, Tnr, Shank1, 
Slc1a3, Camk2b, Snap25, Gria1 
neuron-neuron synaptic transmission (GO:0007270) 7 19.98 6.70E-04 Dnm1, Grin1, Tmod2, Slc17a7, Dlgap2, Napb, Gria1 
regulation of neuronal synaptic plasticity (GO:0048168) 11 30.53 1.28E-09 Bcan, Ncdn, Dlg4, Syp, Grin1, Slc8a2, Rab3a, Rims1, Grin2b, Camk2b, Camk2a 
regulation of long-term neuronal synaptic plasticity 
(GO:0048169) 
6 34.26 2.55E-04 Dlg4, Syp, Grin1, Rims1, Grin2b, Camk2b 
long-term synaptic potentiation (GO:0060291) 8 31.97 2.03E-06 Gfap, Syt12, Slc8a2, Rims1, Grin2b, Tnr, Camk2b, Snap25 
long-term memory (GO:0007616) 6 33.31 3.01E-04 Grin1, Slc17a7, Grin2b, Shank1, Snap25, Gria1 
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Biological Process GO term 
Nr. 
prote
ins 
Fold 
enrichme
nt (%) 
p-value Associated proteins 
Learning or memory 
(GO:0007611) 
memory (GO:0007613) 8 12.02 3.60E-03 Atp1a3, Grin1, Slc8a2, Slc17a7, Grin2b, Shank1, Snap25, Gria1  
associative learning (GO:0008306) 7 14.57 5.49E-03 Atp1a3, Grin1, Grin2b, Atp1a2, Tnr, Shank1, Snap25 
learning (GO:0007612) 10 12.26 1.03E-04 Atp1a3, Grin1, Slc12a5, Slc8a2, Amph, Grin2b, Atp1a2, Tnr, Shank1, Snap25  
Synaptic vesicle cycle  
(GO:0099504) 
vesicle-mediated transport in synapse (GO:0099003) 15 26.76 2.71E-13 Pclo, Syt1, Syt12, Stx1b, Syt2, Cadps, Rab3a, Rims1, Amph, Stx1a, Sh3gl2, Cplx1, Sptbn2, 
Rph3a, Snap25 
neurotransmitter uptake (GO:0001504) 4 57.10 7.53E-03 Slc17a6, Atp1a2, Sv2a, Sv2b 
neurotransmitter transport (GO:0006836) 27 36.71 4.53E-30 Slc17a6, Pclo, Stxbp1, Syt1, Syt12, Slc32a1, Stx1b, Syt2, Cadps, Rab3a, Rims1, Stx1a, 
Slc17a7, Cplx1, Atp1a2, Sptbn2, Sv2a, Sv2b, Slc1a2, Slc1a3, Syn1, Nsf, Snap91, Rph3a, 
Snap25, Syn2, Slc6a11 
import into cell (GO:0098657) 5 21.72 3.43E-02 Slc17a6, Slc8a2, Atp1a2, Sv2a, Sv2b 
vesicle docking (GO:0048278) 6 23.51 2.29E-03 Stxbp1, Syt1, Stx1b, Stx1a, Sptbn2, Nsf 
membrane docking (GO:0022406) 6 17.90 1.10E-02 Stxbp1, Syt1, Stx1b, Stx1a, Sptbn2, Nsf 
regulation of synaptic vesicle priming (GO:0010807) 5  > 100 3.27E-06 Stxbp1, Stx1b, Rims1, Stx1a, Napb 
regulation of protein complex assembly (GO:0043254) 11 6.16 1.73E-02 Add2, Stxbp1, Stx1b, Gda, Map1b, Rims1, Tmod2, Ncam1, Stx1a, Sptbn2, Napb  
vesicle fusion (GO:0006906) 7 15.54 3.58E-03 Syt12, Stx1b, Syt2, Stx1a, Nsf, Rph3a, Snap25 
organelle membrane fusion (GO:0090174) 7 15.21 4.15E-03 Syt12, Stx1b, Syt2, Stx1a, Nsf, Rph3a, Snap25 
single-organism organelle organization (GO:1902589) 28 3.86 4.44E-06 Map1a, Gfap, Add2, Crmp1, Ehd3, Stxbp1, Syt12, Nefm, Dlg4, Cnp, Stx1b, Map6, Nefl, 
Syt2, Map1b, Rab3a, Tmod2, Klc1, Map2, Stx1a, Slc17a7, Shank1, Ina, Slc1a3, Nsf, Rph3a, 
Snap25, Camk2a 
vesicle organization (GO:0016050) 13 10.82 2.71E-06 Dnm1, Stxbp1, Syt12, Dlg4, Stx1b, Syt2, Cadps, Rab3a, Stx1a, Slc17a7, Nsf, Rph3a, Snap25  
regulation of synaptic vesicle exocytosis (GO:2000300) 6 54.50 1.66E-05 Stxbp1, Stx1b, Rab3a, Rims1, Stx1a, Napb 
synaptic vesicle exocytosis (GO:0016079) 13 35.59 1.03E-12 Pclo, Syt1, Syt12, Stx1b, Syt2, Cadps, Rab3a, Rims1, Stx1a, Cplx1, Sptbn2, Rph3a, Snap25  
calcium ion-regulated exocytosis of neurotransmitter 
(GO:0048791) 
7 35.87 1.27E-05 Syt1, Syt12, Stx1b, Syt2, Rims1, Rph3a, Snap25 
positive regulation of calcium ion-dependent exocytosis 
(GO:0045956) 
6 54.50 1.66E-05 Scamp5, Stxbp1, Syt1, Cadps, Rims1, Stx1a 
positive regulation of regulated secretory pathway 
(GO:1903307) 
7 28.55 6.02E-05 Scamp5, Stxbp1, Syt1, Cadps, Rab3a, Rims1, Stx1a 
protein localization to synapse (GO:0035418) 7 77.72 6.17E-08 Homer1, Pclo, Dlg4, Klc1, Shank1, Bsn, Dlgap1 
protein localization (GO:0008104) 28 3.58 2.30E-05 Scamp5, Ehd3, Homer1, Pclo, Dlg2, Stxbp1, Dlg4, Kif5c, Stx1b, Cadps, Rab3a, Rims1, 
Kif5a, Klc1, Cntnap1, Gria2, Stx1a, Kcna1, Cplx1, Grin2b, Shank1, Napb, Nsf, Snap91, 
Rph3a, Bsn, Rab3c, Dlgap1 
synaptic vesicle maturation (GO:0016188) 4 88.82 1.31E-03 Stxbp1, Dlg4, Rab3a, Slc17a7 
developmental maturation (GO:0021700) 10 9.25 1.38E-03 Plp1, Dlg2, Stxbp1, Dlg4, Grin1, Map1b, Rab3a, Cend1, Slc17a7, Shank1 
synaptic vesicle endocytosis (GO:0048488) 5 52.59 4.59E-04 Syt1, Syt12, Syt2, Amph, Sh3gl2 
Results                                                                                                                                 Chapter III 
 
 
 
Functional characterization of novel BRI2 and BRI3 complexes                209 
 
Biological Process GO term 
Nr. 
prote
ins 
Fold 
enrichme
nt (%) 
p-value Associated proteins 
clathrin-dependent endocytosis (GO:0072583) 6 38.68 1.25E-04 Dnm1, Syt1, Syt12, Syt2, Amph, Sh3gl2 
synaptic vesicle recycling (GO:0036465) 6 47.96 3.53E-05 Rab3a, Syt1, Syt12, Syt2, Amph, Sh3gl2 
Ion transport 
(GO:0006811) 
inorganic cation transmembrane transport 
(GO:0098662) 
13 5.42 7.99E-03 Atp1a3, Atp1b2, Grin1, Slc30a3, Slc12a5, Slc8a2, Atp2b2, Cacng2, Kcna1, Slc17a7, Atp1a2, 
Atp2b3, Snap25 
cation transport (GO:0006812) 19 4.81 1.36E-04 Atp1a3, Slc17a6, Slc32a1, Atp1b2, Grin1, Slc30a3, Slc12a5, Slc8a2, Atp2b2, Cacng2, 
Kcna1, Slc17a7, Grin2b, Atp1a2, Atp2b3, Nsf, Camk2b, Snap25, Camk2a 
metal ion transport (GO:0030001) 18 6.48 3.42E-06 Atp1a3, Slc17a6, Atp1b2, Grin1, Slc30a3, Slc12a5, Slc8a2, Atp2b2, Cacng2, Kcna1, 
Slc17a7, Grin2b, Atp1a2, Atp2b3, Nsf, Camk2b, Snap25, Camk2a 
regulation of ion transport (GO:0043269) 15 4.65 7.61E-03 Ehd3, Homer1, Syt1, Cntn1, Dlg4, Gnao1, Atp1b2, Grin1, Atp2b2, Cacng2, Kcna1, Grin2b, 
Atp1a2, Shank1, Camk2a 
L-glutamate transport 
(GO:0015813) 
L-glutamate transmembrane transport (GO:0089711) 4 72.67 2.90E-03 Slc17a6, Slc1a6, Slc1a2, Slc1a3 
L-glutamate transport (GO:0015813) 5 55.51 3.52E-04 Slc17a6, Slc1a6, Slc1a2, Slc1a3, Slc17a7 
Glutamate receptor 
signalling pathway 
(GO:0007215) 
ionotropic glutamate receptor signaling pathway 
(GO:0035235) 
6 46.12 4.44E-05 Atp1a3, Grin1, Gria2, Grin2b, Gria1, Camk2a 
glutamate receptor signaling pathway (GO:0007215) 7 31.79 2.89E-05 Atp1a3, Grin1, Gria2, Grin2b, Gria1, Camk2a,  Homer1 
Neuromuscular process 
(GO:0050905) 
neuromuscular process controlling balance 
(GO:0050885) 
8 24.60 1.55E-05 Dlg4, Nefl, Atp2b2, Cntnap1, Tnr, Shank1, Slc1a3, Camk2b 
neuromuscular process (GO:0050905) 11 18.32 2.88E-07 Dlg4, Grin1, Nefl, Atp2b2, Cntnap1, Kcna1, Grin2b, Tnr, Shank1, Slc1a3, Camk2b  
Behavior 
(GO:0007610) 
locomotory behavior (GO:0007626) 12 10.61 1.68E-05 Atp1a3, Dnm1, Dlg4, Cnp, Gnao1, Grin1, Atp2b2, Cend1, Lsamp, Atp1a2, Tnr, Snap25  
adult behavior (GO:0030534) 10 11.69 1.61E-04 Atp1a3, Dnm1, Homer1, Cnp, Grin1, Cend1, Atp1a2, Sptbn2, Slc1a2, Shank1  
Response to chemical 
(GO:0042221) 
response to fungicide (GO:0060992) 4 39.97 3.06E-02 Grin1, Gria2, Grin2b, Gria1 
response to inorganic substance (GO:0010035) 15 4.65 7.46E-03 Homer1, Syt1, Gnao1, Grin1, Slc30a3, Nefl, Map1b, Mbp, Gria2, Ncam1, Kcna1, Grin2b, 
Slc1a3, Camk2b, Gria1 
Others microtubule-based process (GO:0007017) 14 4.98 8.14E-03 Map1a, Crmp1, Tubb2a, Tubb3, Nefm, Cnp, Kif5c, Map6, Nefl, Tubb2b, Map1b, Kif5a, 
Klc1, Map2 
cytoskeleton organization (GO:0007010) 20 4.42 2.15E-04 Map1a, Gfap, Add2, Crmp1, Tubb2a, Pclo, Tubb3, Nefm, Cnp, Map6, Nefl, Tubb2b, Map1b, 
Tmod2, Map2, Cntnap1, Sptbn2, Shank1, Ina, Bsn 
synapse organization (GO:0050808) 10 12.34 9.71E-05 Pclo, Dlg4, Map1b, Atp2b2, Rab3a, Cacng2, Sptbn2, Tnr, Shank1, Bsn  
sensory perception of mechanical stimulus 
(GO:0050954) 
9 10.77 1.67E-03 Map1a, Dnm1, Atp2b2, Rab3a, Mbp, Kcna1, Grin2b, Slc1a3, Crym 
negative regulation of cellular component organization 
(GO:0051129) 
16 5.09 9.51E-04 Scamp5, Map1a, Gfap, Add2, Crmp1, Ntm, Stxbp1, Dlg4, Stx1b, Map1b, Mbp, Tmod2, 
Sptbn2, Mag, Tnr, Shank1 
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Table III.A.S  6 - Cellular component enrichment analysis of the brain specific BRI2 interactome using Panther online resource . Enriched categories are identified as those with p 
value <0.05, and GO terms presented correspond to the two most specific for each category retrieved in the analysis. Nr. Number. 
GO term Nr. proteins 
Fold enrichment 
(%) p-value Associated proteins 
synaptobrevin 2-SNAP-25-syntaxin-1a-complexin I complex 
(GO:0070032) 
3 > 100 1.61E-03 Stx1a, Cplx1, Snap25 
SNARE complex (GO:0031201) 8 31.35 3.57E-07 Scamp5, Syt1, Stx1b, Stx1a, Cplx1, Napb, Snap25, Syn2 
synaptobrevin 2-SNAP-25-syntaxin-1a complex (GO:0070044) 3 > 100 3.14E-03 Stx1a, Napb, Snap25 
neurof ilament (GO:0005883) 4 79.94 3.00E-04 Nefm, Nefl, Dlgap2, Ina 
polymeric cytoskeletal f iber (GO:0099513) 19 6.67 9.85E-08 Map1a, Gfap, Crmp1, Tubb2a, Dnm1, Tubb3, Nefm, Cnp, Kif5c, Map6, Slc8a2, Nefl, Tubb2b, 
Map1b, Dcx, Kif5a, Klc1, Map2, Dlgap2, Ina 
NMDA selective glutamate receptor complex (GO:0017146) 4 66.61 6.17E-04 Dlgap3, Grin1, Grin2b, Shank1 
cation channel complex (GO:0034703) 11 12.63 2.06E-06 Dlgap3, Dlg2, Dlg4, Grin1, Cacng2, Cntnap1, Stx1a, Kcna1, Grin2b, Shank1, Snap25  
ionotropic glutamate receptor complex (GO:0008328) 9 35.97 7.92E-09 Dlgap3, Dlg2, Dlg4, Grin1, Cacng2, Gria2, Grin2b, Shank1, Gria1  
excitatory synapse (GO:0060076) 12 66.61 1.49E-15 Slc17a6, Ntm, Homer1, Syt1, Dlg4, Syp, Grin1, Stx1b, Slc17a7, Shank1, Bsn, Gria1  
synapse (GO:0045202) 69 15.72 2.70E-63 Scamp5, Atp1a3, Map1a, Srcin1, Sgip1, Add2, Slc17a6, Dnm1, Ntm, Bcan, Dlgap3, Homer1, 
Pclo, Dlg2, Stxbp1, Syt1, Anks1b, Syt12, Nefm, Dlg4, Prrt1, Syp, Slc32a1, Grin1, Gabbr2, 
Slc30a3, Dclk1, Stx1b, Slc8a2, Syt2, Sept5, Map1b, Atp2b2, Prkcg, Rab3a, Rims1, Map2, 
Amph, Gria2, Stx1a, Kcna1, Sh3gl2, Slc17a7, Cplx1, Grin2b, Atp1a2, Sptbn2, Sept3, Sv2a, 
Sv2b, Gap43, Slc1a2, Dlgap2, Shank1, Slc1a3, Syn1, Nsf, Snap91, Camk2b, Rph3a, Snap25, 
Bsn, Cnksr2, Gria1, Syn2, Camk2a, Rab3c, Dlgap1 
juxtaparanode region of  axon (GO:0044224) 3 66.61 1.80E-02 Dlg2, Dlg4, Kcna1 
main axon (GO:0044304) 9 24.30 2.44E-07 Dnm1, Dlg2, Dlg4, Map1b, Mbp, Cntnap1, Kcna1, Mag, Slc1a2 
ciliary rootlet (GO:0035253) 3 59.95 2.47E-02 Kif5a, Kif5c, Klc1 
sodium:potassium-exchanging ATPase complex (GO:0005890) 3 59.95 2.47E-02 Atp1a3, Atp1b2, Atp1a2 
synaptic vesicle membrane (GO:0030672) 16 50.75 1.54E-19 Scamp5, Slc17a6, Syt1, Syt12, Syp, Slc30a3, Syt2, Amph, Gria2, Stx1a, Slc17a7, Sv2a, Sv2b, 
Syn1, Rph3a, Syn2  
synaptic vesicle (GO:0008021) 29 37.15 1.47E-33 Scamp5, Slc17a6, Dnm1, Syt1, Syt12, Dlg4, Syp, Slc32a1, Grin1, Slc30a3, Stx1b, Syt2, Sept5, 
Rab3a, Amph, Gria2, Stx1a, Slc17a7, Grin2b, Sptbn2, Sv2a, Sv2b, Syn1, Snap91, Rph3a, 
Snap25, Gria1, Syn2, Rab3c 
presynaptic active zone (GO:0048786) 8 48.45 1.18E-08 Pclo, Syp, Slc32a1, Rims1, Slc17a7, Sv2a, Syn1, Bsn 
presynaptic membrane (GO:0042734) 13 33.74 3.07E-13 Syt1, Syp, Stx1b, Rims1, Gria2, Stx1a, Kcna1, Grin2b, Sept3, Slc1a2, Snap91, Snap25, Camk2a 
synaptic membrane (GO:0097060) 27 19.76 7.71E-24 Srcin1, Dlgap3, Homer1, Dlg2, Syt1, Anks1b, Dlg4, Syp, Grin1, Gabbr2, Stx1b, Prkcg, Rims1, 
Gria2, Stx1a, Kcna1, Grin2b, Sept3, Slc1a2, Dlgap2, Shank1, Snap91, Snap25, Cnksr2, Gria1, 
Camk2a, Dlgap1 
terminal bouton (GO:0043195) 19 32.45 5.42E-20 Sgip1, Pclo, Stxbp1, Syt1, Syp, Grin1, Syt2, Sept5, Rab3a, Amph, Gria2, Cplx1, Grin2b, Sv2a, 
Sv2b, Syn1, Snap91, Snap25, Syn2 
axon terminus (GO:0043679) 21 21.86 7.62E-19 Sgip1, Pclo, Stxbp1, Syt1, Syp, Slc32a1, Grin1, Syt2, Sept5, Rab3a, Amph, Gria2, Kcna1, 
Cplx1, Grin2b, Sv2a, Sv2b, Syn1, Snap91, Snap25, Syn2 
AMPA glutamate receptor complex (GO:0032281) 4 26.65 2.25E-02 Dlg4, Cacng2, Gria2, Gria1 
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GO term Nr. proteins 
Fold enrichment 
(%) p-value Associated proteins 
postsynaptic density (GO:0014069) 31 26.14 1.76E-31 Map1a, Srcin1, Add2, Dlgap3, Homer1, Pclo, Dlg2, Anks1b, Nefm, Dlg4, Grin1, Dclk1, 
Map1b, Prkcg, Rims1, Map2, Gria2, Grin2b, Gap43, Dlgap2, Shank1, Syn1, Nsf, Snap91, 
Camk2b, Bsn, Cnksr2, Gria1, Syn2, Camk2a, Dlgap1 
postsynaptic specialization (GO:0099572) 31 26.14 1.76E-31 Map1a, Srcin1, Add2, Dlgap3, Homer1, Pclo, Dlg2, Anks1b, Nefm, Dlg4, Grin1, Dclk1, 
Map1b, Prkcg, Rims1, Map2, Gria2, Grin2b, Gap43, Dlgap2, Shank1, Syn1, Nsf, Snap91, 
Camk2b, Bsn, Cnksr2, Gria1, Syn2, Camk2a, Dlgap1 
asymmetric synapse (GO:0032279) 31 25.60 3.30E-31 Map1a, Srcin1, Add2, Dlgap3, Homer1, Pclo, Dlg2, Anks1b, Nefm, Dlg4, Grin1, Dclk1, 
Map1b, Prkcg, Rims1, Map2, Gria2, Grin2b, Gap43, Dlgap2, Shank1, Syn1, Nsf, Snap91, 
Camk2b, Bsn, Cnksr2, Gria1, Syn2, Camk2a, Dlgap1 
dendritic shaft (GO:0043198) 7 23.31 3.58E-05 Homer1, Slc12a5, Map2, Gria2, Slc1a2, Nsf, Gria1 
dendrite (GO:0030425) 37 11.83 4.31E-26 Atp1a3, Srcin1, Crmp1, Bcan, Dlgap3, Homer1, Pclo, Tubb3, Dlg2, Anks1b, Ncdn, Dlg4, 
Gnao1, Slc32a1, Grin1, Slc12a5, Slc8a2, Map1b, Atp2b2, Prkcg, Dcx, Map2, Gnaz, Gria2, 
Kcna1, Cplx1, Grin2b, Atp1a2, Slc1a2, Dlgap2, Shank1, Slc1a3, Nsf, Camk2b, Bsn, Gria1, 
Camk2a 
myelin sheath (GO:0043209) 23 22.10 5.60E-21 Atp1a3, Gfap, Ehd3, P lp1, Dnm1, Stxbp1, Cntn1, Nefm, Cnp, Gnao1, Nefl, Mbp, Cntnap1, 
Ncam1, Atp1a2, Mag, Ina, Mog, Napb, Syn1, Nsf, Snap25, Syn2 
dendritic spine (GO:0043197) 14 18.17 8.97E-11 Atp1a3, Dlgap3, Anks1b, Dlg4, Grin1, Slc8a2, Map1b, Gria2, Grin2b, Atp1a2, Slc1a2, Shank1, 
Slc1a3, Gria1 
neuron spine (GO:0044309) 14 17.93 1.07E-10 Atp1a3, Dlgap3, Anks1b, Dlg4, Grin1, Slc8a2, Map1b, Gria2, Grin2b, Atp1a2, Slc1a2, Shank1, 
Slc1a3, Gria1 
postsynaptic membrane (GO:0045211) 16 16.15 8.02E-12 Srcin1, Dlgap3, Homer1, Dlg2, Anks1b, Dlg4, Grin1, Gabbr2, Gria2, Grin2b, Dlgap2, Shank1, 
Snap91, Cnksr2, Gria1, Dlgap1 
voltage-gated potassium channel complex (GO:0008076) 6 15.78 3.41E-03 Dlg2, Dlg4, Cntnap1, Stx1a, Kcna1, Snap25 
potassium channel complex (GO:0034705) 6 14.45 5.62E-03 Dlg2, Dlg4, Cntnap1, Stx1a, Kcna1, Snap25 
growth cone (GO:0030426) 11 12.42 2.46E-06 Crmp1, Pclo, Basp1, Nefl, Map1b, Tmod2, Klc1, Gria2, Ncam1, Gap43, Snap25  
site of  polarized growth (GO:0030427) 11 12.08 3.27E-06 Crmp1, Pclo, Basp1, Nefl, Map1b, Tmod2, Klc1, Gria2, Ncam1, Gap43, Snap25  
perikaryon (GO:0043204) 7 9.58 1.27E-02 Nefm, Slc12a5, Slc8a2, Map1b, Gria2, Kcna1, Camk2b 
neuronal cell body (GO:0043025) 30 9.46 9.35E-18 Srcin1, Crmp1, Dlgap3, Homer1, Pclo, Tubb3, Dlg2, Ncdn, Nefm, Grin1, Slc12a5, Slc8a2, 
Map1b, Atp2b2, Mbp, Kif5a, Klc1, Map2, Gria2, Ncam1, Kcna1, Cplx1, Sptbn2, Slc1a3, 
Camk2b, Snap25, Bsn, Cnksr2, Gria1, Camk2a 
microtubule (GO:0005874) 13 7.97 1.53E-05 Map1a, Tubb2a, Dnm1, Tubb3, Cnp, Kif5c, Map6, Slc8a2, Tubb2b, Map1b, Dcx, Kif5a, Klc1, 
Map2 
cell junction (GO:0030054) 48 7.54 1.36E-26 Scamp5, Srcin1, Slc17a6, Ehd3, Dlgap3, Homer1, Pclo, Dlg2, Syt1, Basp1, Anks1b, Syt12, 
Dlg4, Prrt1, Syp, Grin1, Gabbr2, Slc30a3, Syt2, Map1b, Cadps, Atp2b2, Prkcg, Rims1, Amph, 
Gria2, Cadm4, Ncam1, Stx1a, Kcna1, Slc17a7, Grin2b, Sptbn2, Sept3, Sv2a, Sv2b, Gap43, 
Dlgap2, Shank1, Syn1, Rph3a, Snap25, Bsn, Gria1, Syn2, Camk2a, Dlgap1  
Golgi apparatus (GO:0005794) 18 3.02 3.46E-02 Scamp5, Atp1a3, Itm2b, Dnm1, Pclo, Syt1, Map6, Slc1a6, Amph, Atl1, Sptbn2, Atp2b3, Syn1, 
Nsf, Rph3a, Snap25, Bsn, Cnksr2 
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Table III.A.S  7 - Brain enriched/specific Nano-HPLC-MS/MS identified candidate BRI2 interacting proteins 
annotated with GO terms related to neuronal differentiation processes. Uniprot accession numbers and gene names 
are listed. 
 
Uniprot Acession Gene name Uniprot Acession Gene name 
P21707 Syt1 Q63622 Dlg2 
P29101 Syt2 P61765 Stxbp1 
Q9JIR4 Rims1 O35095 Ncdn 
Q5BJS7 Cpne9 P31016 Dlg4 
Q9QXY2 Srcin1 P13233 Cnp 
P47819 Gfap P59215 Gnao1 
Q62950 Crmp1 O08875 Dclk1 
Q62718 Ntm P56536 Kif5c 
Q63198 Cntn1 Q63560 Map6 
P12839 Nefm Q63633 Slc12a5 
P35439 Grin1 Q3KRE8 Tubb2b 
P61265 Stx1b P11506 Atp2b2 
P19527 Nefl P63012 Rab3a 
P15205 Map1b Q6QLM7 Kif5a 
P02688 Mbp P97846 Cntnap1 
P15146 Map2 Q8CGU4 Agap2 
P07722 Mag P13596 Ncam1 
Q05546 Tnr Q6PST4 Atl1 
Q9WV48 Shank1 P10499 Kcna1 
P08413 Camk2b Q64548 Rtn1 
P60881 Snap25 P07936 Gap43 
Q5FVI4 Cend1 P24942 Slc1a3 
P60203 Plp1 Q05140 Snap91 
Q62951 Dpysl4 P11275 Camk2a 
Q4QRB4 Tubb3   
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Abstract 
BRI3 is a type II integral membrane protein enriched in the CNS with unclear biological functions. 
Recent studies have established protein interactions for BRI3, namely with Amyloid precursor 
protein and protein phosphatase 1. Thus, like most proteins, BRI3 seems to function through 
interactions with a complex network of proteins, as well as with other molecules.  Therefore, to 
further increase our understanding of BRI3 biology and role it seems essential to elucidate and 
characterize the BRI3 interactome. Here, we pursued the identification of BRI3 interactome in rat 
brain tissue lysates by co-immunoprecipitating BRI3 followed by mass-spectrometry identification. 
Bioinformatic analysis of the identified BRI3 interactome allows us to analyze the biological 
processes, localization and signaling pathways in which they are involved in order to identify 
potentially novel BRI3 functional relationships. We identified 274 different proteins as potential 
BRI3 interactors, which are mainly cytoskeletal proteins, transporters, and membrane traffic proteins. 
These were involved in several biological processes, which in turn suggests a role for BRI3 at the 
nerve terminals namely in synaptic signaling, transmission, and plasticity, as well as in neuronal 
trafficking and neuronal differentiation. Moreover, a strong connection of the BRI3 interactome with 
some nervous system diseases, including Alzheimer s´ disease and cerebrovascular accident, was 
suggested.  
Taken together, the results here presented provide novel insights provides a valuable list of BRI3 
interacting proteins for further studies to investigate their potential roles in BRI3 biology and the 
underlying molecular and mechanisms, as well as in its associated pathologies.  
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III.B.1 Introduction 
BRI3, also known as ITM2C (integral membrane protein 2C) is a type II integral membrane protein 
that belongs to an evolutionarily conserved multigene family of integral membrane proteins 
containing two additional members, BRI1 (ITM2A) and BRI2 (ITM2B). It is found in a variety of 
tissues but is enriched in the central nervous system (CNS) where presents highest levels of 
expression in cerebral cortex, medulla oblongata, amygdala, hippocampus, thalamus, striatum, 
caudate nucleus and spinal cord (Vidal et al. 2001; Choi et al. 2001). The biological function of BRI3 
remains largely unclear, although it has been suggested that it may play a role in neuronal 
differentiation (Gong et al. 2008). Stathmin-2, a neuron-specific microtubule-destabilizing protein, 
was identified in a yeast two-hybrid screen as a BRI3 interacting partner. While overexpression of 
stathmin-2 seems to promote neurite outgrowth in NGF-treated PC12 cells, BRI3 overexpression 
slightly decreases neurite outgrowth. However, the overexpression of both proteins attenuates the 
stathmin-2 induced microtubule disassembly and outgrowth of neurites. Hence, it is possible to 
assume that BRI3 may inhibit neurite outgrowth through interaction with stathmin-2 by decreasing 
the dynamic instability of microtubules (Gong et al. 2008). Moreover, BRI3 was proposed as a 
negative regulator of Aβ production by interacting and regulating the processing of the amyloid 
precursor protein (APP) by masking the access of α- and β-secretases (Matsuda et al. 2009). 
Recently, it was also described protein phosphatase 1 (PP1) as a novel BRI3 interacting partner which 
is able to dephosphorylate the latter. Hence, BRI3 was described as a phosphoprotein although the 
physiological relevance of protein phosphorylation in its biology was not elucidated (Martins et al. 
2016).  
Therefore, to increase our understanding regarding the brain-enriched BRI3 it seems necessary to 
elucidate and characterize its brain interactome which could lead to the discovery of its neuronal 
physiological role, as well as its association with nervous system diseases. Interactomes are 
characterized by the molecular interactions that take place in a particular biological context, creating 
a network that promotes and regulates its trafficking, processing, activity and signaling effects (De 
Las Rivas and Fontanillo 2010; Mehta and Trinkle-Mulcahy 2016). Consequently, the identification 
and study of protein interactomes provide many insights into the biological processes of a particular 
network which might offer valuable information underlying protein cellular functions.   
Here, we have attempted to elucidate the BRI3 protein interactome in rat brain using a combined 
immunoprecipitation and mass spectrometry (MS) approach. Given the described expression 
distribution of BRI3 in the brain, three different brain regions were analyzed in this work: cortex, 
hippocampus, and striatum. Moreover, bioinformatic tools were applied to analyze both the entire 
and the region-specific BRI3 interactome datasets to uncover the organization of BRI3 interacting 
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protein networks in the mammalian brain and consequently identify potentially novel BRI3 
functional relationships. 
 
III.B.2 Materials and Methods 
III.B.2.1 Preparation of rat brain lysates  
Wistar Hannover rats (9-12 weeks) were obtained from Harlan Interfaune Ibérica, SL, and all 
experimental procedures were conducted in accordance with the European legislation for animal 
experimentation (2010/63/EU). No specific ethics approval under EU guidelines was required for 
this project, since the rats were euthanized, by cervical stretching followed by decapitation, for brain 
removal. This is within the European law (Council Directive 86/609/EEC) and the number and 
suffering of the animals possible were minimized. The procedures were approved and supervised by 
our Institutional Animal Care and Use Committee (IACUC): Comissão Responsável pela 
Experimentação e Bem-Estar Animal (CREBEA). Briefly, animals were sacrificed by cervical 
stretching followed by decapitation and cortex, hippocampus and striatum were dissected out on ice. 
Tissues were further weighed and homogenized on ice with a Potter-Elvehjem tissue homogenizer 
with 10-15 pulses at 650-750 rpm, in non-denaturating lysis buffer (50 mM Tris-HCl pH 8.0, 120 
mM NaCl and 4% CHAPS) containing protease inhibitors (1 mM PMSF, 10 mM Benzamidine, 2 
µM Leupeptin, 1.5 µM Aprotinin and 5 µM Pepstatin A) (Santos et al. 2014) and used for 
immunoprecipitation analysis as described below. 
 
III.B.2.2 Co-immunoprecipitation  
Rat cortex, hippocampus and striatum extracts were divided into three equal parts each and pre-
cleared separately using Dynabeads Protein G (Life Technologies). A direct immunoprecipitation 
approach was performed using the rabbit anti-BRI3 antibody (1:150; ab101389, Abcam), pre-
incubated with Dynabeads Protein G for 1 hour at 4oC with rotation.  After, the pre-cleared extracts 
were applied to antibody-Dynabeads and incubated overnight at 4oC with rotation. The 
immunoprecipitates were washed three times with PBS in 3% BSA for 10 min at 4oC with rotation 
and beads were re-suspended in 1% SDS. As negative controls were used extracts incubated with 
only dynabeads protein G or with dynabeads protein G coupled with rabbit IgGs (mock IPs).  
 
III.B.2.3 In-gel protein digestion, nano-HPLC and Mass spectrometry  
The eluted fractions from the brain BRI3 co-IP assays were separated by SDS-PAGE on a 12% Bis-
Tris gel for HPLC analysis. Each lane of the gel was cut into 10 pieces, and the resulting gel pieces 
were washed alternately with 10 mM ammonium hydrogen carbonate (NH4HCO3) and 50% (v/v) 
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10 mM ammonium hydrogen carbonate, 50% (v/v) acetonitrile (ACN) and afterward were digested 
with trypsin in 10 mM HCl and 50 mM ammonium hydrogen carbonate at 37 °C overnight. The 
resulting peptides were extracted from the gel slices twice by means of sonication in 50% (v/v) ACN, 
50% (v/v) 0.1% trifluoroacetic acid (TFA). After the extracts were merged, the ACN was removed 
in a centrifugal vacuum concentrator. The final sample volumes were adjusted to 40 µl with 0.1% 
TFA. Nano-HPLC-MS/MS was carried out on an UltiMate 3000 RSLCnano LC system (Dionex 
Sunnyvale, CA). After the samples had been loaded on a trap column (75 µm X 2 cm, particle size 
= 3 µm, pore size = 100 Å; Dionex) and washed with 0.1% TFA (flow rate: 10 µl/min), the trap 
column was connected with an analytical C18 column (75 µm X 25 cm, particle size = 2 µm, pore 
size = 100 Å; Dionex). The following system of solvents was used for separating the peptides with a 
flow rate of 400 nl/min: 95% ACN, 0.1% formic acid (A); and 80% ACN, 0.1% formic acid (B). 
First, a gradient from 0% to 40% B (95 min) was performed, followed by a second gradient from 
40% to 95% B within 2 min. Finally, 95% B was used for 5 min, followed by equilibration with 
buffer A. The HPLC system was connected to a nanoelectrospray ionization source (Thermo Fisher 
Scientific). Electrospray ionization MS/MS was performed on an LTQ Orbitrap Velos (Thermo 
Fisher Scientific). MS spectra were scanned between 300 and 2000 m/z with a resolution of 30,000 
and a maximal acquisition time of 500 ms. The m/z values initiating MS/MS were set on a dynamic 
exclusion list for 35 s. Lock mass polydimethylcyclosiloxane (m/z 445.120) was used for internal 
recalibration. The 20 most intensive ions (charge _ 1) were selected for MS/MS fragmentation in the 
ion trap. Fragments were generated via low-energy collision induced dissociation on isolated ions 
with a collision energy of 35% and a maximal acquisition time of 50 ms. Raw files were transformed 
to *.mgf files using ProteomeDiscoverer 1.3 software (Thermo Fisher Scientific). Mascot generic 
files were imported into ProteinScape™ 2.1 (Bruker Daltonics, Bremen, Germany) and analyzed 
using MASCOT (version 2.2.0, Matrix Science, London, UK) with a peptide mass tolerance of 10 
ppm and a fragment mass tolerance of 0.5 Da. One missed cleavage site after tryptic digestion was 
allowed in the database search. Carbamidomethylation (C), oxidation (M), and phosphorylation (S, 
T, Y) were regarded as variable modifications. All data were searched against the UniProt/ Swiss-
Prot database (downloaded on June 1, 2011; containing 529,056 entries, plus one shuffled decoy 
entry for each target entry for false discovery rate estimation with taxonomy restriction for human 
(resulting in 40,620 target and decoy entries).  
Two mock IPs for each sample condition (i.e. for each specific brain region) were used as negative 
controls. Therefore, the proteins identified in the mock IPs were excluded from the list of the proteins 
identified in the BRI3 co-IPs, with one exception: the ratio between the number of peptide-spectrum 
matches (PSM) for a given protein in a BRI3 co-IP sample and the PSM in the mock IPs, of the same 
brain region, were equal or higher than 2.0. In addition, were excluded well described common 
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contaminants as presented in (Hodge et al. 2013), and proteins characteristic of hair, skin/epidermis, 
tongue and gums (KRT33A, KRT78, KRT85, KRT14, KRT5, KRT3, KRT31, KRT32, KRT33B, 
KRT35, KRT36, KRT4, KRT77, KRT8, KRT17) which are also highly probable contaminants. 
 
III.B.2.4 Bioinformatic data analysis  
Experimentally detected BRI3 protein-protein interactions documented in the literature were mapped 
using the PSIQUIC View web service (del-Toro et al. 2013) (version 1.4.5, downloaded October 03, 
2016) which enabled access to multiple PSI-MI compliant resources. Moreover, two BRI3 protein 
interactors previously identified and validated recently in our laboratory, protein phosphatase 1 alpha 
(PPP1CA) and protein phosphatase 1 gamma (PPP1CC), were manually added to the list.  
Tissue-expression analysis was performed using the following databases: Human Protein Atlas 
(HPA), (Uhlen et al. 2005; Uhlen et al. 2010; Uhlén et al. 2015) which also retrieves information 
from the Genotype-Tissue Expression (GTEx) portal (Carithers et al. 2015) and FANTOM5 
(Functional Annotation of the Mammalian Genome) (Kawai et al. 2001); TiGER (Liu et al. 2008); 
and UniGene (Wheeler et al. 2003). The HPA was searched for proteins strongly expressed in the 
brain and a list of proteins within the brain ‘Tissue enriched’, ‘Tissue enhanced’ and ‘Group 
enriched’ categories was obtained.  Annotated protein expression is a manually curated score based 
on IHC staining patterns in normal tissues from two or more paired antibodies binding to different 
epitopes of the same protein, which describes the distribution and strength of expression of each 
protein in cells. The TiGER database was searched for proteins preferentially expressed in brain 
based on ESTs by searching ‘Brain’ in ‘Tissue View’. The UniGene database was searched for brain-
restricted genes by using the following search criteria: [brain][restricted]. 
Functional enrichment analysis of Gene Ontology (GO) categories (Biological Process and Cellular 
Component) and KEGG pathways was performed using ClueGO plugin version 2.2.6 (Bindea et al. 
2009) of the Cytoscape software version 3.4.0, freely available online (Shannon et al. 2003), whereas 
analysis of the Protein Class was performed using PANTHER v.10 (Protein Annotation Through 
Evolutionary Relationship) online resource (Mi et al. 2013; Mi et al. 2016). Of note, only enriched 
annotations with a p-value <0.05 were considered. 
Protein-protein interaction (PPI) network construction was achieved using Cytoscape software, and 
topological analysis using the NetworkAnalyzer plugin. Network augmentation was performed by 
retrieving protein-protein data only from the International Molecular Exchange (IMEx) consortium 
partners. Given the lacking information for Rattus norvergicus in these databases, the lists of proteins 
were extrapolated by homology to human. Rat UniProt accession numbers were converted to human 
using the Uniprot tool available online – Uniprot Retrieve/ID mapping 
(http://www.uniprot.org/uploadlists/).  
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Genes that share diseases with BRI3 protein were retrieved using the DisGeNET database (consulted 
on March 17, 2017), which integrates human gene-disease associations from various expert-curated 
databases and text-mining derived associations (Piñero et al. 2017).  
 
III.B.3 Results  
III.B.3.1 Identification of BRI3 brain interactome 
The central goal of this study was the identification of novel BRI3 interacting proteins in the brain. 
Rat brain represents a valuable tool for the study of protein expression and brain function in mammals 
and was used as the protein pool for co-IP of BRI3 protein using a specific antibody. These co-IPs 
were further analyzed Nano HPLC-MS/MS. Given the BRI3 expression distribution, three different 
brain regions were analyzed in this study: cortex, hippocampus, and striatum. The applied workflow 
is presented in Figure III.B.1. Of note, the data obtained were first ‘filtered’ to remove known 
contaminants and taking into account the negative controls (mock IPs), as mentioned in the materials 
and methods section. 
 
Figure III.B 1- Workflow for the identification of novel brain BRI3 interacting proteins using rat brain tissue lysates. 
Co-IP, co-immunoprecipitation; MS, mass spectrometry; DB, database; CX, cerebral cortex; HP, hippocampus; ST, 
striatum. 
As a result, we were able to identify 108 proteins in the cortex, 173 in the hippocampus, and 141 in 
the striatum. In total, we identified 274 different proteins, including BRI3, as potential candidates for 
BRI3 interacting proteins (Supplementary Table III.B.S1). It is important to point out that from this 
list of BRI3 brain interactors two were previously described as BRI3 interacting proteins: APP and 
DLG4 (also known as PSD-95), from a list of 18 proteins (Supplementary Table III.B.S2).  
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Next, we assessed the protein class of BRI3 interactors using the PANTHER protein class system. 
As shown in Figure III.B.2 and Supplementary Table III.B.S3, BRI3 protein interactors are mainly 
cytoskeletal proteins (32%; half of which belong to actin family), transporters (16%), G-proteins 
(7%), transmembrane receptor regulatory/adaptor proteins (4%), membrane traffic proteins (12%), 
structural proteins (6%) and chaperones (6%). 
 
Figure III.B 2- Panther Protein class of the identified BRI3 interactome using the PANTHER online resource. The 
percentage of the BRI3 interacting proteins in each category was calculated and plotted. 
 
Several proteins are known to be expressed in a tissue-specific manner and as a result, the signaling 
mechanisms in which they are involved are diverse, reflecting the specific biological roles of each 
individual tissue (Uhlén et al. 2015). Thus, given that BRI3 is a brain enriched protein, to further 
explore its potential associations to specific cellular mechanisms and signaling pathways in the brain, 
we have constructed a brain-enriched/specific network approach. Tissue-expression analysis of the 
274 BRI3 interacting protein candidates resulted in the identification of 89 proteins specific or highly 
enriched in brain (Table III.B.1), the BRI3 brain-enriched/specific interactome (BRI3 brain ES 
interactome). 
 
 
 
Table III.B 1- Novel candidate BRI3 interacting proteins highly enriched or specific for the brain tissue . Uniprot 
accession numbers, gene and protein names, are listed, as well as the rat brain tissues in where the proteins were found. 
CX, cerebral cortex; HP, hippocampus; ST, striatum. 
Uniprot 
accession Gene name Protein name 
 
Brain regions 
 
P13233 Cnp 2',3'-cyclic-nucleotide 3'-phosphodiesterase  CX, HP, ST  
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Uniprot 
accession Gene name Protein name 
 
Brain regions 
 
P23565 Ina Alpha-internexin  HP, ST  
P0C6S7 Anks1b Ankyrin repeat and sterile alpha motif domain-containing protein 1B  CX, HP 
Q8CGU4 Agap2 Arf-GAP with GTPase, ANK repeat and PH domain-containing protein 
2  
HP 
P85969 Napb Beta-soluble NSF attachment protein  CX 
Q05175 Basp1 Brain acid soluble protein 1  HP 
P11275 Camk2a Calcium/calmodulin-dependent protein kinase type II subunit alpha  ST  
P08413 Camk2b Calcium/calmodulin-dependent protein kinase type II subunit beta  CX, HP, ST  
P68182 Prkacb cAMP-dependent protein kinase catalytic subunit beta  HP, ST  
O55156 Clip2 CAP-Gly domain-containing linker protein 2  ST  
Q8VHK2 Caskin1 Caskin-1  CX 
Q5FVI4 Cend1 Cell cycle exit and neuronal differentiation protein 1 CX 
Q05140 Snap91 Clathrin coat assembly protein AP180  HP 
Q99P82 Cldn11 Claudin-11 CX, HP, ST  
Q99JD4 Clasp2 CLIP-associating protein 2  CX 
Q9Z1T4 Cnksr2 Connector enhancer of kinase suppressor of ras 2  HP 
Q63198 Cntn1 Contactin-1  CX, HP, ST  
Q5BJS7 Cpne9 Copine-9  HP 
Q62950 Crmp1 Dihydropyrimidinase-related protein 1  CX, HP, ST  
Q63622 Dlg2 Disks large homolog 2  CX, HP, ST  
P31016 Dlg4 Disks large homolog 4  CX, HP, ST  
P97838 Dlgap3 Disks large-associated protein 3  CX 
P21575 Dnm1 Dynamin-1  HP, ST  
O35179 Sh3gl2 Endophilin-A1  CX 
Q8K3M6 Erc2 ERC protein 2  ST  
P24942 Slc1a3 Excitatory amino acid transporter 1  HP, ST  
P31596 Slc1a2 Excitatory amino acid transporter 2  HP, ST  
P47819 Gfap Glial fibrillary acidic protein  CX, ST  
P19491 Gria2 Glutamate receptor 2  HP 
P35439 Grin1 Glutamate receptor ionotropic, NMDA 1  HP 
Q00960 Grin2b Glutamate receptor ionotropic, NMDA 2B  HP 
Q9WTT6 Gda Guanine deaminase  HP 
P59215 Gnao1 Guanine nucleotide-binding protein G HP 
P19627 Gnaz Guanine nucleotide-binding protein G HP 
Q9Z214 Homer1 Homer protein homolog 1  CX, ST  
P17105 Itpka Inositol-trisphosphate 3-kinase A  HP 
Q9QYU4 Crym Ketimine reductase mu-crystallin  CX, HP, ST  
Q8K4Y5 Lgi1 Leucine-rich glioma-inactivated protein 1 CX 
P34926 Map1a Microtubule-associated protein 1A  HP 
P15205 Map1b Microtubule-associated protein 1B  CX, HP, ST  
P15146 Map2 Microtubule-associated protein 2  CX, ST  
Q63560 Map6 Microtubule-associated protein 6  CX, HP 
P19332 Mapt Microtubule-associated protein tau  CX, ST  
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Uniprot 
accession Gene name Protein name 
 
Brain regions 
 
Q505J6 Slc25a18 Mitochondrial glutamate carrier 2  CX, HP 
P02688 Mbp Myelin basic protein  ST  
P60203 Plp1 Myelin proteolipid protein  ST  
Q63345 Mog Myelin-oligodendrocyte glycoprotein CX, HP, ST  
P55067 Ncan Neurocan core protein  ST  
P97685 Nfasc Neurofascin HP 
P19527 Nefl Neurofilament light polypeptide  ST  
P12839 Nefm Neurofilament medium polypeptide  CX, ST  
Q04940 Nrgn Neurogranin  CX 
P07936 Gap43 Neuromodulin  CX 
Q9ESI7 Dcx Neuronal migration protein doublecortin HP 
P32736 Opcml Opioid-binding protein/cell adhesion molecule  CX 
P62024 Phactr1 Phosphatase and actin regulator 1 ST  
P11506 Atp2b2 Plasma membrane calcium-transporting ATPase 2  CX 
O88778 Bsn Protein bassoon CX, HP 
Q9Z0W5 Pacsin1 Protein kinase C and casein kinase substrate in neurons protein 1  CX 
P63319 Prkcg Protein kinase C gamma type  CX, HP, ST  
Q9JKS6 Pclo Protein piccolo  ST  
P63012 Rab3a Ras-related protein Rab-3A CX, ST  
Q63941 Rab3b Ras-related protein Rab-3B ST 
P62824 Rab3c Ras-related protein Rab-3C HP, ST  
Q9JIR4 Rims1 Regulating synaptic membrane exocytosis protein 1  HP 
Q64548 Rtn1 Reticulon-1  CX 
Q9JJM9 Sept5 Septin-5  CX, HP 
Q5MPA9 Dclk2 Serine/threonine-protein kinase DCLK2  HP 
Q9WV48 Shank1 SH3 and multiple ankyrin repeat domains protein 1  HP 
Q9QX74 Shank2 SH3 and multiple ankyrin repeat domains protein 2  CX, HP 
Q8CFD0 Sfxn5 Sideroflexin-5  HP 
P48768 Slc8a2 Sodium/calcium exchanger 2  HP 
P06687 Atp1a3 Sodium/potassium-transporting ATPase subunit alpha-3  CX, HP, ST  
Q9QWN8 Sptbn2 Spectrin beta chain, non-erythrocytic 2  CX, HP, ST  
Q9QXY2 Srcin1 SRC kinase signaling inhibitor 1  CX, HP, ST  
P09951 Syn1 Synapsin-1  CX, HP, ST  
Q63537 Syn2 Synapsin-2  HP 
P07825 Syp Synaptophysin  CX, HP, ST  
P60881 Snap25 Synaptosomal-associated protein 25  CX, HP 
P21707 Syt1 Synaptotagmin-1  CX, HP, ST  
P61265 Stx1b Syntaxin-1B  CX, HP, ST  
P61765 Stxbp1 Syntaxin-binding protein 1  CX, HP, ST  
Q05546 Tnr Tenascin-R  HP 
P01830 Thy1 Thy-1 membrane glycoprotein  CX 
Q6AY56 Tuba8 Tubulin alpha-8 chain  HP 
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Uniprot 
accession Gene name Protein name 
 
Brain regions 
 
P85108 Tubb2a Tubulin beta-2A chain HP, ST  
Q3KRE8 Tubb2b Tubulin beta-2B chain  HP, ST  
Q4QRB4 Tubb3 Tubulin beta-3 chain  HP, ST  
Q9QUL6 Nsf Vesicle-fusing ATPase  HP, ST  
 
Biological process and cellular component of the BRI3 brain ES interacting proteins were annotated 
according to GO annotation categories using the ClueGO plugin of the Cytoscape software (Bindea 
et al. 2009). The results suggest that BRI3 brain ES interactors mainly participated in exocytosis, 
synaptic signaling, synaptic transmission, vesicle-mediated transport, synaptic vesicle cycle, and in 
the establishment of synaptic vesicle localization (Table III.B.2). Of note, other biological process 
categories such as ‘cytoskeleton organization’, ‘synapse organization’ and ‘glutamate receptor 
signaling pathway’ were also evidenced (Table III.B.2). In addition, GO analysis demonstrates that 
BRI3 brain ES interactors are located in different areas within the cell, such as neuron projection, 
axon, growth cone, dendrite, presynapse, postsynapse, and synaptic vesicle (Table III.B.3). 
Remarkably, were also found proteins associated with the cytoskeleton and the ionotropic glutamate 
receptor complex (Table III.B.3). 
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Table III.B2- Biological process enrichment analysis of the brain specific/enriched BRI3 interactome using ClueGo plugin of the Cytoscape software . Enriched categories are 
identified as those with p-value <0.05. Nr. Number. 
GO term GO ID Nr. proteins % associated proteins p-value Associated proteins 
exocytosis GO:0006887 9.0 12.5 1.20E-04 Nsf, Rab3a, Rims1, Sept5, Snap25, Sptbn2, Stx1b, Stxbp1, Syt1  
synaptic signaling GO:0099536 15.0 6.4 1.70E-04 Camk2b, Dlg4, Dnm1, Gria2, Grin1, Grin2b, Lgi1, Map1b, Mapt, 
Nrgn, Rab3a, Rims1, Snap25, Sptbn2, Stxbp1 
trans-synaptic signaling GO:0099537 15.0 6.4 1.70E-04 Camk2b, Dlg4, Dnm1, Gria2, Grin1, Grin2b, Lgi1, Map1b, Mapt, 
Nrgn, Rab3a, Rims1, Snap25, Sptbn2, Stxbp1 
synaptic transmission GO:0007268 15.0 6.4 1.70E-04 Camk2b, Dlg4, Dnm1, Gria2, Grin1, Grin2b, Lgi1, Map1b, Mapt, 
Nrgn, Rab3a, Rims1, Snap25, Sptbn2, Stxbp1 
vesicle-mediated transport GO:0016192 14.0 6.7 2.70E-04 Dlg4, Dnm1, Gria2, Nsf, Rab3a, Rims1, Sept5, Snap25, Snap91, 
Sptbn2, Stx1b, Stxbp1, Syp, Syt1 
synaptic vesicle cycle GO:0099504 6.0 20.7 4.00E-04 Dnm1, Rab3a, Rims1, Snap25, Sptbn2, Stxbp1 
synaptic vesicle transport GO:0048489 6.0 20.7 4.00E-04 Dnm1, Rab3a, Rims1, Snap25, Sptbn2, Stxbp1 
establishment of  synaptic vesicle localization GO:0097480 6.0 20.7 4.00E-04 Dnm1, Rab3a, Rims1, Snap25, Sptbn2, Stxbp1 
synaptic vesicle localization GO:0097479 6.0 20.0 4.90E-04 Dnm1, Rab3a, Rims1, Snap25, Sptbn2, Stxbp1 
positive regulation of  synaptic transmission GO:0050806 9.0 10.3 5.90E-04 Camk2b, Dlg4, Dnm1, Gria2, Grin1, Grin2b, Lgi1, Nrgn, Rims1 
synaptic vesicle exocytosis GO:0016079 5.0 26.3 7.50E-04 Rab3a, Rims1, Snap25, Sptbn2, Stxbp1 
calcium ion regulated exocytosis GO:0017156 6.0 17.1 1.20E-03 Rab3a, Rims1, Snap25, Sptbn2, Stxbp1, Syt1 
modulation of  synaptic transmission GO:0050804 12.0 6.5 1.80E-03 Camk2b, Dlg4, Dnm1, Gria2, Grin1, Grin2b, Lgi1, Map1b, Mapt, 
Nrgn, Rims1, Stxbp1 
establishment of  vesicle localization GO:0051650 6.0 15.4 2.30E-03 Dnm1, Rab3a, Rims1, Snap25, Sptbn2, Stxbp1 
regulation of  vesicle-mediated transport GO:0060627 9.0 8.6 2.60E-03 Dlg4, Dnm1, Nsf, Rims1, Sept5, Snap91, Stx1b, Stxbp1, Syt1  
cytoskeleton organization GO:0007010 10.0 7.5 3.00E-03 Clasp2, Cnp, Gda, Itpka, Map1a, Map1b, Nefl, Nefm, Pacsin1, Thy1 
vesicle localization GO:0051648 6.0 14.6 3.00E-03 Dnm1, Rab3a, Rims1, Snap25, Sptbn2, Stxbp1 
single-organism cellular localization GO:1902580 11.0 6.7 3.30E-03 Dlg2, Dlg4, Dnm1, Grin2b, Nfasc, Pacsin1, Rab3a, Rims1, Snap25, 
Sptbn2, Stxbp1 
microtubule cytoskeleton organization GO:0000226 5.0 17.2 6.20E-03 Clasp2, Cnp, Gda, Map1a, Map1b 
negative regulation of  microtubule depolymerization GO:0007026 3.0 50.0 6.20E-03 Clasp2, Map1a, Map1b 
regulation of  exocytosis GO:0017157 6.0 12.8 6.40E-03 Nsf, Rims1, Sept5, Stx1b, Stxbp1, Syt1 
regulation of  microtubule polymerization or depolymerization GO:0031110 4.0 25.0 7.30E-03 Clasp2, Gda, Map1a, Map1b 
microtubule polymerization or depolymerization GO:0031109 4.0 23.5 9.40E-03 Clasp2, Gda, Map1a, Map1b 
regulated exocytosis GO:0045055 6.0 11.1 1.30E-02 Rab3a, Rims1, Snap25, Sptbn2, Stxbp1, Syt1 
glutamate receptor signaling pathway GO:0007215 5.0 14.3 1.40E-02 Camk2a, Dlg4, Grin1, Grin2b, Homer1 
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GO term GO ID Nr. proteins % associated proteins p-value Associated proteins 
regulation of  microtubule cytoskeleton organization GO:0070507 4.0 21.1 1.40E-02 Clasp2, Gda, Map1a, Map1b 
negative regulation of  protein complex disassembly GO:0043242 3.0 37.5 1.50E-02 Clasp2, Map1a, Map1b 
negative regulation of  protein depolymerization GO:1901880 3.0 37.5 1.50E-02 Clasp2, Map1a, Map1b 
regulation of  microtubule depolymerization GO:0031114 3.0 37.5 1.50E-02 Clasp2, Map1a, Map1b 
single-organism intracellular transport GO:1902582 12.0 5.2 1.50E-02 Cnp, Crym, Dnm1, Nfasc, Rab3a, Rims1, Slc1a3, Slc8a2, Snap25, 
Sptbn2, Stxbp1, Thy1 
synapse organization GO:0050808 6.0 10.5 1.70E-02 Camk2b, Dlg4, Erc2, Map1b, Shank1, Snap25 
regulation of  microtubule-based process GO:0032886 4.0 20.0 1.70E-02 Clasp2, Gda, Map1a, Map1b 
presynaptic process involved in synaptic transmission GO:0099531 5.0 13.5 1.80E-02 Rab3a, Rims1, Snap25, Sptbn2, Stxbp1 
neurotransmitter secretion GO:0007269 5.0 13.5 1.80E-02 Rab3a, Rims1, Snap25, Sptbn2, Stxbp1 
signal release from synapse GO:0099643 5.0 13.5 1.80E-02 Rab3a, Rims1, Snap25, Sptbn2, Stxbp1 
cell-cell signaling GO:0007267 15.0 4.2 1.90E-02 Camk2b, Dlg4, Dnm1, Gria2, Grin1, Grin2b, Lgi1, Map1b, Mapt, 
Nrgn, Rab3a, Rims1, Snap25, Sptbn2, Stxbp1 
establishment of  organelle localization GO:0051656 6.0 10.2 2.00E-02 Dnm1, Rab3a, Rims1, Snap25, Sptbn2, Stxbp1 
microtubule depolymerization GO:0007019 3.0 33.3 2.10E-02 Clasp2, Map1a, Map1b 
negative regulation of  microtubule polymerization or depolymerization GO:0031111 3.0 33.3 2.10E-02 Clasp2, Map1a, Map1b 
protein localization to synapse GO:0035418 3.0 30.0 2.90E-02 Anks1b, Dlg4, Homer1 
ionotropic glutamate receptor signaling pathway GO:0035235 3.0 30.0 2.90E-02 Camk2a, Grin1, Grin2b 
intracellular transport GO:0046907 12.0 4.8 2.90E-02 Cnp, Crym, Dnm1, Nfasc, Rab3a, Rims1, Slc1a3, Slc8a2, Snap25, 
Sptbn2, Stxbp1, Thy1 
microtubule-based process GO:0007017 5.0 11.6 3.40E-02 Clasp2, Cnp, Gda, Map1a, Map1b 
neuron projection morphogenesis GO:0048812 9.0 5.9 3.50E-02 Camk2b, Dlg4, Itpka, Map1b, Mbp, Pacsin1, Snap25, Snap91, Thy1 
regulation of  protein depolymerization GO:1901879 3.0 27.3 3.70E-02 Clasp2, Map1a, Map1b 
neurotransmitter transport GO:0006836 5.0 11.4 3.70E-02 Rab3a, Rims1, Snap25, Sptbn2, Stxbp1 
regulation of  synaptic vesicle transport GO:1902803 3.0 27.3 3.70E-02 Dnm1, Rims1, Stxbp1 
cell part morphogenesis GO:0032990 9.0 5.8 3.90E-02 Camk2b, Dlg4, Itpka, Map1b, Mbp, Pacsin1, Snap25, Snap91, Thy1 
cell projection morphogenesis GO:0048858 9.0 5.8 3.90E-02 Camk2b, Dlg4, Itpka, Map1b, Mbp, Pacsin1, Snap25, Snap91, Thy1 
regulation of  neurotransmitter levels GO:0001505 5.0 11.1 3.90E-02 Rab3a, Rims1, Snap25, Sptbn2, Stxbp1 
organelle localization GO:0051640 6.0 8.8 3.90E-02 Dnm1, Rab3a, Rims1, Snap25, Sptbn2, Stxbp1 
cytosolic transport GO:0016482 7.0 7.3 4.10E-02 Dnm1, Rab3a, Rims1, Snap25, Sptbn2, Stxbp1, Thy1 
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GO term GO ID Nr. proteins % associated proteins p-value Associated proteins 
regulation of  protein complex disassembly GO:0043244 3.0 25.0 4.50E-02 Clasp2, Map1a, Map1b 
single-organism membrane organization GO:0044802 7.0 7.1 4.50E-02 Cnp, Dlg2, Dlg4, Grin2b, Nfasc, Pacsin1, Syt1 
developmental maturation GO:0021700 4.0 14.8 4.60E-02 Camk2b, Dlg2, Map1b, Shank1 
positive regulation of  exocytosis GO:0045921 4.0 14.8 4.60E-02 Rims1, Sept5, Stxbp1, Syt1 
 
 
Table III.B3 - Cellular component enrichment analysis of the brain specific/enriched BRI3 interactome using ClueGo plugin of the Cytoscape software. Enriched categories are 
identified as those with p-value <0.05. Nr. Number 
GO term GO ID Nr. genes % associated genes p-value Associated genes 
neuron projection GO:0043005 46.00 5.79 2.50E-14 Atp1a3, Atp2b2, Camk2a, Camk2b, Clip2, Cnksr2, Dcx, Dlg2, Dlg4, Dlgap3, Dnm1, Erc2, Gnao1, Gria2, Grin1, 
Grin2b, Homer1, Itpka, Map1b, Map2, Mapt, Nefl, Nefm, Nfasc, Nrgn, Nsf, Pacsin1, Pclo, Prkcg, Rab3a, Sept5, 
Shank1, Shank2, Slc1a2, Slc1a3, Slc8a2, Snap25, Snap91, Srcin1, Stxbp1, Syn1, Syn2, Syp, Syt1, Thy1, Tubb3  
neuron part GO:0097458 49.00 5.31 3.60E-14 Atp1a3, Atp2b2, Bsn, Camk2a, Camk2b, Clip2, Cnksr2, Dcx, Dlg2, Dlg4, Dlgap3, Dnm1, Erc2, Gnao1, Gria2, 
Grin1, Grin2b, Homer1, Itpka, Map1b, Map2, Mapt, Nefl, Nefm, Nfasc, Nrgn, Nsf, Pacsin1, Pclo, Prkcg, Rab3a, 
Rims1, Sept5, Shank1, Shank2, Slc1a2, Slc1a3, Slc8a2, Snap25, Snap91, Sptbn2, Srcin1, Stxbp1, Syn1, Syn2, 
Syp, Syt1, Thy1, Tubb3 
cell projection GO:0042995 48.00 5.08 6.30E-13 Atp1a3, Atp2b2, Camk2a, Camk2b, Clip2, Cnksr2, Cnp, Dcx, Dlg2, Dlg4, Dlgap3, Dnm1, Erc2, Gfap, Gnao1, 
Gria2, Grin1, Grin2b, Homer1, Itpka, Map1b, Map2, Mapt, Nefl, Nefm, Nfasc, Nrgn, Nsf, Pacsin1, Pclo, Prkcg, 
Rab3a, Sept5, Shank1, Shank2, Slc1a2, Slc1a3, Slc8a2, Snap25, Snap91, Srcin1, Stxbp1, Syn1, Syn2, Syp, Syt1, 
Thy1, Tubb3 
presynapse GO:0098793 22.00 11.70 3.10E-11 Bsn, Dnm1, Erc2, Gria2, Grin1, Grin2b, Nsf, Pacsin1, Pclo, Rab3a, Rims1, Sept5, Shank2, Slc1a2, Snap25, 
Snap91, Sptbn2, Stxbp1, Syn1, Syn2, Syp, Syt1 
axon GO:0030424 29.00 7.82 8.70E-11 Atp1a3, Camk2a, Dlg2, Dlg4, Dnm1, Erc2, Gria2, Grin1, Grin2b, Map1b, Mapt, Nefl, Nefm, Nfasc, Nrgn, Nsf, 
Pacsin1, Pclo, Rab3a, Sept5, Snap25, Snap91, Srcin1, Stxbp1, Syn1, Syn2, Syp, Syt1, Tubb3 
postsynapse GO:0098794 22.00 10.53 2.60E-10 Atp1a3, Camk2a, Camk2b, Cnksr2, Dlg4, Dlgap3, Erc2, Gria2, Grin1, Grin2b, Homer1, Itpka, Map1b, Nrgn, Nsf, 
Shank1, Shank2, Slc1a2, Slc1a3, Slc8a2, Snap91, Srcin1 
terminal bouton GO:0043195 16.00 16.00 5.80E-10 Erc2, Gria2, Grin1, Grin2b, Nsf, Pacsin1, Pclo, Rab3a, Sept5, Snap25, Snap91, Stxbp1, Syn1, Syn2, Syp, Syt1  
dendrite GO:0030425 26.00 6.37 1.70E-07 Atp1a3, Atp2b2, Camk2a, Camk2b, Clip2, Dcx, Dlg2, Dlg4, Dlgap3, Gria2, Grin1, Grin2b, Homer1, Itpka, 
Map1b, Map2, Nrgn, Nsf, Pclo, Prkcg, Shank1, Slc1a2, Slc1a3, Slc8a2, Srcin1, Syn1  
somatodendritic compartment GO:0036477 32.00 5.20 2.00E-07 Atp1a3, Atp2b2, Bsn, Camk2a, Camk2b, Clip2, Cnksr2, Dcx, Dlg2, Dlg4, Dlgap3, Erc2, Gria2, Grin1, Grin2b, 
Homer1, Itpka, Map1b, Map2, Nefm, Nrgn, Nsf, Pclo, Prkcg, Shank1, Shank2, Slc1a2, Slc1a3, Slc8a2, Snap25, 
Srcin1, Syn1 
axon terminus GO:0043679 16.00 9.82 9.20E-07 Erc2, Gria2, Grin1, Grin2b, Nsf, Pacsin1, Pclo, Rab3a, Sept5, Snap25, Snap91, Stxbp1, Syn1, Syn2, Syp, Syt1  
transport vesicle GO:0030133 13.00 12.38 1.40E-06 Dnm1, Gria2, Nrgn, Pclo, Rab3a, Sept5, Snap91, Sptbn2, Stx1b, Syn1, Syn2, Syp, Syt1  
postsynaptic specialization GO:0099572 14.00 11.11 1.50E-06 Camk2a, Camk2b, Dlg4, Erc2, Gria2, Grin1, Grin2b, Homer1, Map1b, Nrgn, Nsf, Shank2, Snap91, Srcin1  
postsynaptic density GO:0014069 14.00 11.11 1.50E-06 Camk2a, Camk2b, Dlg4, Erc2, Gria2, Grin1, Grin2b, Homer1, Map1b, Nrgn, Nsf, Shank2, Snap91, Srcin1 
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GO term GO ID Nr. genes % associated genes p-value Associated genes 
synaptic vesicle GO:0008021 10.00 12.20 7.10E-05 Dnm1, Gria2, Rab3a, Sept5, Snap91, Sptbn2, Syn1, Syn2, Syp, Syt1  
dendritic spine GO:0043197 11.00 10.58 8.50E-05 Atp1a3, Dlgap3, Gria2, Grin1, Grin2b, Itpka, Nrgn, Shank1, Slc1a2, Slc1a3, Slc8a2  
neuron spine GO:0044309 11.00 10.58 8.50E-05 Atp1a3, Dlgap3, Gria2, Grin1, Grin2b, Itpka, Nrgn, Shank1, Slc1a2, Slc1a3, Slc8a2  
exocytic vesicle GO:0070382 10.00 11.76 9.50E-05 Dnm1, Gria2, Rab3a, Sept5, Snap91, Sptbn2, Syn1, Syn2, Syp, Syt1  
presynaptic active zone GO:0048786 5.00 29.41 3.70E-04 Bsn, Pclo, Shank2, Syn1, Syp 
myelin sheath GO:0043209 6.00 17.14 1.10E-03 Atp1a3, Cnp, Gnao1, Mbp, Mog, P lp1 
presynaptic membrane GO:0042734 6.00 17.14 1.10E-03 Erc2, Gria2, Grin2b, Rims1, Slc1a2, Snap91 
NMDA selective glutamate receptor 
complex 
GO:0017146 4.00 36.36 1.10E-03 Dlgap3, Grin1, Grin2b, Shank1 
synaptic membrane GO:0097060 9.00 9.47 1.60E-03 Cnksr2, Dlg4, Erc2, Gria2, Grin2b, Rims1, Shank1, Slc1a2, Snap91  
cytoskeleton GO:0005856 13.00 6.22 2.80E-03 Bsn, Clasp2, Clip2, Map1a, Map1b, Mapt, Nefl, Nefm, Pclo, Sept5, Slc8a2, Snap25, Srcin1  
ionotropic glutamate receptor complex GO:0008328 5.00 19.23 2.90E-03 Dlgap3, Gria2, Grin1, Grin2b, Shank1 
growth cone GO:0030426 9.00 8.11 5.10E-03 Erc2, Gria2, Map1b, Mapt, Nefl, Pclo, Shank2, Snap25, Thy1 
transmembrane transporter complex GO:1902495 9.00 7.96 5.50E-03 Atp1a3, Dlg2, Dlg4, Dlgap3, Gria2, Grin1, Grin2b, Shank1, Snap25 
neuronal cell body GO:0043025 20.00 4.22 8.60E-03 Atp2b2, Bsn, Camk2a, Camk2b, Cnksr2, Dlg2, Dlgap3, Erc2, Gria2, Grin1, Homer1, Map1b, Map2, Nefm, Nrgn, 
Pclo, Shank2, Slc8a2, Snap25, Srcin1 
ion channel complex GO:0034702 8.00 8.00 1.10E-02 Dlg2, Dlg4, Dlgap3, Gria2, Grin1, Grin2b, Shank1, Snap25 
membrane-bounded vesicle GO:0031988 14.00 4.62 2.40E-02 Clip2, Dnm1, Gria2, Nrgn, Pclo, Rab3a, Sept5, Snap91, Sptbn2, Stx1b, Syn1, Syn2, Syp, Syt1  
plasma membrane protein complex GO:0098797 9.00 6.25 2.60E-02 Atp1a3, Dlg2, Dlg4, Dlgap3, Gria2, Grin1, Grin2b, Shank1, Snap25 
secretory vesicle GO:0099503 11.00 5.14 3.30E-02 Clip2, Dnm1, Gria2, Rab3a, Sept5, Snap91, Sptbn2, Syn1, Syn2, Syp, Syt1  
integral component of  plasma 
membrane 
GO:0005887 9.00 5.81 3.60E-02 Atp1a3, Dlg2, Dlg4, Dlgap3, Gria2, Grin1, Grin2b, Shank1, Snap25 
polymeric cytoskeletal f iber GO:0099513 6.00 8.22 3.70E-02 Clasp2, Clip2, Mapt, Nefl, Nefm, Slc8a2 
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Further, using the Cytoscape software, we constructed a PPI network (see materials and methods 
section). This approach allows to infer other proteins that may be involved in BRI3 interactome by 
deciphering their relationships and potential functional protein complexes. BRI3 PPI network is 
presented in Figure 3, summing up previously known and experimentally evidenced interactions. 
Further, in the network the grey nodes correspond to PPI added by the Cytoscape analysis, the 
colorful nodes to the proteins identified in our study and the node size correspond to its degree (k; 
the number of edges linked to it) (Figure III.B.3). This network consists of 244 nodes, including 
BRI3, and 543 interactions (Figure III.B.3).  The average connectivity, i.e. the average number of 
neighbors of a node in the network, is 4.451, and the mean clustering coefficient is 0.083. The mean 
clustering coefficient of the network which characterizes how nearest neighboring nodes of a node 
are connected to each other is about 4 times larger than the clustering coefficient expected for a 
sparse random uncorrelated network (0.02) (Doncheva et al. 2012; Newman 2006). Moreover, the 
results from topological network analysis showed that besides BRI3 which accounted for 92 
interactions, TUBB3 (k =38), TUBB2A (k =28), CRMP1 (k =20), NSF (k =16), MAPT (k =15), 
CAMK2A (k =15), and MAP1B (k =14) were the most connected hub proteins in the network (Figure 
III.B.3).  
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Figure III.B 3- BRI3 brain ES sub-network. Node colors represent the source: blue nodes correspond to proteins 
identified in this study in the cerebral cortex, orange nodes correspond to proteins identified in this study in the 
hippocampus, green nodes correspond to proteins identified in this study in the striatum, and grey nodes are proteins added 
by network annotation. Node size according to the degree in the network. Edge color represents the source of interaction: 
light red edges correspond to connections between proteins identified in this study, purple edges correspond to connections 
between proteins that was manually added to the network (correspond to interactions already described in the literature but 
not identified in the iMEX consortium databases), and grey edges correspond to connections between proteins added by 
network annotation.  
 
Further, integrated metabolic KEGG pathway analysis, using the ClueGo plugin of the Cytoscape 
software (Bindea et al. 2009), was performed to identify the pathways that BRI3 brain ES network 
is involved in. The results shown that the network is mainly involved in the ErbB signaling pathway, 
SNARE interaction in vesicular transport, neurotrophin signaling pathway, MAPK signaling 
pathway, glutamatergic synapse, synaptic vesicle cycle, estrogen signaling pathway, dopaminergic 
synapse, oxytocin signaling pathway and long-term potentiation were the most represented pathways 
(Table III.B.4). Of note, signaling pathways related to gap junction, focal adhesion, adherens 
junction, and apoptosis were also evidenced (Table III.B.4). 
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Table III.B 4- KEGG categories enrichment analysis of the brain specific/enriched BRI3 interactome using ClueGo plugin of the Cytoscape software. Enriched categories are 
identified as those with p-value <0.05. Nr., number. 
KEGG Term KEGG ID Nr. Genes % Associated Genes 
pValue Associated Genes Found 
ErbB signaling pathway KEGG:04012 17 19.32 3.37E-11 ABL1, AKT1, CAMK2A, CAMK2B, CDKN1A, CRK, EGFR, ERBB4, GRB2, 
GSK3B, JUN, MYC, NCK1, PIK3R1, PLCG1, PRKCG, SRC 
Proteoglycans in cancer KEGG:05205 21 10.24 1.58E-08 AKT1, CAMK2A, CAMK2B, CDKN1A, EGFR, ERBB4, FASLG, FLNA, GRB2, 
IQGAP1, MDM2, MYC, PIK3R1, PLCG1, PPP1CA, PPP1CB, PRKACB, PRKCG, 
SMAD2, SRC, TP53 
SNARE interactions in vesicular transport KEGG:04130 10 29.41 3.82E-08 BET1, SNAP23, SNAP29, STX11, STX19, STX1A, STX1B, STX4, STX5, STX6 
Epstein-Barr virus infection KEGG:05169 20 9.80 9.84E-08 AKT1, CDKN1A, GSK3B, IKBKG, JUN, MDM2, MYC, NFKB1, PIK3R1, PLCG1, 
PRKACB, PSMD11, PSMD2, SNW1, TP53, TRAF6, VIM, YWHAH, YWHAQ, 
YWHAZ 
Amphetamine addiction KEGG:05031 12 17.65 3.71E-07 CAMK2A, CAMK2B, FOS, GRIA2, GRIN1, GRIN2B, JUN, PPP1CA, PPP1CB, 
PRKACB, PRKCG, STX1A 
Neurotrophin signaling pathway KEGG:04722 15 12.40 5.97E-07 ABL1, AKT1, CAMK2A, CAMK2B, CRK, FASLG, GRB2, GSK3B, JUN, 
MAP3K3, NFKB1, PIK3R1, PLCG1, TP53, TRAF6 
Hepatitis B  KEGG:05161 16 10.96 1.09E-06 AKT1, CDKN1A, FASLG, FOS, GRB2, IKBKG, JUN, MYC, NFKB1, PIK3R1, 
PRKCG, SRC, STAT1, TP53, YWHAQ, YWHAZ 
Pathways in cancer KEGG:05200 26 6.55 1.45E-06 ABL1, AKT1, BID, CDKN1A, CRK, EGFR, FASLG, FOS, GRB2, GSK3B, 
HSP90AA1, HSP90AB1, IKBKG, JUN, MAX, MDM2, MYC, NFKB1, PIK3R1, 
PLCG1, PRKACB, PRKCG, SMAD2, STAT1, TP53, TRAF6 
Glioma KEGG:05214 11 16.67 3.13E-06 AKT1, CAMK2A, CAMK2B, CDKN1A, EGFR, GRB2, MDM2, PIK3R1, PLCG1, 
PRKCG, TP53 
MAPK signaling pathway KEGG:04010 20 7.84 4.47E-06 AKT1, ARRB1, ARRB2, CRK, EGFR, FASLG, FLNA, FOS, GRB2, IKBKG, JUN, 
MAP3K3, MAPT, MAX, MYC, NFKB1, PRKACB, PRKCG, TP53, TRAF6 
Pathogenic Escherichia coli infection KEGG:05130 10 18.18 5.70E-06 ABL1, FYN, NCK1, TUBA1A, TUBA8, TUBB2A, TUBB2B, TUBB3, YWHAQ, 
YWHAZ 
Prostate cancer KEGG:05215 12 13.48 8.15E-06 AKT1, CDKN1A, EGFR, GRB2, GSK3B, HSP90AA1, HSP90AB1, IKBKG, 
MDM2, NFKB1, PIK3R1, TP53 
Chronic myeloid leukemia KEGG:05220 11 15.07 8.97E-06 ABL1, AKT1, CDKN1A, CRK, GRB2, IKBKG, MDM2, MYC, NFKB1, PIK3R1, 
TP53 
Glutamatergic synapse KEGG:04724 13 11.40 1.70E-05 DLG4, DLGAP1, GNAO1, GRIA2, GRIN1, GRIN2B, HOMER1, PRKACB, 
PRKCG, SHANK1, SHANK2, SLC1A2, SLC1A3 
Synaptic vesicle cycle KEGG:04721 10 15.87 2.12E-05 DNM1, DNM2, NSF, RAB3A, RIMS1, SNAP25, STX1A, STX1B, STXBP1, SYT1 
Estrogen signaling pathway KEGG:04915 12 12.00 2.92E-05 AKT1, EGFR, ESR2, FOS, GNAO1, GRB2, HSP90AA1, HSP90AB1, JUN, PIK3R1, 
PRKACB, SRC 
Amyotrophic lateral sclerosis (ALS) KEGG:05014 9 17.65 3.39E-05 BID, GRIA2, GRIN1, GRIN2B, NEFL, NEFM, SLC1A2, TNFRSF1B, TP53 
T cell receptor signaling pathway KEGG:04660 12 11.43 4.92E-05 AKT1, FOS, FYN, GRB2, GSK3B, IKBKG, JUN, NCK1, NFKB1, PIK3R1, PLCG1, 
PTPRC 
Dopaminergic synapse KEGG:04728 13 10.00 7.60E-05 AKT1, ARRB2, CAMK2A, CAMK2B, FOS, GNAO1, GRIA2, GRIN2B, GSK3B, 
PPP1CA, PPP1CB, PRKACB, PRKCG 
Oxytocin signaling pathway KEGG:04921 14 8.81 1.31E-04 CAMK2A, CAMK2B, CDKN1A, EGFR, FOS, GNAO1, JUN, PIK3R1, PPP1CA, 
PPP1CB, PRKACB, PRKCG, RGS2, SRC 
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Thyroid hormone signaling pathway KEGG:04919 12 10.17 1.70E-04 AKT1, ATP1A3, GSK3B, MDM2, MYC, PIK3R1, PLCG1, PRKACB, PRKCG, 
SRC, STAT1, TP53 
Long-term potentiation KEGG:04720 9 13.43 3.52E-04 CAMK2A, CAMK2B, GRIA2, GRIN1, GRIN2B, PPP1CA, PPP1CB, PRKACB, 
PRKCG 
cAMP signaling pathway KEGG:04024 15 7.50 3.97E-04 AKT1, ATP1A3, ATP2B2, CAMK2A, CAMK2B, FOS, GRIA2, GRIN1, GRIN2B, 
JUN, NFKB1, PIK3R1, PPP1CA, PPP1CB, PRKACB 
Gap junction KEGG:04540 10 11.36 4.61E-04 EGFR, GRB2, PRKACB, PRKCG, SRC, TUBA1A, TUBA8, TUBB2A, TUBB2B, 
TUBB3 
Prolactin signaling pathway KEGG:04917 9 12.50 6.23E-04 AKT1, ESR2, FOS, GRB2, GSK3B, NFKB1, PIK3R1, SRC, STAT1 
FoxO signaling pathway KEGG:04068 12 8.96 6.26E-04 AGAP2, AKT1, CDKN1A, EGFR, FASLG, GABARAP, GABARAPL2, GRB2, 
HOMER1, MDM2, PIK3R1, SMAD2 
Circadian entrainment KEGG:04713 10 10.42 9.84E-04 CAMK2A, CAMK2B, FOS, GNAO1, GRIA2, GRIN1, GRIN2B, MTNR1A, 
PRKACB, PRKCG 
Colorectal cancer KEGG:05210 8 12.90 1.60E-03 AKT1, FOS, GSK3B, JUN, MYC, PIK3R1, SMAD2, TP53 
Chagas disease (American trypanosomiasis) KEGG:05142 10 9.62 1.97E-03 AKT1, FASLG, FOS, GNAO1, IKBKG, JUN, NFKB1, PIK3R1, SMAD2, TRAF6 
Viral carcinogenesis KEGG:05203 14 6.83 2.29E-03 CDKN1A, GRB2, IKBKG, JUN, MDM2, NFKB1, PIK3R1, PRKACB, SNW1, SRC, 
TP53, YWHAH, YWHAQ, YWHAZ 
Pancreatic cancer KEGG:05212 8 12.12 2.47E-03 AKT1, EGFR, IKBKG, NFKB1, PIK3R1, SMAD2, STAT1, TP53 
Cocaine addiction KEGG:05030 7 14.29 2.67E-03 DLG4, GRIA2, GRIN1, GRIN2B, JUN, NFKB1, PRKACB 
Osteoclast dif ferentiation KEGG:04380 11 8.33 2.80E-03 AKT1, FOS, FYN, GRB2, IKBKG, JUN, NFKB1, PIK3R1, SQSTM1, STAT1, 
TRAF6 
Hepatitis C KEGG:05160 11 8.27 2.97E-03 AKT1, CDKN1A, EGFR, GRB2, GSK3B, IKBKG, NFKB1, PIK3R1, STAT1, TP53, 
TRAF6 
Endometrial cancer KEGG:05213 7 13.46 3.84E-03 AKT1, EGFR, GRB2, GSK3B, MYC, PIK3R1, TP53 
Apoptosis KEGG:04210 11 7.86 4.67E-03 AKT1, BID, FASLG, FOS, IKBKG, JUN, NFKB1, PIK3R1, TP53, TUBA1A, 
TUBA8 
PI3K-Akt signaling pathway KEGG:04151 18 5.28 4.69E-03 AKT1, CDC37, CDKN1A, EGFR, FASLG, GRB2, GSK3B, HSP90AA1, 
HSP90AB1, IKBKG, MDM2, MYC, NFKB1, PIK3R1, TP53, YWHAH, YWHAQ, 
YWHAZ 
B cell receptor signaling pathway KEGG:04662 8 10.96 4.79E-03 AKT1, FOS, GRB2, GSK3B, IKBKG, JUN, NFKB1, PIK3R1 
Non-small cell lung cancer KEGG:05223 7 12.50 5.97E-03 AKT1, EGFR, GRB2, PIK3R1, PLCG1, PRKCG, TP53 
Breast cancer KEGG:05224 11 7.53 6.54E-03 AKT1, CDKN1A, EGFR, ESR2, FOS, GRB2, GSK3B, JUN, MYC, PIK3R1, TP53  
Inf lammatory mediator regulation of TRP channels  KEGG:04750 9 9.09 6.99E-03 CAMK2A, CAMK2B, PIK3R1, PLCG1, PPP1CA, PPP1CB, PRKACB, PRKCG, 
SRC 
Cell cycle KEGG:04110 10 8.06 7.62E-03 ABL1, CDKN1A, GSK3B, MDM2, MYC, SMAD2, TP53, YWHAH, YWHAQ, 
YWHAZ 
Bladder cancer KEGG:05219 6 14.63 7.65E-03 CDKN1A, EGFR, MDM2, MYC, SRC, TP53 
Focal adhesion KEGG:04510 13 6.40 7.66E-03 AKT1, CRK, EGFR, FLNA, FYN, GRB2, GSK3B, JUN, PIK3R1, PPP1CA, 
PPP1CB, PRKCG, SRC 
HIF-1 signaling pathway KEGG:04066 9 8.74 9.05E-03 AKT1, CAMK2A, CAMK2B, CDKN1A, EGFR, NFKB1, PIK3R1, PLCG1, PRKCG 
Hippo signaling pathway KEGG:04390 11 7.14 9.80E-03 DLG2, DLG3, DLG4, GSK3B, MYC, PPP1CA, PPP1CB, SMAD2, YWHAH, 
YWHAQ, YWHAZ 
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Insulin secretion KEGG:04911 8 9.41 1.27E-02 ATP1A3, CAMK2A, CAMK2B, PRKACB, PRKCG, RAB3A, SNAP25, STX1A 
Chemokine signaling pathway KEGG:04062 12 6.42 1.30E-02 AKT1, ARRB1, ARRB2, CRK, GRB2, GSK3B, IKBKG, NFKB1, PIK3R1, 
PRKACB, SRC, STAT1 
Small cell lung cancer KEGG:05222 8 9.30 1.34E-02 AKT1, IKBKG, MAX, MYC, NFKB1, PIK3R1, TP53, TRAF6 
Cholinergic synapse KEGG:04725 9 8.11 1.50E-02 AKT1, CAMK2A, CAMK2B, FOS, FYN, GNAO1, PIK3R1, PRKACB, PRKCG 
GnRH signaling pathway KEGG:04912 8 8.70 2.08E-02 CAMK2A, CAMK2B, EGFR, GRB2, JUN, MAP3K3, PRKACB, SRC 
Ras signaling pathway KEGG:04014 13 5.68 2.23E-02 ABL1, AKT1, EGFR, FASLG, GRB2, GRIN1, GRIN2B, IKBKG, NFKB1, PIK3R1, 
PLCG1, PRKACB, PRKCG 
Adherens junction KEGG:04520 7 9.46 2.92E-02 EGFR, FYN, IQGAP1, PTPRB, PTPRJ, SMAD2, SRC 
Choline metabolism in cancer KEGG:05231 8 7.92 3.77E-02 AKT1, EGFR, FOS, GRB2, JUN, PIK3R1, PLCG1, PRKCG 
Acute myeloid leukemia KEGG:05221 6 10.53 4.16E-02 AKT1, GRB2, IKBKG, MYC, NFKB1, PIK3R1 
Herpes simplex infection KEGG:05168 11 5.95 4.18E-02 EEF1D, FASLG, FOS, IKBKG, JUN, NFKB1, PPP1CA, PPP1CB, STAT1, TP53, 
TRAF6 
Toll-like receptor signaling pathway KEGG:04620 8 7.55 4.97E-02 AKT1, FOS, IKBKG, JUN, NFKB1, PIK3R1, STAT1, TRAF6 
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III.B.3.2 BRI3 brain region specific interactome 
The analysis of interactome from the different brain regions may reveal possible differences that 
could provide insight into selective brain region-dependent processes, and thus here we attempt to 
identify specific BRI3 interactors from three different rat brain region: cortex, hippocampus, and 
striatum. Comparative analysis of all of the candidate BRI3 interactors identified in our study (Figure 
III.B.4) indicates that 45 proteins were specifically identified in the cortex, 72 in the hippocampus 
and 44 in the striatum (Figure III.B.4A). Moreover, tissue-expression analysis of those proteins 
resulted in the identification of 14 BRI3 interactors brain enriched/specific in the cortex, 22 in the 
hippocampus, and 10 in the striatum (Figure III.B.4B).  
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Figure III.B 4 - Brain region specific protein interactions in the BRI3 interactome. A- Venn diagram comparison of 
the brain region (cerebral cortex, hippocampus and striatum) specific BRI3 protein interactions identified in this study. B- 
BRI3 interactome identified in this study. Node size according to the degree in the network. Node color represents the 
source of interaction: blue nodes correspond to the BRI3 interactors identified in the cerebral cortex, green nodes 
correspond to the BRI3 interactors identified in the hippocampus, and light red nodes correspond to the BRI3 interactors 
identified in the striatum. Nodes with red border correspond to BRI3 interactors highly enriched or brain specific. CX, 
cerebral cortex; HP, hippocampus; ST, striatum. 
 
Further, network augmentation was performed for the brain enriched/specific BRI3 candidate 
interactors specific for each brain tissue (Supplementary Figure III.B.S1). This approach was 
performed in order to increase our PPI network and enhance our experimental data with additional 
known and experimentally validated protein partners which then allow us to asses if the BRI3 
interactome could be assigned to selective brain regional-dependent pathways. For the cortex, 
specific PPI network (Supplementary Figure III.B.S1A) were mapped a total of 141 proteins with 
146 connections between them. Moreover, the network presented an average number of neighbors 
of 2.071. The hippocampus specific PPI network possessed 127 proteins connected with 141 edges, 
and an average number of neighbors of 2.169 (Supplementary Figure III.B.S1B). Striatum specific 
PPI network resulted in the mapping of 106 proteins connected by 106 edges and presented an 
average number of neighbors of 2.019 (Supplementary Figure III.B.S1C). Cluster comparison 
functional analysis regarding KEGG pathways was performed using the ClueGO plugin from 
Cytoscape between the cortex, hippocampus, and striatum-specific PPI networks (Supplementary 
Table III.B.S4). Noticeably, the analysis revealed that the majority of pathways are in fact common 
between the three specific BRI3 interactomes, and essentially corresponds to pathways already 
highlighted in the analysis of the total BRI3 brain ES interactome: ErbB signaling pathway, 
neurotrophin signaling pathway, dopaminergic synapse, estrogen signaling pathway, long-term 
potentiation, adherens junction, and focal adhesion (Supplementary Table III.B.S4). Nevertheless, 
some pathways seem to be more associated to the cortex specific PPI network: SNARE interactions 
in vesicular transport, and synaptic vesicle cycle (Supplementary Table III.B.S4). 
 
III.B.3.3 Evidence for BRI3 association with nervous system diseases  
Additionally, the significance of BRI3 interactome can be supported by its involvement with human 
nervous system diseases. Therefore, to address this issue DisGeNET database was used (see materials 
and methods section) and a list of all genes that are together with BRI3 are associated with brain 
disease, which was further crossed with the list of BRI3 interactors was identified. This analysis 
resulted in a list of 73 BRI3 protein interactors and its associated diseases which was further 
represented as a network (Figure III.B.5). In fact, almost 30% (73 out of 274 proteins) of the 
identified BRI3 interactors share diseases with BRI3, suggesting a complex functional connection 
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between the proteins. The disease associated with the highest number of BRI3 protein interactors 
was Alzheimer s´ Disease (AD; linked to 64 BRI3 interactors) (Figure III.B.5). Other diseases 
included Cerebrovascular Accident, Cerebral Hemorrhage, Subarachnoid Hemorrhage, Intracranial 
Hemorrhage and Neuritis (Figure III.B.5). 
 
 
Figure III.B 5 - Diseases network shared by BRI3 and its identified protein interactors. The complete list of diseases 
shared by BRI3 and other genes was retrieved from the DisGeNET database. The identified BRI3 protein interactors were 
searched in the obtained list, to create a network of diseases shared between them. Diseases are represented in red circular 
nodes. Proteins are identified by their gene names represented in blue circular nodes. Network nodes are configured by size 
accordingly to node degree (low values to small sizes).  
 
.
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III.B.4 Discussion 
BRI3 is a brain-enriched protein whose biological function remains elusive. In the present study, we 
focused on the identification and BRI3 interacting proteins in the brain and its characterization in 
order to further understand the biological roles of BRI3. Hence, BRI3 was co-IPed from three rat 
brain regions (cerebral cortex, hippocampus, and striatum). In total, we were able to identify 274 
proteins as potential BRI3 interactors, from which two were already described in the literature: APP 
and PSD-95. Remarkably, 89 out of the 274 proteins were found to be specific or strongly expressed 
in the brain. Based on the bioinformatic analysis, the BRI3 candidate interactors were found to be 
involved in a variety of biological processes relevant to CNS development and function and could 
form a complex interaction network. Protein class analysis allows us to conclude that BRI3 mainly 
interacts with cytoskeletal proteins, transporters, and membrane traffic proteins (Figure 2). 
Moreover, the cellular component annotation analysis of the BRI3 ES brain interactors suggested a 
subcellular localization for BRI3 in neuron projections, at synapses, both presynapse and 
postsynapse, and associated with synaptic vesicles and cytoskeleton (Table 3), which in turn suggests 
a role for BRI3 at the nerve terminals. 
Several proteins here identified to be associated with BRI3 protein, participate in the synaptic vesicle 
cycle, namely in synaptic vesicle transport and exocytosis (Table 2 and Table 4) which implies a role 
for BRI3 in synaptic vesicle function. Among the BRI3 interacting protein candidates, we identified 
several key proteins for synaptic vesicle fusion, namely the synaptosomal-associated protein 25 
(Snap-25), syntaxin-1b (Stx1b), Vesicle-fusing ATPase (NSF), the SNARE complex protein Vamp2 
(Vesicle-associated membrane protein 2) and Rab3 (Rab3a, Rab3b, Rab3c) (Jahn and Fasshauer 
2012; Augustine et al. 1999). Moreover, we identified proteins involved in the endocytosis of 
synaptic vesicles from the membrane, including Dynamin-1 (Dnm1) and Endophilin-A1 (Sh3gl2) 
(Saheki and De Camilli 2012). Other synaptic vesicle-associated proteins such as synaptotagmin 1 
(Syt1), and synapsin-1 and -2 (Syn1 and Syn2) were also identified.  
The present work also resulted in the identification of cytoplasmic kinesin motor proteins Kif1c and 
Kif2a, members of the AP-1 and AP-2 complex (Ap1b1, Ap2a2, Ap2b1, Ap2m1) and Arf GAP with 
GTPAse domain, Ankyrin repeat and PH domain 2 protein (Agap2), myosin subunits (Myl3, Myl6, 
Myl9, Myh6, Myh9, Myh10) as well as other proteins involved in vesicle trafficking, such as 
clathrins (Clta, Cltc) and its adaptor protein Snap91. All these proteins are involved in neuronal 
trafficking along the cytoskeleton, a key process in the formation and dynamics of synapses (Maeder 
et al. 2014; Lasiecka and Winckler 2011). Hence, the association of the BRI3 protein with these 
novel potential interactors suggest either a role for BRI3 in axonal and dendritic trafficking or that 
the proper BRI3 protein is transported within axons and dendrites to the nerve terminals where it 
might be functionally required. In fact, the results here presented suggest that BRI3 is expressed both 
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pre- and post-synaptically (Table 3) which strongly suggest a role for BRI3 at the synapse, namely 
in synapse formation. For instance, BRI3 may contribute to the adhesion of synapses, in a process 
involving trans-synaptic interactions between pre- and postsynaptic BRI3. Additionally, given the 
biological functions attributed to the identified BRI3 brain ES interactors (Table 2) it is also plausible 
to assume that the synapse, BRI3 might be directly involved in synaptic signaling and transmission. 
In fact, we identified several proteins in the BRI3 interactome known to be involved in synaptic 
transmission, namely the calcium/calmodulin-dependent protein kinase type II subunit beta 
(Camk2b), Dlg4 (PSD-95), glutamate receptor 2 (Gria2/ GluR2), glutamate receptor ionotropic, 
NMDA 1 (Grin1/NMDAR1), glutamate receptor ionotropic, NMDA 2B (Grin2b/NMDAR2B). 
Remarkably, it is already described for APP, a well-established BRI3 interactor, a role in excitatory 
synaptic transmission by altering AMPA receptor (AMPAR) and NMDA (NMDAR) receptor 
trafficking. For example, APP is able to increase the cell surface levels of the GluR2 subunit of 
AMPARs which potentially enhance excitatory synaptic transmission (Spires et al. 2005; Isaac et al. 
2007). APP also facilitates NMDAR function by increasing cell surface levels of NMDAR1 and 
NMDAR2B subunits (Hoe et al. 2009). However, several evidences suggest a relationship between 
Aβ (a peptide derived from sequential cleavage of APP by β- and γ-secretase) accumulation and 
synaptic dysfunction. Actually, in cultured neurons it was demonstrated that Aβ: (1) leads to decrease 
in PSD-95, a protein involved in recruiting and anchoring glutamate receptor subunits to the post-
synaptic density, and also reduction in surface expression of glutamate receptor subunit GluR1 
(Almeida et al. 2005); (2) promotes endocytosis of NMDA receptors (Snyder et al. 2005). Hence, 
given the nature of BRI3:APP interaction (Matsuda et al. 2009) (BRI3 is a negative regulator of Aβ 
production) it is possible to hypothesize a role for BRI3 in synaptic transmission and plasticity, 
namely in the regulation of the AMPARs and NMDARs receptors trafficking.  
Of note, a high number of proteins of BRI3 brain interactome are cytoskeletal and cytoskeletal 
binding proteins involved in its organization, namely tubulin [tubulin beta-3 chain (Tubb3), tubulin 
beta-2A chain (Tubb2a)], microtubule-associated protein 1b (Map1b), microtubule-associated 
protein tau (Mapt), doublecortin (Dcx), collapsing response mediator protein-2 (Crmp2), CLIP-
associating protein 2 (Clasp2), cofilin-1 (Cfl1), F-actin-capping protein Capz [subunit alpha-2 
(Capza2), subunit beta (Capzb)], and spectrin beta chain (Sptbn2), which translated into an 
overrepresentation of functions like cytoskeleton organization, regulation of microtubule 
polymerization and depolymerization in the BRI3 interactome. Remarkably, the establishment and 
maintenance of neuronal polarity is coordinated by rearrangements of the cytoskeletal architecture 
and depends on the ability of the growth cone to sense extracellular guidance cues (Mattson 1999; 
Tahirovic and Bradke 2009). This fact together with the suggested localization of BRI3 in neuron 
projections and neuronal growth cones (Table 3) is consistent with a BRI3 role in neurite outgrowth, 
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as previously proposed (Gong et al. 2008), by mediating cytoskeleton stability. In concordance with 
this, BRI3 brain ES interactome was strongly associated with signaling pathways with well-
established roles in CNS development and function, namely in several neuronal differentiation 
related events: neurotrophin signaling pathway (Reichardt 2006), ErbB signaling pathway (Iwakura 
and Nawa 2013; Mei and Nave 2014), estrogen signaling pathway (Wang et al. 2003) and MAPK 
signaling pathway (Perron and Bixby 1999; Takeda and Ichijo 2002). Therefore, an association of 
BRI3 with these signaling pathways deserve further investigations. 
Moreover, a comparative analysis of the BRI3 interactome in the three brain regions evidenced that 
14 brain ES proteins were identified specifically in the cortex, 22 in the hippocampus, and 10 in the 
striatum (Figure 5).  Of note, no particular event seems to be exclusively associated a particular brain 
region which supports the sight that the majority of the proteins of the BRI3 interactome are in fact 
relatively stable across the three brain regions.  
Limitations of the present study include the possibility of poor recovery of the membrane and nuclear 
proteins and the lack of detection of proteins which interact only transiently with BRI3 interactome. 
Remarkably, although the BRI3 interactors here identified does not present higher overlap with the 
other previously reported in the literature (2 out of 274), many were functionally related. In fact, 
some genes encoding BRI3 protein interactors here identified are closely interconnected with BRI3 
gene with respect to diseases in each they were found associated (Fig. 3). Interestingly, BRI3 
interactome seems to be strongly associated with AD. Strong evidences suggest imbalanced activities 
of protein kinases and phosphatases (including PP1) in AD thus affecting the phosphorylation state 
of AD-related proteins, such as APP and tau (Oliveira et al. 2015). Recently, we have shown that 
BRI3 is, in fact, a phosphoprotein that can be dephosphorylated by PP1 (Martins et al. 2016). 
However, the relevance and impact of protein phosphorylation in its biology was not elucidated. 
Given the described influence of BRI3 on Aβ production, further studies should investigate its 
function/dysfunction in AD, namely its phosphorylation state, which may provide novel and 
important insights on the pathology mechanisms.  
In conclusion, several novel BRI3 candidate interacting proteins were identified and the 
bioinformatic study of its characteristics revealed a strong association of BRI3 with proteins related 
to several related synaptic functions (synaptic vesicle cycle, synapse formation, synaptic signaling, 
and transmission), neuronal trafficking and neuronal differentiation. Therefore, the findings suggest 
that further studies of BRI3 should address these potential roles and the underlying mechanism, as 
well as its association with nervous system pathologies. 
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Figure III.B.S  1 - BRI3 ES-based region specific sub-networks for the cerebral cortex (A), hippocampus (B) and 
striatum (C). Diamond nodes represent the proteins identified in this study. Node colors are represented according to the 
betweenness-centrality, in which green corresponds to higher betweenness-centrality and red to lower betweenness-
centrality. Node size according to the degree in the network. Edge color represent the source of interaction: blue edges 
correspond to connections between proteins identified in this study in the cortex, and grey edges correspond to connections 
between proteins added by network annotation. 
  
Table III.B.S  1- Novel BRI3 interacting protein candidates. Uniprot accession numbers, gene and protein names, are 
listed, as well as the rat brain tissues in where the proteins were found. CX, cortex; HP, hippocampus; ST, striatum. 
Uniprot 
accession Gene name  Protein name 
 
Brain regions 
 
P26772 Hspe1 10 kDa heat shock protein, mitochondrial  HP 
P68255 Ywhaq 14-3-3 protein theta  CX 
P63102 Ywhaz 14-3-3 protein zeta/delta  ST  
P13233 Cnp 2',3'-cyclic-nucleotide 3'-phosphodiesterase  CX, HP, ST  
P62282 Rps11 40S ribosomal protein S11 HP 
P62850 Rps24 40S ribosomal protein S24 ST 
P62856 Rps26 40S ribosomal protein S26 HP 
P62909 Rps3 40S ribosomal protein S3  ST  
P62703 Rps4x 40S ribosomal protein S4, X isoform HP 
P62083 Rps7 40S ribosomal protein S7  HP, ST  
P62243 Rps8 40S ribosomal protein S8 HP 
P63039 Hspd1 60 kDa heat shock protein, mitochondrial  ST  
P19945 Rplp0 60S acidic ribosomal protein P0  HP, ST  
P62914 Rpl11 60S ribosomal protein L11 CX 
P47198 Rpl22 60S ribosomal protein L22 CX, ST  
P06761 Hspa5 78 kDa glucose-regulated protein  ST  
P60711 Actb Actin, cytoplasmic 1  CX, HP, ST  
P63269 Actg2 Actin, gamma-enteric smooth muscle  HP, ST  
Q6KC51 Ablim2 Actin-binding LIM protein 2  HP 
Q5M7U6 Actr2 Actin-related protein 2  HP 
Q05962 Slc25a4 ADP/ATP translocase 1  HP, ST  
Q09073 Slc25a5 ADP/ATP translocase 2  HP, ST  
Q5QE80 Aox3 Aldehyde oxidase 3  CX 
Q9Z1P2 Actn1 Alpha-actinin-1  CX 
Q63028 Add1 Alpha-adducin  HP 
P04764 Eno1 Alpha-enolase  ST  
P02773 Afp Alpha-fetoprotein  ST  
P23565 Ina Alpha-internexin  HP, ST  
P02667 Csn1s2a Alpha-S2-casein-like A  ST  
P08592 App Amyloid beta A4 protein  CX 
P00762 Prss1 Anionic trypsin-1  ST  
P0C6S7 Anks1b Ankyrin repeat and sterile alpha motif domain-containing protein 
1B  
CX, HP 
P07150 Anxa1 Annexin A1  HP, ST  
Q07936 Anxa2 Annexin A2  CX 
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Uniprot 
accession Gene name Protein name 
 
Brain regions 
 
P52303 Ap1b1 AP-1 complex subunit beta-1  ST  
P18484 Ap2a2 AP-2 complex subunit alpha-2  CX, ST  
P62944 Ap2b1 AP-2 complex subunit beta  HP 
P84092 Ap2m1 AP-2 complex subunit mu  HP, ST  
P12527 Alox5 Arachidonate 5-lipoxygenase  ST  
Q8CGU4 Agap2 Arf-GAP with GTPase, ANK repeat and PH domain-containing 
protein 2  
HP 
P15999 Atp5a1 ATP synthase subunit alpha, mitochondrial ST  
P10719 Atp5b ATP synthase subunit beta, mitochondrial  HP, ST  
Q6PDU7 Atp5l ATP synthase subunit g, mitochondrial  CX, HP, ST  
P35435 Atp5c1 ATP synthase subunit gamma, mitochondrial  CX, HP 
Q06647 Atp5o ATP synthase subunit O, mitochondrial  CX, ST  
Q9ESS6 Bcam Basal cell adhesion molecule  HP 
P85969 Napb Beta-soluble NSF attachment protein  CX 
Q05175 Basp1 Brain acid soluble protein 1  HP 
P11275 Camk2a Calcium/calmodulin-dependent protein kinase type II subunit alpha  ST  
P08413 Camk2b Calcium/calmodulin-dependent protein kinase type II subunit beta  CX, HP, ST  
P15791 Camk2d Calcium/calmodulin-dependent protein kinase type II subunit delta  ST  
P11730 Camk2g Calcium/calmodulin-dependent protein kinase type II subunit 
gamma  
HP 
P62161 Calm1 Calmodulin  CX, HP, ST  
P68182 Prkacb cAMP-dependent protein kinase catalytic subunit beta  HP, ST  
P12369 Prkar2b cAMP-dependent protein kinase type II-beta regulatory subunit  ST  
O55156 Clip2 CAP-Gly domain-containing linker protein 2  ST  
Q8VHK2 Caskin1 Caskin-1  CX 
Q9WU82 Ctnnb1 Catenin beta-1  CX 
Q5FVI4 Cend1 Cell cycle exit and neuronal differentiation protein 1 CX 
Q4KLH6 Cep162 Centrosomal protein of 162 kDa  ST  
Q05140 Snap91 Clathrin coat assembly protein AP180  HP 
P11442 Cltc Clathrin heavy chain 1 HP, ST  
P08081 Clta Clathrin light chain A  ST  
Q99P82 Cldn11 Claudin-11 CX, HP, ST  
Q99JD4 Clasp2 CLIP-associating protein 2  CX 
P45592 Cfl1 Cofilin-1  HP 
P31720 C1qa Complement C1q subcomponent subunit A HP 
P31721 C1qb Complement C1q subcomponent subunit B HP, ST  
P31722 C1qc Complement C1q subcomponent subunit C HP, ST  
P01026 C3 Complement C3  HP 
Q9Z1T4 Cnksr2 Connector enhancer of kinase suppressor of ras 2  HP 
Q63198 Cntn1 Contactin-1  CX, HP, ST  
Q5BJS7 Cpne9 Copine-9  HP 
Q02874 H2afy Core histone macro-H2A.1  HP 
P07335 Ckb Creatine kinase B-type  HP 
O08565 Cxcr4 C-X-C chemokine receptor type 4  ST  
Chapter III   Results 
                                        Functional characterization of novel BRI2 and BRI3 complexes 246 
Uniprot 
accession Gene name  Protein name 
 
Brain regions 
 
Q68FY0 Uqcrc1 Cytochrome b-c1 complex subunit 1, mitochondrial  HP 
P32551 Uqcrc2 Cytochrome b-c1 complex subunit 2, mitochondrial  CX, HP 
P00406 Mtco2 Cytochrome c oxidase subunit 2  HP, ST  
P11240 Cox5a Cytochrome c oxidase subunit 5A, mitochondrial  CX 
P62898 Cycs Cytochrome c, somatic HP 
P08461 Dlat Dihydrolipoyllysine-residue acetyltransferase component of 
pyruvate dehydrogenase complex, mitochondrial  
HP, ST  
Q62950 Crmp1 Dihydropyrimidinase-related protein 1  CX, HP, ST  
P47942 Dpysl2 Dihydropyrimidinase-related protein 2  CX, HP, ST  
Q62952 Dpysl3 Dihydropyrimidinase-related protein 3  CX 
Q63622 Dlg2 Disks large homolog 2  CX, HP, ST  
P31016 Dlg4 Disks large homolog 4  CX, HP, ST  
P97838 Dlgap3 Disks large-associated protein 3  CX 
P97839 Dlgap4 Disks large-associated protein 4  HP 
P60905 Dnajc5 DnaJ homolog subfamily C member 5  HP 
Q07266 Dbn1 Drebrin  CX, HP, ST  
P21575 Dnm1 Dynamin-1  HP, ST  
Q2TA68 O pa1 Dynamin-like 120 kDa protein, mitochondrial  ST  
B0BND0 Enpp6 Ectonucleotide pyrophosphatase/phosphodiesterase family member 
6  
ST  
P62630 Eef1a1 Elongation factor 1-alpha 1  HP, ST  
P85834 Tufm Elongation factor Tu, mitochondrial CX, HP, ST  
O35179 Sh3gl2 Endophilin-A1  CX 
P05432 Errfi1 ERBB receptor feedback inhibitor 1  CX 
Q8K3M6 Erc2 ERC protein 2  ST  
P24942 Slc1a3 Excitatory amino acid transporter 1  HP, ST  
P31596 Slc1a2 Excitatory amino acid transporter 2  HP, ST  
Q3T1K5 Capza2 F-actin-capping protein subunit alpha-2  HP, ST  
Q5XI32 Capzb F-actin-capping protein subunit beta  CX 
P08050 Gja1 Gap junction alpha-1 protein  HP 
Q68FP1 Gsn Gelsolin  HP, ST  
P47819 Gfap Glial fibrillary acidic protein  CX, ST  
P19491 Gria2 Glutamate receptor 2  HP 
P35439 Grin1 Glutamate receptor ionotropic, NMDA 1  HP 
Q00960 Grin2b Glutamate receptor ionotropic, NMDA 2B  HP 
P04797 Gapdh Glyceraldehyde-3-phosphate dehydrogenase  ST  
Q62638 Glg1 Golgi apparatus protein 1  ST  
Q9WTT6 Gda Guanine deaminase  HP 
P43425 Gng7 Guanine nucleotide-binding protein G CX 
P10824 Gnai1 Guanine nucleotide-binding protein G CX 
P59215 Gnao1 Guanine nucleotide-binding protein G HP 
P19627 Gnaz Guanine nucleotide-binding protein G HP 
P52287 Gnb3 Guanine nucleotide-binding protein G HP, ST  
Q6Q7Y5 Gna13 Guanine nucleotide-binding protein subunit alpha-13  ST  
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Uniprot 
accession Gene name Protein name 
 
Brain regions 
 
P63018 Hspa8 Heat shock cognate 71 kDa protein  HP 
Q5XHZ0 Trap1 Heat shock protein 75 kDa, mitochondrial  CX 
P82995 Hsp90aa1 Heat shock protein HSP 90-alpha  ST  
P34058 Hsp90ab1 Heat shock protein HSP 90-beta  CX 
P04256 Hnrnpa1 Heterogeneous nuclear ribonucleoprotein A1  HP 
Q6URK4 Hnrnpa3 Heterogeneous nuclear ribonucleoprotein A3  CX 
G3V9R8 Hnrnpc Heterogeneous nuclear ribonucleoprotein C  HP 
Q9JJ54 Hnrnpd Heterogeneous nuclear ribonucleoprotein D0  HP 
Q8VHV7 Hnrnph1 Heterogeneous nuclear ribonucleoprotein H  HP 
Q6AY09 Hnrnph2 Heterogeneous nuclear ribonucleoprotein H2  ST  
P61980 Hnrnpk Heterogeneous nuclear ribonucleoprotein K  CX, HP 
F1LQ48 Hnrnpl Heterogeneous nuclear ribonucleoprotein L  HP 
Q62826 Hnrnpm Heterogeneous nuclear ribonucleoprotein M  HP 
A7VJC2 Hnrnpa2b1 Heterogeneous nuclear ribonucleoproteins A2/B1  HP, ST  
P06349 Hist1h1t Histone H1t ST  
A9UMV8 H2afj Histone H2A.J  HP, ST  
P0C0S7 H2afz  Histone H2A.Z  CX, ST  
P84245 H3f3b Histone H3.3 ST  
P62804 Hist1h4b Histone H4  HP, ST  
Q9Z214 Homer1 Homer protein homolog 1  CX, ST  
P03994 Hapln1 Hyaluronan and proteoglycan link protein 1  CX, HP, ST  
P17105 Itpka Inositol-trisphosphate 3-kinase A  HP 
Q5PQL7 Itm2c Integral membrane protein 2C  HP 
Q99NA5 Idh3a Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial  HP 
Q9QYU4 Crym Ketimine reductase mu-crystallin  CX, HP, ST  
O35787 Kif1c Kinesin-like protein KIF1C  CX 
Q9WV63 Kif2a Kinesin-like protein KIF2A  HP 
Q8K4Y5 Lgi1 Leucine-rich glioma-inactivated protein 1 CX 
P43244 Matr3 Matrin-3  CX, HP 
D4A7N1 Chchd6 MICOS complex subunit Mic25  ST  
Q3KR86 Immt MICOS complex subunit Mic60  CX, HP, ST  
P34926 Map1a Microtubule-associated protein 1A  HP 
P15205 Map1b Microtubule-associated protein 1B  CX, HP, ST  
P15146 Map2 Microtubule-associated protein 2  CX, ST  
Q5M7W5 Map4 Microtubule-associated protein 4  CX, HP, ST  
Q63560 Map6 Microtubule-associated protein 6  CX, HP 
P19332 Mapt Microtubule-associated protein tau  CX, ST  
P97700 Slc25a11 Mitochondrial 2-oxoglutarate/malate carrier protein  HP 
Q505J6 Slc25a18 Mitochondrial glutamate carrier 2  CX, HP 
Q75Q39 Tomm70 Mitochondrial import receptor subunit TOM70  ST  
P02688 Mbp Myelin basic protein  ST  
P60203 Plp1 Myelin proteolipid protein  ST  
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Uniprot 
accession Gene name  Protein name 
 
Brain regions 
 
Q63345 Mog Myelin-oligodendrocyte glycoprotein CX, HP, ST  
Q9QZ76 Mb Myoglobin CX 
Q9WUJ3 Pde4dip Myomegalin  CX 
P16409 Myl3 Myosin light chain 3  ST  
Q64119 Myl6 Myosin light polypeptide 6  HP, ST  
Q64122 Myl9 Myosin regulatory light polypeptide 9  CX 
Q9JLT0 Myh10 Myosin-10  CX, HP, ST  
P02563 Myh6 Myosin-6  CX 
Q62812 Myh9 Myosin-9  HP 
Q5RJQ4 Sirt2 NAD-dependent protein deacetylase sirtuin-2  CX 
P19234 Ndufv2 NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial  CX, HP, ST  
Q5BK63 Ndufa9 NADH dehydrogenase 1 alpha subcomplex subunit 9, 
mitochondrial  
HP 
Q66HF1 Ndufs1 NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial  HP, ST  
P55161 Nckap1 Nck-associated protein 1  HP 
O35867 Ppp1r9a Neurabin-1  HP, ST  
P55067 Ncan Neurocan core protein  ST  
P97685 Nfasc Neurofascin HP 
P16884 Nefh Neurofilament heavy polypeptide  CX, HP, ST  
P19527 Nefl Neurofilament light polypeptide  ST  
P12839 Nefm Neurofilament medium polypeptide  CX, ST  
Q04940 Nrgn Neurogranin  CX 
P07936 Gap43 Neuromodulin  CX 
Q9ESI7 Dcx Neuronal migration protein doublecortin HP 
O09017 Nr2f6 Nuclear receptor subfamily 2 group F member 6  HP 
P13084 Npm1 Nucleophosmin  HP, ST  
P32736 O pcml Opioid-binding protein/cell adhesion molecule  CX 
Q63425 Prx Periaxin ST 
P62024 Phactr1 Phosphatase and actin regulator 1 ST 
P16036 Slc25a3 Phosphate carrier protein, mitochondrial  HP, ST  
P16617 Pgk1 Phosphoglycerate kinase 1  HP 
P11505 Atp2b1 Plasma membrane calcium-transporting ATPase 1  HP, ST  
P11506 Atp2b2 Plasma membrane calcium-transporting ATPase 2  CX 
Q64542 Atp2b4 Plasma membrane calcium-transporting ATPase 4  HP, ST  
P30427 Plec Plectin  CX, HP, ST  
P0CG51 Ubb Polyubiquitin-B  ST  
P17659 Kcna6 Potassium voltage-gated channel subfamily A member 6  CX, ST  
P48679 Lmna Prelamin-A/C CX 
P62963 Pfn1 Profilin-1  HP 
P67779 Phb Prohibitin HP, ST  
Q5XIH7 Phb2 Prohibitin-2  CX, HP 
Q62969 Ptgis Prostacyclin synthase  HP 
O88778 Bsn Protein bassoon CX, HP 
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Uniprot 
accession Gene name Protein name 
 
Brain regions 
 
Q9Z0W5 Pacsin1 Protein kinase C and casein kinase substrate in neurons protein 1  CX 
P63319 Prkcg Protein kinase C gamma type  CX, HP, ST  
Q9JKS6 Pclo Protein piccolo  ST  
P26284 Pdha1 Pyruvate dehydrogenase E1 component subunit alpha, somatic 
form, mitochondrial  
HP 
P49432 Pdhb Pyruvate dehydrogenase E1 component subunit beta, 
mitochondrial  
CX, HP 
P11980 Pkm Pyruvate kinase PKM  HP, ST  
F1M386 Rapgef2 Rap guanine nucleotide exchange factor 2  HP 
Q9QUH6 Syngap1 Ras/Rap GTPase-activating protein SynGAP  CX, HP, ST  
Q6NYB7 Rab1A Ras-related protein Rab-1A HP 
P05712 Rab2a Ras-related protein Rab-2A HP 
P63012 Rab3a Ras-related protein Rab-3A CX, ST  
Q63941 Rab3b Ras-related protein Rab-3B ST  
P62824 Rab3c Ras-related protein Rab-3C HP, ST  
P09527 Rab7a Ras-related protein Rab-7a  HP 
Q9JIR4 Rims1 Regulating synaptic membrane exocytosis protein 1  HP 
Q64548 Rtn1 Reticulon-1  CX 
P0C6P5 Arhgef28 Rho guanine nucleotide exchange factor 28  HP 
D4AE41 Rbmxl1 RNA binding motif protein, X-linked-like-1  HP 
P11507 Atp2a2 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2  HP, ST  
B3GNI6 Sept11 Septin-11 HP, ST 
Q9JJM9 Sept5 Septin-5  CX, HP 
Q5MPA9 Dclk2 Serine/threonine-protein kinase DCLK2  HP 
Q9WV48 Shank1 SH3 and multiple ankyrin repeat domains protein 1  HP 
Q9QX74 Shank2 SH3 and multiple ankyrin repeat domains protein 2  CX, HP 
Q9JLU4 Shank3 SH3 and multiple ankyrin repeat domains protein 3  ST  
Q63965 Sfxn1 Sideroflexin-1  ST  
Q9JHY2 Sfxn3 Sideroflexin-3 HP 
Q8CFD0 Sfxn5 Sideroflexin-5  HP 
P48768 Slc8a2 Sodium/calcium exchanger 2  HP 
P06685 Atp1a1 Sodium/potassium-transporting ATPase subunit alpha-1  ST  
P06687 Atp1a3 Sodium/potassium-transporting ATPase subunit alpha-3  CX, HP, ST  
O35413 Sorbs2 Sorbin and SH3 domain-containing protein 2  HP, ST  
P16086 Sptan1 Spectrin alpha chain, non-erythrocytic 1  HP 
Q9QWN8 Sptbn2 Spectrin beta chain, non-erythrocytic 2  CX, HP, ST  
Q9QXY2 Srcin1 SRC kinase signaling inhibitor 1  CX, HP, ST  
P48721 Hspa9 Stress-70 protein, mitochondrial  CX, HP 
P09951 Syn1 Synapsin-1  CX, HP, ST  
Q63537 Syn2 Synapsin-2  HP 
Q62876 Syngr1 Synaptogyrin-1  CX 
P07825 Syp Synaptophysin  CX, HP, ST  
P60881 Snap25 Synaptosomal-associated protein 25  CX, HP 
Q6P6S0 Snap47 Synaptosomal-associated protein 47  CX 
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Uniprot 
accession Gene name  Protein name 
 
Brain regions 
 
P21707 Syt1 Synaptotagmin-1  CX, HP, ST  
P61265 Stx1b Syntaxin-1B  CX, HP, ST  
P61765 Stxbp1 Syntaxin-binding protein 1  CX, HP, ST  
Q05546 Tnr Tenascin-R  HP 
Q568Y5 Tspan11 Tetraspanin-11  CX 
P01830 Thy1 Thy-1 membrane glycoprotein  CX 
P86252 Pura Transcriptional activator protein Pur-alpha  HP, ST  
Q68A21 Purb Transcriptional activator protein Pur-beta  HP 
Q5XIA3 Lcmt2 tRNA wybutosine-synthesizing protein 4  CX 
P04692 Tpm1 Tropomyosin alpha-1 chain  HP, ST  
P09495 Tpm4 Tropomyosin alpha-4 chain  CX 
P68370 Tuba1a Tubulin alpha-1A chain  HP 
Q6AYZ1 Tuba1c Tubulin alpha-1C chain  HP, ST  
Q68FR8 Tuba3 Tubulin alpha-3 chain  CX 
Q5XIF6 Tuba4a Tubulin alpha-4A chain  HP, ST  
Q6AY56 Tuba8 Tubulin alpha-8 chain  HP 
P85108 Tubb2a Tubulin beta-2A chain HP, ST  
Q3KRE8 Tubb2b Tubulin beta-2B chain  HP, ST  
Q4QRB4 Tubb3 Tubulin beta-3 chain  HP, ST  
Q6P9T8 Tubb4b Tubulin beta-4B chain  HP, ST  
P69897 Tubb5 Tubulin beta-5 chain HP, ST  
Q9QYF3 Myo5a Unconventional myosin-Va  CX, HP, ST  
P63045 Vamp2 Vesicle-associated membrane protein 2  CX, HP 
Q9Z270 Vapa Vesicle-associated membrane protein-associated protein A  CX 
Q9QUL6 Nsf Vesicle-fusing ATPase  HP, ST  
P31000 Vim Vimentin CX, ST  
Q9Z2L0 Vdac1 Voltage-dependent anion-selective channel protein 1  HP, ST  
P81155 Vdac2 Voltage-dependent anion-selective channel protein 2  CX, HP, ST  
Q9R1Z0 Vdac3 Voltage-dependent anion-selective channel protein 3  CX, HP, ST  
P62815 Atp6v1b2 V-type proton ATPase subunit B, brain isoform  CX 
 
Results       Chapter III 
 
 
 
Functional characterization of novel BRI2 and BRI3 complexes        251 
 
Table III.B.S 2 – BRI3 protein interactors obtained from online databases. Information about the identified BRI3 interactors, as well as, the UniProt accession number, the species 
and the experimental evidence supporting the interactions, as well as the cell line or tissue where was detected. 
Gene Protein 
Uniprot 
accession 
number 
Species Experimental evidence Cell line/Tissue References 
APP 
 Amyloid beta A4 protein P05067 Homo sapiens 
Two-hybrid 
Co-IP  
HeLa cells co-transfected with BRI3 and APP cDNAs 
 (Matsuda et al. 2009) 
BACE1 β-secretase β-amyloid protein converting enzyme 1 P56817 Homo sapiens 
Two-hybrid 
Co-IP  
HEK293 cells co-transfected with BRI3 and BACE1 
cDNAs 
 
(Wickham et al. 2005) 
CUL7 Cullin-7 Q14999 Homo sapiens Affinity Capture-MS HEK293 cells transfected with CUL7 cDNA (Hanson et al. 2014)  
Dlg4 Disks large homolog 4 
P31016 BRI3 Hs – Dlg4 Rat Peptide array assay ---- (Arbuckle et al. 2010) 
 
Q62108 BRI3 Hs – Dlg4 Ms Peptide array assay ---- (Arbuckle et al. 2010)  
FURIN Furin P09958 Homo sapiens in vivo assay CHO-FD11 cells (Wickham et al. 2005) 
 
LLGL2 Lethal(2) giant larvae protein homolog 2 Q6P1M3 Homo sapiens Peptide array assay ---- 
(Arbuckle et al. 2010) 
 
 
MTNR1B Melatonin receptor type 1B P49286 Homo sapiens 
Tandem affinity 
purification- MS 
 
HEK293 cells (Daulat et al. 2007) 
MVB12B Multivesicular body subunit 12B Q9H7P6 Homo sapiens Affinity Capture-MS HEK293 cells  (Huttlin et al. 2015) 
PPP1CA/Ppp1ca Serine/threonine-protein phosphatase PP1-alpha 
catalytic subunit 
P62136 Homo sapiens Co-IP  SH-SY5Y cells transfected BRI3 cDNA 
 (Martins et al. 2016) 
P62138 Homo sapiens Co-IP  Rat primary cortical and hippocampal cultures  
PPP1CC/Ppp1cc Serine/threonine-protein phosphatase PP1-gamma catalytic subunit 
P36873 Homo sapiens Two-hybrid 
Co-IP  
SH-SY5Y cells transfected BRI3 cDNA 
 
(Esteves et al. 2013; 
Martins et al. 2016) 
P63088 Rattus norvergicus Co-IP  Rat primary cortical and hippocampal cultures  (Martins et al. 2016) 
 
RNF7 
 
RING-box protein 2 Q9UBF6 Homo sapiens Two-hybrid ---- (Rual et al. 2005)  
RYK Tyrosine-protein kinase RYK P34925 Homo sapiens Tandem affinity purification- MS HEK293 cells (Berndt et al. 2011) 
 
STMN2 
 
Stathmin-2 Q93045 Homo sapiens Co-IP  PC12 cells (Gong et al. 2008) 
STT3A Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit STT3A 
P46977 Homo sapiens Two-hybrid ---- (Stelzl et al. 2005) 
TMEM17 Transmembrane protein 17 Q86X19 Homo sapiens Proximity labeling technology 293 Flp-In T-REx cells (Gupta et al. 2015) 
 
TMEM216 
 
Transmembrane protein 216 
 
Q86X19 
 
Homo sapiens 
 
Proximity labeling 
technology 
 
293 Flp-In T-REx cells 
 
 
(Gupta et al. 2015) 
Ubc Polyubiquitin-C Q63429 Rattus norvergicus Affinity Capture-MS Rat brain (Na et al. 2012) 
Co-IP, co-immunoprecipitation; MS, mass spectrometry; Hs, Homo sapiens; Ms, Mus musculus; Rat, Rattus norvergicus. 
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Table III.B.S  3 - Protein class enrichment analysis of the brain specific BRI2 interactome using Panther online resource . Enriched categories are identified as those with a p-value 
<0.05. Nr. Number. 
GO term Nr. proteins Fold enrichment (%) p-value Associated proteins 
tubulin (PC00228) 11 40.91 1.74E-12 Tubb2a,Tubb3,Tubb4b,Tuba3a,Tuba8,Tuba4a,Tubb2b,Tuba1a,Tubb5,Tuba1c,Tuba3a 
microtubule family cytoskeletal protein (PC00157) 18 7.00 4.45E-08 Map1a,Kif2a,Tubb2a,Dnm1,Tubb3,Clip2,Tubb4b,Kif1c,Tuba3a,Tuba8,Tuba4a,Tubb2b,Map1b,Tu
ba1a,Tubb5,Opa1,Tuba1c,Tuba3a 
cytoskeletal protein (PC00085) 54 5.83 3.44E-23 Map1a,Myh6,Sorbs2,Kif2a,Gfap,Sept11,Actg2,Tpm4,Myo5a,Cfl1,Tpm1,Tubb2a,Dnm1,Myl9,Tub
b3,Clip2,Tubb4b,Nefm,Myl6,Capza2,Kif1c,Capzb,Pde4dip,Actn1,Vim,Myl3,Tuba3a,Nefl,Tuba8,T
uba4a,Sept5,Tubb2b,Map1b,Plec,Sptan1,Myh10,Ctnnb1,Tuba1a,Tubb5,Dbn1,Lmna,Gsn,Sptbn2,A
blim2,Opa1,Actb,Pacsin1,Myh9,Ina,Add1,Tuba1c,Syn1,Tuba3a,Syn2 
anion channel (PC00049) 6 14.66 8.85E-04 Atp5a1,Vdac2,Vdac3,Atp6v1b2,Atp5b,Vdac1 
ion channel (PC00133) 14 3.41 1.69E-02 Atp5a1,Atp1a3,Vdac2,Atp2a2,Atp2b1,Atp1a1,Vdac3,Atp2b2,Atp6v1b2,Gria2,Atp2b4,Grin2b,Atp
5b,Vdac1 
transporter (PC00227) 27 2.26 1.62E-02 Atp5a1,Atp1a3,Atp5o,Slc25a11,Vdac2,Slc25a4,Slc25a18,Sfxn3,Stxbp1,Atp2a2,Atp2b1,Sfxn1,Atp
1a1,Slc8a2,Vdac3,Atp2b2,Sfxn5,Atp6v1b2,Gria2,Atp2b4,Grin2b,Slc1a2,Atp5b,Slc1a3,Slc25a5,Vd
ac1,Slc25a3 
actin binding motor protein (PC00040) 7 11.30 7.69E-04 Myh6,Tpm4,Myo5a,Tpm1,Pde4dip,Myh10,Myh9 
actin family cytoskeletal protein (PC00041) 27 5.80 9.14E-11 Myh6,Sorbs2,Actg2,Tpm4,Myo5a,Cfl1,Tpm1,Myl9,Myl6,Capza2,Capzb,Pde4dip,Actn1,Myl3,Ple
c,Sptan1,Myh10,Dbn1,Gsn,Sptbn2,Ablim2,Actb,Pacsin1,Myh9,Add1,Syn1,Syn2  
heterotrimeric G-protein (PC00117) 6 10.06 7.25E-03 Gna13,Gnai1,Gnao1,Gnaz,Gng7,Gnb3 
G-protein (PC00020) 12 4.41 5.03E-03 Sept11,Gna13,Eef1a1,Dnm1,Gnai1,Gnao1,Sept5,Gnaz,Tufm,Gng7,Opa1,Gnb3  
transmembrane receptor regulatory/adaptor protein (PC00226) 6 9.17 1.21E-02 Dlgap3,Anks1b,Dlg4,Ap2a2,Dlgap4,Caskin1 
cation transporter (PC00068) 16 6.19 2.48E-06 Atp5a1,Atp1a3,Atp5o,Sfxn3,Atp2a2,Atp2b1,Sfxn1,Atp1a1,Slc8a2,Atp2b2,Sfxn5,Atp6v1b2,Atp2b
4,Slc1a2,Atp5b,Slc1a3 
membrane traf f icking regulatory protein (PC00151) 8 5.90 1.62E-02 Stxbp1,Syt1,Syp,Pacsin1,Syn1,Vapa,Syngr1,Syn2 
membrane traf f ic protein (PC00150) 21 5.10 3.81E-07 Stxbp1,Syt1,Syp,Clta,Cltc,Stx1b,Ap1b1,Erc2,Rtn1,Ap2b1,Snap47,Pacsin1,Napb,Syn1,Cpne9,Vam
p2,Vapa,Snap91,Snap25,Syngr1,Syn2 
structural protein (PC00211) 10 5.35 4.84E-03 Clasp2,Gfap,Plp1,Nefm,Vim,Nefl,Mbp,Lmna,Ablim2,Ina 
non-motor actin binding protein (PC00165) 12 5.21 9.70E-04 Cfl1,Capza2,Capzb,Actn1,Plec,Sptan1,Dbn1,Gsn,Sptbn2,Add1,Syn1,Syn2 
chaperone (PC00072) 10 4.34 2.66E-02 Ywhaq,Hsp90aa1,Tomm70a,Hspe1,Clip2,Hsp90ab1,Ywhaz,Trap1,Hspd1,Npm1 
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Table III.B.S  4 - KEGG pathway cluster analysis of the individual specific BRI3 interactors in cortex, hippocampus and striatum using the ClueGo plugin of the Cytoscape 
software. Enriched categories are identified as those with p-value <0.05.  
KEGG term ID KEGG Term Nr. Genes % Associated 
Genes 
Term 
pValue 
Genes Cluster #1 (cortex specif ic 
BRI3 interactors) 
Genes Cluster #2 
(hippocampus specif ic BRI3 
interactors) 
Genes Cluster #3 
(striatum specif ic BRI3 interactors) 
KEGG:0004012 ErbB signaling pathway 18.00 20.45 1.80E-11 ABL1, AKT1, CBL, CRK, EGFR, 
GRB2, GSK3B, NCK1, PIK3R1, 
PLCG1, SRC 
ABL1, CAMK2A, CRK, ERBB4, 
GRB2, JUN, MYC, NCK1 
CAMK2A, CAMK2B, CAMK2D, 
CAMK2G 
KEGG:0004130 SNARE interactions in vesicular 
transport 
11.00 32.35 4.50E-09 BET1, SNAP23, SNAP29, STX16, 
STX19, STX1A, STX1B, STX3, 
STX4, STX5, STX6 
  
KEGG:0004722 Neurotrophin signaling pathway 16.00 13.22 3.70E-07 ABL1, AKT1, CRK, FASLG, GRB2, 
GSK3B, PIK3R1, PLCG1, PRKCD, 
YWHAE 
ABL1, CAMK2A, CRK, GRB2, 
JUN 
CALM1, CAMK2A, CAMK2B, 
CAMK2D, CAMK2G 
KEGG:0005205 Proteoglycans in cancer 20.00 9.76 8.90E-07 ACTG1, AKT1, CBL, EGFR, 
FASLG, GRB2, PIK3R1, PLCG1, 
SRC 
CAMK2A, ERBB4, FLNA, GRB2, 
IQGAP1, MYC, PPP1CB, SMAD2 
CAMK2A, CAMK2B, CAMK2D, 
CAMK2G, SMAD2, TNF 
KEGG:0004660 T cell receptor signaling pathway 14.00 13.33 3.10E-06 AKT1, CBL, FYN, GRB2, GSK3B, 
LCP2, NCK1, PIK3R1, PLCG1 
DLG1, FYN, GRB2, IKBKG, JUN, 
NCK1, PTPRC 
TNF 
KEGG:0004728 Dopaminergic synapse 15.00 11.54 7.10E-06 AKT1, GSK3B ARRB2, ATF2, CAMK2A, 
GNAO1, GRIA2, GRIN2B, 
PLCB4, PPP1CB 
CALM1, CAMK2A, CAMK2B, 
CAMK2D, CAMK2G, GRIA4, 
GRIN2B 
KEGG:0005214 Glioma 11.00 16.67 8.70E-06 AKT1, EGFR, GRB2, PIK3R1, 
PLCG1 
CAMK2A, GRB2 CALM1, CAMK2A, CAMK2B, 
CAMK2D, CAMK2G, E2F3 
KEGG:0004915 Estrogen signaling pathway 13.00 13.00 1.20E-05 AKT1, EGFR, ESR2, GRB2, PIK3R1, 
PRKCD, SRC 
ATF2, GNAO1, GRB2, 
HSP90AB1, JUN, PLCB4 
CALM1, HSP90AB1 
KEGG:0005161 Hepatitis B 15.00 10.27 3.10E-05 AKT1, FASLG, GRB2, IL6, PIK3R1, 
SRC, YWHAB 
ATF2, CDK2, GRB2, IKBKG, 
JUN, MYC, STAT1 
E2F3, TNF 
KEGG:0004713 Circadian entrainment 12.00 12.50 5.70E-05 MTNR1B CAMK2A, GNAO1, GRIA2, 
GRIN1, GRIN2B, MTNR1B, 
PLCB4 
CALM1, CAMK2A, CAMK2B, 
CAMK2D, CAMK2G, GRIA4, 
GRIN2B, MTNR1B 
KEGG:0004720 Long-term potentiation 10.00 14.93 9.10E-05  CAMK2A, GRIA2, GRIN1, 
GRIN2B, PLCB4, PPP1CB 
CALM1, CAMK2A, CAMK2B, 
CAMK2D, CAMK2G, GRIN2B 
KEGG:0004520 Adherens junction 10.00 13.51 2.20E-04 ACTG1, EGFR, FYN, SRC FYN, INSR, IQGAP1, PTPRB, 
PTPRJ, SMAD2 
ACTN1, SMAD2 
KEGG:0004912 GnRH signaling pathway 11.00 11.96 2.40E-04 EGFR, GRB2, PRKCD, SRC CAMK2A, GRB2, JUN, PLCB4 CALM1, CAMK2A, CAMK2B, 
CAMK2D, CAMK2G 
KEGG:0004750 Inflammatory mediator regulation 
of TRP channels 
11.00 11.11 5.00E-04 PIK3R1, PLCG1, PRKCD, SRC CAMK2A, PLCB4, PPP1CB CALM1, CAMK2A, CAMK2B, 
CAMK2D, CAMK2G 
KEGG:0005220 Chronic myeloid leukemia 9.00 12.33 1.40E-03 ABL1, AKT1, CBL, CRK, GRB2, 
PIK3R1 
ABL1, CRK, GRB2, IKBKG, MYC E2F3 
KEGG:0004144 Endocytosis 17.00 6.54 2.40E-03 ASAP1, CBL, DNM1, DNM2, EGFR, 
ITCH, PDCD6IP, SH3GL1, SH3GL2, 
SH3GL3, SH3KBP1, SRC 
AGAP2, ARRB2, ERBB4, SMAD2 CHMP5, SMAD2 
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KEGG:0004933 AGE-RAGE signaling pathway in 
diabetic complications 
10.00 9.90 3.40E-03 AKT1, IL6, PIK3R1, PLCG1, PRKCD JUN, PLCB4, SMAD2, STAT1 SMAD2, TNF 
KEGG:0005321 Inflammatory bowel disease 
(IBD) 
8.00 12.31 3.80E-03 HLA-DQA1, IL6 JUN, SMAD2, STAT1 HLA-DMA, HLA-DRB1, SMAD2, 
TNF 
KEGG:0004066 HIF-1 signaling pathway 10.00 9.71 3.90E-03 AKT1, EGFR, IL6, PIK3R1, PLCG1 CAMK2A, INSR CAMK2A, CAMK2B, CAMK2D, 
CAMK2G 
KEGG:0004114 Oocyte meiosis 11.00 8.87 3.90E-03 YWHAB, YWHAE, YWHAH CAMK2A, CDK2, PPP1CB CALM1, CAMK2A, CAMK2B, 
CAMK2D, CAMK2G, YWHAG 
KEGG:0005142 Chagas disease (American 
trypanosomiasis) 
10.00 9.62 4.10E-03 AKT1, FASLG, IL6, PIK3R1 GNAO1, IKBKG, JUN, PLCB4, 
SMAD2 
SMAD2, TNF 
KEGG:0005164 Influenza A 13.00 7.43 5.10E-03 ACTG1, AKT1, FASLG, GSK3B, 
HLA-DQA1, IL6, PIK3R1 
ATF2, JUN, STAT1 HLA-DMA, HLA-DRB1, TNF 
KEGG:0004510 Focal adhesion 14.00 6.90 6.00E-03 ACTG1, AKT1, CRK, EGFR, FYN, 
GRB2, GSK3B, PIK3R1, SRC 
CRK, FLNA, FYN, GRB2, JUN, 
PPP1CB, TNR 
ACTN1 
KEGG:0005215 Prostate cancer 9.00 10.11 6.00E-03 AKT1, EGFR, GRB2, GSK3B, 
PIK3R1 
CDK2, GRB2, HSP90AB1, IKBKG E2F3, HSP90AB1 
KEGG:0005152 Tuberculosis 13.00 7.26 6.10E-03 AKT1, HLA-DQA1, IL6, SRC CAMK2A, STAT1 CALM1, CAMK2A, CAMK2B, 
CAMK2D, CAMK2G, HLA-DMA, 
HLA-DRB1, TNF 
KEGG:0004724 Glutamatergic synapse 10.00 8.77 8.00E-03  DLG4, DLGAP1, GNAO1, GRIA2, 
GRIN1, GRIN2B, PLCB4, 
SHANK1, SLC38A1 
GRIA4, GRIN2B 
KEGG:0005223 Non-small cell lung cancer 7.00 12.50 8.80E-03 AKT1, EGFR, GRB2, PIK3R1, 
PLCG1 
GRB2 E2F3, RXRB 
KEGG:0004919 Thyroid hormone signaling 
pathway 
10.00 8.47 1.00E-02 ACTG1, AKT1, GSK3B, PIK3R1, 
PLCG1, SRC 
MYC, PLCB4, STAT1 RXRB 
KEGG:0005332 Graft-versus-host disease 6.00 14.63 1.00E-02 FASLG, HLA-DQA1, IL6  HLA-DMA, HLA-DRB1, TNF 
KEGG:0004110 Cell cycle 10.00 8.06 1.40E-02 ABL1, GSK3B, YWHAB, YWHAE, 
YWHAH 
ABL1, CDK2, MYC, SMAD2 E2F3, SMAD2, YWHAG 
KEGG:0004721 Synaptic vesicle cycle 7.00 11.11 1.60E-02 DNM1, DNM2, STX1A, STX1B, 
STX3 
NSF, RIMS1  
KEGG:0004360 Axon guidance 12.00 6.82 1.60E-02 ABL1, FYN, GSK3B, NCK1, 
PIK3R1, PLCG1, SRC, SRGAP3 
ABL1, CAMK2A, FYN, NCK1 CAMK2A, CAMK2B, CAMK2D, 
CAMK2G 
KEGG:0004922 Glucagon signaling pathway 9.00 8.74 1.60E-02 AKT1, PYGM ATF2, CAMK2A, PLCB4 CALM1, CAMK2A, CAMK2B, 
CAMK2D, CAMK2G 
KEGG:0004911 Insulin secretion 8.00 9.41 1.90E-02 STX1A ATF2, CAMK2A, PLCB4 CAMK2A, CAMK2B, CAMK2D, 
CAMK2G, PCLO 
KEGG:0005310 Asthma 5.00 16.13 1.90E-02 HLA-DQA1  HLA-DMA, HLA-DRB1, PRG2, TNF 
KEGG:0005212 Pancreatic cancer 7.00 10.61 2.00E-02 AKT1, EGFR, PIK3R1 IKBKG, SMAD2, STAT1 E2F3, SMAD2 
KEGG:0004931 Insulin resistance 9.00 8.26 2.10E-02 AKT1, GSK3B, IL6, PIK3R1, 
PRKCD, PYGM 
INSR, PPP1CB TNF 
KEGG:0004068 FoxO signaling pathway 10.00 7.46 2.20E-02 AKT1, EGFR, FASLG, GRB2, IL6, 
PIK3R1 
AGAP2, CDK2, GRB2, INSR, 
SMAD2 
SMAD2 
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IV.1 Overview 
BRI2 and BRI3 are two type II transmembrane proteins with unclear functions. While BRI3 is mainly 
expressed in the CNS, BRI2 is an ubiquitously expressed protein. However, several lines of evidence 
suggest an important role for BRI2 in the CNS: 
- BRI2 is a central protein of the FBD and FDD pathogenesis since mutated forms of this protein 
appear in FBD and FDD patients. Mutations of the stop codon in the BRI2 gene are responsible 
for the generation of a longer open reading frame causing the release of a longer propeptide by 
furin-mediated proteolysis, the ABri and ADan which tend to aggregate in amyloid deposits in 
the brain and cause FBD and FDD, respectively (Vidal et al. 1999; Vidal et al. 2000); 
- BRI2 was found deposited in the hippocampus of early stages of AD cases, associated with Aβ 
plaques (Del Campo et al. 2014); 
- BRI2 RIP in the cis- or medial-Golgi results in the formation of several secreted peptides. The 
first cleavage by furin and related proteases within its ectodomain leads to the release of a 3 kDa 
C-terminal propeptide (Choi et al. 2004). BRI2 staining in dystrophic neurites in some 
neurodegenerative disorders and its distribution within neuronal cell bodies and axons suggests 
that BRI2 is transported along neuronal processes and potentially a role at the nerve terminals; 
- Bri2 +/- mice exhibit synaptic and memory deficits (Tamayev et al. 2010b).  
 
 
Most proteins function as part of complexes rather than as individuals, this is essential for proper 
protein function. The study of protein-protein interactions contributes to understanding the protein s´ 
normal functions and the information obtained can help one to predict biological processes and 
signaling pathways that a protein is involved.  
Previous work from our laboratory identified BRI3 protein in a Yeast Two-Hybrid screen of a human 
brain cDNA library using PP1γ2 as bait (Esteves et al. 2013). Although BRI2 was not identified in 
this screen it was also explored as a possible PP1 interactor. 
 
IV.2 BRI2 protein 
In the work here presented BRI2 was described as a novel PP1 interacting protein. The interaction 
of BRI2 with both PP1α and PP1γ isoforms was validated using different techniques which permitted 
concluding that BRI2 interacts directly with PP1 both in vitro and ex vivo. BRI2 interacts with PP1 
through a conserved RVxF motif located in its intracellular N-terminal domain. Although some 
phosphorylatable residues for BRI2 were recently described using high-throughput techniques this 
is the first report identifying BRI2 as a phosphoprotein which can be dephosphorylated by PP1. In 
fact, when BRI2:PP1 interaction is abolished BRI2 phosphorylation levels greatly increase. 
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However, the BRI2 residues altered by PP1 dephosphorylation were not identified and this deserves 
further investigation, as well as the identification of the BRI2 protein kinases.  
The identification of the BRI2/PP1 was of paramount importance since it opened new perspectives 
for the study of protein phosphorylation as a key regulatory mechanism for the biological function 
of BRI2. It was already demonstrated that BRI2 N-glycosylation at Asn170 is essential for its proper 
trafficking through the membrane compartments to the cell surface (Tsachaki et al. 2011), however, 
there was no previous evidence suggesting a role for post-translational modifications on BRI2 
processing. The involvement of protein phosphorylation on BRI2 processing was reported for the 
first time during the work here described. Dephosphorylation of BRI2 by PP1 is able to increase its 
processing by ADAM10 resulting in increased production of the membrane-bound NTF, which is 
further subjected to intramembrane regulated proteolysis by SPPLa/b to release the intracellular 
domain of BRI2. The underlying regulatory mechanisms responsible for favoring BRI2 processing 
by phosphorylation should be addressed. For instance, BRI2 phosphorylation/dephosphorylation 
may control its affinity to specific interacting proteins, such as ADAM10 and SPPL2a/b, by inducing 
conformational changes and these should be explored. It is also possible that 
phosphorylation/dephosphorylation affects BRI2 interaction with proteins responsible for its 
targeting to the subcellular compartments where processing occurs. The results here presented 
suggest that BRI2 trafficking is not altered by PP1 dephosphorylation since a normal distribution 
vesicle-structures covering the whole cytoplasm and the cell membrane is observed, and it does not 
accumulate in intracellular compartments. However, this issue was not addressed in this study and 
further studies such as biotinylation studies to evaluate BRI2 levels at the cell surface, and by 
inhibiting ‘de novo’ protein synthesis (for instance with cycloheximide) (Rebelo et al. 2008), thus 
allowing the monitoring of BRI2 protein pool in a time-dependent manner.  
 
IV.2.1. BRI2 neuritogenic role 
Moreover, a role for BRI2:PP1 complex was established in the dynamic regulation of neuritogenesis, 
since BRI2 phosphorylation is able to promote neurite outgrowth. Significantly, the impact of BRI2 
phosphorylation on its neuritogenic role was well correlated with its processing. Indeed, by 
modulating BRI2 processing using the ADAM10 specific inhibitor, GI254023X, it was possible to 
unravel a dual role for BRI2 in neuritogenesis: phosphorylation of full-length protein promotes the 
emergence of neurites whereas the increased BRI2 NTFs play a relevant role in neurites’ elongation 
and stabilization. The results here presented regarding the BRI2 neuritogenic role were accomplished 
with BRI2 overexpression; however BRI2 knockdown experiments will likely prove to be useful. 
The SH-SY5Y neuroblastoma cell line was largely used in this work since it is a widely used neuronal 
differentiation model (Agholme et al. 2010; da Rocha et al. 2015). However, to further address the 
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BRI2 neuritogenic role primary neuronal cultures which are physiologically more relevant should be 
used as cell model in the future. This will allow us to further evaluate BRI2 role on both axonal and 
dendritic growth as well as branching. In addition, to elucidate BRI2 contributions to neurite 
outgrowth for full-length BRI2 and its fragments, cultured neurons from BRI2 knockout (KO) and 
phosphorylation mutants should be worthwhile.  
Given our results and the previously published results, it is clear the involvement of BRI2 in 
neuritogenesis, however, the underlying mechanisms and signaling pathways have not been 
elucidated. Hence, the BRI2 interactome was identified in order to uncover the signaling mechanisms 
responsible for the BRI2 role in neuritogenesis, and also to explore potential novel cellular functions 
for BRI2 in the CNS.   
Bioinformatic analysis of the BRI2 interactome identified almost 50% of the novel BRI2 candidate 
interacting proteins as cytoskeletal proteins, which translated in an overrepresentation of functions 
like cytoskeleton organization and microtubule-based processes, strengthening the proposed role of 
this protein in neuronal differentiation. Therefore, it is feasible to propose that a mechanism by which 
BRI2 is able to induce neurite outgrowth relies on the modulation of different signaling pathways 
that converge on changes in the cytoskeleton. BRI2 is able to form homodimers linked by disulfide 
bonds that appear at the cell surface resembling the structure of a cell-surface receptor (Tsachaki et 
al. 2010). By acting as a cell receptor BRI2 may initiate intracellular signal transduction in response 
to extracellular signaling molecules (Figure IV.1). Moreover, the soluble ectodomain products 
resulting from BRI2 cleavage could also be implicated in neurite outgrowth by binding to a growth 
factor receptor (Figure IV.1). Taking into consideration the results here presented, these points to 
protein phosphorylation as a key regulator of BRI2 mediated neurite outgrowth it is possible that: (1) 
BRI2 full-length phosphorylation induces conformational changes in the protein affecting the 
binding specificity and affinity for the protein partners thus regulating its receptor activity; (2) by 
increasing BRI2 processing, phosphorylation increases the levels of the secreted fragments that can 
further act as a neuritogenic ligand that binds to and activates a growth factor receptor; (3) by 
increasing BRI2 processing, phosphorylation leads to increased generation of the BRI2 intracellular 
domain (BRI2ICD) that can translocate to the nucleus (Mentrup et al. 2015) where it may 
promote gene transcription (Figure IV.1).  
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Figure IV. 1 - Schematic representation of the proposed mechanisms for BRI2 phosphorylation-mediated neurite 
outgrowth. A – BRI2 may act as a receptor initiating intracellular signal transduction in response to extracellular 
signaling molecules. BRI2 forms homodimers linked by disulfide bonds that appear at the cell surface, resembling the 
structure of a cell-surface receptor. BRI2 contains two extracellular cysteines at the C-terminus that most likely are capable 
of forming an intramolecular disulfide bond. In addition, BRI2 contains within its transmembrane domain, the GXXXG 
motif that has been found to contribute to protein homo- and hetero-association. BRI2 full-length phosphorylation may 
induce conformational changes in the protein affecting the binding specificity and affinity for the extracellular signaling 
molecules thus regulating its receptor activity. B – BRI2 proteolytic processing fragments induced neurite outgrowth. 
BRI2 phosphorylation promotes BRI2 processing increasing the levels of the proteolytic processing fragments that can 
further act as neuritogenic molecules. The soluble secreted fragments BRI2 BRICHOS and BRI2 CTF may function as 
ligands by binding to and activating growth factor receptors; BRI2ICD can translocate to the nucleus where it may 
promote gene transcription.  
 
In conclusion, with the work here presented we gathered a wide range of evidences suggesting a role 
for BRI2 in neurite outgrowth and several underlying mechanisms were proposed which might be 
pursued in a near future. Moreover, the study of BRI2 and its potential value in neuritogenic 
therapeutic applications seems to be very promising. 
 
IV.2.2 Potential novel roles for BRI2 in the CNS  
In addition, by further analyzing the BRI2 brain interactome here identified, novel potential roles for 
BRI2 emerged, namely with roles in synapse formation and activity. 
Remarkably, the results lead us to propose other roles for BRI2 in neuronal differentiation, namely 
in synapse formation. Several proteins identified as candidate BRI2 interactors were found to be 
associated with microtubule transport machinery, as is the case for kinesin heavy chain isoforms 5a 
and 5c (Kif5a and kif5c, respectively), and kinesin light chain isoform 1 (Klc1). Kinesins are 
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important for trafficking in axons and dendrites (Rahman et al. 1998; Xia et al. 1998) that are crucial 
for the formation and dynamics of both presynaptic and postsynaptic structures. Thus, these results 
suggest that in neurons BRI2 is transported by anterograde axonal transport to the distal nerve 
terminals. The results also suggest the expression of BRI2 both in pre-and postsynapse and so one 
can propose a role for BRI2 in promoting synaptic formation via trans-synaptic interactions of its 
extracellular domains which may contribute to the adhesion of synapses (Figure IV.2). This point 
deserves further investigation in order to confirm the distribution of BRI2 in synapses.  
 
 
 
Figure IV. 2 - Schematic diagram of putative functions for BRI2 at synapses. BRI2 is suggested to be expressed both 
in pre- and postsynapse, and via trans-synaptic interactions of its extracellular domains could promote synapse formation. 
BRI2 protein via interaction with several interacting proteins could be involved in synaptic transmission and plasticity by 
enhancing AMPAR and NMDAR surface expression.  
 
Furthermore, novel candidate BRI2 interactors subunits of the AMPARs and NMDARs, as well as 
PSD-95 were identified. PSD-95 interacts with both AMPARs and NMDARs through its PDZ (PSD-
95/Dlg/ZO-1) domain and is able to regulate its expression at synapses (Béïque and Andrade 2003; 
El-Husseini et al. 2000; Niethammer et al. 1996; Kornau et al. 1995). Although no previous studies 
have identified PSD-95 as a BRI2 interactor, a functional evidence suggesting a relationship between 
those proteins were already pointed out: in a synaptosomal proteome characterization of the mouse 
model FDDKI, PSD-95 expression was found decreased (Vitale et al. 2012). Hence, we hypothesize 
a role for BRI2 in the postsynaptic compartment in which it may be involved in synaptic transmission 
and plasticity by altering the AMPA and NMDA receptors trafficking (Figure IV.2). Consistent with 
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this proposed role for BRI2 is the already mentioned phenotype observed in Itm2b (+/-) mice 
(synaptic and memory deficits). Remarkably, PSD-95 knockout mice display phenotypic similarities, 
such as abnormal synaptic plasticity as well as abnormal memory and learning (Feyder et al. 2010). 
In essence, it seems important to further explore the novel proposed roles for BRI2 since the 
understanding of its normal function will provide novel insights into its dysfunctions that contribute 
to the development of the neurodegenerative disorders FBD, FDD, and AD.  
 
IV.2.3. Relevance of BRI2 in neurodegenerative diseases 
FBD and FDD, respectively, as discussed, are two rare early-onset forms of dementia, caused by 
different autosomal dominant mutations in the BRI2 gene. These diseases share clinical symptoms 
such as progressive cognitive impairment, cerebellar ataxia, and spasticity (Tsachaki et al. 2008). 
Similar to wild-type BRI2, mutant forms undergo proteolytic processing by furin leading to the 
secretion of the propetides, ABri in FBD and ADan in FDD. In the brain of patients these peptides 
were found in amyloid deposits, and as soluble monomeric forms in plasma (Vidal et al. 1999; Vidal 
et al. 2000; Ghiso et al. 2001; Tomidokoro et al. 2005). For several years the production and 
deposition of these peptides were acknowledged as being responsible for the pathologies of FBD and 
FDD. However, recent studies using knock-in mouse models of FDD and FBD, FDDKI and FBDKI 
respectively, proposed the loss of BRI2 function as the mechanism responsible for the synaptic and 
memory deficits in these diseases rather than amyloidosis, since a significant reduction of mature 
BRI2 levels is observed (Tamayev et al. 2010b; Tamayev et al. 2010a). In fact, a recent study 
reported that the cleavage of BRI2 by proprotein convertases is more efficient for the wild-type BRI2 
than for mutant BRI2 since the mutant sequences may interfere both with the proper folding of BRI2 
and the enzymatic activity of proprotein convertases (Garringer et al. 2017). Therefore, given our 
results that suggest a regulation of BRI2 function and processing by protein phosphorylation, it seems 
critical to further evaluate the phosphorylation levels of BRI2 mutant forms in FBD and FDD, as 
well as the formation of complexes with PP1. Curiously, BRI2 affects APP processing and reduces 
Aβ production. Given that FBD and FDD share many neuropathological features with AD, it is 
possible that common cellular events result in neuronal loss in these diseases. Therefore, the study 
of FBD and FDD could also provide insights into the neurodegenerative mechanism underlying AD. 
Remarkably, BRI2 was also found to be deposited in the hippocampus of early stages of AD cases 
and clearly associated with Aβ plaques. In fact, in brain homogenates from AD patients the BRI2 
binds to APP. Thus, BRI2 abnormal accumulation and its subcellular localization may prevent the 
formation of the BRI2-APP complex formation leading to an increase in APP processing and Aβ 
production (Del Campo et al. 2014). Interestingly, abnormal protein phosphorylation levels have 
been associated with several neuropathological disorders including AD due to abnormal protein 
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kinase and protein phosphatase activities (Chung 2009). Remarkably, BRI2 was also found to be 
deposited in the hippocampus of early stages of AD cases and clearly associated with Aβ plaques. In 
fact, in brain homogenates from AD patients the BRI2 binds to APP. Thus, BRI2 abnormal 
accumulation and its subcellular localization may prevent the formation of the BRI2-APP complex 
formation leading to an increase in APP processing and Aβ production. 
 
IV.3. BRI3 
BRI3 is a type II transmembrane protein mainly expressed in the brain. Given its distribution pattern 
it seems important in the CNS function, however, its biological function remains undisclosed.  
Therefore the finding that BRI3 is a phosphoprotein that interacts directly with PP1 opens a new 
perspective in the study of BRI3 biology. BRI3 interacts with PP1 through a conserved RVxF motif 
located in its intracellular N-terminal domain. Furthermore, BRI3 is a substrate of PP1 being 
dephosphorylated by the later. However, the relevance of phosphorylation was not determined since 
no clear phenotype is observed when the BRI3:PP1 complex formation is impaired.  
BRI3 is also processed by furin and other members of the pro-protein convertase family, however, 
in contrast to BRI2, it fails to undergo shedding by ADAM-10 as well as intramembrane proteolysis 
by SPPL2a/b (Martin et al. 2009). Therefore, the involvement of protein phosphorylation in its 
processing is unlikely. Although, it seems to be of paramount importance to explore the role of BRI3 
phosphorylation, namely dephosphorylation by PP1 associated with its trafficking, as this 
modification may induce conformational changes which may affect the interaction with other protein 
partners.    
The development of BRI3 loss- and gain-of-function models will further provide valuable insights 
into BRI3 physiological functions. In addition, knock-in models expressing BRI3 phosphorylation 
mutants would help us to study the impact of protein phosphorylation on BRI3 without protein 
overexpression.  
 
IV.3.1. Potential roles for BRI3 in the CNS 
Bioinformatic analysis of the BRI3 brain interactome provided hints regarding BRI3 biology and its 
physiological roles in the CNS. Given the localization of its interactors, one can hypothesize that 
BRI3 in neurons is localized at synapses, both presynapse and postsynapse, and associated with 
synaptic vesicles and the cytoskeleton. 
The work here presented led to the identification of high number of candidate BRI3 interactors 
involved in neuronal trafficking along the cytoskeleton, namely kinesins, members of the AP 
complex and clathrins. This suggests that BRI3 protein is transported within axons and dendrites to 
the nerve terminals where it may be functionally required. Moreover, it is plausible that BRI3 is 
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expressed both in pre- and postsynapse and by trans-synaptic interactions and may have a role in 
synapse formation. Interactions for BRI2 with proteins involved in synaptic transmission were also 
detected, namely PSD-95, NMDAR1 and NMDAR2B suggesting an additional role for BRI2 in 
excitatory synaptic transmission by altering AMPARs and NMDARs trafficking, as is described for 
other transmembrane proteins (Spires et al. 2005; Isaac et al. 2007; Hoe et al. 2009). However, the 
underlying mechanisms deserve further investigations. Curiously, BRI3 is a negative regulator of Aβ 
production by interacting with APP (Matsuda et al. 2009). Since Aβ is able to induce synaptic 
dysfunction by either decreasing surface expression or by promoting endocytosis of the glutamate 
receptors (Almeida et al. 2005; Snyder et al. 2005). Therefore, we propose a novel role for BRI3:APP 
complex in synaptic transmission and plasticity by regulating AMPARs and NMDARs trafficking.   
Furthermore, a previous study suggested a possible role for BRI3 in neuronal differentiation. Briefly, 
BRI3 by interacting with the microtubule-destabilizing protein SCG10, attenuates the SCG10 
mediated neurite outgrowth by preventing microtubule disassembly (Gong et al. 2008). The work 
here presented supports a role for BRI3 in neurite outgrowth by mediating cytoskeleton dynamics 
since a high number of proteins identified as BRI3 interactors are cytoskeletal and cytoskeletal 
binding proteins involved in its organization.  
In summary, the involvement of BRI3 in the above mentioned biological processes should be further 
addressed, as well as other several issues regarding BRI3 biology, namely the localization and 
function of different BRI3 forms (ex. phosphorylated).  
 
IV.3.2. BRI3 and nervous system diseases 
Although no mutation has yet been reported for BRI3, as is described for BRI2, some associations 
for BRI3 with pathological conditions have been pointed out: (1) a polymorphism (AÆG) of BRI3 
was associated with the prevalence of subarachnoid hemorrhage in Japanese individuals (Yoshida et 
al. 2010); (2) as a negative regulator of Aβ production, BRI3 could have a role in the pathogenesis 
of AD; however, so far no clear association has been established for BRI3 in the pathogenesis of AD. 
Remarkably, a high number of BRI3 protein interactors here identified were found to share with 
BRI3 the association to some nervous system disorders, particularly with AD. Therefore, it would be 
advantageous to study BRI3 dysfunction as a potential underlying mechanism in the pathogenesis of 
the disease. Evidences suggest imbalanced activities of protein kinases and phosphatases in AD 
which affect the phosphorylation state of AD-related proteins, such as APP and Tau (Oliveira et al. 
2015). Consequently, either the phosphorylation levels of BRI3 and the BRI3:APP complex 
formation should be addressed in AD which could potentially provide novel and important insights 
on the pathology mechanisms.  
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IV.4. CONCLUDING REMARKS 
The work presented in this thesis provides important novel insights into the biological properties of 
BRI2 and BRI3 proteins. Moreover, it takes advantage of the identification of novel BRI2 and BRI3 
containing protein complexes to uncover putative roles and the underlying mechanisms in which 
these proteins may be involved. 
 
In conclusion, this work resulted in: 
- identification of both BRI2 and BRI3 as phosphoproteins; 
- validation of BRI2 and BRI3 as novel PP1 interacting proteins; 
- identification of BRI2 phosphorylation as a regulatory mechanism of its proteolytic 
processing; 
- uncovering the BRI2 neuritogenic role and its regulation by phosphorylation; 
- uncovering novel biological roles and the underlying mechanisms for BRI2 and BRI3 
proteins. 
 
The identification of protein phosphorylation as a regulatory mechanism of both BRI2 and BRI3 
opens a new perspective in the study of their biological function, as well as their dysfunction which 
could be involved in the pathogenesis of specific neurodegenerative disorders. Moreover, our work 
suggests some novel putative roles for BRI2 and BRI3. Remarkably, the majority of biological 
processes associated with both proteins were similar (neurite outgrowth, synapse formation, synaptic 
signaling, and transmission) suggesting the existence of functional complementation of both proteins 
in the CNS. In fact, both are inhibitors of Aβ production by affecting APP processing, and the 
interaction of both proteins with PP1 and APP might underlie neurodegenerative diseases. Although 
the work here presented does not provide functional evidences for the novel proposed roles for BRI2 
and BRI3, emerges as an important basis for future studies.   
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